---
created: 2024-09-04T00:04:57 (UTC -09:00)
tags: []
source: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
author: McEvoy, John William, McCarthy, Cian P, Bruno, Rosa Maria, Brouwers, Sofie, Canavan, Michelle D, Ceconi, Claudio, Christodorescu, Ruxandra Maria, Daskalopoulou, Stella S, Ferro, Charles J, Gerdts, Eva, Hanssen, Henner, Harris, Julie, Lauder, Lucas, McManus, Richard J, Molloy, Gerard J, Rahimi, Kazem, Regitz-Zagrosek, Vera, Rossi, Gian Paolo, Sandset, Else Charlotte, Scheenaerts, Bart, Staessen, Jan A, Uchmanowicz, Izabella, Volterrani, Maurizio, Touyz, Rhian M, ,
---

# 2024 ESC Guidelines for the management of elevated blood pressure and hypertension | European Heart Journal | Oxford Academic

> ## Excerpt
> Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approac

---
# 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and _endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)_

John William McEvoy, Cian P McCarthy, Rosa Maria Bruno, Sofie Brouwers, Michelle D Canavan, Claudio Ceconi, Ruxandra Maria Christodorescu, Stella S Daskalopoulou, Charles J Ferro, Eva Gerdts [... Show more](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#)

[Author Notes](javascript:;)

_European Heart Journal_, ehae178, [https://doi.org/10.1093/eurheartj/ehae178](https://doi.org/10.1093/eurheartj/ehae178)

Published:

30 August 2024

-   [![pdf](https://academic.oup.com//oup.silverchair-cdn.com/UI/app/svg/pdf.svg)PDF](https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehae178/58916755/ehae178.pdf)
-   [Cite](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#)

[Guidelines](javascript:;), [Blood pressure](javascript:;), [Hypertension](javascript:;), [Hypertension-mediated organ damage](javascript:;), [Blood pressure measurement](javascript:;), [Ambulatory blood pressure monitoring](javascript:;), [Home blood pressure monitoring](javascript:;), [Antihypertensive medication](javascript:;), [Hypertension treatment](javascript:;), [Hypertension targets](javascript:;), [Secondary hypertension](javascript:;), [Cardiovascular disease risk estimation](javascript:;), [Cardiovascular disease prevention](javascript:;), [Resistant hypertension](javascript:;), [Hypertension screening](javascript:;)

Topic:

-   [hypertension](javascript:;)
-   [cardiovascular diseases](javascript:;)
-   [heart disease risk factors](javascript:;)
-   [blood pressure](javascript:;)
-   [blood pressure determination](javascript:;)
-   [guidelines](javascript:;)

## Table of contents

-   1\. Preamble 
    
-   2\. Introduction 
    
-    2.1. What is new 
    
-   3\. Pathophysiology of elevated blood pressure and hypertension 
    
-   4\. Clinical consequences of elevated blood pressure and hypertension 
    
-   5\. Measuring blood pressure 
    
-    5.1. Introduction and pertinent definitions 
    
-    5.2. Practical recommendations for measuring blood pressure 
    
-     5.2.1. Clinical validation of equipment for measuring blood pressure 
    
-     5.2.2. Office blood pressure measurement 
    
-     5.2.3. Home blood pressure measurement 
    
-     5.2.4. Ambulatory blood pressure measurement 
    
-     5.2.5. Comparison of home and ambulatory blood pressure monitoring 
    
-    5.3. What is the best method for measuring blood pressure to diagnose hypertension? 
    
-     5.3.1. Blood pressure measurement for hypertension screening  
    
-     5.3.2. Blood pressure measurement for diagnosing hypertension  
    
-    5.4. What is the best method for measuring blood pressure for long-term management of hypertension? 23
    
-     5.4.1. Home monitoring 
    
-     5.4.2. Ambulatory monitoring 
    
-    5.5. Measuring blood pressure in selected groups 
    
-     5.5.1. Pregnancy 
    
-     5.5.2. Atrial fibrillation 
    
-     5.5.3. Orthostatic hypotension 
    
-    5.6. Novel methods of measuring blood pressure 
    
-   6\. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment 
    
-    6.1. Definition and classification of elevated blood pressure and hypertension 
    
-    6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease 
    
-     6.2.1. Role of cardiovascular disease risk assessment 
    
-    6.3. Predicting cardiovascular disease risk 
    
-     6.3.1. 10-year cardiovascular disease risk-prediction models 
    
-    6.4. Refining cardiovascular disease risk estimation beyond risk models 
    
-     6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers 
    
-     6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women 
    
-     6.4.3. Additional risk decision tests 
    
-    6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment 
    
-   7\. Diagnosing hypertension and investigating underlying causes 
    
-    7.1. Screening for hypertension 
    
-    7.2. Confirming the diagnosis of hypertension 
    
-    7.3. Communicating the diagnosis 
    
-    7.4. Baseline assessment and diagnostic approach 
    
-     7.4.1. Medical history, medication history, and physical examination 
    
-     7.4.2. Drug adherence and persistence with treatment 
    
-     7.4.3. Routine and optional tests 
    
-      7.4.3.1. The kidneys 
    
-      7.4.3.2. The heart 
    
-      7.4.3.3. The arteries 
    
-     7.4.4. Genetic testing 
    
-    7.5. Resistant hypertension: definition and diagnosis 
    
-    7.6. Secondary hypertension: when to screen/further investigations  
    
-     7.6.1. General considerations 
    
-     7.6.2. Primary aldosteronism 
    
-     7.6.3. Renovascular hypertension 
    
-     7.6.4. Obstructive sleep apnoea syndrome 
    
-     7.6.5. Phaeochromocytoma/paraganglioma 
    
-   8\. Preventing and treating elevated blood pressure and hypertension  
    
-    8.1. Prevention strategies in early life 
    
-    8.2. Non-pharmacological interventions 
    
-     8.2.1. Dietary sodium and potassium intake 
    
-      8.2.1.1. Sodium 
    
-      8.2.1.2. Potassium 
    
-     8.2.2. Physical activity and exercise 
    
-     8.2.3. Weight reduction and diet 
    
-     8.2.4. Alcohol, coffee, and soft drinks 
    
-     8.2.5. Smoking 
    
-    8.3. Pharmacological interventions 
    
-     8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes 
    
-     8.3.2. Drug classes with evidence on clinical outcomes in the target population 
    
-     8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension 
    
-     8.3.4. Drug combinations and up-titrating strategies 
    
-     8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations 
    
-     8.3.6. Timing of blood pressure-lowering drug treatment 
    
-    8.4. Selecting patients for pharmacological blood pressurelowering treatment 
    
-    8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets 
    
-     8.5.1. Expected degree of blood pressure reduction with approved drugs 
    
-     8.5.2. The ideal target of blood pressure-lowering treatment 
    
-     8.5.3. Personalizing treatment strategies 
    
-     8.5.4. Duration and monitoring of drug therapy 
    
-    8.6. Device-based blood pressure lowering 
    
-     8.6.1. Catheter-based renal denervation 
    
-     8.6.2. Other devices 
    
-    8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets 
    
-     8.7.1. Adverse effects of blood pressure-lowering medications 
    
-      8.7.1.1. Symptomatic adverse effects 
    
-      8.7.1.2. Renal effects 
    
-      8.7.1.3. Erectile dysfunction 
    
-     8.7.2. Pill burden and non-adherence 
    
-     8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people 
    
-     8.7.4. Clinical inertia in blood pressure lowering 
    
-   9\. Managing specific patient groups or circumstances 
    
-    9.1. Young adulthood (18–40 years) 
    
-     9.1.1. Definition and epidemiology 
    
-     9.1.2. Secondary hypertension in young adulthood 
    
-     9.1.3. Measurement and management of blood pressure in young adults 
    
-    9.2. Pregnancy 
    
-     9.2.1. Definition and epidemiology 
    
-     9.2.2. Classifying hypertension in pregnancy 
    
-     9.2.3. Measuring blood pressure in pregnancy 
    
-     9.2.4. Investigating hypertension in pregnancy 
    
-     9.2.5. Preventing hypertension and pre-eclampsia 
    
-     9.2.6. Treatment initiation and blood pressure targets 
    
-     9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg) 
    
-     9.2.8. Managing severe hypertension in pregnancy (>160/110 mmHg) 
    
-     9.2.9. Managing blood pressure post-partum 
    
-     9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy 
    
-    9.3. Very old age (≥85 years), frailty, multimorbidity, and polypharmacy 
    
-     9.3.1. Definition of frailty 
    
-     9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients 
    
-     9.3.3. Starting blood pressure-lowering treatment in very old or frail patients 
    
-     9.3.4. Maintaining blood pressure lowering in very old or frail patients 
    
-    9.4. Isolated systolic and diastolic hypertension 
    
-     9.4.1. Definition of isolated systolic hypertension 
    
-     9.4.2. Isolated systolic hypertension, risk factors, and ageing 
    
-     9.4.3. Isolated systolic hypertension in young adults 
    
-     9.4.4. Isolated diastolic hypertension 
    
-    9.5. Orthostatic hypotension with supine hypertension 
    
-    9.6. Diabetes 
    
-     9.6.1. Diabetes and elevated blood pressure/hypertension 
    
-     9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes 
    
-     9.6.3. Managing blood pressure in diabetes 
    
-    9.7. Chronic kidney disease 
    
-     9.7.1. Relationship between hypertension and chronic kidney disease 
    
-     9.7.2. Blood pressure lowering in chronic kidney disease 
    
-     9.7.3. Managing blood pressure in chronic kidney disease 
    
-     9.7.4. Blood pressure targets in chronic kidney disease 
    
-    9.8. Cardiac disease 
    
-     9.8.1. Blood pressure thresholds and targets in patients with cardiac disease 
    
-     9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve 
    
-     9.8.3. Valvular heart disease 
    
-     9.8.4. Heart failure 
    
-     9.8.5. Heart rhythm disease (including AF) 
    
-    9.9. Chronic cerebrovascular disease and/or cognitive impairment 
    
-     9.9.1. Role of hypertension in chronic cerebrovascular disease 
    
-     9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack 
    
-     9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment 
    
-    9.10. Aortopathy 
    
-     9.10.1. Coarctation of the aorta 
    
-     9.10.2. Bicuspid aortic valve-related aortopathy 
    
-     9.10.3. Preventing aortic dilation and dissection in high-risk patients 
    
-    9.11. Different ethnic groups 
    
-    9.12. Nocturnal hypertension 
    
-     9.12.1. Definition 
    
-     9.12.2. Epidemiology 
    
-     9.12.3. Night-time blood pressure as a cardiovascular disease risk factor 
    
-     9.12.4. Treatment of nocturnal hypertension 
    
-    9.13. Resistant hypertension 
    
-     9.13.1. Definition of resistant hypertension 
    
-     9.13.2. Non-pharmacological interventions 
    
-     9.13.3. Pharmacological interventions 
    
-     9.13.4. Devices for blood pressure lowering 
    
-    9.14. Management of specific causes of secondary hypertension 
    
-     9.14.1. General considerations 
    
-     9.14.2. Primary aldosteronism 
    
-     9.14.3. Renovascular hypertension 
    
-     9.14.4. Phaeochromocytoma/paraganglioma 
    
-     9.14.5. Obstructive sleep apnoea syndrome 
    
-     9.14.6. Drug-induced hypertension 
    
-      9.14.6.1. Anticancer drug-induced hypertension 
    
-     9.14.7. Other forms of secondary hypertension 
    
-   10\. Acute and short-term lowering of blood pressure 
    
-    10.1. Acute blood pressure management in hypertensive emergencies 
    
-     10.1.1. Definition and characteristics of hypertensive emergencies 
    
-     10.1.2. Acute management of hypertensive emergencies 
    
-     10.1.3. Prognosis and follow-up 
    
-    10.2. Acute blood pressure management in acute intracerebral haemorrhage 
    
-    10.3. Acute blood pressure management in acute ischaemic stroke  
    
-    10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy 
    
-     10.4.1. Pre-eclampsia 
    
-     10.4.2. Severe acute hypertension in pregnancy 
    
-    10.5. Peri-operative acute management of elevated blood pressure  
    
-     10.5.1. Blood pressure-lowering drugs in the peri-operative phase 
    
-   11\. Patient-centred care in hypertension 
    
-    11.1. Definition 
    
-    11.2. Communicating consequences of treatment 
    
-    11.3. Self-measuring and monitoring 
    
-    11.4. Facilitating medication adherence and persistence 
    
-    11.5. Multidisciplinary management 
    
-   12\. Key messages 
    
-   13\. Gaps in the evidence 
    
-   14\. ‘What to do’ and ‘what not to do’ messages from the guidelines  
    
-   15\. Evidence tables 
    
-   16\. Data availability statement 
    
-   17\. Author information 
    
-   18\. Appendix 
    
-   19\. References 
    

## Tables of Recommendations

-   Recommendation Table 1 — Recommendations for measuring blood pressure (see Evidence Tables 1–8) 
    
-   Recommendation Table 2 — Recommendations for categorizing blood pressure (see Evidence Table 9) 
    
-   Recommendation Table 3 — Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11) 
    
-   Recommendation Table 4 — Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14) 
    
-   Recommendation Table 5 — Recommendations for blood pressure screening (see Evidence Table 15) 
    
-   Recommendation Table 6 — Recommendations for confirming hypertension diagnosis 
    
-   Recommendation Table 7 — Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16) 
    
-   Recommendation Table 8 — Recommendations for assessing renal hypertension-mediated organ damage 
    
-   Recommendation Table 9 — Recommendations for assessing cardiac hypertension-mediated organ damage 
    
-   Recommendation Table 10 — Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17) 
    
-   Recommendation Table 11 — Recommendations for genetic testing in hypertension management 
    
-   Recommendation Table 12 — Recommendations for resistant hypertension work-up (see Evidence Table 18) 
    
-   Recommendation Table 13 — Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20) 
    
-   Recommendation Table 14 — Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21) 
    
-   Recommendation Table 15 — Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26) 
    
-   Recommendation Table 16 — Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29) 
    
-   Recommendation Table 17 — Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32) 
    
-   Recommendation Table 18 — Recommendations for blood pressure targets with treatment (see Evidence Table 34) 
    
-   Recommendation Table 19 — Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33) 
    
-   Recommendation Table 20 — Recommendations for device-based treatment of hypertension (see Evidence Table 35) 
    
-   Recommendation Table 21 — Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37) 
    
-   Recommendation Table 22 — Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40) 
    
-   Recommendation Table 23 — Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41) 
    
-   Recommendation Table 24 — Recommendations for managing hypertension in patients with orthostatic hypotension 
    
-   Recommendation Table 25 — Recommendations for managing hypertension in patients with diabetes 
    
-   Recommendation Table 26 — Recommendations for managing hypertension in patients with chronic kidney disease 
    
-   Recommendation Table 27 — Recommendations for managing hypertension in patients with cardiac disease 
    
-   Recommendation Table 28 — Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment 
    
-   Recommendation Table 29 — Recommendations for managing hypertension in different ethnic groups 
    
-   Recommendation Table 30 — Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43) 
    
-   Recommendation Table 31 — Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45) 
    
-   Recommendation Table 32 — Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke 
    
-   Recommendation Table 33 — Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46) 
    
-   Recommendation Table 34 — Recommendations for communicating consequences of treatment (see Evidence Table 47) 
    
-   Recommendation Table 35 — Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48) 
    
-   Recommendation Table 36 — Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49) 
    

## List of tables

-   Table 1 Classes of recommendations 
    
-   Table 2 Levels of evidence 
    
-   Table 3 New recommendations 
    
-   Table 4 Revised recommendations 
    
-   Table 5 Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood pressure and hypertension 
    
-   Table 6 Comparison of ambulatory and home blood pressure monitoring 
    
-   Table 7 Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis to the patient (note that gender influences these representations) 
    
-   Table 8 Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension 
    
-   Table 9 Optional tests that may be used as clinically indicated in the initial work-up of a patient with elevated blood pressure or hypertension to assess hypertension-mediated organ damage or established cardiovascular disease 
    
-   Table 10 Current definition of resistant hypertension 
    
-   Table 11 Conditions found to cause pseudo-resistance or resistance to blood pressure-lowering treatment 
    
-   Table 12 Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio 
    
-   Table 13 Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, symptoms, or medical history 
    
-   Table 14 Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovascular disease risk 
    
-   Table 15 What to do and what not to do 
    

## List of figures

-   Figure 1 Pathophysiology of elevated blood pressure and hypertension 
    
-   Figure 2 Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease 
    
-   Figure 3 Summary of office blood pressure measurement 
    
-   Figure 4 Summary of home blood pressure measurement 
    
-   Figure 5 Summary of ambulatory blood pressure measurement 
    
-   Figure 6 Blood pressure categories 
    
-   Figure 7 Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure 
    
-   Figure 8 Cardiovascular disease risk modifiers to consider for up-classification of risk 
    
-   Figure 9 Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure 
    
-   Figure 10 Protocol for confirming hypertension diagnosis 
    
-   Figure 11 Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications 
    
-   Figure 12 Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice 
    
-   Figure 13 Summary of primary aldosteronism as a common form of secondary hypertension 
    
-   Figure 14 Summary of renovascular disease as a common form of secondary hypertension 
    
-   Figure 15 Summary of obstructive sleep apnoea as a common form of secondary hypertension 
    
-   Figure 16 Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk 
    
-   Figure 17 Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction 
    
-   Figure 18 Practical algorithm for pharmacological blood pressure lowering 
    
-   Figure 19 Central Illustration 
    
-   Figure 20 Systolic blood pressure categories and treatment target range 
    
-   Figure 21 Frailty assessment in the management of blood pressure 
    
-   Figure 22 Management of resistant hypertension 
    
-   Figure 23 Patient-centred care 
    
-   Figure 24 The five dimensions of adherence (WHO, 2003) applied to hypertension 
    

## Abbreviations and acronyms

 -   ABI
    
    Ankle–brachial index
    
 -   ABPM
    
    Ambulatory blood pressure monitoring
    
 -   ACCORD
    
    Action to Control Cardiovascular Risk in Diabetes
    
 -   ACE
    
    Angiotensin-converting enzyme
    
 -   ACR
    
    Albumin:creatinine ratio
    
 -   AF
    
    Atrial fibrillation
    
 -   AHI
    
    Apnoea–hypopnoea index
    
 -   ALARA
    
    As low as reasonably achievable
    
 -   ALLHAT
    
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
    
 -   AOBP
    
    Automated office blood pressure (measurement)
    
 -   ARB
    
    Angiotensin receptor blocker
    
 -   ARNi
    
    Angiotensin receptor-neprilysin inhibitor
    
 -   ARR
    
    Aldosterone-to-renin ratio
    
 -   ASCVD
    
    Atherosclerotic cardiovascular disease
    
 -   BMI
    
    Body mass index
    
 -   BP
    
    Blood pressure
    
 -   BSA
    
    Body surface area
    
 -   CAC
    
    Coronary artery calcium
    
 -   CAD
    
    Coronary artery disease
    
 -   CCB
    
    Calcium channel blocker
    
 -   CHAP
    
    Chronic Hypertension and Pregnancy
    
 -   CI
    
    Confidence interval
    
 -   CKD
    
    Chronic kidney disease
    
 -   CKD-EPI
    
    Chronic Kidney Disease Epidemiology Collaboration
    
 -   COVID-19
    
    Coronavirus disease 2019
    
 -   CPAP
    
    Continuous positive airway pressure
    
 -   CPG
    
    Clinical Practice Guidelines
    
 -   CT
    
    Computed tomography
    
 -   CVD
    
    Cardiovascular disease
    
 -   DASH
    
    Dietary Approaches to Stop Hypertension
    
 -   DBP
    
    Diastolic blood pressure
    
 -   DECIDE-Salt
    
    Diet, ExerCIse and carDiovascular hEalth–Salt
    
 -   EACTS
    
    European Association for Cardio-Thoracic Surgery
    
 -   ECG
    
    Electrocardiogram
    
 -   eGFR
    
    Estimated glomerular filtration rate
    
 -   EPIC
    
    European Prospective Investigation into Cancer and Nutrition
    
 -   ESC
    
    European Society of Cardiology
    
 -   ESH
    
    European Society of Hypertension
    
 -   ESPRIT
    
    Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs
    
 -   FMD-RVH
    
    Fibromuscular dysplasia-induced renovascular hypertension
    
 -   GFR
    
    Glomerular filtration rate
    
 -   GLP-1
    
    Glucagon-like peptide-1
    
 -   GP
    
    General practitioner
    
 -   HbA1c
    
    Glycated haemoglobin
    
 -   HBPM
    
    Home blood pressure monitoring
    
 -   HDL
    
    High-density lipoprotein
    
 -   HFpEF
    
    Heart failure with preserved ejection fraction
    
 -   HF(m)rEF
    
    Heart failure with (mildly) reduced ejection fraction
    
 -   HIV
    
    Human immunodeficiency virus
    
 -   HMOD
    
    Hypertension-mediated organ damage
    
 -   i.m.
    
    Intramuscular
    
 -   i.v.
    
    Intravenous
    
 -   KDIGO
    
    Kidney Disease: Improving Global Outcomes
    
 -   LA
    
    Left atrial
    
 -   LDL
    
    Low-density lipoprotein
    
 -   LV
    
    Left ventricular
    
 -   LVH
    
    Left ventricular hypertrophy
    
 -   MRA
    
    Mineralocorticoid receptor antagonist
    
 -   MRI
    
    Magnetic resonance imaging
    
 -   NNT
    
    Number needed to treat
    
 -   NT-proBNP
    
    N-terminal pro-brain natriuretic peptide
    
 -   OSAS
    
    Obstructive sleep apnoea syndrome
    
 -   PPGL
    
    Phaeochromocytoma/paraganglioma
    
 -   PREOP-ACEI
    
    Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition
    
 -   PREMs
    
    Patient-Reported Experience Measures
    
 -   PROMS
    
    Patient-Reported Outcome Measures
    
 -   PTRA
    
    Percutaneous transluminal renal angioplasty
    
 -   PWV
    
    Pulse wave velocity
    
 -   RAAS
    
    Renin-angiotensin-aldosterone system
    
 -   RADIANCE-HTN
    
    A Study of the Recor Medical Paradise System in Clinical Hypertension
    
 -   RAS
    
    Renin–angiotensin system
    
 -   RCT
    
    Randomized controlled trial
    
 -   RVH
    
    Renovascular hypertension
    
 -   RWT
    
    Relative wall thickness
    
 -   SBP
    
    Systolic blood pressure
    
 -   SCORE2
    
    Systematic COronary Risk Evaluation 2
    
 -   SCORE2-OP
    
    Systematic COronary Risk Evaluation 2–Older Persons
    
 -   SGLT2
    
    Sodium–glucose co-transporter 2
    
 -   SNP
    
    Single-nucleotide polymorphism
    
 -   SNS
    
    Sympathetic nervous system
    
 -   SPC
    
    Single-pill combination
    
 -   SPRINT
    
    Systolic Blood Pressure Intervention Trial
    
 -   SSaSS
    
    Salt Substitute and Stroke Study
    
 -   STEP
    
    Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients
    
 -   STEP-1
    
    Semaglutide Treatment Effect in People with Obesity
    
 -   TIA
    
    Transient ischaemic attack
    
 -   TRIUMPH
    
    Treating Resistant Hypertension Using Lifestyle Modification to Promote Health
    
 -   TSH
    
    Thyroid-stimulating hormone
    
 -   WHO
    
    World Health Organization
    
 -   WML
    
    White matter lesion
    

## 1\. Preamble

Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated when warranted by new evidence. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website ([https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines](https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines)). This guideline version updates and replaces the previous version from 2018.

The Members of this task force were selected by the ESC to include professionals involved in the medical care of patients with this pathology, as well as patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The task force performed a critical review and evaluation of the published literature on diagnostic and therapeutic approaches including assessment of the risk-benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to predefined scales as outlined in _[Tables 1](javascript:;)_ and _[2](javascript:;)_ below. Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) were also evaluated as the basis for recommendations and/or discussion in these guidelines. The task force followed ESC voting procedures and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members. Members of the task force with declared interests on specific topics were asked to abstain from voting on related recommendations.

Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375722)

Classes of recommendations

![Classes of recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il1.jpeg?Expires=1728462844&Signature=Y0NNSv60jeHOwJxH4v9cd81tPUbbMIkmgAjiOs0o4lmgYuTGYTh2Fg~jOuWDDShtFV3ZY8hQelpORhHOgbLRbSAGdnFXqU5Za3byuEkVFXR8PbgkhJmJh12jznM-DUDiE1C4pGWF1kYwP4h9KkobOCqSqFjkRfyVIKebWerFAjAGJKYZ2eeQzsd1O1i-vDPJpEDcEhrPUNRoRwx~cl1rTgIqlWV3kwdBooZMEGnUeATPaDoJUx9dQli9ZB9~oWRv7kDkNNIDeINz-sob72qBRNiyejOgp9vcc7xbCoUzQrrB1bVj80cFQkcJ6Kazn8dfCjmiYpWgxHVsYzPF20SAeQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375723)

Levels of evidence

![Levels of evidence](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il2.jpeg?Expires=1728462844&Signature=FNy2Dfjps8T6LBo75RlmW2WjbImnkSoGp6Z3JzyR-GwnpXL93ER2Ru0QgpNxUjR2PsbQi1HXMrC3NYk~Bd5gJ1iTbqpTx3EkxgMjXv63nPrNIYrr~UuPJv3uuFu1tvgUYylvpNJbaQmMKj5jHw0yPsy57PmEdFml2XsRUVphd48yckivo5WUe0yRLZOXqaZ3Wv2DFgrrmcgrmvwgD8Sh8ng8i-1eMPaCeCTwSsa88Ma~mI5cSTVM4D6RNc~MtCyBMVdfWS7JPGwSWE58YVePXgghniYmjt73qYX2dK5KFv5ncNHDPIS~P6qLg3p2sw4q8zu2EvW2j1a-o5Nz0IhHnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules, which can be found on the ESC website ([http://www.escardio.org/guidelines](http://www.escardio.org/guidelines)) and have been compiled in a report published in a supplementary document with the guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry.

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. In addition to review by the CPG Committee, ESC Guidelines undergo multiple rounds of double-blind peer review by external experts, including members from across the whole of the ESC region, all National Cardiac Societies of the ESC and from relevant ESC Subspecialty Communities. After appropriate revisions, the guidelines are signed off by all the experts in the task force. The finalized document is signed off by the CPG Committee for publication in the _European Heart Journal_.

ESC Guidelines are based on analyses of published evidence, chiefly on clinical trials and meta-analyses of trials, but potentially including other types of studies. Evidence tables summarizing key information from relevant studies are generated early in the guideline development process to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and reinforce transparency in the guidelines development process. The tables are published in their own section of ESC Guidelines and reference specific recommendation tables.

Off-label use of medication may be presented in these guidelines if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

-   The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient’s interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent;
    
-   Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.
    

## 2\. Introduction

This 2024 document updates the 2018 ESC/European Society of Hypertension (ESH) Guidelines on the management of arterial hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> While the current document builds on prior guidelines, it also incorporates important updates and new recommendations based on current evidence. For example:

1.  The title has changed from ‘Guidelines on the management of arterial hypertension’ to ‘Guidelines on the management of elevated blood pressure and hypertension’. This is based on evidence that the risk for cardiovascular disease (CVD) attributable to blood pressure (BP) is on a continuous exposure scale, not a binary scale of normotension vs. hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a>,<a href="javascript:;" reveal-id="ehae178-B3" data-open="ehae178-B3" class="link link-ref link-reveal xref-bibr">3</a></sup> Updated evidence also increasingly demonstrates the benefit on CVD outcomes of BP-lowering medications among persons with high CVD risk and BP levels that are elevated but that do not meet traditional thresholds used to define hypertension. The term ‘arterial’ is removed from the title of the 2024 Guidelines, as arterial hypertension can also occur in the pulmonary arteries, which is not a focus here.
    
2.  The 2024 Guidelines continue to define hypertension as office systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. However, a new BP category called ‘Elevated BP’ is introduced. Elevated BP is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg.
    
3.  A major, evidence-based change in the 2024 Guidelines is the recommendation to pursue a target systolic BP of 120–129 mmHg among adults receiving BP-lowering medications. There are several important caveats to this recommendation, including: (i) the requirement that treatment to this BP target is well tolerated by the patient, (ii) the fact that more lenient BP targets can be considered in persons with symptomatic orthostatic hypotension, those aged 85 years or over, or those with moderate-to-severe frailty or limited life expectancy, and (iii) a strong emphasis on out-of-office BP measurement to confirm the systolic BP target of 120–129 mmHg is achieved. For those selected individual cases where a target systolic BP of 120–129 mmHg is not pursued, either due to intolerance or the existence of conditions that favour a more lenient BP target, we recommend targeting a BP that is as low as reasonably achievable. Personalized clinical decision-making and shared decisions with the patient are also emphasized.
    
4.  Another important change in the 2024 Guidelines compared with earlier versions is the increased focus on evidence related to fatal and non-fatal CVD outcomes rather than surrogate outcomes such as BP lowering alone. Except for lifestyle interventions and low-risk non-pharmacological interventions aimed at implementation or care delivery, the current guidelines require that, for a Class I recommendation to be made for a drug or procedural intervention, the evidence must show benefit on CVD outcomes and not only BP lowering.
    
5.  The task force comprised of a balanced representation of males and females.
    
6.  The present guidelines consider sex and gender as an integral component throughout the document, rather than in a separate section at the end. In this document, sex is the biological condition of being female or male from conception, based on genes, and gender is the socio-cultural dimension of being a woman or a man in a given society, based on gender roles, gender norms, gender identity, and gender relations valid in the respective society at a given timepoint.<sup><a href="javascript:;" reveal-id="ehae178-B4" data-open="ehae178-B4" class="link link-ref link-reveal xref-bibr">4</a>,<a href="javascript:;" reveal-id="ehae178-B5" data-open="ehae178-B5" class="link link-ref link-reveal xref-bibr">5</a></sup>
    
7.  The 2024 Guidelines are written to make them more ‘user friendly’. Input from general practitioners (GPs) was obtained in this regard, and one task force member is a GP. Given the ageing population in Europe, there was also a focus on tailoring treatment with respect to frailty and into older age, which is addressed in multiple sections. Moreover, patient input and their lived experiences are considered throughout. We also now include evidence tables in the Supplementary section to provide improved transparency regarding our recommendations. As appropriate, readers who wish to seek additional details and information are referred to the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and to the ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il4.jpeg?Expires=1728462844&Signature=Uok7hDvPxFT3d~1RJy9LSmybAUAgvvgord~KlDRiQKZ88AMXHz9o4X15d1PsK2yVQ0VxGXPeoUCFNqKQ-Qb-n4RpImN5fVooV5060kD6jtBqmFJVY-ZDEuVR6uBgYDYlVoGTJnsEU7EdNFNAyjztFXZlbYXKO3vocogQ4UXRI51gv1ouSmwujlS63F0twr0MqIFkn8F~yiZUrnwpvtXC0~bCDuwdmFDsFcQyOv4IGiZ71BkKWNrchFwE~-B64ue1J3mdlmyYUT09Glfb38ZNvBbcOTYpW24ld6q4AMjc4dM-k4oD~pIXGwjwnY0S7EXzaeVTMcr1HH5AbgsJE-hVSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  [ESC CardioMed](https://doi.org/10.1093/med/9780198784906.001.0001).<sup><a href="javascript:;" reveal-id="ehae178-B6" data-open="ehae178-B6" class="link link-ref link-reveal xref-bibr">6</a></sup>
    
8.  The task force recognized that a major challenge in guideline usage is poor implementation. This likely contributes to suboptimal control of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B7 ehae178-B8 ehae178-B9" data-open="ehae178-B7 ehae178-B8 ehae178-B9" class="link link-ref link-reveal xref-bibr">7–9</a></sup> To address this, a dedicated section on implementation is included in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA). Moreover, through a new initiative, we include information from national societies following a survey on guideline implementation completed during the national society peer review of the guidelines document. It is hoped this information may help inform national societies about potential barriers to implementation.
    

### 2.1. What is new

These 2024 Guidelines contain a number of new and revised recommendations, which are summarized in _[Tables 3](javascript:;)_ and _[4](javascript:;)_, respectively.

Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375734)

New recommendations

![New recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t3.jpeg?Expires=1728462844&Signature=LvInzHkasbylidSNQ-4bnslhs3cSntjWrmo7xnhqAjsDVA58fXXWE~ZMYaDryY4z-8C5oH6igWPQzZghIxy4YTr606u1vCtSYpMl0VeeGpj4WjifimCv4kjes~v85UuibxLnmHTIxxIWHac--WmHg-gi-STttdwCEpqUMkYLjyEASxCDCbvBs2ULcAsYy2mkbzL~HqZIQ-ObDG8iEkI7ahdedUn0e85T74a-hSS~-McFTMpNHXCtOLvlFjwEeUIM4LTmg4CWEGQYX1jFsKQvvmD7HU8HKtx2I03i1wEVxgG-iv-kKEHNACWRvMqWT5gp3basn0vhGyYUzeqZtBHDnA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375735)

Revised recommendations

![Revised recommendations](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t4.jpeg?Expires=1728462844&Signature=PSmRnw58w9els3~aAKAQEB49k1vZpkRp8ROT73K7WZCwyi3TB98Go5PehuDB~M~fXmoYV6tb7r6Yfm8jiAq6t~7j-KqwfNYCK0wtqmfpzr8Fay3BNHkRn1Zf8I6765ZWPELQ61BGVBa~xknTsZfyEVXBV8nBPC~lK-oE4gz9FCrtOZgdFy9hXHbmXIGMoDyvCZaOrrUiKYtxUDXeK15CiUjql6pgReThvsQIe1J5SZB3hHM3xDfwBZM0XUFJoDiyuv-3gCa3tbbisx76ahdy~hIkkdNnlQihQzoqH~Vs2~7Pb-zAGt5tSdI8fubVl5HuHt5z5we6MYXN~q5xMjgttA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 3\. Pathophysiology of elevated blood pressure and hypertension

Persistently high BP in systemic arteries is the hallmark of hypertension, which is the most important modifiable risk factor for all-cause and CVD morbidity and mortality globally.<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a></sup> Most patients with hypertension have essential or primary hypertension, where the exact cause remains unknown, while an estimated 10% have secondary hypertension, with an identifiable cause (notably some studies indicate that the prevalence of secondary hypertension may be substantially higher, with modern systematic screening).<sup><a href="javascript:;" reveal-id="ehae178-B10" data-open="ehae178-B10" class="link link-ref link-reveal xref-bibr">10</a></sup>

The pathophysiology of hypertension involves complex interactions between environmental and behavioural factors, genes, hormonal networks, and multiple organ systems (renal, cardiovascular, and central nervous system<sup><a href="javascript:;" reveal-id="ehae178-B11" data-open="ehae178-B11" class="link link-ref link-reveal xref-bibr">11</a></sup>) (_[Figure 1](javascript:;)_). In addition, vascular and immune mechanisms are involved.<sup><a href="javascript:;" reveal-id="ehae178-B12" data-open="ehae178-B12" class="link link-ref link-reveal xref-bibr">12</a></sup> Dysregulation of these processes leads to hypertension, which if uncontrolled, can lead to hypertension-mediated organ damage (HMOD) and adverse CVD outcomes.

![Pathophysiology of elevated blood pressure and hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f1.jpeg?Expires=1728462844&Signature=mYBuPuhVcIN0y7IZVhdhDhoLYn4SmlBqZlEf7W2oO5nIOptYXxC4FvryPHraXX4GlLu7tSx3FWgFnBlb8Gr2lxexrO-biGLIixvkWbp42qkEuDn9~PGgeX~4V8y3~2YeV9QIZuKZS7fM68Zmz9zo5Sy4JWlH~VtDNmro2uwTzz5Wtlob7Z5hBLanqk9bS0QKnFTAywSPXPxQIGZyRut-HCGBaYn6qu-Lss~Gg630HcBaUwPbz6s-98MKkSeK~2FMDIb4m2R8jEq2wT~95QUT4dfMGbdWcOzST0eBH9icyHb4RLG-DpUuojahGdpT8E3ykcincrLrs~i6llpQMp4V6g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 1

Pathophysiology of elevated blood pressure and hypertension.

BP, blood pressure; PNS, parasympathetic nervous system; RAAS, renin-angiotensin-aldosterone system; SNP, single-nucleotide polymorphism; SNS, sympathetic nervous system. Complex interplay between genes, environmental, and behavioural factors, organs, physiological systems, and neurohumoral processes contribute to BP regulation. Dysfunction of these processes leads to hypertension. The contribution of these factors to elevated BP and hypertension may differ among males and females.

[Open in new tab](https://academic.oup.com/view-large/figure/479375739/ehae178f1.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f1.jpeg?Expires=1728462844&Signature=nH1uYHoixGbyJIuWsFsWIV4qipo8gDRAN1uMmMXBMj-h2RgjrOWKhYxjWXU67PgHKGWWXbhggF~NDaFup8mseHzD1NIdGmLHWeegdSTbZLLsZc3GTUzo7B3qfUd5QO-Rw5xl~IA05cxqBSRFo9LtLmhEI9T1uKLJ7fvpe7T~HtntVsZQgfi-9RFwRMhtlnuLTSx9ge6WXgNORGsfkdC7dY9pM0CofNWjDfv58IEXTQSuXszcFhbZX1sTutaLIQXlqTyb0fnobrAVmcQu4vVnCA8~O6Xv4BciRrol8GjyjvPf991JqjO~cuJuaKKb6aszZG64M-C-r92W4oAbGaCZBQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375739&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Details on the pathophysiological processes, molecular mechanisms, and environmental and psychosocial elements that underlie hypertension are provided in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

## 4\. Clinical consequences of elevated blood pressure and hypertension

Longstanding hypertension causes organ damage and ultimately leads to cardiovascular, cerebrovascular, and clinical renal disease, which are all major contributors to the global burden of chronic disease (_[Figure 2](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B2" data-open="ehae178-B2" class="link link-ref link-reveal xref-bibr">2</a>,<a href="javascript:;" reveal-id="ehae178-B13 ehae178-B14 ehae178-B15 ehae178-B16 ehae178-B17 ehae178-B18 ehae178-B19 ehae178-B20 ehae178-B21 ehae178-B22" data-open="ehae178-B13 ehae178-B14 ehae178-B15 ehae178-B16 ehae178-B17 ehae178-B18 ehae178-B19 ehae178-B20 ehae178-B21 ehae178-B22" class="link link-ref link-reveal xref-bibr">13–22</a></sup> Organs adversely affected by elevated BP and hypertension include the heart, brain, kidneys, eyes, and vessels (macrocirculation and microcirculation in organs with low resistance, such as the brain or kidney<sup><a href="javascript:;" reveal-id="ehae178-B23" data-open="ehae178-B23" class="link link-ref link-reveal xref-bibr">23</a></sup>), which undergo structural and functional changes. Although factors besides BP can contribute to these changes (i.e. dyslipidaemia, hyperglycaemia), we use the term ‘hypertension-mediated organ damage’ to indicate the presence of subclinical complications of hypertension that indicate high risk for subsequent clinical events. HMOD may have different profiles in men and women; for instance, left ventricular hypertrophy (LVH) and left atrial dilatation are more frequent in women.<sup><a href="javascript:;" reveal-id="ehae178-B24 ehae178-B25 ehae178-B26 ehae178-B27 ehae178-B28" data-open="ehae178-B24 ehae178-B25 ehae178-B26 ehae178-B27 ehae178-B28" class="link link-ref link-reveal xref-bibr">24–28</a></sup>

![Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f2.jpeg?Expires=1728462844&Signature=ByruCCljoRJXcx2XtJZ7DYMcICChPUQu2s4qn7w1oGY7ImyW5ekGlzeFAA4l55~dUo8-ktD7CY3X8eM-mlNyiJ~WMZ78TKrVjp-lmRMKh4JquWhmrvmQEla5153C9hfdgftBj-lyvg9UIL3L3b4ROamCv4Wigxogepza0UTYfxXWsv5ngutYgGbCDznP3n5DZ2qNAC5iBY~-AD0LuWyfErybP3UxQjjCNH-tDuCj9aFsv8j6aupFh-1X1s82lXST8Q5vjcE8Nz3NiBo7Rqr5kDKyRCCBIIfztbMfBqyT4Frrx3cKAokVs6lRP6f3c-YWLvh8xLAILLzKsitLkEJOlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 2

Persistently elevated blood pressure and hypertension lead to hypertension-mediated organ damage and cardiovascular disease.

AF, atrial fibrillation; CAD, coronary artery disease; GFR, glomerular filtration rate; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy. See the [supplementary data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) online for detailed information on sex differences.

[Open in new tab](https://academic.oup.com/view-large/figure/479375743/ehae178f2.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f2.jpeg?Expires=1728462844&Signature=sP04~8WY-ilxhvFvNyfx6mCbe1uUpaXwQ7g3-0~qpT6G~8NL0dZY9SrGWIz4v-a4HL-v2qpIlJCzl47NJq4ttVvXx~LqC7ASMAxqQcStCvzVt1OlVXvNvc-HWb2AWkN~VPqq4TpL1RNwNizI83Xv9KPGQxIOkcTlSJYhqJJGKeNZpOSMc08pRNsX9XxRIRzmtitSEVpm3it3ws3soQW3~k8yJLBHoLmBiOUIRTgmxLy5KT8pDPTVEqUl5ZSWigk0~Lpj-dEpvEPo8LonqcAoh9hn-htkLW9WVSdrFqa27UmvFu5iuGCaH88ZiPFiTvymIuGyFQB2ue-aLwmkF7n25w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375743&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Evidence of HMOD usually indicates long-standing elevated BP and/or hypertension and confers incremental prognostic information regarding CVD risk in all BP categories.<sup><a href="javascript:;" reveal-id="ehae178-B29 ehae178-B30 ehae178-B31" data-open="ehae178-B29 ehae178-B30 ehae178-B31" class="link link-ref link-reveal xref-bibr">29–31</a></sup> Unless treated, HMOD can progress from asymptomatic to symptomatic, ultimately resulting in overt CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a></sup>

The pathophysiological mechanisms underlying HMOD in the heart, brain, kidneys, vessels, and eyes are detailed in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). The clinical consequences of HMOD, especially cerebrovascular disease (stroke and cognitive decline), kidney disease (acute and chronic), and heart disease \[heart failure, atrial fibrillation (AF), ischaemic heart disease, and valvular disease\] are also discussed in the [Supplementary text](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). In addition, the Supplement highlights the impact of different measures of BP on CVD risk, including systolic BP, diastolic BP, pulse pressure, and BP variability.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32 ehae178-B33 ehae178-B34 ehae178-B35 ehae178-B36" data-open="ehae178-B32 ehae178-B33 ehae178-B34 ehae178-B35 ehae178-B36" class="link link-ref link-reveal xref-bibr">32–36</a></sup>

## 5\. Measuring blood pressure

### 5.1. Introduction and pertinent definitions

This section reviews practical aspects of BP measurement, including technique and clinical validation of devices. It also reviews the evidence for the most appropriate BP measurement methods when screening populations for hypertension, diagnosing hypertension, and managing patients receiving BP-lowering interventions. The current guidelines promote use of out-of-office measurement for diagnosis and ongoing management of hypertension, reflecting increasing evidence for the stronger relationship of home and ambulatory monitoring with outcomes, the ability to detect white-coat and masked hypertension, new BP treatment targets as low as 120–129 mmHg systolic (_[Table 5](javascript:;)_), and evidence supporting enabling patient involvement and shared decision-making.

Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375749)

Comparison of office, home, and ambulatory blood pressure measurement thresholds for elevated blood pressure and hypertension

|  | Office BP (mmHg)<sup><a href="javascript:;" reveal-id="tblfn116" data-open="tblfn116" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> | Home BP (mmHg) | Daytime ABPM (mmHg) | 24 h ABPM (mmHg) | Night-time ABPM (mmHg) |
| --- | --- | --- | --- | --- | --- |
| **Reference** |  |  |  |  |  |
| Non-elevated BP | <120/70 | <120/70 | <120/70 | <115/65 | <110/60 |
| Elevated BP | 120/70–<140/90 | 120/70–<135/85 | 120/70–<135/85 | 115/65–<130/80 | 110/60–<120/70 |
| Hypertension | ≥140/90 | ≥135/85 | ≥135/85 | ≥130/80 | ≥120/70 |

ABPM, ambulatory blood pressure monitoring; BP, blood pressure.

<sup>a</sup>The BP thresholds provided assume that a standardized approach to office BP measurement is performed (_[Figure 3](javascript:;)_). However, evidence indicates that office BP measurement in routine clinical settings is often not done using a standardized approach and, in this case, the routine office BP value may be 5–10 mmHg higher than it would have been if measured using the recommended standardized approach.<sup><a href="javascript:;" reveal-id="ehae178-B65" data-open="ehae178-B65" class="link link-ref link-reveal xref-bibr">65</a>,<a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a></sup>

© ESC 2024

**Definitions:**

**Systolic BP:** arterial BP during systole (maximum arterial pulsatile pressure). This is measured using an auscultatory device at the onset of the first Korotkoff sound. Oscillometric devices estimate systole using an algorithm that imputes from mean arterial pressure.<sup><a href="javascript:;" reveal-id="ehae178-B37" data-open="ehae178-B37" class="link link-ref link-reveal xref-bibr">37</a></sup>

**Diastolic BP:** arterial BP during diastole (minimum arterial pulsatile pressure). This is measured using an auscultatory device at the time of complete disappearance of the Korotkoff sounds (fifth sound). If there is no disappearance of sounds (no fifth sound) then the fourth Korotkoff sound (muffling) is used to estimate diastolic BP. Oscillometric devices estimate diastole using an algorithm that imputes from mean arterial pressure.<sup><a href="javascript:;" reveal-id="ehae178-B37" data-open="ehae178-B37" class="link link-ref link-reveal xref-bibr">37</a></sup>

**Inter-arm difference:** systolic BP difference of >10 mmHg when BP is measured sequentially in each arm.<sup><a href="javascript:;" reveal-id="ehae178-B38" data-open="ehae178-B38" class="link link-ref link-reveal xref-bibr">38</a></sup>

**Postural/orthostatic hypotension:** decrement of ≥20 mmHg in systolic BP and/or ≥10 mmHg in diastolic BP when BP is measured in the standing position at 1 and/or 3 min after standing following a 5-min period in the sitting or lying position.

**White-coat hypertension:** BP that is above the threshold for diagnosing hypertension in the office but below the threshold in home/ambulatory settings, e.g. ≥140/90 mmHg in office but <135/85 mmHg at home/ambulatory daytime (or 24-h BP < 130/80 mmHg).

**Masked hypertension:** BP that is below the hypertension diagnostic threshold in the office but above the hypertension diagnostic threshold in home/ambulatory settings, e.g. <140/90 mmHg in clinic but ≥135/85 mmHg at home/ambulatory daytime (or 24-h BP ≥130/80 mmHg).

**Office BP:** also known as clinic BP. The two terms are interchangeable. This guidelines document uses ‘office BP’ preferentially. Of note, office BP can be measured manually or using an automated device. In addition, automated office BP (AOBP) can be conducted in a setting attended by a healthcare professional or in an unattended fashion. Finally, not all office BP measurements are equal, with some facilities using a standardized method (which is recommended and outlined below) and others unfortunately using suboptimal approaches to office BP measurement.

**Home BP measurement (HBPM):** an out-of-office approach to measuring BP when the patient measures their own BP at home using a validated monitor (usually an upper-arm oscillometric cuff device).

**Ambulatory BP measurement (ABPM):** an out-of-office BP measurement that uses a fully automated oscillometric device, usually for a 24-h period, and measures BP at set intervals.

### 5.2. Practical recommendations for measuring blood pressure

#### 5.2.1. Clinical validation of equipment for measuring blood pressure

A prerequisite of BP measurement is that it must be undertaken using a device that has been clinically validated and confirmed to be accurate. Of the commercially available oscillometric BP measurement devices, as few as 6% have been adequately tested.<sup><a href="javascript:;" reveal-id="ehae178-B39 ehae178-B40 ehae178-B41" data-open="ehae178-B39 ehae178-B40 ehae178-B41" class="link link-ref link-reveal xref-bibr">39–41</a></sup> National and international organizations provide lists of validated monitors (e.g. [www.stridebp.org](https://www.stridebp.org), [www.validatebp.org](https://www.validatebp.org)).

Since the 2018 ESC/ESH Guidelines on the management of arterial hypertension, three arbiters of device accuracy (the Association for the Advancement of Medical Instrumentation, the ESH, and the International Organization for Standardization) have published a universal standard for validating devices for measuring BP.<sup><a href="javascript:;" reveal-id="ehae178-B42" data-open="ehae178-B42" class="link link-ref link-reveal xref-bibr">42</a></sup> This standard will likely become widely adopted. Validation standards and methodology need to be developed and implemented for novel BP measurement devices that are non-occlusive and ‘cuffless’.<sup><a href="javascript:;" reveal-id="ehae178-B43" data-open="ehae178-B43" class="link link-ref link-reveal xref-bibr">43</a>,<a href="javascript:;" reveal-id="ehae178-B44" data-open="ehae178-B44" class="link link-ref link-reveal xref-bibr">44</a></sup>

#### 5.2.2. Office blood pressure measurement

All BP measurements can be influenced by circumstances of measurement, including position, ambient temperature, the technique of measurement, accuracy of equipment, and physical condition of the patient.<sup><a href="javascript:;" reveal-id="ehae178-B45" data-open="ehae178-B45" class="link link-ref link-reveal xref-bibr">45</a></sup> For BP measurements in the office, we recommend following a standardized method (_[Figure 3](javascript:;)_).

![Summary of office blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f3.jpeg?Expires=1728462844&Signature=K8WtezBkKT~XJSWx4DYuELTbqNvvDlccvLsV9daea8gH9SlhAVolPn~l3mTcUNykE2pJ3Qxtz-Z0NorzdP47tOI0HAlHiHiFhxLn7MK62xi2cH3Zerj0cVQ-6gwEpZddLI~HwOKpD3Ian86Vq84mllk5It-r1Ij5Xz7VDqrY9CNrb-yOxFljVjyMLqYqRoVsk9yjUYkubb7Xfs0XQk-NPKMeztNn9cwf2xzhIBCggRPIheDYLCXjOSENOLjY5by4oheFTTL8dB2nR9tTzgS9qTEwrX9ttOzwk0ZCocMmDGPQrSUYLehQwS-CCEiZYCMDqyIrwWECnvHCMytvxVNuEQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 3

Summary of office blood pressure measurement.

BP, blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375766/ehae178f3.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f3.jpeg?Expires=1728462844&Signature=Na6W3bNYknLppBYBXjy3QeP6H3BBZYixsYfggXvSTwV~NejpjoHLZhrT0JwCfg5gwpM6qWrjGEfdA8dfxOTLldOn92RU1IFi0dI114eEQR0wk5QV73ioq9HUbWvE5Rs-o7X4G~Q513gkEothHdlVkhpJ3an3UKpNjaArSiT7tsr8pFuwHx2km3-~2ejrrDz6qYmixAtdUwTHNxxHwLINMxaYjiaFoyE-Vm0fh8OVDi-yDbvgjbaxyFlUMozcvK24GHelzvh4VZeGW9j9mdvRCEfT8TjASAHRxxl40Yo5QMlo654GKiFeJXgdkYgej6b7cgriqMMD3j8SEvf6TT4nhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375766&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

**Patient preparation:** BP should be measured with the patient seated comfortably after 5 min of rest. Patients should avoid exercising and stimulants (caffeine, tobacco) for at least 30 min before measurement. The patient’s bladder should be emptied if needed.<sup><a href="javascript:;" reveal-id="ehae178-B46" data-open="ehae178-B46" class="link link-ref link-reveal xref-bibr">46</a></sup> Patients should be seated with their legs unfolded and their back supported at the time of measurement. The arm should be supported (to avoid isometric exercise-induced increases in BP). Clothing at the location of the cuff placement should be removed; rolling up of shirt sleeves should be avoided as this can result in a tourniquet effect.

**BP measurement technique:** auscultatory or oscillometric techniques can be used to measure BP non-invasively. The manual auscultatory approach is the traditional method of measuring systolic and diastolic BP at the brachial artery site using a stethoscope. In contrast, oscillometric devices compute mean arterial BP using the oscillation amplitude with cuff deflation (or inflation) and then estimate systolic and diastolic BP. Oscillometric devices can be semi-automated (taking one reading per activation) or fully automated (obtaining multiple readings before averaging them). Oscillometric devices are not typically validated for use in AF, and the manual auscultatory method is preferred in these circumstances when feasible.<sup><a href="javascript:;" reveal-id="ehae178-B47 ehae178-B48 ehae178-B49" data-open="ehae178-B47 ehae178-B48 ehae178-B49" class="link link-ref link-reveal xref-bibr">47–49</a></sup>

**BP cuff selection and positioning:** an appropriately sized cuff should be used, as an under-sized or over-sized cuff will artificially elevate or reduce BP, respectively.<sup><a href="javascript:;" reveal-id="ehae178-B50" data-open="ehae178-B50" class="link link-ref link-reveal xref-bibr">50</a></sup> The bladder length should be 75%–100% and the width 35%–50% of the arm circumference. The arm circumference can be measured at the mid-point of the olecranon and the acromion but many cuffs include sizing indicators. The cuff should be positioned on the patient’s upper arm at the level of the heart with the lower edge of the cuff a few centimetres above the antecubital fossa. The stethoscope should not be placed under the cuff. In those with significant obesity where a correctly fitting upper arm cuff is not available, measurement at the lower arm or wrist can be considered as an alternative.<sup><a href="javascript:;" reveal-id="ehae178-B51" data-open="ehae178-B51" class="link link-ref link-reveal xref-bibr">51</a></sup>

**BP measurement by manual auscultation:** three BP measurements should be taken, each 1–2 min apart, and additional measurements only if the readings differ by >10 mmHg (e.g. this may occur with arrhythmias or white-coat effects). The BP recorded should be the average of the last two BP readings.

**BP measurement using AOBP measurement:** as noted above, AOBP using oscillometric devices may be obtained with (attended) or without (unattended) clinicians or staff present. Clear evidence regarding superiority of unattended vs. attended AOBP in managing BP to reduce rates of CVD is lacking; however, because BP readings may differ for unattended vs. attended measurements,<sup><a href="javascript:;" reveal-id="ehae178-B52" data-open="ehae178-B52" class="link link-ref link-reveal xref-bibr">52</a></sup> we advise that a consistent approach be used depending on local resource and preference. AOBP monitors typically make three or six readings at 1-min intervals and provide an average. AOBP correlates more closely with mean ABPM than with the manual auscultatory technique and may reduce measurement error and white-coat effects.<sup><a href="javascript:;" reveal-id="ehae178-B53" data-open="ehae178-B53" class="link link-ref link-reveal xref-bibr">53</a></sup>

**Inter-arm BP difference:** at the initial visit, BP should be measured in both arms to detect an inter-arm difference. Though devices allowing simultaneous measurement in both arms exist, sequential arm measurement is considered sufficiently reliable.<sup><a href="javascript:;" reveal-id="ehae178-B54" data-open="ehae178-B54" class="link link-ref link-reveal xref-bibr">54</a>,<a href="javascript:;" reveal-id="ehae178-B55" data-open="ehae178-B55" class="link link-ref link-reveal xref-bibr">55</a></sup> Measurement in the contralateral arm should be undertaken once the three measurements in the index arm have been taken, and if a difference is detected, further measurement in the original arm is indicated to ensure the difference is consistent. If systolic BP differs by >10 mmHg between arms, subsequent measurements are obtained using the arm with the higher BP value. Significant inter-arm BP differences may reflect arterial stenosis or coarctation of the aorta, which may require investigation. Also, of note, in some patients one arm is preferred to the other for routine BP measurement (e.g. to avoid measurement of BP in an arm with an arteriovenous fistula or an arm where axillary lymph node dissection has occurred).

**Postural/orthostatic hypotension:** patients should be assessed for orthostatic hypotension at the initial visit and if concerning symptoms arise. After 5 min of rest in the sitting or lying position, BP should be measured at 1 min and/or 3 min after standing, with a threshold for orthostatic hypotension of ≥20/10 mmHg (systolic BP/diastolic BP) drop. Measurement after lying may be more sensitive for detecting orthostatic hypotension and may better predict falls but may be less feasible than measurement after sitting in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B56" data-open="ehae178-B56" class="link link-ref link-reveal xref-bibr">56</a></sup>

**Pulse assessment:** heart rate should be recorded at the initial visit and arrhythmia excluded.

#### 5.2.3. Home blood pressure measurement

HBPM is an out-of-office approach to measuring BP when the patient measures their own BP at home using a validated monitor (usually an upper-arm oscillometric cuff device).<sup><a href="javascript:;" reveal-id="ehae178-B57" data-open="ehae178-B57" class="link link-ref link-reveal xref-bibr">57</a>,<a href="javascript:;" reveal-id="ehae178-B58" data-open="ehae178-B58" class="link link-ref link-reveal xref-bibr">58</a></sup> A consistent approach to HBPM should be used (_[Figure 4](javascript:;)_). Patients should be counselled to follow the same preparation steps as used in clinics, which are outlined in _Section [5.2.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.2.2)_. Two measurements should be taken at each measurement session, performed 1–2 min apart. Measurements should be made twice a day (morning and evening) at the same time for a minimum of 3 days and up to 7 days.<sup><a href="javascript:;" reveal-id="ehae178-B59" data-open="ehae178-B59" class="link link-ref link-reveal xref-bibr">59</a></sup> At the end of the measurement period, all readings are averaged. If the average after 3 days is close to the treatment threshold, then measurement should continue for the full 7 days. Patients should be informed to keep a record of their home BP values and to ask their healthcare provider that the device accuracy be intermittently checked. Devices older than 4 years may be inaccurate and, if inaccurate, should be replaced.<sup><a href="javascript:;" reveal-id="ehae178-B60" data-open="ehae178-B60" class="link link-ref link-reveal xref-bibr">60</a></sup>

![Summary of home blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f4.jpeg?Expires=1728462844&Signature=FwYXdFteHT2YFdhjU3J1wjCb5tpFtHWQlw3KUJ6T0J~1zTUc1Ka9Y2S~h0TRcAClrPp0Y0HsyAy~zQVdMN2k7YC3zI72DLdf3BYygs7Wxv1iiDJl0jDA670hnQyfAURzSNNqvFeAV1tsY6VuGS~xAjVVShYT5oEbk4dTwQB8~XBefkZBeqJRxY7ntN2nTjbiJ11Jht19mxZvjOF86vBnUlM2sJMNdHvHjpEbk0YT6euEKtCKiL1Q8rcQ7DhE5YNH8kNHFk5AMYWPhWBK37HjPYGAflC-5UDjbW8tCW3ljE80vP6mRuqmIe~3zYfc24Ec2ELW~mtkfj7gTjdoWfn8vg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 4

Summary of home blood pressure measurement.

BP, blood pressure; HBPM, home blood pressure measurement. <sup>a</sup>Morning HBPM readings should be obtained before breakfast and before intake of medication but not immediately after awakening.

[Open in new tab](https://academic.oup.com/view-large/figure/479375777/ehae178f4.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f4.jpeg?Expires=1728462844&Signature=EDoLVnByLZXdZ-bMUYJ1QJr8KnDx4KCEWw4w9JSGEmseTuq8Kr83ceLBE34Hn7b2MoIFzTF-j-C~xvpEf-5-1RgGhCwfHesbFvA4zANaM6nTwb0sCj7e2pDbZ4v4c1KbV~f36tiAqbeRYQxFxRoStpB8xGL2NP9ryqIJSZPmyICDvxi0xmJCrDbk74ZSnpXyqisqU8YCXYwMDW9a7YXNbhhJN1I6R3qzeBRTt0o3EiZbOEfnVeNhcVQngOr~fe02qHxhQFrG1gdAR2p6-7XRK6G5UtzUPFirlH1RJS8tIVUt1Rp2HZcdUfPwKaaNVpBPmntWLoTZ7OF-Ih4mRlkltg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375777&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

An average HBPM of ≥135/85 mmHg (equivalent to an office BP of ≥140/90 mmHg) should be used to diagnose hypertension and an average systolic BP of 120–134 mmHg or diastolic BP of 70–84 mmHg should be used to diagnose elevated BP. Of note, we use the same lower BP threshold (120/70 mmHg) for both office and HBPM in defining elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B61" data-open="ehae178-B61" class="link link-ref link-reveal xref-bibr">61</a></sup>

#### 5.2.4. Ambulatory blood pressure measurement

ABPM (summarized in _[Figure 5](javascript:;)_) is an out-of-office BP measurement that uses a fully automated device, usually for a 24-h period. The devices measure BP by the oscillometric method and are programmed to measure BP at set intervals. Readings are usually obtained at 15–30 min intervals during the day (typically 7 a.m. to 11 p.m.) and 30–60 min intervals at night (typically 11 p.m. to 7 a.m.). The software usually provides average BP measurements for daytime, night-time, and 24 h. A minimum of 70% useable BP recordings is required for a valid measurement session, typically numbering ≥27 measurements over 24 h. Preferably, seven nocturnal readings should also be obtained.<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> However, emerging data indicate that ≥8/≥4 wake/sleep readings may be adequate if more cannot be obtained.<sup><a href="javascript:;" reveal-id="ehae178-B63" data-open="ehae178-B63" class="link link-ref link-reveal xref-bibr">63</a></sup> Prior to using mean ABPM values (either 24 h, daytime, or night-time) the raw BP values at each measurement should be reviewed for possible outlier or erroneous values. A diary should record activities (e.g. meals and exercise) and sleep time to assist interpretation. The diagnostic thresholds for elevated BP and hypertension using ABPM, and comparison with office BP and HBPM, are provided in _[Table 5](javascript:;)_.<sup><a href="javascript:;" reveal-id="ehae178-B61" data-open="ehae178-B61" class="link link-ref link-reveal xref-bibr">61</a>,<a href="javascript:;" reveal-id="ehae178-B64" data-open="ehae178-B64" class="link link-ref link-reveal xref-bibr">64</a></sup>

![Summary of ambulatory blood pressure measurement.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f5.jpeg?Expires=1728462844&Signature=qlzR4QkvGYA4ZTRGMjaefBzrbTxZBy8boJ1pB3VW3BjdXs3c0VXYK9moU31A5IArNjucH~4-nZkAfSxrRjg-jfdl-d3Cu6iQDcFfcwVxCeQ-SFSI51uh4hCz8Klz7iPUyM1e8E9JZekEbNre3lNOAKcZOIeM3sdLLcCdtFgkF-QzwBNfH8pVwR4cDSqqq6H9fjwF98pMyzrX0UdheCz-A9Q1CuOGzC9m0pCiIJ5z~vmSRqAmIySGW5b~433SquEAdUoahNJrLgq1GXSKphvWdXdXLW3xVgunMlil~Fs05fDNpuE7j5v2IQNLZg9ORrOM8-CICWF7w1Dj7CjY5I6rZg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 5

Summary of ambulatory blood pressure measurement.

ABPM, ambulatory blood pressure measurement; BP, blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375781/ehae178f5.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f5.jpeg?Expires=1728462844&Signature=eUpTk4VA65c1yskj0uTcTEe942q3wGDTAR5qtp8RhuypMpqKBCd0drDXKCZ5Oqjfv0oHR~0TS8gV6mRyOPY3zmdbvk2FTDNKCLlojGDx4TG7ke6gTXSlhRrbzjCDuo-yjpL6sqNHjunnPFaK-QPaC3gmV~A5Itc67E1E6jZuY0cO4f6LsGUHmpttlT3K1WX1dGHYWnIO7j1n6yqUSxR2TkBmc3vDMP3cpq05q0MEX~heApEbhs8DVVgQIq9FtKFyLMy6AytIF9LZsmNAxW6zu20JdJ5~S9rqJTNSj2xiJq~O22vyvHGN4BoQbrKMn3gcRyH~gTi1PL3n3ZjrfVDVAg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375781&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 5.2.5. Comparison of home and ambulatory blood pressure monitoring

There is overlap between home and ambulatory monitoring in terms of differentiating between hypertensive phenotypes. However, around 15% of people will have diagnostic disagreement, of whom approximately 50% will represent clinically significant differences of >5 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B67" data-open="ehae178-B67" class="link link-ref link-reveal xref-bibr">67</a></sup> The advantages and disadvantages of home and ambulatory monitoring are outlined in _[Table 6](javascript:;)_.

Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375784)

Comparison of ambulatory and home blood pressure monitoring

<table role="presentation" aria-labelledby="
                        label-63593" aria-describedby="
                        caption-63593"><tbody><tr><td><strong>Ambulatory monitoring</strong><br><em>Advantages</em><ul class="bullet"><li><p class="chapter-para">Can identify white-coat and masked hypertension</p></li><li><p class="chapter-para">Measurement in real-life settings and during usual activities</p></li><li><p class="chapter-para">Stronger prognostic evidence</p></li><li><p class="chapter-para">Night-time readings</p></li><li><p class="chapter-para">Abundant information from a single investigation, including short-term diurnal BP variability</p></li><li><p class="chapter-para">Additional BP phenotyping (e.g. nocturnal dipping status)</p></li></ul><em>Disadvantages</em><ul class="bullet"><li><p class="chapter-para">Relatively expensive and sometimes limited availability</p></li><li><p class="chapter-para">Can be uncomfortable and affect sleep</p></li></ul></td></tr><tr><td><strong>Home monitoring</strong><br><em>Advantages</em><ul class="bullet"><li><p class="chapter-para">Identify white-coat and masked hypertension</p></li><li><p class="chapter-para">Cheap and widely available</p></li><li><p class="chapter-para">Measurement at home, which may be more relaxed than at doctor’s office</p></li><li><p class="chapter-para">Patient engagement in BP measurement and telemedicine potential</p></li><li><p class="chapter-para">Easily repeated and used over longer periods to assess day-to-day BP variability</p></li></ul><em>Disadvantages</em><ul class="bullet"><li><p class="chapter-para">Only static BP at rest is typically available</p></li><li><p class="chapter-para">Potential for measurement error due to improper measurement technique or unvalidated or poorly calibrated device</p></li><li><p class="chapter-para">Nocturnal readings not usually possible</p></li></ul></td></tr></tbody></table>

BP, blood pressure.

© ESC 2024

### 5.3. What is the best method for measuring blood pressure to diagnose hypertension?

#### 5.3.1. Blood pressure measurement for hypertension screening

Opportunistic screening is typically performed using office BP measurement and is key in detecting possible hypertension. However, a single screening office BP alone does not typically have sufficient diagnostic test performance to establish a diagnosis, especially for BP values close to diagnostic thresholds. Therefore, a single screening office BP requires some form of repeat BP assessment to confirm a diagnosis (preferably out-of-office or repeat office if out-of-office is not available). Relatedly, the BP threshold for acting on a screening office BP by conducting repeat BP assessments should also be lower than the office BP threshold used for diagnosing hypertension. This latter consideration is particularly relevant in the presence of increased CVD risk or markers of HMOD. Also of note, populations where masked hypertension is more prevalent include men, those who smoke, those with excessive alcohol intake, or those with diabetes or obesity.<sup><a href="javascript:;" reveal-id="ehae178-B68" data-open="ehae178-B68" class="link link-ref link-reveal xref-bibr">68</a>,<a href="javascript:;" reveal-id="ehae178-B69" data-open="ehae178-B69" class="link link-ref link-reveal xref-bibr">69</a></sup> While a screening office BP of >160/100 mmHg is almost always consistent with a diagnosis of hypertension, a small proportion of patients will have extreme white-coat effects that motivate prompt repeat BP assessment.<sup><a href="javascript:;" reveal-id="ehae178-B68" data-open="ehae178-B68" class="link link-ref link-reveal xref-bibr">68</a></sup> Hypertension screening approaches are discussed further in _Section [7.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.1)_.

#### 5.3.2. Blood pressure measurement for diagnosing hypertension

After detecting high BP in the office, subsequent BP measurement for diagnosing hypertension depends on the clinical circumstances. Office BP has lower specificity than ABPM for detecting hypertension, so diagnosis based on office BP alone is less desirable unless resources do not allow out-of-office measurements.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> For screening BP of 160–179 mmHg systolic or 100–109 mmHg diastolic, prompt confirmation (within 1 month) using either office or out-of-office methods is recommended, as delays in treatment are associated with increased CVD event rates.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> For BP of ≥180/110 mmHg, assessment for hypertensive emergency is recommended. In the setting of hypertensive emergency, immediately commencing BP-lowering treatment is recommended, otherwise, prompt confirmation (preferably within a week) can be considered prior to commencing treatment (_Sections [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6) and [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_).

For screening BP of 140–159/90–99 mmHg, out-of-office BP should be measured to confirm the diagnosis.<sup><a href="javascript:;" reveal-id="ehae178-B72" data-open="ehae178-B72" class="link link-ref link-reveal xref-bibr">72</a></sup> When treatment of elevated BP is being considered (e.g. 120–139/70–89 mmHg) for individuals with high risk CVD conditions or sufficiently high 10-year predicted CVD risk, out-of-office BP measurement is recommended, both to confirm BP and to assess for masked hypertension. Out-of-office measurements may also be helpful for individuals with office BP of 130–139/85–89 mmHg to diagnose masked hypertension. Further details on the diagnostic evaluation of hypertension are provided in _Section [7.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.2)_.

### 5.4. What is the best method for measuring blood pressure for long-term management of hypertension?

While repeat office measurement of BP remains the commonest approach to long-term management of hypertension, several lines of investigation support augmenting office BP measurements with out-of-office assessment.

#### 5.4.1. Home monitoring

There are over 50 trials of different self-monitoring-based interventions.<sup><a href="javascript:;" reveal-id="ehae178-B73" data-open="ehae178-B73" class="link link-ref link-reveal xref-bibr">73</a></sup> Self-monitoring is associated with lower mean systolic BP at 12 months \[−3.2 mmHg; 95% confidence interval (CI) −4.9 to −1.6 mmHg\].<sup><a href="javascript:;" reveal-id="ehae178-B74" data-open="ehae178-B74" class="link link-ref link-reveal xref-bibr">74</a></sup> Furthermore, there are known benefits of telemonitoring, digital interventions, and mobile health in managing BP.<sup><a href="javascript:;" reveal-id="ehae178-B75 ehae178-B76 ehae178-B77 ehae178-B78" data-open="ehae178-B75 ehae178-B76 ehae178-B77 ehae178-B78" class="link link-ref link-reveal xref-bibr">75–78</a></sup> Self-monitoring is also likely to be cost-effective.<sup><a href="javascript:;" reveal-id="ehae178-B79" data-open="ehae178-B79" class="link link-ref link-reveal xref-bibr">79</a></sup> Unfortunately, in clinical practice, some patients may not provide reliable information on their home BP, and both their device and measurement technique need to be checked.

#### 5.4.2. Ambulatory monitoring

ABPM provides a reference BP measurement but repeat ABPM testing is sometimes not practical due to resource constraints and, uncommonly, low patient acceptability.<sup><a href="javascript:;" reveal-id="ehae178-B80" data-open="ehae178-B80" class="link link-ref link-reveal xref-bibr">80</a></sup> There is a paucity of data on treatment guided by ABPM vs. that of office or HBPM measurements. A trial of treatment guided by HBPM vs. clinic and ambulatory monitoring found equivalence in BP control and HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B81" data-open="ehae178-B81" class="link link-ref link-reveal xref-bibr">81</a></sup> Other studies reported a non-significant trend to worse BP control with ambulatory vs. office BP monitoring, though the ambulatory group also received fewer medications.<sup><a href="javascript:;" reveal-id="ehae178-B82" data-open="ehae178-B82" class="link link-ref link-reveal xref-bibr">82</a></sup> Potential advantages of ABPM over HBPM include diagnosing nocturnal hypertension or symptomatic transient hypotension or hypertension with exertion. As such, ABPM and HBPM should be considered complementary and additive, rather than competing approaches to long-term BP management.<sup><a href="javascript:;" reveal-id="ehae178-B83" data-open="ehae178-B83" class="link link-ref link-reveal xref-bibr">83</a></sup>

### 5.5. Measuring blood pressure in selected groups

#### 5.5.1. Pregnancy

Monitoring BP during pregnancy is typically done at antenatal visits, which vary dependent on trimester (with increasing frequency towards term). BP tends to reach a nadir at 20–30 weeks of pregnancy before increasing towards term at 40 weeks.<sup><a href="javascript:;" reveal-id="ehae178-B84" data-open="ehae178-B84" class="link link-ref link-reveal xref-bibr">84</a></sup> Only a small number of automated oscillometric BP monitors have been adequately validated in pregnancy and several have failed, usually due to providing BP values that are erroneously high.<sup><a href="javascript:;" reveal-id="ehae178-B85" data-open="ehae178-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Auscultatory measurement with sphygmomanometry is consequently the clinical standard in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B85" data-open="ehae178-B85" class="link link-ref link-reveal xref-bibr">85</a></sup> Self-monitoring at home is not yet proven to be effective in gestational hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B86" data-open="ehae178-B86" class="link link-ref link-reveal xref-bibr">86</a>,<a href="javascript:;" reveal-id="ehae178-B87" data-open="ehae178-B87" class="link link-ref link-reveal xref-bibr">87</a></sup> While norms for BP during pregnancy remain unclear, the 2022 Chronic Hypertension and Pregnancy (CHAP) trial indicated benefit of targeting clinic BP below 140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B88" data-open="ehae178-B88" class="link link-ref link-reveal xref-bibr">88</a></sup> Consideration of secondary causes of hypertension is important in young women with gestational hypertension. Further details are provided in _Section [9.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.2)_ and the 2018 ESC Guideline for the management of cardiovascular disease during pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup>

#### 5.5.2. Atrial fibrillation

Hypertension is a risk factor for AF.<sup><a href="javascript:;" reveal-id="ehae178-B90" data-open="ehae178-B90" class="link link-ref link-reveal xref-bibr">90</a>,<a href="javascript:;" reveal-id="ehae178-B91" data-open="ehae178-B91" class="link link-ref link-reveal xref-bibr">91</a></sup> Oscillometric BP monitors are not always accurate in the presence of AF, due to the greater variability of BP beat to beat, so multiple auscultatory measurements are recommended.<sup><a href="javascript:;" reveal-id="ehae178-B48" data-open="ehae178-B48" class="link link-ref link-reveal xref-bibr">48</a>,<a href="javascript:;" reveal-id="ehae178-B92" data-open="ehae178-B92" class="link link-ref link-reveal xref-bibr">92</a>,<a href="javascript:;" reveal-id="ehae178-B93" data-open="ehae178-B93" class="link link-ref link-reveal xref-bibr">93</a></sup> Some oscillometric BP monitors include an algorithm for detecting AF, but an electrocardiogram (ECG) is still required to confirm the diagnosis.<sup><a href="javascript:;" reveal-id="ehae178-B49" data-open="ehae178-B49" class="link link-ref link-reveal xref-bibr">49</a>,<a href="javascript:;" reveal-id="ehae178-B94" data-open="ehae178-B94" class="link link-ref link-reveal xref-bibr">94</a></sup>

#### 5.5.3. Orthostatic hypotension

Postural or orthostatic hypotension is common,<sup><a href="javascript:;" reveal-id="ehae178-B95" data-open="ehae178-B95" class="link link-ref link-reveal xref-bibr">95</a>,<a href="javascript:;" reveal-id="ehae178-B96" data-open="ehae178-B96" class="link link-ref link-reveal xref-bibr">96</a></sup> present in approximately 10% of all hypertensive adults and up to 50% of older institutionalized adults.<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a>,<a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a></sup> Orthostatic hypotension is defined as a BP drop of ≥20/10 mmHg 1 and/or 3 min after standing following a 5-min period in the seated or lying position.<sup><a href="javascript:;" reveal-id="ehae178-B99 ehae178-B100 ehae178-B101" data-open="ehae178-B99 ehae178-B100 ehae178-B101" class="link link-ref link-reveal xref-bibr">99–101</a></sup> Diagnosis is made in the office. Routine ABPM is not currently suitable for formally assessing orthostatic hypotension,<sup><a href="javascript:;" reveal-id="ehae178-B102" data-open="ehae178-B102" class="link link-ref link-reveal xref-bibr">102</a></sup> though it may help in some cases, particularly when accompanied by a patient symptom diary.<sup><a href="javascript:;" reveal-id="ehae178-B103" data-open="ehae178-B103" class="link link-ref link-reveal xref-bibr">103</a></sup>

### 5.6. Novel methods of measuring blood pressure

New methods to measure BP are under development. Continuous office and out-of-office BP recordings and ABPM and HBPM have been developed that derive beat-to-beat, reading-to-reading, and day-to-day BP variability. However, there is no agreement on the optimum approach to measuring variability, and there is no trial evidence that reducing BP variability specifically can reduce CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B104" data-open="ehae178-B104" class="link link-ref link-reveal xref-bibr">104</a></sup> Other emerging technologies include wearable, wrist-based BP measurement devices, devices evaluating central BP, and cuffless devices implementing plethysmographic or other technologies.<sup><a href="javascript:;" reveal-id="ehae178-B105" data-open="ehae178-B105" class="link link-ref link-reveal xref-bibr">105</a>,<a href="javascript:;" reveal-id="ehae178-B106" data-open="ehae178-B106" class="link link-ref link-reveal xref-bibr">106</a></sup> However, there is at present insufficient scientific consensus on the accuracy standards and validation procedures that these cuffless devices must comply with prior to commercialization.<sup><a href="javascript:;" reveal-id="ehae178-B43" data-open="ehae178-B43" class="link link-ref link-reveal xref-bibr">43</a>,<a href="javascript:;" reveal-id="ehae178-B44" data-open="ehae178-B44" class="link link-ref link-reveal xref-bibr">44</a>,<a href="javascript:;" reveal-id="ehae178-B107 ehae178-B108 ehae178-B109" data-open="ehae178-B107 ehae178-B108 ehae178-B109" class="link link-ref link-reveal xref-bibr">107–109</a></sup>

In view of these issues, none of these cuffless measurement modalities are currently recommended for routine clinical use.

Recommendation Table 1

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375807)

Recommendations for measuring blood pressure (see Evidence Tables 1–8)

![Recommendations for measuring blood pressure (see Evidence Tables 1–8)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt1.jpeg?Expires=1728462844&Signature=2WVr0-HB2QLbbMn4zqssKyWfLyOzUw27lnFBbeSycUfB1bhb-BWsKgA6mKcXV5COE4ZRTZ3uLP9tFhLeuMKMfwjRrrKLZAQtOscc0A0Duus-4fRq1rSKm5R2p7j0pduoYfkQ~w-V4rBXG-b5wdCqcPXorhdSFUAqZwonERzLc~elmaYx-tM3gKO6kZhORKWkyNGfQg0gl6ww2ZsT3BMngGc3Ma-20LdL3MWyg2MPvcLYtBh1iNVOdbUlKb9Mh6ghunZHwsLWQHQ56RxIWEudwHwEmRKLnbKMvf37~avCAWtnfaoiaRPFPXue-TC3aK65gz57gV9XMqc8I0fSMnpSxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 6\. Definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment

### 6.1. Definition and classification of elevated blood pressure and hypertension

Epidemiological studies demonstrate a continuous and log-linear association between BP and adverse CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a></sup> Starting at levels as low as 90 mmHg systolic, the higher the BP the higher the relative risk of CVD including atherosclerosis.<sup><a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a></sup> These observational data are complemented by randomized clinical trials (RCTs),<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> which have provided experimental evidence regarding the BP range for which BP lowering with treatment is proven to reduce CVD events. Of note, some studies suggest a stronger relative risk for CVD for a given BP among females compared with males.<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a>,<a href="javascript:;" reveal-id="ehae178-B118" data-open="ehae178-B118" class="link link-ref link-reveal xref-bibr">118</a></sup>

A healthy lifestyle should be encouraged for all adults to prevent an increase in BP and development of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B119" data-open="ehae178-B119" class="link link-ref link-reveal xref-bibr">119</a>,<a href="javascript:;" reveal-id="ehae178-B120" data-open="ehae178-B120" class="link link-ref link-reveal xref-bibr">120</a></sup> To aid pharmacological treatment decisions, the 2024 ESC Guidelines recommend a simplified categorization of adults according to their BP (_[Figure 6](javascript:;)_). In compiling this categorization, priority was given to evidence from randomized trials over observational data. However, it is important to reiterate that the risk of CVD attributable to BP is continuous and that interpreting randomized trial data is an iterative process involving an element of subjectivity. As such, no categorization of BP can be considered immutable or flawless.

![Blood pressure categories.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f6.jpeg?Expires=1728462844&Signature=QEu3RcLVpoEpx811aKThAKsEdP5sTCXEguaLx9uhbjJDPgdC18swZXOXEI10KnWSb1tR7SaGDB9kKT1RHR7ptLu4ZoVQGqJJe8qnHkG9Oi8Yb1XwkBq0iPMLGQ6KmESI~WEMuTy6gC1Vute~A1ehEtnD7p8C92WOq~xwesBe7QFEN5mETOgS5t07T-YKSTyyNIsJ239jwOmr12Qysfb1IzUK6cQvDdhyIdiw-dQnQiQ872FgoM6mlbLwxr2aRyWcvERR-9wAmcqGAPrY~v~WAoS51I2ZkeKiE2NF076r8jDbZyzJrIDg6VMlbgBOdhlVXr5aJYlnRfpuYgOQxl6~-A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 6

Blood pressure categories.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. We note that the respective non-daytime ABPM thresholds for elevated BP and hypertension diagnosis are listed in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ (_[Table 5](javascript:;)_).

[Open in new tab](https://academic.oup.com/view-large/figure/479375812/ehae178f6.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f6.jpeg?Expires=1728462844&Signature=f54ROSdlfc0QbDjXISigER7GhnJk3tq645GaxXL1yYE6k1HiMxPru-LGrUDTenmp-IgYT4mMm1fdokzYoSdmfYjLBMIJ-gQlV-O5Yiy87crAAl4Bhj0WQlRg25dHLm3KGFOSLDb~hL-y2nAEelp7SAvscKyhU6ofnslQPHagmmmc6YtQFB3d3ReKrobbjZIAjn0~Wc33D1KA83yIJwrfGhuBIlMkI2jk23S5Zz0dMxrAxSAxkm-ZIcWLwCKflyZEoP~R7GcrqB36l9jt8g~GRTEoImc4UWoOGg19sn9PbyiKqQuum81Gk286dAqkIOhtT4LdePHgFzgK6UFC9O4~sQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375812&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

The 2024 Guidelines define hypertension as a confirmed office systolic BP of ≥140 mmHg or diastolic BP of ≥90 mmHg. For this diagnosis to be made, confirmation is recommended with out-of-office measurements (HBPM or ABPM) or at least one repeat office measurement at a subsequent visit, as detailed in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ and _Section [7.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.2)_. This definition is based on several factors. First, meta-analyses of randomized trials provide evidence among all adults and across various settings for the benefit of BP-lowering therapy among patients with BP above this threshold.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B121" data-open="ehae178-B121" class="link link-ref link-reveal xref-bibr">121</a>,<a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> Second, most adults with BP above this threshold are at increased CVD risk, typically with 10-year risk estimates of ≥10% for fatal and non-fatal CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B123 ehae178-B124 ehae178-B125" data-open="ehae178-B123 ehae178-B124 ehae178-B125" class="link link-ref link-reveal xref-bibr">123–125</a></sup> The higher the patient’s baseline absolute risk for CVD, the greater the net benefit from BP-lowering treatment and, at the population level, the lower the estimated number needed to treat (NNT).<sup><a href="javascript:;" reveal-id="ehae178-B126 ehae178-B127 ehae178-B128" data-open="ehae178-B126 ehae178-B127 ehae178-B128" class="link link-ref link-reveal xref-bibr">126–128</a></sup> Third, this more traditional BP threshold for hypertension is already widely used by policymakers to define a disease state, and maintaining this BP threshold to define hypertension (vs. lowering it) does not require most adults to be labelled with what is widely considered a disease.<sup><a href="javascript:;" reveal-id="ehae178-B129" data-open="ehae178-B129" class="link link-ref link-reveal xref-bibr">129</a></sup>

Here, we introduce a new BP category called ‘elevated BP’, which is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg. Within this BP range, the efficacy of BP-lowering therapy has been established in meta-analyses of RCTs,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> but average CVD risk in the elevated BP group is not sufficiently high to merit drug treatment in all patients.<sup><a href="javascript:;" reveal-id="ehae178-B123" data-open="ehae178-B123" class="link link-ref link-reveal xref-bibr">123</a>,<a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a>,<a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a></sup> Pharmacological treatment initiation is, however, suggested for a subgroup of patients within this BP range who are at increased global risk of CVD as identified by the risk stratification approach outlined in _Sections [6.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5.3)_, _[6.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5.4)_, and [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7).

Non-elevated BP is defined as a systolic BP of <120 mmHg and a diastolic BP of <70 mmHg. Fewer individuals within this BP range are at increased risk of CVD,<sup><a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a></sup> and evidence for CVD benefit with BP-lowering pharmacological treatment is lacking due to an absence of trials. We use the term ‘non-elevated BP’ to define this BP category in recognition that these are treatment categories and not prognostic categories. Because the relative risk for CVD starts to increase at BP below this threshold (even as low as 90 mmHg systolic BP), particularly among women,<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a>,<a href="javascript:;" reveal-id="ehae178-B118" data-open="ehae178-B118" class="link link-ref link-reveal xref-bibr">118</a></sup> we avoid terms like ‘normal BP’, ‘optimal BP’, or ‘normotension’ in defining this category.

Recommendation Table 2

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375816)

Recommendations for categorizing blood pressure (see Evidence Table 9)

![Recommendations for categorizing blood pressure (see Evidence Table 9)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt2.jpeg?Expires=1728462844&Signature=RxCiKLR3NzlU3OPF9hQr47IL9YyGkmkLC0o1DIMY8XOk9m0iiXXtQM0I6ZTOK4OTSoIqC0tJdM~hyACNIHP6PS2zar8PHptCepLyInxuLq1d6C~7-kW~o6juGwRLRBVGS4YxA7pr3pulO6o7R1wOoyrWWQvQoLbFqH2hOS5ttMJOxPbaV1E7jUtehOgUsd4JKWb-FMp-CW8zo1CChlMjKd3b3omKVJ47HfBKm4CPTvXqRv3lpffefILD2ilypxHk0oNyjJUtJZOAVSILun4nx1BLIVkMAAAkeqDmhll9kHKiMM~5VGeFEh0QJiaLLi5CIBDX5uCeaWJlpg-R5HbEXg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.2. Principles of a risk-based approach for managing blood pressure and preventing cardiovascular disease

In the context of BP-lowering interventions, randomized trials demonstrate a consistent relative risk reduction in adverse CVD outcomes per unit reduction in BP.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B139" data-open="ehae178-B139" class="link link-ref link-reveal xref-bibr">139</a></sup> However, many medical interventions incur costs and have side effects. Therefore, guidance is needed on selecting patients most likely to benefit from BP-lowering treatment. This is especially true among adults with elevated BP (office systolic BP of 120–139 mmHg and/or diastolic BP of 70–89 mmHg). Practical aspects for implementing a risk-based approach are further discussed in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)._

#### 6.2.1. Role of cardiovascular disease risk assessment

The risk of adverse CVD outcomes increases log-linearly with constant increments in systolic BP and diastolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B22" data-open="ehae178-B22" class="link link-ref link-reveal xref-bibr">22</a>,<a href="javascript:;" reveal-id="ehae178-B32" data-open="ehae178-B32" class="link link-ref link-reveal xref-bibr">32</a>,<a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B140" data-open="ehae178-B140" class="link link-ref link-reveal xref-bibr">140</a></sup> Concurrently, at higher BP, there is clustering of additional CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B141" data-open="ehae178-B141" class="link link-ref link-reveal xref-bibr">141</a>,<a href="javascript:;" reveal-id="ehae178-B142" data-open="ehae178-B142" class="link link-ref link-reveal xref-bibr">142</a></sup> Consequently, many patients with hypertension will have an estimated 10-year risk for CVD events of ≥10%,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B121" data-open="ehae178-B121" class="link link-ref link-reveal xref-bibr">121</a>,<a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a></sup> which, for the purposes of these guidelines, is considered sufficiently high risk to merit consideration of BP-lowering treatment in the setting of elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B143" data-open="ehae178-B143" class="link link-ref link-reveal xref-bibr">143</a></sup>

Using BP thresholds for hypertension alone for allocating treatment would lead to under-treatment of many high-risk patients.<sup><a href="javascript:;" reveal-id="ehae178-B144" data-open="ehae178-B144" class="link link-ref link-reveal xref-bibr">144</a>,<a href="javascript:;" reveal-id="ehae178-B145" data-open="ehae178-B145" class="link link-ref link-reveal xref-bibr">145</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a></sup> A substantial proportion of excess CVD events attributable to BP occur in patients with BP levels below the traditional threshold for hypertension diagnosis. As the efficacy of BP lowering on preventing CVD events extends down to a systolic BP of 120 mmHg and a diastolic BP of 70 mmHg,<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a></sup> patients with elevated BP and increased CVD risk can also derive benefit from BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B124" data-open="ehae178-B124" class="link link-ref link-reveal xref-bibr">124</a>,<a href="javascript:;" reveal-id="ehae178-B145" data-open="ehae178-B145" class="link link-ref link-reveal xref-bibr">145</a></sup>

The heterogeneity in CVD risk among adults with elevated BP is larger than in those with hypertension, as such patients tend to be younger, and their absolute CVD risk depends more on the prevalence of concomitant CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B123" data-open="ehae178-B123" class="link link-ref link-reveal xref-bibr">123</a>,<a href="javascript:;" reveal-id="ehae178-B147" data-open="ehae178-B147" class="link link-ref link-reveal xref-bibr">147</a></sup> Consequently, formally estimating the patient’s CVD risk, encapsulating demographics and other CVD risk factors, is recommended to guide BP-lowering treatment decisions among patients with elevated BP.<sup><a href="javascript:;" reveal-id="ehae178-B148 ehae178-B149 ehae178-B150 ehae178-B151" data-open="ehae178-B148 ehae178-B149 ehae178-B150 ehae178-B151" class="link link-ref link-reveal xref-bibr">148–151</a></sup>

### 6.3. Predicting cardiovascular disease risk

Certain conditions on their own are associated with sufficient CVD risk such that patients with elevated BP alongside these conditions can be considered for BP-lowering therapy (_[Figure 7](javascript:;)_). These include moderate or severe chronic kidney disease (CKD),<sup><a href="javascript:;" reveal-id="ehae178-B152" data-open="ehae178-B152" class="link link-ref link-reveal xref-bibr">152</a></sup> established clinical CVD (coronary heart disease, cerebrovascular disease, peripheral arterial disease, or heart failure)<sup><a href="javascript:;" reveal-id="ehae178-B153 ehae178-B154 ehae178-B155 ehae178-B156 ehae178-B157 ehae178-B158" data-open="ehae178-B153 ehae178-B154 ehae178-B155 ehae178-B156 ehae178-B157 ehae178-B158" class="link link-ref link-reveal xref-bibr">153–158</a></sup> concomitant HMOD (see _[Figure 7](javascript:;)_; _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_; [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_),<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a></sup> diabetes mellitus, and familial hypercholesterolaemia (probable or definite).<sup><a href="javascript:;" reveal-id="ehae178-B160 ehae178-B161 ehae178-B162 ehae178-B163" data-open="ehae178-B160 ehae178-B161 ehae178-B162 ehae178-B163" class="link link-ref link-reveal xref-bibr">160–163</a></sup> Regarding diabetes, some adults aged <60 years with type 2 diabetes and elevated BP have 10-year CVD risk of <10%. Accordingly, the diabetes-specific Systematic COronary Risk Evaluation 2 (SCORE2)-Diabetes risk-prediction model should be considered to confirm CVD risk is sufficiently high (≥10%) among individuals with type 2 diabetes mellitus who are aged <60 years.<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a></sup>

![Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f7.jpeg?Expires=1728462844&Signature=jUkmMK5Augjst5-F3t497CryQ5-etvqjHfpk43gNpn~S5IRtduTMOFjB85DjstCgnxrheI4Ce5iKPnBL-uQ17LEEbUF3Eoee2uRO5jxK5Q6HBWalc7iFJR33ZcHwfdmPv2z51dTrkd6JQpFfGA6NfUDvZilyjkvBn19Aug~b22JKteyBHAkYf~yrcIIwdD3GSdK20ICgKazE3nAUnz4pZhS~f2ZHXcy9M3gz2qxz9-cTwTygqvBgRShMGQsfwUuPpTh777DcxdTpm-ZpdhH2A~K~rs1SX~jmKPbkrI0zEz6NKieqVsdU6bzFgZLM5kLRLsxTwEUlvLUNoMFLBb84VQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 7

Sufficiently high cardiovascular risk conditions that warrant blood pressure-lowering treatment among adults with elevated blood pressure.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. <sup>a</sup>Coronary heart disease, cerebrovascular disease, peripheral arterial disease. <sup>b</sup>See _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_. <sup>c</sup>SCORE2-Diabetes should be considered to identify lower-risk individuals (<10% 10-year CVD risk), who may not require BP-lowering medication, particularly in individuals <60 years.

[Open in new tab](https://academic.oup.com/view-large/figure/479375825/ehae178f7.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f7.jpeg?Expires=1728462844&Signature=Elbick~hzxfvgSzluRMhnfOd4fsfNEPbG2CpRWSbVtWGf8CqJIgZJSo6ZAvyx5NzK3UO~tFoBW0AkApT66g3Q75hDVsNMDPLxv~-5-cFVZ-NFRJdn84ye7wIoxGMajE3WEnWQ9s8eQhbmXb8kqc8pFFZjcTepi9P8CM0rXJgo1y0mEaq~0O0bY5xfL5DR5kINh093km2KWyL-n8sz1AcbyjSED7ajD9J4~gBVFjhybcB8hB~nxHOJEkbwdRq8vDW-CQMibw8HexcUV4AKLvJiZ8vDiOrh3-narFvuxHjUWaJK1xaBhPblooISVgEEYXC2z980d1b4LXW0mQ9tzWo0Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375825&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In the absence of these sufficiently high-risk conditions, risk-prediction models (SCORE2 and SCORE-OP) have been developed in the general population to predict 10-year risk of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> In adults with elevated BP without the above sufficiently high-risk conditions, risk-prediction models are recommended to inform BP-lowering treatment decisions. Risk-prediction models are more accurate than clinical judgment or tallying of individual risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B167 ehae178-B168 ehae178-B169" data-open="ehae178-B167 ehae178-B168 ehae178-B169" class="link link-ref link-reveal xref-bibr">167–169</a></sup>

#### 6.3.1. 10-year cardiovascular disease risk-prediction models

Prediction models differ in their input variables, predicted endpoints (outputs), and populations in which they were derived and validated. We endorse the use of SCORE2 for individuals aged 40–69 years and SCORE2–Older Persons (SCORE2-OP) for individuals aged ≥70 years for predicting 10-year global risk of fatal and non-fatal CVD events (stroke or myocardial infarction).<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> The management of adults aged <40 years is discussed in _Section [9.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.1)_. The SCORE2 and SCORE2-OP models are preferred over other 10-year risk-prediction models, as they predict both fatal and non-fatal CVD events, have been validated and recalibrated to European populations, and because SCORE2-OP is adjusted for the competing risk of non-cardiovascular mortality. Calculating SCORE2 or SCORE2-OP is recommended for individuals with elevated BP who are not already at sufficiently high CVD risk due to established CVD, moderate or severe CKD, probable or definite familial hypercholesterolaemia, diabetes mellitus, or HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

For the purpose of BP-lowering treatment decisions, individuals with elevated BP and a predicted 10-year CVD risk of ≥10% by SCORE2 or SCORE2-OP are considered in these guidelines to be sufficiently high risk, with details on the choice of lifestyle or drugs to facilitate BP-lowering treatment in this setting provided in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)._<sup><a href="javascript:;" reveal-id="ehae178-B171" data-open="ehae178-B171" class="link link-ref link-reveal xref-bibr">171</a>,<a href="javascript:;" reveal-id="ehae178-B172" data-open="ehae178-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> A number of considerations influenced our choice to recommend a single risk threshold of ≥10%, vs. the alternative option of using age-specific risk thresholds, such as those provided in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> For example, contemporary data indicate the heightened importance of BP control in older adults due to their higher absolute CVD risk (resulting in a lower NNT) and concomitantly to reduce age-dependent adverse outcomes attributable to increased BP, such as dementia. Recent treat-to-target trials (testing systolic BP targets of approximately 120 mmHg) used a single CVD risk inclusion threshold and were also enriched with older adults.<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a></sup> In addition, the average CVD event rate in the control arm of a landmark meta-analysis showing the benefits of more intensive BP-lowering treatment was approximately equivalent to a 10% 10-year risk.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> Finally, the task force, which included patient members, felt that age-specific risk thresholds could result in BP treatment decisions being made solely based on age, which is difficult to support scientifically or otherwise. To try to avoid any confusion with the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, we use the terms ‘sufficiently high risk’ or ‘increased risk’ to describe a person with 10-year CVD risk of ≥10% (rather than the terms ‘high risk’ or ‘very high risk’).

Recommendation Table 3

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375830)

Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11)

![Recommendations for assessing cardiovascular disease risk among individuals with elevated blood pressure (office systolic blood pressure 120–139 mmHg or diastolic blood pressure 70–89 mmHg) (see Evidence Tables 10 and 11)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt3.jpeg?Expires=1728462844&Signature=XB6d2MwjxGCHyvxbNfRUjsPQg6gMTqMDkeS3PIjaBVJl9nCHzx7M-C8KlBDe6dbv8fcl1mfeDUWp9xQcBsHYq2nvZhG3EuogTnbPyv4MNNvroHHc8Zxr20pe9GNxwxZ43DMhhz8bIgzc2bCZT6WLVXtKjazoY307qrdctykV8vwhgu0m8sgZ99XGbPR-nKPeRJc7mZLCcAubLK~ElpBLVk-2Z5GWrTG3DIoVoSNaBX6qHcAidfW8JzjvftiP4OGHjLF5aOTa6bZ5bGgi43YGcYjXTldpG9fddgDsKwS8cooXCfmHbR4DWae~lA5cr5cDO2evEPBl9sanO2~miGdbFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.4. Refining cardiovascular disease risk estimation beyond risk models

The SCORE2 and SCORE2-OP risk-prediction models incorporate traditional risk factors such as age, sex, systolic BP, cholesterol values, and smoking status to predict 10-year risk of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B165" data-open="ehae178-B165" class="link link-ref link-reveal xref-bibr">165</a>,<a href="javascript:;" reveal-id="ehae178-B166" data-open="ehae178-B166" class="link link-ref link-reveal xref-bibr">166</a></sup> However, they do not include ‘non-traditional’ CVD risk factors (detailed below and hereafter termed 'risk modifiers’). Non-traditional CVD risk modifiers can improve the predictive performance (i.e. discrimination) of other CVD risk-prediction models, and may also apply to SCORE2 or SCORE2-OP.<sup><a href="javascript:;" reveal-id="ehae178-B173" data-open="ehae178-B173" class="link link-ref link-reveal xref-bibr">173</a></sup> For example, among individuals with elevated BP and borderline increased 10-year predicted CVD risk by SCORE2 or SCORE2-OP (estimates of 5% to <10%), these non-traditional CVD risk modifiers may help up-classify the patient's risk and thereby prompt BP-lowering treatment (_[Figure 8](javascript:;)_).

![Cardiovascular disease risk modifiers to consider for up-classification of risk.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f8.jpeg?Expires=1728462844&Signature=H~SkuF6eDh1bGFfOsI1rUzoUeERKdvbGOfsWbnp9bkYB0PRITApdX-5VgItbwcy5BkqdSI2OL-~oeQQDpsL5mWQ8vIwISq9Nal-HgcFL50tNtclqKeyPQNO4BPGb3jXlhvEXqDkB-foHYGPaVY5a8ixuphLgb3VSaeCT~Cu3O1bjwX900sjQ6Xfu3Jou~T31cFPDWERstGXNtUyRfNr1Ovynmct952bJUTUimAScBzcaOcnZYULVScWzZxwCtVvFGAH1sH4xC2wQZdH54nll25IqC-YaIhCu~LHT14CGmDBisbRgLYj6lLbVGc8zJqb7xLRtlNlKD31qptHpSK2t9g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 8

Cardiovascular disease risk modifiers to consider for up-classification of risk.

ASCVD, atherosclerotic cardiovascular disease; HIV, human immunodeficiency virus.

[Open in new tab](https://academic.oup.com/view-large/figure/479375833/ehae178f8.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f8.jpeg?Expires=1728462844&Signature=C5B3yVsyglRFDYrtgE9AVbdxe-Y7CkumzqbNJwglssF6PdUwyKjm9Ny3ZuJRUea7sqG1pbUFql1LTt3Ofro2rN-SrIeENagY0SOMHSUX9Xsp8CspxvBCt9Lq55XEsHVU-gmoUU7Cx34o8w-K6-jnZYrU~3NqfFhZHa792tOAEMAOejJNRPF03YCs5WY3QUupAlMdTXzbNdpxqDAfDp~xA7HFgIkq8zxEqi7rgqT8fBQZWF78xuUbrmxrBjPCg5A7sdMxNfM4eNR87MK2WldKMr55WtWEe07cfpuPvw8bbpxv2-qIR1MFxDXDLxYeMD~-5DM1hSUGB~s9kw3FSNIizw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375833&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 6.4.1. Sex-specific non-traditional cardiovascular disease risk modifiers

Sex differences in the distribution of traditional and non-traditional CVD risk factors have been documented among patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B174" data-open="ehae178-B174" class="link link-ref link-reveal xref-bibr">174</a></sup> Although sex itself is included as an input variable in the SCORE2 and SCORE2-OP, and though these models were derived separately in men and women, some sex-specific, non-traditional risk modifiers were not included, and their associated impact on CVD risk may not be fully captured by SCORE2, SCORE2-OP, or SCORE2-Diabetes.

The relationship between BP and overall CVD risk is similar in both sexes, though some studies even suggest a stronger relative risk for CVD for a given BP level among females compared with males.<sup><a href="javascript:;" reveal-id="ehae178-B117" data-open="ehae178-B117" class="link link-ref link-reveal xref-bibr">117</a></sup> Female-specific, non-traditional CVD risk modifiers often arise at specific times throughout the life course, especially during pregnancy and the peri-partum period. Women with a history of hypertensive disorders of pregnancy, including gestational hypertension and pre-eclampsia, have a two-fold higher long-term risk of CVD vs. women without these pregnancy conditions.<sup><a href="javascript:;" reveal-id="ehae178-B175 ehae178-B176 ehae178-B177" data-open="ehae178-B175 ehae178-B176 ehae178-B177" class="link link-ref link-reveal xref-bibr">175–177</a></sup> The relative long-term CVD risk associated with hypertensive disorders of pregnancy may also be higher in younger vs. older pregnant women.<sup><a href="javascript:;" reveal-id="ehae178-B178" data-open="ehae178-B178" class="link link-ref link-reveal xref-bibr">178</a>,<a href="javascript:;" reveal-id="ehae178-B179" data-open="ehae178-B179" class="link link-ref link-reveal xref-bibr">179</a></sup> Most, but not all, of the excess CVD risk associated with hypertensive disorders of pregnancy is captured by conventional CVD risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B176" data-open="ehae178-B176" class="link link-ref link-reveal xref-bibr">176</a>,<a href="javascript:;" reveal-id="ehae178-B178" data-open="ehae178-B178" class="link link-ref link-reveal xref-bibr">178</a></sup> Gestational diabetes is independently associated with an approximately two-fold increase in the long-term relative risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B180" data-open="ehae178-B180" class="link link-ref link-reveal xref-bibr">180</a></sup> Other complications such as pre-term delivery, recurrent miscarriage, and one or more stillbirths are associated with a 40% relative increase in long-term CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B181 ehae178-B182 ehae178-B183 ehae178-B184 ehae178-B185" data-open="ehae178-B181 ehae178-B182 ehae178-B183 ehae178-B184 ehae178-B185" class="link link-ref link-reveal xref-bibr">181–185</a></sup> Accordingly, a history of specific pregnancy complications, including gestational hypertension, pre-eclampsia, gestational diabetes, pre-term delivery, one or more stillbirths, and recurrent miscarriage, can be considered as non-traditional CVD risk modifiers to up-classify women with elevated BP and borderline increased 10-year predicted CVD risk (5% to <10%) to sufficiently high risk, thereby influencing the risk-based management of their elevated BP.

Evidence whether other female-specific conditions (infertility, polycystic ovary syndrome, and premature menopause) and male-specific conditions (androgenic alopecia and erectile dysfunction) improve prediction of CVD sufficiently to inform risk-based BP-lowering treatment decisions is inconclusive at present.

#### 6.4.2. Non-traditional cardiovascular disease risk modifiers shared by men and women

In addition to sex-specific risk modifiers, several other non-traditional risk factors are associated with an increased risk of CVD, but few have been shown to improve risk prediction or discrimination beyond traditional CVD risk factors.

We advise considering high-CVD-risk race/ethnicity (e.g. South Asian),<sup><a href="javascript:;" reveal-id="ehae178-B186 ehae178-B187 ehae178-B188" data-open="ehae178-B186 ehae178-B187 ehae178-B188" class="link link-ref link-reveal xref-bibr">186–188</a></sup> family history of premature onset atherosclerotic CVD (CVD event in males aged <55 years and/or females <65 years),<sup><a href="javascript:;" reveal-id="ehae178-B189" data-open="ehae178-B189" class="link link-ref link-reveal xref-bibr">189</a>,<a href="javascript:;" reveal-id="ehae178-B190" data-open="ehae178-B190" class="link link-ref link-reveal xref-bibr">190</a></sup> socio-economic deprivation,<sup><a href="javascript:;" reveal-id="ehae178-B191" data-open="ehae178-B191" class="link link-ref link-reveal xref-bibr">191</a></sup> inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis, and psoriasis affecting 10% or more of body surface area or requiring systemic therapy),<sup><a href="javascript:;" reveal-id="ehae178-B192 ehae178-B193 ehae178-B194 ehae178-B195 ehae178-B196 ehae178-B197 ehae178-B198 ehae178-B199 ehae178-B200 ehae178-B201 ehae178-B202" data-open="ehae178-B192 ehae178-B193 ehae178-B194 ehae178-B195 ehae178-B196 ehae178-B197 ehae178-B198 ehae178-B199 ehae178-B200 ehae178-B201 ehae178-B202" class="link link-ref link-reveal xref-bibr">192–202</a></sup> HIV,<sup><a href="javascript:;" reveal-id="ehae178-B203 ehae178-B204 ehae178-B205" data-open="ehae178-B203 ehae178-B204 ehae178-B205" class="link link-ref link-reveal xref-bibr">203–205</a></sup> and severe mental illness (major depressive disorder, bipolar disorder, and schizophrenia)<sup><a href="javascript:;" reveal-id="ehae178-B206 ehae178-B207 ehae178-B208" data-open="ehae178-B206 ehae178-B207 ehae178-B208" class="link link-ref link-reveal xref-bibr">206–208</a></sup> as shared non-traditional risk modifiers to up-classify the risk of individuals with a borderline increased 10-year predicted risk using SCORE2/SCORE2-OP (5% to <10%) to sufficiently high CVD risk.

#### 6.4.3. Additional risk decision tests

Coronary artery calcium (CAC) scoring improves CVD risk prediction and reclassifies risk when added to conventional CVD risk factor-based estimation models.<sup><a href="javascript:;" reveal-id="ehae178-B209" data-open="ehae178-B209" class="link link-ref link-reveal xref-bibr">209</a>,<a href="javascript:;" reveal-id="ehae178-B210" data-open="ehae178-B210" class="link link-ref link-reveal xref-bibr">210</a></sup> A CAC score of >100 Agatston units or ≥75th percentile for age, sex, and ethnicity favours up-classification of CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B127" data-open="ehae178-B127" class="link link-ref link-reveal xref-bibr">127</a></sup> Internal or external carotid plaque may also improve CVD risk prediction.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a></sup> Similarly, femoral artery plaque detection may improve CVD risk prediction.<sup><a href="javascript:;" reveal-id="ehae178-B212 ehae178-B213 ehae178-B214" data-open="ehae178-B212 ehae178-B213 ehae178-B214" class="link link-ref link-reveal xref-bibr">212–214</a></sup> Arterial stiffness, as assessed by pulse wave velocity (PWV), is associated with increased risk of CVD events and improves CVD risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B215 ehae178-B216 ehae178-B217 ehae178-B218" data-open="ehae178-B215 ehae178-B216 ehae178-B217 ehae178-B218" class="link link-ref link-reveal xref-bibr">215–218</a></sup> Common arterial stiffness thresholds for increased risk include carotid–femoral PWV of >10 m/s and brachial–ankle PWV of >14 m/s. After assessing 10-year predicted CVD risk and non-traditional risk factors, if a risk-based treatment decision remains uncertain for patients with elevated BP, it is reasonable to measure a CAC score or, alternatively, carotid or femoral plaque, or arterial stiffness; most especially after shared decision-making with the patient and after considering cost (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_ for more details on these tests). There is also evidence that elevated cardiac biomarker levels (specifically high-sensitivity cardiac troponin and B-type natriuretic peptide/N-terminus B-type natriuretic peptide) are significant and effective risk modifiers,<sup><a href="javascript:;" reveal-id="ehae178-B219" data-open="ehae178-B219" class="link link-ref link-reveal xref-bibr">219</a>,<a href="javascript:;" reveal-id="ehae178-B220" data-open="ehae178-B220" class="link link-ref link-reveal xref-bibr">220</a></sup> with further supportive data from hypertensive participants.<sup><a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a>,<a href="javascript:;" reveal-id="ehae178-B221" data-open="ehae178-B221" class="link link-ref link-reveal xref-bibr">221</a>,<a href="javascript:;" reveal-id="ehae178-B222" data-open="ehae178-B222" class="link link-ref link-reveal xref-bibr">222</a></sup> Of note, these cardiac biomarkers can be considered markers of HMOD (_Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_); however, we focus on them in this risk modifier section because they may be elevated due to other reasons besides high BP (such as atherosclerosis or heart rhythm disease).

Recommendation Table 4

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375843)

Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14)

![Recommendations for refining cardiovascular disease risk (see Evidence Tables 12–14)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt4.jpeg?Expires=1728462844&Signature=PlbVdJGTjJxwhzSHh0gAPDnVOb4ZGNWlEsltDKpfsImSkv7cEycnoxFcsnGsYj~5xbMqmieX4HGhPx8wZm8-OoCHHTAnd7VjBiAwdBh5h-8FlUb4GT47M3jybZYdl8zHN1FKd~BwvJCNfU1u0oJE4DaT5ShUR6DMvvF7IWmbUg5D8EjlLsTuCcwrg7JYXBmYZOeK9WvUXhyH4j4o6J8kbUy38EiktrbasIc5U4u35UIeJf5MLCJdUexUNgqiwN8d6dwILp25vczYEWF7iEZ3xoZKU0Tjfq0lAhP~03LDK1ERUoB3~vIHLEXZO1hf-w4ww1as6Y9~2vWTBYJfo~tgBQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 6.5. Summary of the cardiovascular disease risk stratification approach for allocating blood pressure treatment

Measured BP combined with 10-year CVD risk-prediction models and non-traditional risk modifiers should be used for stratifying risk when allocating BP-lowering treatment for persons with elevated BP (_[Figure 9](javascript:;)_). It is important to stress here that patients with confirmed hypertension are recommended to receive BP-lowering treatment and no further risk stratification is needed.

![Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f9.jpeg?Expires=1728462844&Signature=KpMaGupz2ya-wDITBmsRAA0BrB5p35jmQPWt2DLgya79lPUlrYimInemd3Qv95ssux0jMYlSpH0aQfssGWqhpY0R-DzpCOd27-19nRcnBzDoQdenILgw4xeqrtujZ~Km~sZpL6JqDIwykNWDsX1RcaispzW5Xg~6Ung89FNO~wF1-LhkN8ygCGDvWqLyIfvTLM3ThCga-ycM6buxPGFQ0TrxLo1FSZs1PqsIo73ELIr~iVqRVpQLQzZBNwF-5SeZ3vlI0Y7rMnWpzy1B40j4dYS1c0BBzcCYpUD86FzKoMykuUAFRF5qsy4jC52YWBFbu~E~fQXfILqSoyotjxPjZA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 9

Summary of cardiovascular disease risk-stratification approach for blood pressure treatment in adults with elevated blood pressure.

ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.

[Open in new tab](https://academic.oup.com/view-large/figure/479375846/ehae178f9.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f9.jpeg?Expires=1728462844&Signature=3vWi5~-pEbbUpXZDlx1aBtC7ALFr6DzwYVd96O~qzX5Ak8PspOBF~txKVb2T3dSAeNj81eaAnfpxL6okPIGHDz47J3J8fXm1V~z2plz48y5HqdJ3v~XRk0tVKo6tVkNNAeHe~8c0X9AuQWMHr-8V6Xu0MEtpnJjQa9I1DHO2X1nAseFRNsokf-y9t72dfa7G1gfzUVdgkLxzio0xN2-pzyPOZPQDa4gOVInOVhQLNLOXEic~mbCoKgzmBRD-LlTcYA9TGVknsC-IZT0DVpkz~9WBIKw24ECo0Q9oWsYKLnT1GvIaDKIAZNPnePZDloYRgap63f1IqMnbFwbJ-tAxSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375846&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

For patients with elevated BP, the presence of diabetes, familial hypercholesterolaemia, established CVD (defined as prior acute or chronic coronary syndrome, cerebrovascular disease, symptomatic peripheral arterial disease, or heart failure), moderate or severe CKD, or HMOD confers increased CVD risk. One caveat is that, specifically for individuals with elevated BP and type 2 diabetes mellitus only aged <60 years, SCORE2-Diabetes should be considered to identify lower CVD risk individuals (<10% over 10 years).

Otherwise, for patients without these high-risk conditions, 10-year risk of CVD should be calculated using SCORE2 (if aged 40–69 years) and SCORE2-OP (if aged ≥70 years). Patients with elevated BP and a 10-year predicted risk of CVD events ≥10% are considered sufficiently high risk to warrant BP-lowering treatment (either by lifestyle or drug treatment, see _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_). For patients with elevated BP and borderline increased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 10 years), up-classification of risk may be considered in the presence of sex-specific or shared non-traditional risk modifiers. After considering sex-specific and shared non-traditional risk modifiers, if a risk-based BP-lowering treatment decision remains uncertain, it may be reasonable to measure CAC score, carotid or femoral plaque, high-sensitivity cardiac troponin or B-type natriuretic peptide biomarkers, or arterial stiffness.

Risk stratification for patients with non-elevated BP (systolic BP of <120 mmHg and diastolic BP of <70 mmHg) is not required for the purpose of allocating BP-lowering treatment, as the safety and efficacy of commencing BP-lowering treatment below this threshold is uncertain. Risk assessment may nonetheless be needed in this setting when considering other prevention therapies (e.g. lipid lowering).

## 7\. Diagnosing hypertension and investigating underlying causes

### 7.1. Screening for hypertension

Hypertension is predominantly an asymptomatic condition that is typically detected by systematic or opportunistic screening in a healthcare setting. Systematic screening refers to any process where individuals are identified and invited to a healthcare setting solely to measure their BP and CVD risk profile. Opportunistic screening refers to BP being measured when the patient presents to a healthcare setting for any reason, such as a routine check-up or the treatment of an acute or chronic condition. Self-screening and non-physician screening are also increasingly used.<sup><a href="javascript:;" reveal-id="ehae178-B227 ehae178-B228 ehae178-B229 ehae178-B230" data-open="ehae178-B227 ehae178-B228 ehae178-B229 ehae178-B230" class="link link-ref link-reveal xref-bibr">227–230</a></sup>

Few data are available on the effectiveness of different hypertension screening strategies to reduce the morbidity and mortality associated with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B231 ehae178-B232 ehae178-B233" data-open="ehae178-B231 ehae178-B232 ehae178-B233" class="link link-ref link-reveal xref-bibr">231–233</a></sup> More evidence is needed before systematic screening programmes with BP measurement can be recommended in all adults to reduce CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B231" data-open="ehae178-B231" class="link link-ref link-reveal xref-bibr">231</a></sup>

Opportunistic BP screening in a primary care setting appears effective, with an estimated 90% of all adults aged >40 years in the UK having a BP check within a 5-year time period,<sup><a href="javascript:;" reveal-id="ehae178-B234" data-open="ehae178-B234" class="link link-ref link-reveal xref-bibr">234</a></sup> though these findings may not extrapolate to other countries. When patients provide HBPM recordings, these can also be used as part of an opportunistic screening programme (see _Section [5.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.2)_).<sup><a href="javascript:;" reveal-id="ehae178-B235" data-open="ehae178-B235" class="link link-ref link-reveal xref-bibr">235</a></sup>

Despite ongoing uncertainty about the effect of hypertension screening programmes on CVD outcomes, many studies have demonstrated that screening (mostly opportunistic screening) increases hypertension detection, and that the benefits of screening likely outweigh harms.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a></sup> Global initiatives to raise BP awareness, such as the May Measurement Month,<sup><a href="javascript:;" reveal-id="ehae178-B228" data-open="ehae178-B228" class="link link-ref link-reveal xref-bibr">228</a></sup> or targeted initiatives, such as the barbershop health outreach programmes,<sup><a href="javascript:;" reveal-id="ehae178-B229" data-open="ehae178-B229" class="link link-ref link-reveal xref-bibr">229</a></sup> are successful examples of BP screening campaigns.

Screening for hypertension, like for global CVD risk assessment, should be intermittently repeated, e.g. every 3 years. Considering the rate of progression to hypertension in European population samples,<sup><a href="javascript:;" reveal-id="ehae178-B236" data-open="ehae178-B236" class="link link-ref link-reveal xref-bibr">236</a></sup> it is reasonable to measure BP at least every 3 years in the case of non-elevated BP and low–moderate CVD risk (i.e. individuals aged <40 years). More frequent BP checks (i.e. yearly) should be considered in individuals 40 years or older and individuals with elevated BP not currently meeting indications for treatment<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> (_[Figure 10](javascript:;)_).

![Protocol for confirming hypertension diagnosis.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f10.jpeg?Expires=1728462844&Signature=VaNkFtFyx71Aet5twLBY7UHGt~C8latTaQpDznqJXGA4l9LZbDVLt4ixkoFeshvvAXHB2P1Fh3xVBLI8jtlNMtyG-CGUr-tEsWBGBGv7U13KOhj1Hr8AM0lujgKiyddeDnsksj4p7i51pomIrBj9sSL828tYyADXR62y-0kev9M0mDSZ8~em1483gVG1guHyYU-oq0DOKp5TEBq~X0clbOHhyG-GqureWaSJF0WTmyUc2dXvlJunKw0EpryKuK0QQHkcxMuYHsN0blfCBpCZsfTgro3zf~yrtvYZwzHsvX9-Fq2aq4SIHms4YbXXe~jmIcCfI6RgC9oSc9ko08gyYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 10

Protocol for confirming hypertension diagnosis.

BP, blood pressure; CVD, cardiovascular disease; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons.

[Open in new tab](https://academic.oup.com/view-large/figure/479375857/ehae178f10.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f10.jpeg?Expires=1728462844&Signature=2LQjABOtkrPJ4t70APxLvmve4-eYMKHamuxACGijYPTUWdlkAOsCUEOvoreEVNpZDTq5pvBWe~uGd6N4VxcCrCkiwNMFbS4cqK4OhVh7VgiWd5-M~4Y8Mya1MkFMLM0CDVgdYw7bbf4WV6BTgWciAJSC2qkNDl~BOtHFJuUFo~Gn2AFXyjg7iM-IwMGuCL6TaWfsr0FPnaqG7FxIrp8mfG9lbIFXfleild6DjnLE6t~ps8gQjbsTCN4W501IC2a62R60vRIbmsvsfAB7d9bGj0Ql~4k-lMtXpgeaMfE2KGKO35SBkOhwv9S~BPHAEs3ocMMVzMub9apK4WbsOHS2Rg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375857&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 5

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375858)

Recommendations for blood pressure screening (see Evidence Table 15)

![Recommendations for blood pressure screening (see Evidence Table 15)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt5.jpeg?Expires=1728462844&Signature=G9GChx-2PZRUgLRHAZC8m6rQcnWXikUD0Yaz3LLico9rwbMMwuzyKWaA1Ga4BGAt0rrhkqd5Pqkcqvk5JdaQsS0VWJevWCEEPbT-i8Ds~-HuQh05MGR4pkJUXPUosm3EP2bwt~nRWHaSF2VKZSf4tIJ1Yvv3-~1j~0TrdYQsSO8fKzytEfzGy9diP2s2EYIR89V~fih8XQ3aPD9T-kovGw27jE-bT95fEZTrSnk9n8fJ3CeOMbJ2ka6E-blJJgFB2GvWPWUebNXEAHKIey-i5faSrrQBG0zq2vBR-OF90Hdg0Wzvkc3k7MWyeOnO2JbA3XX1V8w70v3HFLfQFclxcg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.2. Confirming the diagnosis of hypertension

As noted in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_, assessment at a single visit by office BP has lower specificity compared with ABPM for diagnosing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B70" data-open="ehae178-B70" class="link link-ref link-reveal xref-bibr">70</a>,<a href="javascript:;" reveal-id="ehae178-B238 ehae178-B239 ehae178-B240 ehae178-B241" data-open="ehae178-B238 ehae178-B239 ehae178-B240 ehae178-B241" class="link link-ref link-reveal xref-bibr">238–241</a></sup> Accordingly, a protocol for confirming the diagnosis of hypertension is proposed (_[Figure 10](javascript:;)_), with out-of-office BP measurement as the preferred method for confirming cases of elevated BP or hypertension. For initial screening systolic BP of >160 mmHg and/or diastolic BP of >100 mmHg, a prompt re-evaluation (within days to weeks but not >1 month) preferably with ABPM or HBPM is advisable.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup> BP of >180/110 mmHg at screening requires exclusion of hypertensive emergencies, which should be managed as appropriate (see <sup><a href="javascript:;" reveal-id="ehae178-B242" data-open="ehae178-B242" class="link link-ref link-reveal xref-bibr">242</a></sup> and _Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_) with prompt treatment. For individuals with BP of >180/110 mmHg at screening but without hypertensive emergency, prompt confirmation (preferably within a week) can be considered prior to commencing treatment.

Recommendation Table 6

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375861)

Recommendations for confirming hypertension diagnosis

![Recommendations for confirming hypertension diagnosis](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt6.jpeg?Expires=1728462844&Signature=gXCkjwIf3cuMYXfwgi8EqTSRZDJ09sBC9ceg3-nneclAwzBC0LRGZlnu2XqPZTJOehhFxALlGVlVOTkMjQeaUbFKRt1rUG~SaaZjgKUSDfwb3EcHWoMb2l8D069F07yWvQjHOxdzVxn1YruSPFlFvjl2QAeZ3-y7~xZ3AiSaTUO~eu12Q12mEzqBkF326OEzR71UEE7nUOQny4-vFq3Mvwvy3klnCOsV7wpit8~tYpS-9dUy1X5UmGRZ5Pb~ZFQvtt5qgiZnTjiDkEXE1q~5omeoBdqKBTVfLjeSD8miM3~13kk2Hey7mX1QXjRfV3sTyk73NRGClRv7MCPMb9B50A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.3. Communicating the diagnosis

Behavioural responses to health-related threats are strongly influenced by five core themes (termed ‘illness representations’), which are identity, timeline, cause, consequences, and control/cure.<sup><a href="javascript:;" reveal-id="ehae178-B243" data-open="ehae178-B243" class="link link-ref link-reveal xref-bibr">243</a>,<a href="javascript:;" reveal-id="ehae178-B244" data-open="ehae178-B244" class="link link-ref link-reveal xref-bibr">244</a></sup> These illness representations form the basis of how patients understand a diagnosis, and can influence their responses after being diagnosed with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B243" data-open="ehae178-B243" class="link link-ref link-reveal xref-bibr">243</a></sup> This conceptual framework can help guide the clinical communication of a diagnosis of hypertension. For example, patients’ understanding of the chronic nature of hypertension (i.e. timeline theme) is key for ensuring long-term engagement with medical treatment.<sup><a href="javascript:;" reveal-id="ehae178-B245" data-open="ehae178-B245" class="link link-ref link-reveal xref-bibr">245</a></sup> Prior to commencing treatment, it is helpful to understand the extent to which patients believe that medications are necessary and ascertain if they have concerns.<sup><a href="javascript:;" reveal-id="ehae178-B246" data-open="ehae178-B246" class="link link-ref link-reveal xref-bibr">246</a></sup> The core illness representations and beliefs about medicines for clinicians to consider are included in _[Table 7](javascript:;)._

Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375864)

Key illness representations and treatment beliefs: how these apply to communicating a hypertension diagnosis to the patient (note that gender influences these representations)

| Illness representation | Example patient question | Application to a hypertension diagnosis conversation |
| --- | --- | --- |
| Identity | What is the disease/illness label and the related symptoms? | The condition where your systolic BP is ≥140 and/or diastolic BP ≥90 mmHg is called hypertension. We classify systolic BP 120–139 or diastolic BP 70–89 mmHg as elevated BP. For most people, this has no noticeable signs or symptoms, therefore, we need to monitor your BP to assess how medications and behavioural changes are working. |
| Control | Is the illness controllable through medical intervention or behavioural change? | Hypertension can usually be controlled with medication and behavioural changes such as dietary changes and regular physical activity. For some people we need to try a few different options before we get BP under control. |
| Timeline | Is this an acute or chronic problem? | This is a serious long-term or chronic condition condition that will require long-term management. This means that it may need to be managed throughout life. |
| Consequences | What are the physical and psychosocial consequences? | If hypertension is not controlled, then there is a risk of a serious acute cardiovascular disease event such as a stroke or heart attack; however, if it is managed through the right medical intervention and behavioural changes, then this risk can be reduced and the condition will have less consequences for your life. |
| Causes | What caused the condition? | Multiple factors contribute to someone developing hypertension. These include both non-modifiable factors (e.g. genetics and age) and modifiable factors (e.g. diet, weight, and physical activity). We are best focusing on those things that we can control to reduce your BP. |

| Treatment beliefs | Example patient question | Application to a hypertension diagnosis communication |
| --- | --- | --- |
| Necessity | To what extent is treatment necessary? | Taking BP-lowering medication every day is necessary to keep your BP under control and to help prevent a more serious health problem developing. Do you think that these medicines will help you? |
| Concerns | To what extent does treatment cause concern? | Some patients have concerns about taking daily medications throughout their life, e.g. about side effects. Do you have any concerns about taking your BP medications every day? |

BP, blood pressure.

© ESC 2024

The 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice recommend “an informed discussion about CVD risk and treatment benefits—tailored to the needs of a patient” as part of a diagnosis communication in hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> This can be facilitated using an interdisciplinary healthcare-provided approach (see _Section [11](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s10)_) and by visual information or other more accessible material that might optimally communicate hypertension-related risk.<sup><a href="javascript:;" reveal-id="ehae178-B128" data-open="ehae178-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> Visualizing risk by medical imaging to motivate risk-reducing behaviour changes may also be beneficial.<sup><a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a></sup>

### 7.4. Baseline assessment and diagnostic approach

#### 7.4.1. Medical history, medication history, and physical examination

The purpose of clinical evaluation is to diagnose hypertension, delineate factors potentially contributing to hypertension, identify other CVD risk factors, define relevant comorbidities, screen for potential secondary causes of hypertension (where indicated), and establish whether there is evidence of HMOD or existing cardiac, cerebrovascular, or renal disease.

Details on medical history and physical examination steps are summarized in the supplement (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), as well as drugs or substances that may increase BP (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

#### 7.4.2. Drug adherence and persistence with treatment

Adherence is defined as the extent to which a patient’s behaviour, e.g. with respect to taking medication, coincides with agreed recommendations from a healthcare provider. Persistence represents the amount of time from initiation to discontinuation of therapy.<sup><a href="javascript:;" reveal-id="ehae178-B248" data-open="ehae178-B248" class="link link-ref link-reveal xref-bibr">248</a></sup> Adherence to medical therapies is especially suboptimal in asymptomatic conditions such as hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B249 ehae178-B250 ehae178-B251 ehae178-B252 ehae178-B253 ehae178-B254" data-open="ehae178-B249 ehae178-B250 ehae178-B251 ehae178-B252 ehae178-B253 ehae178-B254" class="link link-ref link-reveal xref-bibr">249–254</a></sup> Non-adherence to BP-lowering therapy correlates with a higher risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B255" data-open="ehae178-B255" class="link link-ref link-reveal xref-bibr">255</a>,<a href="javascript:;" reveal-id="ehae178-B256" data-open="ehae178-B256" class="link link-ref link-reveal xref-bibr">256</a></sup> Objective methods to assess adherence, such as detecting prescribed drugs in blood or urine samples and directly observed treatment (witnessed pill intake during ABPM), have demonstrated their potential usefulness, particularly in the setting of apparently resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> However, all methods for testing drug adherence have limitations.

Non-adherence to BP-lowering therapy depends on many factors (_[Figure 11](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B253" data-open="ehae178-B253" class="link link-ref link-reveal xref-bibr">253</a></sup> Effective patient–physician communication is crucial to improve adherence.<sup><a href="javascript:;" reveal-id="ehae178-B258" data-open="ehae178-B258" class="link link-ref link-reveal xref-bibr">258</a>,<a href="javascript:;" reveal-id="ehae178-B259" data-open="ehae178-B259" class="link link-ref link-reveal xref-bibr">259</a></sup> Single-pill combinations improve persistence in BP-lowering treatment and are associated with lower all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B260" data-open="ehae178-B260" class="link link-ref link-reveal xref-bibr">260</a></sup>

![Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f11.jpeg?Expires=1728462844&Signature=YKZ8wJztmO~ApfgnRBlUWFDWLB0S4zsx6ndlm2CAKKjV25JbqRE20dts~9s8XOGmidmO7M~LWlC9cAy1Qw4A0fGseDfFtyRIjP3OxzgTPikdb6u06G9BrkvtUUY26famm-R3IgOoDo3EWZpU0SOO6CUpdFbQfWEztw0pazWrOyRMTmbSdrjLK0g2YkJJLXLuk-P7rJCTdKwVP9Z67XjKHIXlt7NYEpdqOe7dPLvp~t38XMVyNAzbVsJEF7JxMBBFBCwtcBlMf2WR8XlcofmImmM9hDPTk-vQojqOqeiMfWJCEHsE9EElb8JRBRPStBIzh7OppElWzBqe7U2oSCDqeA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 11

Definitions, assessments, and potential interventions for the three phases of adherence to BP-lowering medications.

[Open in new tab](https://academic.oup.com/view-large/figure/479375873/ehae178f11.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f11.jpeg?Expires=1728462844&Signature=SJKORupXlbBXtkFLaWenL-61v5cKn61tFlZv-lW0gQHBBIzjVvzdRYiiTtAjPDK8RjWi08W7dLHI3k7iqYnshAbs9~crzpkrHpiy~pm5I8mffQjG8WZYBGTiAvWbKF5Giu4yeKGamen4YDFJkMpCtaxfZAO0FdMJdJ6CsThkXL2WIImMyfaXXW-l6f~xEUdjFNOzRSDfDCHgcIZjabRghOLjyFyYpkKLg~YsaC0S5pFk64qJ5Mt0i0hEh5gpxZrVt-nt1hxI~JCywlUhLDLsQKUyarILsI0LQY1bmyyUGj26TjA31ONWWGgFKdyfMX7mpAzO1kyKMMTTciXWEF3cEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375873&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Recommendation Table 7

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375874)

Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16)

![Recommendations for assessing adherence and persistence with treatment (see Evidence Table 16)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt7.jpeg?Expires=1728462844&Signature=s5-SHaCGdhHGuob~YYZTLgz4yodEItFm~gDAB70Jqh7Ghm-BXNko3d~1Zc7dkdxz6S8r4vBZsTp4JUo4EpZKPme-HF8odrQyJq27qDFtjBOAsRQsWugTcW4w4IykCl3s61e9B2hhdJm25K7oIfl66IKgbl525pR4nalc6N5vHrzDOGdY5Rb1HFcf9Dp4JqA0HllF2HcciqqHBlAxpHIPWU3AEaSde5dCBoMF5WNHmAQDm1JXF3AbyF9uomnsD0YUssxjffLMbmg~T6HaX6HZXnKjdAuKnAadVrU0u4zMftdmzz-OxG1CFgTfmJlZzCr6KFCxyU-g4I2xwuO1uelm1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.4.3. Routine and optional tests

Routine tests include laboratory and clinical tests to detect increased CVD risk and relevant comorbidities (e.g. hyperlipidaemia and diabetes) (_[Table 8](javascript:;)_).

Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375877)

Routine tests recommended in the initial work-up of a patient with elevated blood pressure or hypertension

| Routine test | Clinical utility |
| --- | --- |
| Fasting blood glucose (and HbA1c if fasting blood glucose is elevated) | Assessing CVD risk and comorbidities |
| Serum lipids: total cholesterol, LDL cholesterol, HDL and non-HDL cholesterol, triglycerides | Assessing CVD risk |
| Blood sodium and potassium, haemoglobin and/or haematocrit, calcium, and TSH | Screening secondary hypertension (primary aldosteronism, Cushing’s disease, polycythaemia, hyperparathyroidism, and hyperthyroidism) |
| Blood creatinine and eGFR; urinalysis and urinary albumin-to-creatinine ratio | Assessing CVD risk and HMOD  
Guiding treatment choice  
Screening secondary hypertension (renoparenchymal and renovascular) |
| 12-lead ECG | Assessing HMOD (left atrial enlargement, left ventricular hypertrophy)  
Assessing irregular pulse and other comorbidities (AF, previous acute myocardial infarction) |

AF, atrial fibrillation; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HMOD, hypertension-mediated organ damage; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.

© ESC 2024

Optional tests should be considered in the initial assessment if they are likely to change patient management, with the main rationale being to improve CVD risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> As highlighted in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, for adults with elevated BP who also have a 10-year estimated CVD risk of 5% to <10%, optional tests including those for HMOD may be considered if up-classification of risk on the basis of an abnormal test result could prompt initiation of BP-lowering therapy.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Evidence of subclinical microvascular neurodegeneration and/or lacunar brain disease due to small-vessel pathology may also indicate HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a></sup>

While the role of optional tests for HMOD (_[Table 9](javascript:;)_) in the management of elevated BP is emphasized in these guidelines, we also note that these tests may help to optimize treatment in hypertensive adults with BP of >140/90 mmHg who are prescribed BP-lowering therapy (e.g. by facilitating patient adherence and overcoming clinician inertia in achieving an intensive BP treatment target of as low as 120 mmHg systolic). The role of visualizing HMOD in helping motivate risk-reducing changes in patients and overcome physician inertia has been tested in interventional trials (_Section [7.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae178-B265 ehae178-B266 ehae178-B267" data-open="ehae178-B265 ehae178-B266 ehae178-B267" class="link link-ref link-reveal xref-bibr">265–267</a></sup>

Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375880)

Optional tests that may be used as clinically indicated in the initial work-up of a patient with elevated blood pressure or hypertension to assess hypertension-mediated organ damage or established cardiovascular disease

| Optional test | Clinical utility |
| --- | --- |
| Echocardiography | Assessing HMOD (hypertensive heart disease)  
Assessing established CVD (previous acute myocardial infarction, heart failure)  
Assessing thoracic aorta dilation |
| CAC by cardiac CT or carotid or femoral artery ultrasound imaging | Assessing HMOD (atherosclerotic plaque) |
| Large artery stiffness (carotid–femoral or brachial–ankle PWV) | Assessing HMOD (arterial stiffness) |
| High-sensitivity cardiac troponin and/or NT-proBNP | Assessing HMOD |
| Ankle–brachial index | Assessing established CVD (lower-extremity arterial disease) |
| Abdominal ultrasound | Assessing established CVD (abdominal aneurysm) |
| Fundoscopy | Assessing HMOD (hypertensive retinopathy)  
Diagnosing hypertensive emergency/malignant hypertension (haemorrhages and exudates, papilloedema) |

CAC, coronary artery calcium; CT, computed tomography; CVD, cardiovascular disease; HMOD, hypertension-mediated organ damage; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity.

© ESC 2024

HMOD assessment is also an important way to identify young adults <40 years old who have increased CVD risk, since 10-year estimated CVD risk by SCORE2 cannot be calculated in this age group (see _Section [8.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.1)_). More details on diagnostic thresholds for HMOD by the various assessment options, including important sex differences, are provided in [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[Figure 12](javascript:;)_.

![Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f12.jpeg?Expires=1728462844&Signature=uDV2m3oVzq~UiD~~4~kayV4iqp15J4FQOXuWLrqWT6A2ElffyjlZfl8RPgj0B0lP2Pl-nF3c-MPwTGEzzM2UgsoAOcQ3mjMb-aAhV-V3ColENYP1UTxnkwqe7A7XqfvpBp587lIXBTx3xmd5qCOReKVaMqeXd6KPRnx8yLWSkViyTDBntwynIS6su8ngkMYdj6Y1Vsa56301g3qy7ipmvMQh2VnQRh41iXbr8IB8u~rMvHGyUhxHUJ~r2hKv0O-dmz6-RhiIWmYWFnW6j4E0rul9hTviI5uLEhpTXCWhw2G1~~7TdWc2NFF8HkQv4jma9wYfkBQSW7h1~NgpdcgcgQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 12

Tests and criteria for defining hypertension-mediated organ damage and considerations for their use in clinical practice.

ACR, albumin:creatinine ratio; BP, blood pressure; BSA, body surface area; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; hs-cTnT, high-sensitivity cardiac troponin T; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide; PWV, pulse wave velocity; RWT, relative wall thickness; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. More details and references can be found in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1 and S5](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

[Open in new tab](https://academic.oup.com/view-large/figure/479375882/ehae178f12.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f12.jpeg?Expires=1728462844&Signature=V8MWPQq~wVD8A6y4-KFub3NdyCIs9at~EOxCnnlTZSeaY4CSC-jUOPds7fvng6Cc4nDc-BSk1fUFEE5SptN6mOR4oT2inya1DCS-G1QW6EyRbHjuMzZ1rj1ANWIMXrA2e~PU20BY7f-2CxKV3WuisNK1rJAJ85RxchLdOC3XgeLsaMYaG6TFKpqE7bHwcN-SMD2o2yQpHHUQx6iIDAMk12G6evdZY0BSlUnZd9KOsqRISode6KMdvTVFn8Pdp-XXa~QY9J~gwOjsKXJwH5dQStL1WoY8Z4glIKCFUn~3LmpU0u5sQFgDQIMP54iGgVJCGOapb9ww3VRCfDRNSb2-Og__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375882&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Finally, some individuals may be at heightened risk for CVD events when cardiac and vascular HMOD measurements like LVH and increased PWV do not regress over time with appropriate treatment and BP control.<sup><a href="javascript:;" reveal-id="ehae178-B14" data-open="ehae178-B14" class="link link-ref link-reveal xref-bibr">14</a>,<a href="javascript:;" reveal-id="ehae178-B268 ehae178-B269 ehae178-B270 ehae178-B271" data-open="ehae178-B268 ehae178-B269 ehae178-B270 ehae178-B271" class="link link-ref link-reveal xref-bibr">268–271</a></sup>

Investigations aimed at screening for secondary hypertension are additional optional tests and are detailed in _Section [7.6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.6)_. Of note, patients with an incidental adrenal nodule or nodules (typically detected on imaging of the abdomen done for other clinical reasons) warrant screening for elevated BP and hypertension. Those with adrenal incidentalomas and hypertension warrant a basic work-up for secondary hypertension to include screening for primary aldosteronism, Cushing's syndrome and phaeochromocytoma.

##### 7.4.3.1. The kidneys

CKD is defined as abnormalities of kidney structure or function, present for at least 3 months with implications for health.<sup><a href="javascript:;" reveal-id="ehae178-B272" data-open="ehae178-B272" class="link link-ref link-reveal xref-bibr">272</a></sup> Renal function is evaluated initially using serum creatinine and an estimated glomerular filtration rate (eGFR) equation (preferably race-free CKD-EPI) and typically for proteinuria.<sup><a href="javascript:;" reveal-id="ehae178-B273" data-open="ehae178-B273" class="link link-ref link-reveal xref-bibr">273</a></sup> Our definition of moderate-to-severe CKD requires an eGFR of <60 mL/min/1.73 m<sup>2</sup> or albuminuria of ≥30 mg/g (≥3 mg/mmol). Intensive BP control in patients with CKD reduces rates of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B274" data-open="ehae178-B274" class="link link-ref link-reveal xref-bibr">274</a>,<a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a></sup> CKD can influence the choice of BP-lowering treatment (_Sections [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and _[9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_), as well as newer drugs for cardiovascular prevention, such as sodium–glucose co-transporter 2 (SGLT2) inhibitors and finerenone.

We recommend repeat measurement of eGFR and urine albumin:creatinine ratio (ACR) at least annually if clinically significant CKD is diagnosed. Renal ultrasound and Doppler examination to evaluate causes of CKD and to exclude renoparenchymal and renovascular hypertension (RVH) should also be considered.<sup><a href="javascript:;" reveal-id="ehae178-B276" data-open="ehae178-B276" class="link link-ref link-reveal xref-bibr">276</a>,<a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a></sup>

Recommendation Table 8

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375888)

Recommendations for assessing renal hypertension-mediated organ damage

![Recommendations for assessing renal hypertension-mediated organ damage](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt8.jpeg?Expires=1728462844&Signature=0J8sg7IWcnicYTR1oLAYY2pnsHG0gjr0cxcaoLjF04sUQ0YhObIGDrUZnC67Iv39Dnzs57~MxFOJjymvXqZyQPNRzxR80AJkJaTVcPUuwe4DCAA0~sy8lD7i0Ll6-D1PUnxeJT7fTBy8FTRPmlCaLbE6ULEcNcMNAMdjq1ZlslonDJVJFihvt7pJI95b2bfKJoLgIPo8-x24XGDHOoecEGOg36m4YIzwlxfagZXl46JixZ5vyLZ8p2L35JFpkki21g5RPhV2kRcqKMlEsHB1-2qUThR1U5kSFAZ8A-DIgVGgO9FATtCahRxSZMZ6qt-jTFYDu4CttscexKtLtKUylQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 7.4.3.2. The heart

A 12-lead ECG is a part of the initial routine work-up for all patients with hypertension and should be repeated whenever patients present with an irregular pulse or cardiac symptoms. The ECG should be analysed for LVH ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_) and AF.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B278 ehae178-B279 ehae178-B280 ehae178-B281 ehae178-B282" data-open="ehae178-B278 ehae178-B279 ehae178-B280 ehae178-B281 ehae178-B282" class="link link-ref link-reveal xref-bibr">278–282</a></sup>

Echocardiography is recommended in patients with hypertension when the ECG is abnormal, murmurs are detected, or there are cardiac symptoms. A full, standardized, two-dimensional echocardiogram should be performed, preferably with tissue Doppler and strain assessment. Echocardiography can be considered for all patients with newly diagnosed hypertension, if local resources and reimbursement policies allow. Over 5 years of follow-up, subclinical left ventricular diastolic dysfunction predicts the incidence of CVD.<sup><a href="javascript:;" reveal-id="ehae178-B283 ehae178-B284 ehae178-B285" data-open="ehae178-B283 ehae178-B284 ehae178-B285" class="link link-ref link-reveal xref-bibr">283–285</a></sup> In addition, LVH detected by echocardiography predicts total and cardiovascular mortality and CVD events in the general population,<sup><a href="javascript:;" reveal-id="ehae178-B286" data-open="ehae178-B286" class="link link-ref link-reveal xref-bibr">286</a>,<a href="javascript:;" reveal-id="ehae178-B287" data-open="ehae178-B287" class="link link-ref link-reveal xref-bibr">287</a></sup> including in young adults.<sup><a href="javascript:;" reveal-id="ehae178-B26" data-open="ehae178-B26" class="link link-ref link-reveal xref-bibr">26</a>,<a href="javascript:;" reveal-id="ehae178-B268" data-open="ehae178-B268" class="link link-ref link-reveal xref-bibr">268</a>,<a href="javascript:;" reveal-id="ehae178-B288" data-open="ehae178-B288" class="link link-ref link-reveal xref-bibr">288</a>,<a href="javascript:;" reveal-id="ehae178-B289" data-open="ehae178-B289" class="link link-ref link-reveal xref-bibr">289</a></sup> Data on the associations with CVD of other metrics for detecting HMOD in the heart are also available.<sup><a href="javascript:;" reveal-id="ehae178-B26" data-open="ehae178-B26" class="link link-ref link-reveal xref-bibr">26</a>,<a href="javascript:;" reveal-id="ehae178-B268" data-open="ehae178-B268" class="link link-ref link-reveal xref-bibr">268</a>,<a href="javascript:;" reveal-id="ehae178-B290" data-open="ehae178-B290" class="link link-ref link-reveal xref-bibr">290</a></sup> Since cardiac size and function differ by sex, sex-specific thresholds for detecting HMOD in the heart are used to avoid under-diagnosis in women.<sup><a href="javascript:;" reveal-id="ehae178-B25" data-open="ehae178-B25" class="link link-ref link-reveal xref-bibr">25</a>,<a href="javascript:;" reveal-id="ehae178-B174" data-open="ehae178-B174" class="link link-ref link-reveal xref-bibr">174</a>,<a href="javascript:;" reveal-id="ehae178-B291" data-open="ehae178-B291" class="link link-ref link-reveal xref-bibr">291</a></sup>

Recommendation Table 9

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375892)

Recommendations for assessing cardiac hypertension-mediated organ damage

![Recommendations for assessing cardiac hypertension-mediated organ damage](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt9.jpeg?Expires=1728462844&Signature=fTJloJhr8wcFigzaJpW3DbmdQ9llLaPjECTcRr9CfQrbvq2J73bxUyRcXHzXDyPuOzNqZ2M8swCIxlwiRYoTUpva8l3aY6Qr677BtJQ6Xw08rX6~~RGoEukWxg25GtKX1LpnbHIX7si2UnTIZo5I0EWuwdFGzAONLygsAJg6DE~4DEn2KdPzSMpmrTT82zmGxcHNwCIvOcYs5DbAEenxK4qwYX6YlGvmgda4IWlwAz1~NTrt9d5wzUbILrqnAwVZP8BvR7N9fQbBvJP0XXzboyIsT4rW--KLYsmTdQK2a~dARkhWxqnowpmFsfbxAxrkuvMsoVITKtP3ywmZLjo75Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

##### 7.4.3.3. The arteries

Cardiac computed tomography (CT) may be used to measure CAC and, if intravascular contrast is administered, fully visualize coronary artery disease to improve risk stratification.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B293" data-open="ehae178-B293" class="link link-ref link-reveal xref-bibr">293</a></sup> As noted in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, CAC scoring can reclassify CVD risk upwards or downwards in addition to conventional risk factors.<sup><a href="javascript:;" reveal-id="ehae178-B127" data-open="ehae178-B127" class="link link-ref link-reveal xref-bibr">127</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a>,<a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B233" data-open="ehae178-B233" class="link link-ref link-reveal xref-bibr">233</a>,<a href="javascript:;" reveal-id="ehae178-B294" data-open="ehae178-B294" class="link link-ref link-reveal xref-bibr">294</a></sup> Carotid ultrasound detects presence or absence of carotid plaque (wall thickness ≥ 1.5 mm) and stenosis. Presence of plaque in the carotid or femoral arteries improves risk prediction for CVD events in asymptomatic patients on top of conventional risk-factor assessment.<sup><a href="javascript:;" reveal-id="ehae178-B211" data-open="ehae178-B211" class="link link-ref link-reveal xref-bibr">211</a>,<a href="javascript:;" reveal-id="ehae178-B247" data-open="ehae178-B247" class="link link-ref link-reveal xref-bibr">247</a>,<a href="javascript:;" reveal-id="ehae178-B265" data-open="ehae178-B265" class="link link-ref link-reveal xref-bibr">265</a>,<a href="javascript:;" reveal-id="ehae178-B267" data-open="ehae178-B267" class="link link-ref link-reveal xref-bibr">267</a>,<a href="javascript:;" reveal-id="ehae178-B295" data-open="ehae178-B295" class="link link-ref link-reveal xref-bibr">295</a>,<a href="javascript:;" reveal-id="ehae178-B296" data-open="ehae178-B296" class="link link-ref link-reveal xref-bibr">296</a></sup> Systematic use of intima media thickness does not appear to consistently improve prediction of future CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B297" data-open="ehae178-B297" class="link link-ref link-reveal xref-bibr">297</a></sup> Arterial stiffness is measured as carotid–femoral PWV or brachial–ankle PWV, and can contribute to predictive value and risk reclassification.<sup><a href="javascript:;" reveal-id="ehae178-B28" data-open="ehae178-B28" class="link link-ref link-reveal xref-bibr">28</a>,<a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B215" data-open="ehae178-B215" class="link link-ref link-reveal xref-bibr">215</a>,<a href="javascript:;" reveal-id="ehae178-B216" data-open="ehae178-B216" class="link link-ref link-reveal xref-bibr">216</a></sup> PWV is currently used mostly for research purposes or in specialist referral centres. Checking for inter-arm BP difference may identify a subclavian stenosis as vascular HMOD.<sup><a href="javascript:;" reveal-id="ehae178-B38" data-open="ehae178-B38" class="link link-ref link-reveal xref-bibr">38</a></sup> Other tests assessing the vasculature \[such as abdominal ultrasound or ankle–brachial index (ABI)\] should also be considered in patients with hypertension, when specific cardiovascular complications (abdominal aneurysm, peripheral artery disease) are clinically suspected. Finally, microvascular HMOD can be assessed by fundoscopy. A simplified classification has been proposed and validated.<sup><a href="javascript:;" reveal-id="ehae178-B298" data-open="ehae178-B298" class="link link-ref link-reveal xref-bibr">298</a></sup> In hypertensive individuals, the presence of mild or moderate hypertensive retinopathy is associated with an increased risk of CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B299" data-open="ehae178-B299" class="link link-ref link-reveal xref-bibr">299</a></sup> Fundoscopy is recommended also in hypertensive diabetic patients and in the work-up of malignant hypertension and hypertensive emergencies.

Recommendation Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375895)

Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17)

![Recommendations for assessing vascular hypertension-mediated organ damage (see Evidence Table 17)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt10.jpeg?Expires=1728462844&Signature=3TlO-zkCTvNmcfTHLgruFN78dnJkzDEVSRlIVx7kO6fBeFzwL0MFQJ6da7kESp9lhaAUq4W4bMvjWAdw8cSytSvm5jpIlaQk7GMEurPLh0ZTdSnQTygMQ7s4EKrtyrRDkpf8vFJ4wEQQVs2lNpJbBmFzxmmUf1WaRSB71e5v4Tvq0r-Y7mKfVRhT6qS4KJfvJwPXGI7GaSz4Ik7XGHyhwC3QITzviY4mIWj3Eg5DbmCcPxoj83J5xL8NTr0Gwdu8kfX18b6oi8BCnzL~879hk9zKHsj-iO8MAZ77AwqwGLeBTHQDCFzOKXRigkBjON9LWE4Cnq64cnV2KtjZCZgJwA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 7.4.4. Genetic testing

Hypertension is considered a complex polygenic disorder, because many genes or gene combinations influence BP.<sup><a href="javascript:;" reveal-id="ehae178-B300" data-open="ehae178-B300" class="link link-ref link-reveal xref-bibr">300</a>,<a href="javascript:;" reveal-id="ehae178-B301" data-open="ehae178-B301" class="link link-ref link-reveal xref-bibr">301</a></sup> However, some well-defined phenotypes relating to single-gene mutations (i.e. monogenic forms of hypertension) have been identified (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S6](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). These are rare, but knowledge of the genetic defect may allow targeted treatment of the proband and also proper management of the patient’s siblings.<sup><a href="javascript:;" reveal-id="ehae178-B302" data-open="ehae178-B302" class="link link-ref link-reveal xref-bibr">302</a>,<a href="javascript:;" reveal-id="ehae178-B303" data-open="ehae178-B303" class="link link-ref link-reveal xref-bibr">303</a></sup> As such, genetic testing should be considered only for those with a high prior probability of having a monogenic condition and such patients should be referred to specialized centres. In most patients with elevated BP or hypertension, routine genetic testing is not recommended. Family history and a pedigree analysis can help to find a heritable pattern of hypertension or hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B304" data-open="ehae178-B304" class="link link-ref link-reveal xref-bibr">304</a></sup>

Recommendation Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375898)

Recommendations for genetic testing in hypertension management

![Recommendations for genetic testing in hypertension management](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt11.jpeg?Expires=1728462844&Signature=IWBQB3TvsHKotPHWLZH4J7JNQ8GVJJXbrEAVdX4i0nxThiC-zOcn4ctsRUXuQIITb~NbFF57SXHXZRXlbDVlY9keeL-zEcybbwPYMxAipUfzn0IPK9~cVGumZgiX-l7yFMzPxSQFSeHKVkHc07mJhGdSwL5RHxjBZMsKf6P6oamEnfdv89wHmO9GrY2ooRmEYQ3enG6OkZqwREL13f9rKQN4imNkxKTKb8vTz0MSD4BEuH0pLGwXYNVeo7tWdxL2xCB-Nh54mC3Cq5r7kHa8qWgxLbkHnyzyxH2rvDIEE-1-~FJJsUbvp553T87JpRV2majSf2i-CBOXKw5Ee6rw8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.5. Resistant hypertension: definition and diagnosis

Despite availability and use of multiple BP-lowering medications, many patients worldwide have uncontrolled hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B306 ehae178-B307 ehae178-B308" data-open="ehae178-B306 ehae178-B307 ehae178-B308" class="link link-ref link-reveal xref-bibr">306–308</a></sup> Considering this, societies have introduced the term ‘drug-resistant hypertension’, or ‘treatment-resistant hypertension’, or ‘resistant hypertension’,<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> which has been reported in 10%–20% of patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B310" data-open="ehae178-B310" class="link link-ref link-reveal xref-bibr">310</a>,<a href="javascript:;" reveal-id="ehae178-B311" data-open="ehae178-B311" class="link link-ref link-reveal xref-bibr">311</a></sup>

Resistant hypertension is not a disease _per se_. Compared with treated patients who achieve BP control, patients with resistant hypertension (by any definition) have a worse prognosis: risk of myocardial infarction, stroke, end-stage renal disease, and death in these adults may be two- to six-fold higher.<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Secondary causes of hypertension are also more likely in the presence of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B312" data-open="ehae178-B312" class="link link-ref link-reveal xref-bibr">312</a></sup>

All resistant hypertension definitions require a diuretic in the prescribed multiple-drug regimen, because excess salt intake and salt and water retention are key players in resistance to BP-lowering treatments (_[Table 10](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> In addition, excluding pseudo-resistance is a prerequisite. Specifically, pseudo-resistance indicates poor adherence to BP-lowering treatment, which should be verified by careful questioning of the patient in the first instance (_Section [7.4.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.4.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a></sup> In addition, white-coat hypertension must be excluded.<sup><a href="javascript:;" reveal-id="ehae178-B263" data-open="ehae178-B263" class="link link-ref link-reveal xref-bibr">263</a></sup> Contributors to pseudo-resistance are listed in _[Table 11](javascript:;)_. Objective evaluation of adherence (either directly observed treatment or detecting prescribed drugs in blood or urine samples) should also be considered, if resources allow.

Table 10

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375903)

Current definition of resistant hypertension

| Definition of resistant hypertension |
| --- |
| Hypertension is defined as resistant when a treatment strategy including appropriate lifestyle measures and treatment with maximum or maximally tolerated doses of a diuretic (thiazide or thiazide-like), a RAS blocker, and a calcium channel blocker fail to lower office systolic and diastolic BP values to <140 mmHg and/or <90 mmHg, respectively. These uncontrolled BP values must be confirmed by out-of-office BP measurements (HBPM or ABPM—_Section [5.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.1)_ for relevant BP thresholds). |

| Key considerations |
| --- |
| 
-   Resistant hypertension is not a disease, but an indicator that should be used to identify patients at high risk for CVD, in which secondary hypertension is also frequent;
    
-   Pseudo-resistant hypertension must be excluded, including that caused by non-adherence to treatment;
    
-   In patients with decreased eGFR (i.e. <30 mL/min/1.73 m<sup>2</sup>) an adequately up-titrated loop diuretic is necessary to define resistant hypertension;
    
-   Patients with suspected resistant hypertension should be referred to specialized centres;
    
-   These ESC Guidelines do not include the terms ‘controlled resistant hypertension’ (BP at target but requiring ≥4 medications) or ‘refractory hypertension’ (BP not at target despite ≥5 medications).
    

 |

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HBPM, home blood pressure monitoring; RAS, renin–angiotensin system.

© ESC 2024

Table 11

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375904)

Conditions found to cause pseudo-resistance or resistance to blood pressure-lowering treatment

| Causes of pseudo-resistant hypertension |
| --- |
| Poor adherence to and persistence with treatment  
White-coat phenomenon  
Poor BP measurement method  
Marked brachial artery calcification (Osler phenomenon)  
Clinician inertia (inadequate doses, inappropriate combinations of BP-lowering drugs)  
Munchausen syndrome (rare) |

| Causes of resistant hypertension |
| --- |
| _Behavioural factors_  
Overweight/obesity  
Physical inactivity  
Excess daily dietary sodium  
Excess habitual alcohol consumption |
| _Use of drugs or substances that may increase BP_  
See [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ |
| _Undetected secondary hypertension_  
See _[Table 13](javascript:;)_ |

BP, blood pressure.

© ESC 2024

The work-up of patients presumed to have resistant hypertension is complex and often requires technologies that are not available to GPs.<sup><a href="javascript:;" reveal-id="ehae178-B257" data-open="ehae178-B257" class="link link-ref link-reveal xref-bibr">257</a>,<a href="javascript:;" reveal-id="ehae178-B309" data-open="ehae178-B309" class="link link-ref link-reveal xref-bibr">309</a></sup> Accordingly, we recommend these patients are referred to specialized centres.

Recommendation Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375906)

Recommendations for resistant hypertension work-up (see Evidence Table 18)

![Recommendations for resistant hypertension work-up (see Evidence Table 18)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt12.jpeg?Expires=1728462844&Signature=caJR51vtBWj9AfwhUkA0wfGuXiWOJ-LNu491--CVN2B-6ZEQ4wJv47d6hQtJKAHJy~NuimuVWTqRFI5YDF-nmbDZOx4tVmbX1Zug229iBdJN0sATklrdKu8WASzhQUOHLOdfgZNY4ZfkOY5Xtz1nb5plnSfREzifhjgdrhLEKEEyH3G7Un0SLvi7yHG0V6MYYE2P5nmbRqortkU3xZZaC0Ty-Ti~pH4Lw6KHrMInuuNQSweLjmooi8c1OGSGJAoGAs6g2OZkMS29Vjg0LzR5rVtNOdfV8SO8utWJHieIPrqEz2HRad-zU-F4WzED0C8uml7SOcUDToYohD~kwO6VJg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 7.6. Secondary hypertension: when to screen/further investigations

#### 7.6.1. General considerations

Secondary hypertension is more prevalent than previously thought (_[Figures 13](javascript:;)–[15](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B312 ehae178-B313 ehae178-B314 ehae178-B315 ehae178-B316 ehae178-B317" data-open="ehae178-B312 ehae178-B313 ehae178-B314 ehae178-B315 ehae178-B316 ehae178-B317" class="link link-ref link-reveal xref-bibr">312–317</a></sup> Depending on the definition used and the cohort studied, the prevalence of secondary hypertension is 10%–35% in all hypertensive patients<sup><a href="javascript:;" reveal-id="ehae178-B318" data-open="ehae178-B318" class="link link-ref link-reveal xref-bibr">318</a>,<a href="javascript:;" reveal-id="ehae178-B319" data-open="ehae178-B319" class="link link-ref link-reveal xref-bibr">319</a></sup> and up to 50% of patients with resistant hypertension (though the latter prevalence estimate included persons with eGFR < 40 mL/min/1.73 m<sup>2</sup>).<sup><a href="javascript:;" reveal-id="ehae178-B312" data-open="ehae178-B312" class="link link-ref link-reveal xref-bibr">312</a></sup> Primary aldosteronism is a common cause,<sup><a href="javascript:;" reveal-id="ehae178-B315" data-open="ehae178-B315" class="link link-ref link-reveal xref-bibr">315</a>,<a href="javascript:;" reveal-id="ehae178-B320" data-open="ehae178-B320" class="link link-ref link-reveal xref-bibr">320</a></sup> with, e.g. a high prevalence of hyperaldosteronism (up to 12%) observed in patients with BP of >180/110 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B316" data-open="ehae178-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> Despite these numbers, screening rates for primary aldosteronism, even in high-risk groups such as those with resistant hypertension<sup><a href="javascript:;" reveal-id="ehae178-B321" data-open="ehae178-B321" class="link link-ref link-reveal xref-bibr">321</a></sup> and hypokalaemia,<sup><a href="javascript:;" reveal-id="ehae178-B322" data-open="ehae178-B322" class="link link-ref link-reveal xref-bibr">322</a></sup> are low (around 2% and 4% of eligible patients, respectively). In most healthcare systems, GPs are typically the ‘gatekeeper’ of access to specialized care and should be involved in screening patients for common causes of secondary hypertension, especially sleep apnoea and primary aldosteronism ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S3](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Primary aldosteronism is associated with an increased risk of CVD events, which may be partly independent of BP.<sup><a href="javascript:;" reveal-id="ehae178-B323" data-open="ehae178-B323" class="link link-ref link-reveal xref-bibr">323</a>,<a href="javascript:;" reveal-id="ehae178-B324" data-open="ehae178-B324" class="link link-ref link-reveal xref-bibr">324</a></sup>

![Summary of primary aldosteronism as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f13.jpeg?Expires=1728462844&Signature=FlGb~NC-zR4AZZjkzNBaZDqkbw0xShKVNXHugkUFVC8fDGfJ0hU2xvmfGLKSxBkf8bdyIZ6My04d6umuvKbUHQ9YYgayTwhVdcEUZFsar5KvV2Lm71hsgRL93wRJowEpC3Hg7-61L3xtHMqqriXgiyG~EZrt-oSGG~vDpRLPo4KY4L2ojBKbJvGMXJbLYExcGBJ0X8fDaZP6f5L17XHtKVp1Vg~Uhk9EViHV91MmLUgAO59wYZipc5lHZyzxgCkb56AK6W7AR6hi1gDKbAw0QiRMUxB3ZkqClscdyAtil0i5y-EohZfCsRZCe6ES-UCVCXgXIHh3zMUogoiwohJK4g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 13

Summary of primary aldosteronism as a common form of secondary hypertension.

AF, atrial fibrillation; HMOD, hypertension-mediated organ damage.

[Open in new tab](https://academic.oup.com/view-large/figure/479375910/ehae178f13.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f13.jpeg?Expires=1728462844&Signature=ms6~Nz0iGMX0gd5xdMOtcOj278S6o6I2EBv0~saCvGUarCVUf5Wm8auvi3muYwy9pOPtkrboCvU2O5yP4r9v3UkCm0uRIL-0Zry7FM-gQbN1R3YWlLD9tQTiL9~k4Z2qVOFn-2XK9D4n4yQ4NfZrp3RxcZPec7AJ9znvmY~0M0BjwKi09IcGUEJh-aZ1OZbV4ip3yFcmAkyiM4xoeZE26KpJIBFuA1R1k-cTqy9fPZa8ApJ7odp5onOmRgKqzTCCiHe6Pcs7RO7nQmWf8Od1tkzqbxm7o8C4y9ThMWro-fSOBixjgeu2uhcu7qYBwF-rtVmjfbMThqR4WFWg0zkCtQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375910&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Summary of renovascular disease as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f14.jpeg?Expires=1728462844&Signature=tDoq1vXjtinRDCKLYgop8kHNobqQIUO-5hHaLreOx9Eoq~5sT-8XTZDGqPCfalKWE9JCi5Zc1ley4T2VtPr5x8~Xey2buNBhNxgj8-9O95o2fbVeP-r1LES4NTFzafil9OnidNjC~SeVzKJyHuBn22h~dueN7hGJQSCdParGKDUQVDr0zdKFTNV4yaMGqN5HmJV2M6XysQqfPWBOTvsYva9QNZmydnQWGib1UJKeZvzq4VFjPTE~pQuSX5zLt6zL4Oev5Cgpb-KKGZAwgW0vhUI~iryy1FyUipx1V4DcKVefnXKmDy4vjbtKH1PwJ04FLFZWYrO6GmD1JNyQCUdlLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 14

Summary of renovascular disease as a common form of secondary hypertension.

CT-Angio, computed tomography angiography; CV, cardiovascular; FMD, fibromuscular dysplasia; GFR, glomerular filtration rate; MRI, magnetic resonance imaging; RAS, renin–angiotensin system.

[Open in new tab](https://academic.oup.com/view-large/figure/479375911/ehae178f14.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f14.jpeg?Expires=1728462844&Signature=kQ8jZSdpRpBdYptmK~LsG72V~GUYTkSsX~hqPDyy6AJSkj10HmbUwJDhUR0cv90exN6X1cumFmc17gHyHVr-G1t2VrqheZD4JuwJO5kTXxhR3zQU0Dn2GGYeyHHA1A9QG-Xj7JPAqCrx~Fqx9~1hc-hAuoSEmuMnfwwBmUye4CM9XJygQkJKv-rMCvf-bSJT6oB9WbnJfH1ZwqDdKnTntKsCArRG69WQN6UZuCQ3Mj4yhyb8oTTZ6IpKJa03qoPFHNPP3m9rk0K7lmv4Bnwbj9Ug5oW1rvvMxw~Q84aeOB4V5FcnuKrqlpYtsQt-5omWCyB3wpy3~GSHkIfNr6V5cg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375911&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Summary of obstructive sleep apnoea as a common form of secondary hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f15.jpeg?Expires=1728462844&Signature=zNYXlHSzFyreJ4gk2mAWaZ21L18DF9jWLSCkXEEPocj-nVEY7LromVEvoDPIIf2v1wiu-VxAD06HXDusbEV5sPmlwsIanCqy9PXYdDC8nDwnhrMiDmXezeNdrxJV8ALZ~mSB9r3u6taZPMTGfX4H82Sd9MnZ0~jeA1k9wxbJqXFKiuM7XzIZ5LW5Qyfw7eyk9OoKd57wSl5JN9cfYlG56BPeX6sBWzuV7iWlPITPwkchnVPAHPrN1qUNx5ADDue9DyOFXCoBAzt4F8AbjfcvuDiFZCl8OEiv6VYZ2mlO-Hq42G0A9u9y80i9aM8azxGjt153cVEEO9rnXS4PikcR6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 15

Summary of obstructive sleep apnoea as a common form of secondary hypertension.

AF, atrial fibrillation; ABPM, ambulatory blood pressure monitor; CPAP, continuous positive airway pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479375912/ehae178f15.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f15.jpeg?Expires=1728462844&Signature=m17LUhkbS88oSnBdzxHX700dSXREM22wSngJA2Iqk03SaLzesY3J3KtX2EKZHWxLj8tFNZKsmm4pSEnUDYdKJ2uEXtxyY2y9iFunCXOHHCy5KPxqLRJrbPe-vt259C7~nikXqwEJxiNYnITk3YH-jVPZQZDPVnsgRSAAA7Jm7o2jwMlhS3C6cpuL3jXnXJA6X6SIaMaKWH4U~1wVrIAWK54ykui299L9-Zt4IxF2vTY6fhcgcd-3RvuJaL~W0ZYNXQitHqcJri3SFpOigMv58xQ21WRo8F6vo6IvuTKMDiuyTv4lTMc5VkXR9IFMYmiB5hD6Gnv8bJb9ml6Unju46Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375912&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 7.6.2. Primary aldosteronism

Though spontaneous or diuretic-induced hypokalaemia are strongly suggestive of primary aldosteronism, a history of hypokalaemia is not present in most patients diagnosed with this condition. The aldosterone-to-renin ratio (ARR) is thus recommended for primary aldosteronism screening (see _[Figure 13](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B325" data-open="ehae178-B325" class="link link-ref link-reveal xref-bibr">325</a></sup> This test can easily be done in treatment-naïve patients, though it is far more common for the ARR test to be considered when patients are already being treated for elevated BP or hypertension. This is relevant because ARR can be influenced by the drugs being taken at the time of testing. Accordingly, there are 2 approaches to screen for aldosteronism among patients who are already undergoing treatment for elevated BP or hypertension:

-   The first is to conduct ARR testing in treated patients with an indication for aldosteronism screening as efficiently as possible and without changing or stopping their baseline BP-lowering medications, simply to facilitate such testing. The ARR result then needs to be interpreted in the context of the specific medication(s) the patient is taking. Advantages of this approach include reducing barriers to screening and no change in medication in these patients, many of whom do not have BP controlled and in whom further deterioration in their BP control by stopping or changing medication may increase risk of CVD. Disadvantages include the interpretation of the ARR result, which depends on the specific medications taken at the time of testing.<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> Input from a hypertension specialist or endocrinologist may be necessary.
    
-   To reliably estimate renin and aldosterone status (and therefore ARR), and to facilitate a ‘clean’ screen for aldosteronism, a second approach is to discontinue drugs that affect these variables whenever feasible before ARR testing (_[Table 12](javascript:;)_). Such interfering drugs include, beta-blockers, centrally acting drugs (e.g., clonidine and alpha-methyldopa) renin-angiotensin system (RAS) blockers and diuretics.<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a></sup> Long-acting calcium channel blockers (CCBs), either dihydropyridine or non-dihydropyridine, and alpha-receptor antagonists do not interfere with the ARR and can be used instead of interfering medications before ARR testing. Should drugs that do not interfere with the ARR be contraindicated or insufficient to control BP, centrally acting sympatholytic drugs can also then be used, but at the risk of slightly more false positives (by renin suppression). Furthermore, when mineralocorticoid receptor antagonists (MRAs) cannot be stopped for safety reasons (i.e. severe hypokalaemia or severe hypertension among patients with severe hyperaldosteronism), recent evidence suggests that the accuracy of ARR testing under this treatment is only marginally impacted, particularly in the presence of florid primary aldosteronism.<sup><a href="javascript:;" reveal-id="ehae178-B327" data-open="ehae178-B327" class="link link-ref link-reveal xref-bibr">327</a></sup>
    

Assessing sodium intake (preferably 24 h urinary sodium, or sodium-to-creatinine ratio in the morning urine sample) is also important for interpreting the ARR, as is time in menstrual cycle for females. ARR cut-offs vary depending on unit of measurement and by local laboratory. For detailed information, readers are referred to the latest primary aldosteronism guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B328" data-open="ehae178-B328" class="link link-ref link-reveal xref-bibr">328</a>,<a href="javascript:;" reveal-id="ehae178-B329" data-open="ehae178-B329" class="link link-ref link-reveal xref-bibr">329</a></sup>

Table 12

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375917)

Drugs and conditions that affect aldosterone, renin, and aldosterone-to-renin ratio

| Factor | Effect on plasma aldosterone levels | Effect on renin levels | Effect on ARR |
| --- | --- | --- | --- |
| **Serum potassium status** |
| Hypokalaemia | **↓** | **→↑** | **↓ (FN)** |
| Potassium loading | **↑** | **→↓** | **↑** |
| Sodium restriction | **↑** | **↑↑** | **↓ (FN)** |
| Sodium loading | **↓** | **↓↓** | **↑ (FP)** |
| **Drugs** |
| Beta-adrenergic blockers | **↓** | **↓↓** | **↑ (FP)** |
| Calcium channel blockers (DHPs) | **→↓** | **→↑** | **→↓ (FN** with short-acting DHPs**)** |
| ACE inhibitors | **↓** | **↑↑** | **↓ (FN)** |
| ARBs | **↓** | **↑↑** | **↓ (FN)** |
| Potassium-sparing diuretics | **↑** | **↑↑** | **↓ (FN)** |
| Potassium-wasting diuretics | **→↑** | **↑↑** | **↓ (FN)** |
| Alpha-2 agonists (clonidine, methyldopa) | **↓** | **↓↓** | **↑ (FP)** |
| NSAIDs | **↓** | **↓↓** | **↑ (FP)** |
| Steroids | **↓** | **→↓** | **↑ (FP)** |
| Contraceptive agents (drospirenone) | **↑** | **↑** | **↑ (FP)** |

↑, raised; ↓, lowered; →, no effect; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARR, aldosterone-to-renin ratio; DHPs, dihydropyridines; FN, false negative; FP, false positive; NSAID, non-steroidal anti-inflammatory drug.

© ESC 2024

#### 7.6.3. Renovascular hypertension

Renovascular hypertension (RVH) defines a condition where renal artery occlusion or stenosis decreases renal perfusion pressure to a level that activates the renin–angiotensin–aldosterone system (RAAS), thereby raising BP. Major causes are atherosclerosis and fibromuscular dysplasia (_[Figure 14](javascript:;)_ and [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S1](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Atherosclerosis is the most common form of RVH, especially in older adults.<sup><a href="javascript:;" reveal-id="ehae178-B318" data-open="ehae178-B318" class="link link-ref link-reveal xref-bibr">318</a></sup> Fibromuscular dysplasia is a systemic non-atherosclerotic vascular disease involving medium-sized muscular arteries. When renal arteries are involved, fibromuscular dysplasia may induce RVH (FMD-RVH), especially in children and younger women.<sup><a href="javascript:;" reveal-id="ehae178-B330 ehae178-B331 ehae178-B332" data-open="ehae178-B330 ehae178-B331 ehae178-B332" class="link link-ref link-reveal xref-bibr">330–332</a></sup>

Though not highly sensitive, very elevated renin levels raise the suspicion for RVH. The work-up of RVH (_[Table 13](javascript:;)_) is based on imaging tests, such as renal artery Doppler ultrasound, with bilateral assessment of renal arterial resistive index, or abdominal CT angiography, or magnetic resonance imaging (MRI), in line with current ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases,<sup><a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a></sup> which will be updated in 2024. Of note, bystander renal artery stenosis may be present in patients with essential hypertension, without causing secondary hypertension due to RVH. Since fibromuscular dysplasia is a systemic disease, CT or MRI angiography from head to pelvis is recommended in patients with FMD-RVH.<sup><a href="javascript:;" reveal-id="ehae178-B277" data-open="ehae178-B277" class="link link-ref link-reveal xref-bibr">277</a>,<a href="javascript:;" reveal-id="ehae178-B332" data-open="ehae178-B332" class="link link-ref link-reveal xref-bibr">332</a></sup>

Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375921)

Optional tests that should be used to screen for secondary hypertension in the presence of suggestive signs, symptoms, or medical history

| Cause of secondary hypertension | Screening test |
| --- | --- |
| Primary aldosteronism | Aldosterone-to-renin ratio  
Helpful information can also be provided by reviewing prior potassium levels (hypokalaemia increases the likelihood of coexistent primary hyperaldosteronism) |
| Renovascular hypertension | Renal doppler ultrasound  
Abdominal CT angiogram or MRI |
| Phaeochromocytoma/paraganglioma | 24 h urinary and/or plasma metanephrine and normetanephrine |
| Obstructive sleep apnoea syndrome | Overnight ambulatory polysomnography |
| Renal parenchymal disease | Plasma creatinine, sodium, and potassium  
eGFR  
Urine dipstick for blood and protein  
Urinary albumin-to-creatinine ratio  
Renal ultrasound |
| Cushing’s syndrome | 24 h urinary free cortisol  
Low-dose dexamethasone suppression test |
| Thyroid disease (hyper- or hypothyroidism) | TSH |
| Hyperparathyroidism | Parathyroid hormone  
Calcium and phosphate |
| Coarctation of the aorta | Echocardiogram  
Aortic CT angiogram |

CT, computed tomography; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone.

© ESC 2024

#### 7.6.4. Obstructive sleep apnoea syndrome

Obstructive sleep apnoea syndrome (OSAS) is prevalent in hypertension and particularly in resistant hypertension, with studies indicating that up to 60% of patients with resistant hypertension have features of OSAS.<sup><a href="javascript:;" reveal-id="ehae178-B314" data-open="ehae178-B314" class="link link-ref link-reveal xref-bibr">314</a></sup> OSAS should be suspected in patients with hypertension and suggestive symptoms (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S2](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_), in all patients with resistant hypertension, and in patients with non-dipping or reverse-dipping pattern at 24 h BP monitoring, especially if obese (_[Figure 15](javascript:;)_). Using validated questionnaires may help identify patients at high risk of OSAS.<sup><a href="javascript:;" reveal-id="ehae178-B333" data-open="ehae178-B333" class="link link-ref link-reveal xref-bibr">333</a></sup> Lack of suggestive symptoms does not rule out OSAS. A simplified polysomnogram confirms the diagnosis \[apnoea–hypopnoea index (AHI) > 5\] and can quantify the severity of OSAS (mild: AHI < 15; moderate: AHI of 15–30; severe: AHI > 30).<sup><a href="javascript:;" reveal-id="ehae178-B334" data-open="ehae178-B334" class="link link-ref link-reveal xref-bibr">334</a></sup>

#### 7.6.5. Phaeochromocytoma/paraganglioma

Phaeochromocytomas/paragangliomas (PPGLs) are a rare form of secondary hypertension characterized by a highly heterogeneous clinical presentation.<sup><a href="javascript:;" reveal-id="ehae178-B335" data-open="ehae178-B335" class="link link-ref link-reveal xref-bibr">335</a>,<a href="javascript:;" reveal-id="ehae178-B336" data-open="ehae178-B336" class="link link-ref link-reveal xref-bibr">336</a></sup> PPGLs are usually discovered incidentally.<sup><a href="javascript:;" reveal-id="ehae178-B337" data-open="ehae178-B337" class="link link-ref link-reveal xref-bibr">337</a></sup>

A PPGL should be suspected in the presence of signs and symptoms of catecholamine excess or in syndromic PPGL, in patients with a family history of PPGL, and in carriers of a germline mutation in one of the PPGL-causing genes.<sup><a href="javascript:;" reveal-id="ehae178-B338" data-open="ehae178-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> Since normetanephrine and metanephrine are secreted constitutively, as opposed to the highly variable nature of catecholamine secretion, they are preferred as screening tests for PPGL (_[Table 13](javascript:;)_).

Recommendation Table 13

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375927)

Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20)

![Recommendations for screening for secondary hypertension (see Evidence Tables 19 and 20)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt13.jpeg?Expires=1728462844&Signature=ujVZJHmDj6WAF3hX9uRHBPyJVM-sUAagb2962zh~wV8f4tjYSIaAy42IfxYi-bkCdsNG3A4i1VWDxC9ivUUtTwpDTN27zlevYGTs8cICOZbL3x9FGvJj1cGbUjzTj7bQ-ZtP2LFuk5gcTqv3goR36DYpq4FvsCZG8tl6XlYT35jKhtqbG6eOoC-1eiH6HHEZ0BKj8zGiB16TXbRUXiNYGtLtdUvGzZXSBJIg-lm~TputWFfWC3ndvwAwWsFR7bimqsS6rdkQzjcFb5X6oaXqRcu4srNO~aBi6T6OcxBy8dZln6qtF7CayycRIZ-ZWEKj35Rbt8Z0hNZp5-xogqaKxg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 8\. Preventing and treating elevated blood pressure and hypertension

The ultimate goal of preventing and treating elevated BP and hypertension is to reduce CVD, to improve quality of life, and to prevent premature death. Crucially, besides BP, other CVD risk factors need to be comprehensively addressed (e.g. smoking, glucose, dyslipidaemia) as detailed in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Indeed, it is worth emphasizing that, when combined, these CVD risk factors have multiplicative (not additive) effects on CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B340" data-open="ehae178-B340" class="link link-ref link-reveal xref-bibr">340</a></sup>

### 8.1. Prevention strategies in early life

Detailed information on this topic is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA). High BP tracks from childhood to adulthood.<sup><a href="javascript:;" reveal-id="ehae178-B341" data-open="ehae178-B341" class="link link-ref link-reveal xref-bibr">341</a>,<a href="javascript:;" reveal-id="ehae178-B342" data-open="ehae178-B342" class="link link-ref link-reveal xref-bibr">342</a></sup> Hypertension in childhood was redefined in a 2022 ESC Consensus Document.<sup><a href="javascript:;" reveal-id="ehae178-B343" data-open="ehae178-B343" class="link link-ref link-reveal xref-bibr">343</a></sup>

Recommendation Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375932)

Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21)

![Recommendations for screening for hypertension in children and adolescents (see Evidence Table 21)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt14.jpeg?Expires=1728462844&Signature=wzXORHHZIpEvS2BESTAdsgrR1QU625m5iUW88W7pLDAew7Q3zKbf2xs~nXXX6su5JwHEHGubm2tpUZVF7EMb4olfWtC8-c4OEr-O6Gi7Zv0sUb6AQBYTNxcDpLRe4XeJgTsvHI9FzuCSdWFE1XCbsf3VyXLKjxCcf7W~eGmrfSy3GY46rPW4bLd3DkdZoxvuLqq~Ds~xJpfGrlPFz5G4E5S7mDBhR9Q2zO820~6z-IulFBfvvufrHt~ytlssnGz8QECBOdJfzOM34IKnWaylAl3vekUhFTFDh7ml~5SaMZ4qbtqqy82oSL7hEy5jHlg8IlzQ~VjnXJoCN3dQyV5mtg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.2. Non-pharmacological interventions

A major underlying contributor to elevated BP and hypertension in the general adult population is unhealthy lifestyle, with severe consequences for all-cause and CVD mortality. As such, we give lifestyle interventions to reduce BP a special status in our recommendations throughout these guidelines (_[Figures 16](javascript:;)_ and _[17](javascript:;)_). This is reflected by a modified approach to the class of recommendations for lifestyle interventions compared with medical interventions (pharmacological or procedural). Given the salutary benefits of healthy lifestyle on a range of outcomes that extend well beyond BP-lowering effects,<sup><a href="javascript:;" reveal-id="ehae178-B347" data-open="ehae178-B347" class="link link-ref link-reveal xref-bibr">347</a></sup> including broad mental and physical health benefits, we do not require lifestyle interventions to have RCT evidence for efficacy in reducing CVD events through BP lowering to achieve a Class I recommendation. In deciding to give lifestyle interventions this status, the task force also recognizes that: (i) lifestyle interventions are less likely to be subjected to clinical outcomes trials (e.g. due to funding limitations and lack of interest from industry), and (ii) the risks of adverse effects and toxicity relating to healthy lifestyle interventions are low. In contrast, in these guidelines, to achieve a Class I recommendation (irrespective of level of evidence) there needs to be evidence that medical interventions that reduce BP also decrease CVD events by BP lowering.

![Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f16.jpeg?Expires=1728462844&Signature=vm-F8G6U5QVDf3R3wWZtcvxXzvAw899-fOdRDit9dj4R16UavCP~v0mS8waoBj~fyTdZ9ligmamXHmeWKKbNeoXyia3lLZu6PyNi2c3DnUdxYT4mOce25P2VZBesLNfix~EHBjKIIT6FfdnSlgK00CZW9bbIhgub4tlc4EHbZxpeyvbu0N19d4lMxx7eJI6oEGbt3PyPWMWxjx8ntr-AfzbyocJyphWkBvyFyYVBRGdpNUb3RZ4j0UZ-bBe67oxiGB1mLzE790I9AclI6cv6Z3B5LyEWqU0sS-nZJHFW~JdBm7g0wcm8G2546GPXPujIActrPiIQyjpGKPXM0tXG1w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 16

Physical activity according to different types of exercise and reduction of blood pressure and overall cardiovascular disease risk.

Priority is given to aerobic exercise training (green). BP, blood pressure; CVD, cardiovascular disease.

[Open in new tab](https://academic.oup.com/view-large/figure/479375935/ehae178f16.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f16.jpeg?Expires=1728462844&Signature=CnlLGIzk6SdgXQfdhoZYOAWarzop03mID5Ctva0mnBe~C50yg5s0UUQy5mvxc2MinMJL~MJimNqT9fHMzejjoCRvqdn0rSmEKawGZAJby7tqXNmDxex26CBEijgk7gJybo9oy0Xb15DIA4W7lcewPARZfeIB339zsdWAp9yjrtj97CJYdMS4dWmp2nl1g~mSfTxp4KdpmiXxchZ8M7h4YBEtLntkRiXfdyx4TSRVWP9bLJRNk7yJedDc1HfS54B7eVMy4gcm6Epmu0m4Xy--DCQgNbtUCUpGzCgh9bURI43s8ZoPNfnV6lPLXe1aP8xknJtmRHxIgQXQ3rehweyOSg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375935&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

![Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f17.jpeg?Expires=1728462844&Signature=FK-aP2Qky-gsFLmKHRcqYgsZQOeiSfYTfagaZQIEuaym2RntVPLJWVbxTfX-oT9QDlZEn6CghQ0KB~AR8TLvwWX-d59ykXzerBwPfOY~jV-FToguCcys~nmMtE4kvMk9YARf7tApXm60yYYjKXzemzq7OMba42kYhGinOLNv7F2XyuBPVQl7D8lz28f3Tn9slmCaEvfOUW31U-X43TXJxkfZ1oC80CyJP-kR9oAL5wzVsQ3fiUxd2xHEKwQWqZ-3d~m5tDhXCrrsQf3MhNdntAPbfMKl68y4QjWTDnyhKwGF2sJlxeO7t4Cv4z09c-hlKec7WPLEV7OCxicsGHdnLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 17

Effects of main lifestyle factors on blood pressure and cardiovascular risk reduction.

BP, blood pressure; CV, cardiovascular. Smoking cessation reduces overall cardiovascular risk but not BP (long arrow). Salt reduction reduces BP and (for persons with high baseline intake) reduces cardiovascular risk. Increased potassium intake and higher physical activity, as well as optimized weight management, reduce BP and are associated with lower overall cardiovascular risk (short arrows).

[Open in new tab](https://academic.oup.com/view-large/figure/479375936/ehae178f17.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f17.jpeg?Expires=1728462844&Signature=H-bpnRL~IV4f9DErIypFFbjHP~XJjv0DG-MHq5mbQjEUayvwAzqIEm1LrC9-pGvyEup7RIvrtwiNRpwXlXvsOKJUqNa97kOaYyEQnMsNa3-AMU73lrpEDdeGDrscmjwH-Hnby6JQhovd5bsWLAQTsmy278-nBW7R9T37ZVhdKylY5XVxEKcu-w9oaFfY43T2eHommnhrspstrAbkyE5Cbsd4lRACZuLmme2C9pm2KqCRwSYrhEG6PSs97a58ovGBCxo--ibqPGrtI8-1tmlFhn-k8PiKyB2PdMAE~BhnCe-eifHLsHwSTgwdk-z04B53ruBj6AMBkkJaKBNHIeAjyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375936&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 8.2.1. Dietary sodium and potassium intake

##### 8.2.1.1. Sodium

Reducing dietary salt (sodium chloride) intake in individuals with high baseline intake lowers CVD event rates.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a></sup> Extensive observational studies have reported dose–response associations between high dietary sodium intake and CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B349 ehae178-B350 ehae178-B351" data-open="ehae178-B349 ehae178-B350 ehae178-B351" class="link link-ref link-reveal xref-bibr">349–351</a></sup> The potential impact of salt reduction on population health is significant, particularly in countries where the population’s average salt intake is high. Pooled data from long-term follow-up salt-reduction trials demonstrate that reducing salt by 2.5 g/day is associated with an approximately 20% reduction in CVD events at the population level.<sup><a href="javascript:;" reveal-id="ehae178-B349" data-open="ehae178-B349" class="link link-ref link-reveal xref-bibr">349</a></sup>

The health benefits of salt reduction are likely mediated, largely, by BP-lowering effects.<sup><a href="javascript:;" reveal-id="ehae178-B352 ehae178-B353 ehae178-B354" data-open="ehae178-B352 ehae178-B353 ehae178-B354" class="link link-ref link-reveal xref-bibr">352–354</a></sup> An almost linear relationship has been described in a dose–response meta-analysis between sodium intake ranging from 0.4 to 7.6 g/day and reduction of systolic and diastolic BP is independent of baseline BP.<sup><a href="javascript:;" reveal-id="ehae178-B355" data-open="ehae178-B355" class="link link-ref link-reveal xref-bibr">355</a>,<a href="javascript:;" reveal-id="ehae178-B356" data-open="ehae178-B356" class="link link-ref link-reveal xref-bibr">356</a></sup> Women appear to be, on average, more sodium sensitive than men,<sup><a href="javascript:;" reveal-id="ehae178-B357" data-open="ehae178-B357" class="link link-ref link-reveal xref-bibr">357</a></sup> and may have greater outcome benefits when receiving comparable sodium-restricted diets.<sup><a href="javascript:;" reveal-id="ehae178-B358" data-open="ehae178-B358" class="link link-ref link-reveal xref-bibr">358</a></sup> Trial evidence for the BP-lowering benefits of salt reduction extend down to daily sodium intakes of <1.5 g/day.<sup><a href="javascript:;" reveal-id="ehae178-B356" data-open="ehae178-B356" class="link link-ref link-reveal xref-bibr">356</a>,<a href="javascript:;" reveal-id="ehae178-B358 ehae178-B359 ehae178-B360 ehae178-B361" data-open="ehae178-B358 ehae178-B359 ehae178-B360 ehae178-B361" class="link link-ref link-reveal xref-bibr">358–361</a></sup>

The task force acknowledges that the observational data linking sodium intake to CVD outcomes are mixed and that some studies have not found a link between salt intake and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B362" data-open="ehae178-B362" class="link link-ref link-reveal xref-bibr">362</a>,<a href="javascript:;" reveal-id="ehae178-B363" data-open="ehae178-B363" class="link link-ref link-reveal xref-bibr">363</a></sup> In addition, a potential J-curve exists between sodium intake and CVD events (whereby some analyses suggest that sodium reduction to very low levels could be harmful).<sup><a href="javascript:;" reveal-id="ehae178-B363" data-open="ehae178-B363" class="link link-ref link-reveal xref-bibr">363</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> While there are differences of opinion, the task force agreed that, on balance, (i) observational J-curve data are often due to reverse causality or confounding,<sup><a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B365" data-open="ehae178-B365" class="link link-ref link-reveal xref-bibr">365</a>,<a href="javascript:;" reveal-id="ehae178-B366" data-open="ehae178-B366" class="link link-ref link-reveal xref-bibr">366</a></sup> (ii) the relationship between dietary sodium and stroke is typically linear in shape, without any J-curve, (iii) if the J-curve were causal, the adverse effect of very low sodium on CVD would have to be mediated by some harmful mechanism that overcomes the expected benefit mediated by BP lowering (which is unlikely), and (iv) estimation of sodium intake using spot-urine sodium testing (which was commonly done in studies reporting a J-curve) may not be as valid as other methods.<sup><a href="javascript:;" reveal-id="ehae178-B367" data-open="ehae178-B367" class="link link-ref link-reveal xref-bibr">367</a></sup> For example, most (but not all)<sup><a href="javascript:;" reveal-id="ehae178-B362" data-open="ehae178-B362" class="link link-ref link-reveal xref-bibr">362</a></sup> reports measuring 24 h urine sodium excretion (a surrogate measure of sodium intake) have not reported a J-curve association with CVD.<sup><a href="javascript:;" reveal-id="ehae178-B350" data-open="ehae178-B350" class="link link-ref link-reveal xref-bibr">350</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a></sup> Furthermore the causal evidence demonstrating reduced CVD with sodium restriction (using potassium-enriched salt substitutes) in the Salt Substitute and Stroke Study (SSaSS) and Diet, ExerCIse and carDiovascular hEalth-Salt (DECIDE-Salt) trials was compelling,<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a></sup> even though sodium restriction in these trials was not below 2 g/day.

It is recommended to restrict total dietary sodium intake to approximately 2 g/day or less (equivalent to approximately 5 g or about a teaspoon of salt per day). This includes added salt and salt already contained in food. While the feasibility of this sodium target can be debated, the evidence for the benefits of this sodium target among patients with elevated BP or hypertension is sufficient, particularly in terms of lowering BP. The optimal sodium intake in the general population with non-elevated BP is less clear (noting also that the BP-lowering effect of salt reduction among patients with non-elevated BP appears lower).<sup><a href="javascript:;" reveal-id="ehae178-B353" data-open="ehae178-B353" class="link link-ref link-reveal xref-bibr">353</a>,<a href="javascript:;" reveal-id="ehae178-B354" data-open="ehae178-B354" class="link link-ref link-reveal xref-bibr">354</a></sup> A more feasible compromise in the general population might be a target sodium intake range of 2–4 g/day.<sup><a href="javascript:;" reveal-id="ehae178-B369" data-open="ehae178-B369" class="link link-ref link-reveal xref-bibr">369</a>,<a href="javascript:;" reveal-id="ehae178-B370" data-open="ehae178-B370" class="link link-ref link-reveal xref-bibr">370</a></sup> It needs to be emphasized that large parts of daily sodium intake occur by means of sodium consumption contained in processed foods.

##### 8.2.1.2. Potassium

Optimal dietary potassium intake, e.g. by consuming diets rich in fruits and vegetables, has BP-lowering effects and may be associated with lower CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B364" data-open="ehae178-B364" class="link link-ref link-reveal xref-bibr">364</a>,<a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a>,<a href="javascript:;" reveal-id="ehae178-B371 ehae178-B372 ehae178-B373" data-open="ehae178-B371 ehae178-B372 ehae178-B373" class="link link-ref link-reveal xref-bibr">371–373</a></sup> The association between potassium intake, systolic BP, and CVD events may be sex-specific, being stronger in women.<sup><a href="javascript:;" reveal-id="ehae178-B374" data-open="ehae178-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> The World Health Organization (WHO) recommends over 3.5 g/day (∼90 mmol/day) of dietary potassium.<sup><a href="javascript:;" reveal-id="ehae178-B375" data-open="ehae178-B375" class="link link-ref link-reveal xref-bibr">375</a></sup> Excessive potassium supplementation should, however, be avoided<sup><a href="javascript:;" reveal-id="ehae178-B374" data-open="ehae178-B374" class="link link-ref link-reveal xref-bibr">374</a></sup> and CKD guidelines recommend dietary potassium restriction to <2.4 g/day in persons with advanced CKD (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B376" data-open="ehae178-B376" class="link link-ref link-reveal xref-bibr">376</a></sup>

A lower urinary sodium-to-potassium ratio (Na<sup>+</sup>/K<sup>+</sup> ratio; a surrogate for reduced dietary sodium intake complemented by increased potassium intake) has been associated with a greater reduction in systolic and diastolic BP than with a higher ratio.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B377" data-open="ehae178-B377" class="link link-ref link-reveal xref-bibr">377</a></sup>

In patients with hypertension and high dietary sodium, increased dietary intake of potassium (in addition to lower dietary sodium) should be considered.<sup><a href="javascript:;" reveal-id="ehae178-B348" data-open="ehae178-B348" class="link link-ref link-reveal xref-bibr">348</a>,<a href="javascript:;" reveal-id="ehae178-B350" data-open="ehae178-B350" class="link link-ref link-reveal xref-bibr">350</a>,<a href="javascript:;" reveal-id="ehae178-B378" data-open="ehae178-B378" class="link link-ref link-reveal xref-bibr">378</a></sup> In patients with persistently high sodium intake (>5 g/day) and without moderate-to-advanced CKD, particularly women, an increase in potassium intake by 0.5–1.0 g/day may be considered to achieve a favourable Na<sup>+</sup>/K<sup>+</sup> ratio of 1.5–2.0 and to reduce CVD risk. Potassium supplementation can be achieved by substituting sodium using potassium enriched salts (75% sodium chloride and 25% potassium chloride)<sup><a href="javascript:;" reveal-id="ehae178-B368" data-open="ehae178-B368" class="link link-ref link-reveal xref-bibr">368</a>,<a href="javascript:;" reveal-id="ehae178-B379" data-open="ehae178-B379" class="link link-ref link-reveal xref-bibr">379</a>,<a href="javascript:;" reveal-id="ehae178-B380" data-open="ehae178-B380" class="link link-ref link-reveal xref-bibr">380</a></sup> or by increasing dietary potassium intake \[e.g. a 125 g (medium) banana contains about 450 mg potassium, or unsalted boiled spinach (840 mg/cup) or mashed avocado (710 mg/cup)\]. In patients with CKD and/or those taking potassium-sparing medication, such as some diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) or spironolactone, serum levels of potassium should be monitored (noting that phlebotomy recommendations to avoid spuriously high potassium results should be followed).

#### 8.2.2. Physical activity and exercise

In a systematic review and meta-analyses, aerobic (endurance) exercise was suggested as the first-line exercise therapy for reducing BP in patients with elevated BP and hypertension vs. alternative forms of exercise, such as dynamic or isometric resistance training.<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a></sup> In patients with hypertension, regular aerobic exercise substantially lowers systolic BP by up to 7–8 mmHg and diastolic BP by up to 4–5 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B382" data-open="ehae178-B382" class="link link-ref link-reveal xref-bibr">382</a></sup> For non-white patients with hypertension, dynamic resistance training elicits BP reductions that appear comparable to aerobic exercise.<sup><a href="javascript:;" reveal-id="ehae178-B383" data-open="ehae178-B383" class="link link-ref link-reveal xref-bibr">383</a></sup> Isometric resistance training also achieves clinically relevant BP reductions in patients with hypertension, but results are inconsistent and more data from more high-quality intervention trials are required (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B384" data-open="ehae178-B384" class="link link-ref link-reveal xref-bibr">384</a>,<a href="javascript:;" reveal-id="ehae178-B385" data-open="ehae178-B385" class="link link-ref link-reveal xref-bibr">385</a></sup> With respect to mode and intensity of aerobic exercise, high-intensity interval training elicits comparable BP reductions to moderate continuous exercise, with high-intensity interval training achieving greater improvement in physical fitness.<sup><a href="javascript:;" reveal-id="ehae178-B386" data-open="ehae178-B386" class="link link-ref link-reveal xref-bibr">386</a></sup>

In patients with known hypertension, engaging in physical activity is associated with reduced CVD mortality risk vs. sedentary patients with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B387" data-open="ehae178-B387" class="link link-ref link-reveal xref-bibr">387</a></sup>

An exaggerated BP response to exercise may yield diagnostic merits for predicting incident hypertension and CVD. In a meta-analysis, an exaggerated BP response to exercise was associated with an increased risk for masked hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B388" data-open="ehae178-B388" class="link link-ref link-reveal xref-bibr">388</a></sup> The risk of coronary heart disease also increases with higher systolic BP during exercise, independent of systolic BP at rest.<sup><a href="javascript:;" reveal-id="ehae178-B389" data-open="ehae178-B389" class="link link-ref link-reveal xref-bibr">389</a></sup>

Prior recommendations for at least 150 min/week of moderate intensity aerobic exercise (≥30 min, 5–7 days/week) can be maintained.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> Alternatively, 75 min of vigorous-intensity exercise per week over 3 days may be performed, with additional benefits derived by achieving 300 min of moderate-intensity or 150 min of vigorous-intensity aerobic physical activity per week.<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a>,<a href="javascript:;" reveal-id="ehae178-B391" data-open="ehae178-B391" class="link link-ref link-reveal xref-bibr">391</a></sup> As acute aerobic exercise induces intensity-dependent short-term reductions in ambulatory BP after exercise, patients with elevated BP and hypertension may benefit from daily exercise to improve their 24 h BP profile and avoid BP peaks on sedentary days.<sup><a href="javascript:;" reveal-id="ehae178-B392" data-open="ehae178-B392" class="link link-ref link-reveal xref-bibr">392</a></sup> Aerobic exercise should be complemented by low- or moderate-intensity resistance training (2–3 times per week), e.g. dynamic resistance, starting at 2–3 sets of 10–15 repetitions at 40%–60% of one-repetition maximum<sup><a href="javascript:;" reveal-id="ehae178-B393" data-open="ehae178-B393" class="link link-ref link-reveal xref-bibr">393</a></sup> or isometric resistance training with three sets of 1–2 min contractions, such as hand-grip, plank, or wall sit (_[Figure 16](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B381" data-open="ehae178-B381" class="link link-ref link-reveal xref-bibr">381</a>,<a href="javascript:;" reveal-id="ehae178-B394" data-open="ehae178-B394" class="link link-ref link-reveal xref-bibr">394</a></sup>

In uncontrolled hypertension at rest, high-intensity exercise should be applied with caution, with resting systolic BP of >200 mmHg and diastolic BP of >110 mmHg indicating relative contraindications.<sup><a href="javascript:;" reveal-id="ehae178-B395" data-open="ehae178-B395" class="link link-ref link-reveal xref-bibr">395</a></sup> Age, sex, gender,<sup><a href="javascript:;" reveal-id="ehae178-B396" data-open="ehae178-B396" class="link link-ref link-reveal xref-bibr">396</a></sup> ethnicity, and comorbidities, as well as individual preferences, should be considered for individual exercise prescription. Detailed information on exercise prescription in terms of frequency, intensity, time (duration) and type and progression are available in the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease,<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup> which include recommendations for pre-participation screening and cardiopulmonary exercise testing.<sup><a href="javascript:;" reveal-id="ehae178-B390" data-open="ehae178-B390" class="link link-ref link-reveal xref-bibr">390</a></sup>

#### 8.2.3. Weight reduction and diet

Visceral obesity is common and associated with incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B397" data-open="ehae178-B397" class="link link-ref link-reveal xref-bibr">397</a>,<a href="javascript:;" reveal-id="ehae178-B398" data-open="ehae178-B398" class="link link-ref link-reveal xref-bibr">398</a></sup> An average weight loss of 5 kg has been associated with an average systolic and diastolic BP reduction of 4.4 and 3.6 mmHg, respectively.<sup><a href="javascript:;" reveal-id="ehae178-B399" data-open="ehae178-B399" class="link link-ref link-reveal xref-bibr">399</a></sup> Data show that, starting at an index body mass index (BMI) of 40 kg/m<sup>2</sup>, a median weight loss of 13% is associated with a 22% lower risk for hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B400" data-open="ehae178-B400" class="link link-ref link-reveal xref-bibr">400</a>,<a href="javascript:;" reveal-id="ehae178-B401" data-open="ehae178-B401" class="link link-ref link-reveal xref-bibr">401</a></sup> Maintaining even moderate weight loss of 5%–10% of initial body weight can improve not only BP, but also glucose and lipid metabolism, and potentially reduce premature all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B402 ehae178-B403 ehae178-B404" data-open="ehae178-B402 ehae178-B403 ehae178-B404" class="link link-ref link-reveal xref-bibr">402–404</a></sup> However, achieving long-term effects in patients with hypertension via weight loss is challenging and the magnitude of these effects remains unclear.<sup><a href="javascript:;" reveal-id="ehae178-B405" data-open="ehae178-B405" class="link link-ref link-reveal xref-bibr">405</a>,<a href="javascript:;" reveal-id="ehae178-B406" data-open="ehae178-B406" class="link link-ref link-reveal xref-bibr">406</a></sup> Weight stabilization during middle-age appears to be an important and attainable goal to prevent obesity-related increase in BP later in life.<sup><a href="javascript:;" reveal-id="ehae178-B407" data-open="ehae178-B407" class="link link-ref link-reveal xref-bibr">407</a></sup>

Evidence-based diets, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension (DASH) diet, are established interventions in patients with hypertension to reduce their BP and CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B408" data-open="ehae178-B408" class="link link-ref link-reveal xref-bibr">408</a>,<a href="javascript:;" reveal-id="ehae178-B409" data-open="ehae178-B409" class="link link-ref link-reveal xref-bibr">409</a></sup> Additional information on healthy dietary patterns is provided in the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice and [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

In combination with weight-loss and exercise interventions<sup><a href="javascript:;" reveal-id="ehae178-B410" data-open="ehae178-B410" class="link link-ref link-reveal xref-bibr">410</a></sup> and low sodium intake,<sup><a href="javascript:;" reveal-id="ehae178-B411" data-open="ehae178-B411" class="link link-ref link-reveal xref-bibr">411</a></sup> the DASH diet has added effect on BP reduction.<sup><a href="javascript:;" reveal-id="ehae178-B412" data-open="ehae178-B412" class="link link-ref link-reveal xref-bibr">412</a></sup> Pharmacological treatment of obesity with orlistat achieved a slight reduction of 2.6 mmHg in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B413" data-open="ehae178-B413" class="link link-ref link-reveal xref-bibr">413</a></sup> The greatest BP-lowering effects of weight-loss medications may be achieved with the glucagon-like peptide 1 (GLP-1) receptor agonists.<sup><a href="javascript:;" reveal-id="ehae178-B414 ehae178-B415 ehae178-B416" data-open="ehae178-B414 ehae178-B415 ehae178-B416" class="link link-ref link-reveal xref-bibr">414–416</a></sup> For example, in the Semaglutide Treatment Effect in People with Obesity (STEP-1) trial, the GLP-1 analogue semaglutide resulted in a mean weight reduction of 12.4% and a 5.1 mmHg reduction in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B415" data-open="ehae178-B415" class="link link-ref link-reveal xref-bibr">415</a></sup>

#### 8.2.4. Alcohol, coffee, and soft drinks

In a 2020 Cochrane review, the short-term effects of alcohol on BP were dose dependent; low-dose alcohol (<14 g) did not affect BP within 6 h, medium-dose (14–28 g) decreased both systolic and diastolic BP, and high-dose alcohol (>30 g) first decreased BP up to 12 h and then increased BP following >13 h of consumption by 3.7 mmHg systolic and 2.4 mmHg diastolic.<sup><a href="javascript:;" reveal-id="ehae178-B417" data-open="ehae178-B417" class="link link-ref link-reveal xref-bibr">417</a></sup> The trials in this Cochrane review included small numbers of women. In the longer term, no evidence has been found for a protective effect of chronic alcohol consumption on hypertension, for either sex. In contrast, even low-dose alcohol consumption (10 g/day) increases chronic risk of hypertension by 14% in men, but not in women.<sup><a href="javascript:;" reveal-id="ehae178-B418" data-open="ehae178-B418" class="link link-ref link-reveal xref-bibr">418</a></sup> As per the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice, men and women are recommended to stay within the upper limit of drinking alcoholic beverages (100 g/week of pure alcohol). Defining number of drinks depends on portion size, the standards of which differ per country, but translates to 8–14 g/drink.<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> Emerging data indicate it is likely healthiest to avoid all alcohol, where possible.<sup><a href="javascript:;" reveal-id="ehae178-B419" data-open="ehae178-B419" class="link link-ref link-reveal xref-bibr">419</a></sup>

Coffee intake is not associated with a higher risk of hypertension in the general population; in fact, higher coffee consumption may be associated with a lower risk for incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B420" data-open="ehae178-B420" class="link link-ref link-reveal xref-bibr">420</a></sup> Data regarding the association between tea drinking and CVD are inconclusive, though mechanistic trials have suggested benefits on BP lowering.<sup><a href="javascript:;" reveal-id="ehae178-B421" data-open="ehae178-B421" class="link link-ref link-reveal xref-bibr">421</a></sup> In contrast, energy drinks with high concentrations of ingredients such as taurine and caffeine increase BP and may lead to acute or chronic cardiovascular complications in young adults.<sup><a href="javascript:;" reveal-id="ehae178-B422 ehae178-B423 ehae178-B424" data-open="ehae178-B422 ehae178-B423 ehae178-B424" class="link link-ref link-reveal xref-bibr">422–424</a></sup>

Consuming two or more servings per day of sugar-sweetened beverages was associated with a 35% higher risk of coronary artery disease in women in the Nurses’ Health Study.<sup><a href="javascript:;" reveal-id="ehae178-B425" data-open="ehae178-B425" class="link link-ref link-reveal xref-bibr">425</a></sup> In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, both sugar- and artificially sweetened soft drinks were associated with higher all-cause mortality.<sup><a href="javascript:;" reveal-id="ehae178-B426" data-open="ehae178-B426" class="link link-ref link-reveal xref-bibr">426</a></sup> In children and adolescents, sugar-sweetened beverages increased systolic BP and the risk for incident hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B427" data-open="ehae178-B427" class="link link-ref link-reveal xref-bibr">427</a></sup> It is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy intake.

#### 8.2.5. Smoking

To stop smoking is arguably the most effective measure in preventing major CVD events at the individual level, likely through improved vascular health.<sup><a href="javascript:;" reveal-id="ehae178-B428 ehae178-B429 ehae178-B430 ehae178-B431" data-open="ehae178-B428 ehae178-B429 ehae178-B430 ehae178-B431" class="link link-ref link-reveal xref-bibr">428–431</a></sup> Estimated health benefits will be even more substantial looking at all-cause morbidity and mortality, e.g. including smoking cessation for cancer prevention.

The effects of electronic cigarettes (e-cigarettes) on BP remain unclear and to date there are no robust outcomes data. However, growing evidence suggests that e-cigarettes can increase BP (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B432" data-open="ehae178-B432" class="link link-ref link-reveal xref-bibr">432</a>,<a href="javascript:;" reveal-id="ehae178-B433" data-open="ehae178-B433" class="link link-ref link-reveal xref-bibr">433</a></sup>

Among adults, smoking affects ambulatory BP by raising daily BP,<sup><a href="javascript:;" reveal-id="ehae178-B434" data-open="ehae178-B434" class="link link-ref link-reveal xref-bibr">434</a></sup> but effects of chronic smoking on office BP appear to be small.<sup><a href="javascript:;" reveal-id="ehae178-B435" data-open="ehae178-B435" class="link link-ref link-reveal xref-bibr">435</a></sup> Smoking cessation advice helps, but more intensive interventions are superior.<sup><a href="javascript:;" reveal-id="ehae178-B436" data-open="ehae178-B436" class="link link-ref link-reveal xref-bibr">436</a>,<a href="javascript:;" reveal-id="ehae178-B437" data-open="ehae178-B437" class="link link-ref link-reveal xref-bibr">437</a></sup> As recommended by previous ESC Guidelines, smoking cessation is recommended to reduce CVD risk and improve non-CVD health.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup>

Recommendation Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375965)

Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26)

![Recommendations for non-pharmacological treatment of blood pressure and cardiovascular risk reduction (see Evidence Tables 22–26)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt15.jpeg?Expires=1728462844&Signature=C3~W0a8CE1JbRc03OCvOmuncFYsOYufN1NKvhJCzjSNBBMRCDgbZNtxhnuYb3JMv28x1Za--WOM-DzsGGzBKSciEikkveo7jS0lzpaV7l5VA899Y4-D6vX38utBgBxN7OfpsgF~Fm2SqxpeFFxnwVr0x1lMvjL3aUD7rEtisE~lMi61BlTj~ic3dBxTDhGxDT4htSmBZhTA0j0a9zEq1ylVd4KUJItoukxSofLPFwr3JC-tFpwZpnBZ3j6buTl8sFHfk2~Z~1Svst8ORDIry36gEafXBwYDjTIByH6koRia1zexcDFB0mDZSSkHf9kvzJF-PCRLIqQEIcHyzspi7AQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.3. Pharmacological interventions

#### 8.3.1. Treatment strategy to reduce adverse cardiovascular disease outcomes

The main goal of reducing BP is to prevent adverse CVD outcomes. The relative risk reduction afforded by a fixed degree of BP reduction is largely independent of pre-treatment BP.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a></sup> There is a clear relationship between the intensity of BP lowering and the relative and absolute reduction in risk of CVD events for all adults, regardless of age (at least up to 85 years), sex, prior CVD, diabetes, or AF.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B443 ehae178-B444 ehae178-B445" data-open="ehae178-B443 ehae178-B444 ehae178-B445" class="link link-ref link-reveal xref-bibr">443–445</a></sup> With this strong evidence for the ‘the lower the better, but within reason’ paradigm, decision rules are required for selecting patients most likely to benefit from treatment.<sup><a href="javascript:;" reveal-id="ehae178-B172" data-open="ehae178-B172" class="link link-ref link-reveal xref-bibr">172</a></sup> In this section, a summary of evidence for BP-lowering drug treatment is provided, followed by strategies for their use for preventing CVD.

#### 8.3.2. Drug classes with evidence on clinical outcomes in the target population

The major drug classes with robust evidence for BP-mediated reduction in CVD events are ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics (thiazides and thiazide-like diuretics such as hydrochlorothiazide, chlorthalidone, and indapamide), and beta-blockers (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B446" data-open="ehae178-B446" class="link link-ref link-reveal xref-bibr">446</a>,<a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> The first four are recommended as first-line options for starting hypertension treatment in the general population. Beta-blockers can be added preferentially in circumstances such as in the presence of angina or heart failure, after myocardial infarction, or for controlling heart rate, where they are the cornerstone of therapy.<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B448" data-open="ehae178-B448" class="link link-ref link-reveal xref-bibr">448</a>,<a href="javascript:;" reveal-id="ehae178-B449" data-open="ehae178-B449" class="link link-ref link-reveal xref-bibr">449</a></sup> In such settings, second-generation (cardioselective) and, specifically, third-generation (vasodilating) beta-blockers are preferred.<sup><a href="javascript:;" reveal-id="ehae178-B450" data-open="ehae178-B450" class="link link-ref link-reveal xref-bibr">450</a></sup> However, beta-blockers are less effective than ACE inhibitors, ARBs, CCBs, or diuretics at preventing stroke, and have a higher discontinuation rate due to side effects.<sup><a href="javascript:;" reveal-id="ehae178-B451" data-open="ehae178-B451" class="link link-ref link-reveal xref-bibr">451</a>,<a href="javascript:;" reveal-id="ehae178-B452" data-open="ehae178-B452" class="link link-ref link-reveal xref-bibr">452</a></sup> Beta-blockers and diuretics, especially when combined, are associated with an increased risk of new-onset diabetes in predisposed patients.<sup><a href="javascript:;" reveal-id="ehae178-B453" data-open="ehae178-B453" class="link link-ref link-reveal xref-bibr">453</a>,<a href="javascript:;" reveal-id="ehae178-B454" data-open="ehae178-B454" class="link link-ref link-reveal xref-bibr">454</a></sup> The effect of RAS blockers and CCBs on preventing progression of HMOD also appears to be superior to beta-blockers.<sup><a href="javascript:;" reveal-id="ehae178-B455 ehae178-B456 ehae178-B457 ehae178-B458" data-open="ehae178-B455 ehae178-B456 ehae178-B457 ehae178-B458" class="link link-ref link-reveal xref-bibr">455–458</a></sup> Beta-blockers should also be avoided in patients with isolated systolic hypertension or more generally with arterial stiffness, as they increase stroke volume (given the lower heart rate).<sup><a href="javascript:;" reveal-id="ehae178-B218" data-open="ehae178-B218" class="link link-ref link-reveal xref-bibr">218</a></sup>

When therapy and adherence with the above-mentioned drug classes is optimized but insufficient to reach BP goals, other drug classes can be used for treating hypertension. Of these, spironolactone, an MRA, appears to be the most effective at further lowering BP in resistant hypertension; however, more evidence of CVD risk-lowering effects with MRAs among all hypertensive populations, especially those without resistant hypertension, is needed.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Specifically, while use of MRAs in patients with heart failure has provided clinical evidence on the effectiveness of MRAs for preventing CVD events, dedicated outcome trials in patients with primary hypertension without heart failure are lacking. Because the present guidelines require trial evidence for CVD outcome benefit for a BP-lowering drug or procedure to achieve a Class I recommendation, and given no outcome trials of MRAs have been conducted in general samples of patients with primary hypertension, we have given MRAs a Class IIa recommendation (see below). We acknowledge that spironolactone was provided a Class I recommendation in the 2018 ESC/ESH Guidelines on the management of arterial hypertension. However, to be consistent with our requirement for trial evidence for CVD outcomes benefit in patients with hypertension, the task force agreed to provide a Class IIa recommendation for spironolactone in these 2024 Guidelines. Importantly, it was also agreed that a Class IIa recommendation (i.e. should be considered) is an endorsement of MRAs for treating resistant hypertension but one that acknowledges some uncertainty of outcomes benefit. Future outcome trials of MRAs, perhaps including finerenone,<sup><a href="javascript:;" reveal-id="ehae178-B460 ehae178-B461 ehae178-B462" data-open="ehae178-B460 ehae178-B461 ehae178-B462" class="link link-ref link-reveal xref-bibr">460–462</a></sup> are encouraged in patients with hypertension.

Clinical outcome evidence from trials for other BP-lowering drug classes, such as alpha-blockers, hydralazine, minoxidil, other potassium-sparing diuretics, and centrally acting agents, is less compelling and caution regarding adverse effects is warranted. However, they may be a final addition if all other therapeutic efforts are insufficient to decrease BP. Of note, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial, the alpha-blocker arm was stopped early due to futility of benefit for the CVD outcome.<sup><a href="javascript:;" reveal-id="ehae178-B463" data-open="ehae178-B463" class="link link-ref link-reveal xref-bibr">463</a></sup>

#### 8.3.3. New therapies with blood pressure-lowering properties that await supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension

A few other drug classes with indication in heart failure have emerged that also have BP-lowering properties. For example, the angiotensin receptor–neprilysin inhibitor (ARNi) sacubitril/valsartan, which was initially developed for hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B464" data-open="ehae178-B464" class="link link-ref link-reveal xref-bibr">464</a></sup> reduces CVD mortality and morbidity in patients with heart failure, an effect that may have been mediated, in part, by superior BP lowering compared with enalapril alone.<sup><a href="javascript:;" reveal-id="ehae178-B465" data-open="ehae178-B465" class="link link-ref link-reveal xref-bibr">465</a>,<a href="javascript:;" reveal-id="ehae178-B466" data-open="ehae178-B466" class="link link-ref link-reveal xref-bibr">466</a></sup> In a _post hoc_ subgroup analysis, sacubitril/valsartan lowered BP in adults with both heart failure with preserved ejection fraction (HFpEF) and resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B467" data-open="ehae178-B467" class="link link-ref link-reveal xref-bibr">467</a></sup> In the context of research studies, sacubitril/valsartan has been used in higher doses (200 mg or 400 mg once daily) for treating hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B464" data-open="ehae178-B464" class="link link-ref link-reveal xref-bibr">464</a>,<a href="javascript:;" reveal-id="ehae178-B466" data-open="ehae178-B466" class="link link-ref link-reveal xref-bibr">466</a>,<a href="javascript:;" reveal-id="ehae178-B468" data-open="ehae178-B468" class="link link-ref link-reveal xref-bibr">468</a>,<a href="javascript:;" reveal-id="ehae178-B469" data-open="ehae178-B469" class="link link-ref link-reveal xref-bibr">469</a></sup>

SGLT2 inhibitors have shown favourable effects on CVD events and renal haemodynamics in patients with and without type 2 diabetes, and in heart failure trials.<sup><a href="javascript:;" reveal-id="ehae178-B470" data-open="ehae178-B470" class="link link-ref link-reveal xref-bibr">470</a></sup> In these trials, SGLT2 inhibitors did lower BP, though only modestly.<sup><a href="javascript:;" reveal-id="ehae178-B471" data-open="ehae178-B471" class="link link-ref link-reveal xref-bibr">471</a></sup> Small trials among adults with hypertension have confirmed the potential for BP lowering with this drug class.<sup><a href="javascript:;" reveal-id="ehae178-B472" data-open="ehae178-B472" class="link link-ref link-reveal xref-bibr">472</a>,<a href="javascript:;" reveal-id="ehae178-B473" data-open="ehae178-B473" class="link link-ref link-reveal xref-bibr">473</a></sup>

Other new drugs with preliminary data include GLP-1 agonists and the new non-steroidal MRAs, e.g. finerenone, in managing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B415" data-open="ehae178-B415" class="link link-ref link-reveal xref-bibr">415</a>,<a href="javascript:;" reveal-id="ehae178-B460" data-open="ehae178-B460" class="link link-ref link-reveal xref-bibr">460</a>,<a href="javascript:;" reveal-id="ehae178-B461" data-open="ehae178-B461" class="link link-ref link-reveal xref-bibr">461</a></sup> In addition, novel aldosterone synthase inhibitors (baxdrostat and lorundrostat) have significantly lowered BP in patients with uncontrolled hypertension in phase 2 trials.<sup><a href="javascript:;" reveal-id="ehae178-B474" data-open="ehae178-B474" class="link link-ref link-reveal xref-bibr">474</a>,<a href="javascript:;" reveal-id="ehae178-B475" data-open="ehae178-B475" class="link link-ref link-reveal xref-bibr">475</a></sup>

The dual endothelin-A and -B receptor antagonist aprocitentan also reduced office and 24 h BP compared with placebo at 4 weeks in patients with resistant hypertension in a phase 3 trial.<sup><a href="javascript:;" reveal-id="ehae178-B476" data-open="ehae178-B476" class="link link-ref link-reveal xref-bibr">476</a></sup> Zilebesiran, an investigational RNA interference agent administered subcutaneously, inhibits hepatic angiotensinogen synthesis and a single dose reduced 24 h BP over approximately 6 months.<sup><a href="javascript:;" reveal-id="ehae178-B477" data-open="ehae178-B477" class="link link-ref link-reveal xref-bibr">477</a></sup>

#### 8.3.4. Drug combinations and up-titrating strategies

To treat hypertension, many patients will require more than one BP-lowering medication. Combining drugs from different drug classes can have additive or synergistic effects and lead to greater BP reduction than increasing the dose of one drug.<sup><a href="javascript:;" reveal-id="ehae178-B478 ehae178-B479 ehae178-B480 ehae178-B481 ehae178-B482 ehae178-B483" data-open="ehae178-B478 ehae178-B479 ehae178-B480 ehae178-B481 ehae178-B482 ehae178-B483" class="link link-ref link-reveal xref-bibr">478–483</a></sup> The superior BP-lowering efficacy of combination therapy is mediated, at least in part, by the potential of combination therapy to target multiple pathophysiological pathways contributing to perturbed BP in each patient.<sup><a href="javascript:;" reveal-id="ehae178-B484" data-open="ehae178-B484" class="link link-ref link-reveal xref-bibr">484</a></sup> A further benefit of combination therapy is the potential to use lower doses of each individual BP-lowering agent, which may reduce side effects and improve adherence and persistence,<sup><a href="javascript:;" reveal-id="ehae178-B485" data-open="ehae178-B485" class="link link-ref link-reveal xref-bibr">485</a></sup> though the evidence for this hypothesis has been questioned.<sup><a href="javascript:;" reveal-id="ehae178-B486" data-open="ehae178-B486" class="link link-ref link-reveal xref-bibr">486</a></sup>

Upfront low-dose combination therapy is therefore recommended in persons with hypertension, with the potential advantages of fewer side effects and swifter BP control being important for long-term adherence.<sup><a href="javascript:;" reveal-id="ehae178-B487 ehae178-B488 ehae178-B489" data-open="ehae178-B487 ehae178-B488 ehae178-B489" class="link link-ref link-reveal xref-bibr">487–489</a></sup> If combination BP-lowering therapy is pursued, single-pill combinations are preferred. For those with elevated BP who have an indication for BP-lowering treatment, monotherapy is recommended in the first instance.

One caveat to combination therapy in hypertension is that patient-level response to individual BP-lowering drug classes can be heterogeneous (suggesting some patients may benefit from more personalized treatment compared with routine combinations).<sup><a href="javascript:;" reveal-id="ehae178-B490" data-open="ehae178-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> This is relevant also with respect to race/ethnicity (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_). Another caveat is that the evidence for reduced CVD outcomes with BP-lowering drugs in combination therapy is based on observational studies.<sup><a href="javascript:;" reveal-id="ehae178-B491 ehae178-B492 ehae178-B493" data-open="ehae178-B491 ehae178-B492 ehae178-B493" class="link link-ref link-reveal xref-bibr">491–493</a></sup> There are no outcomes data from prospective trials that prove superiority of upfront combination therapy (either as single-pill combinations or as separate pills) over upfront monotherapy in the isolated treatment of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B486" data-open="ehae178-B486" class="link link-ref link-reveal xref-bibr">486</a></sup> Therefore, we considered giving upfront combination therapy (either as separate pills or as single-pill combinations) a Class IIa recommendation in these guidelines. However, given the totality of evidence for outcomes benefit in observational studies, randomized trial data for better BP control and adherence, and importantly, also given CVD outcomes benefit for polypills (a form of single-pill combination) in randomized trials,<sup><a href="javascript:;" reveal-id="ehae178-B494 ehae178-B495 ehae178-B496" data-open="ehae178-B494 ehae178-B495 ehae178-B496" class="link link-ref link-reveal xref-bibr">494–496</a></sup> we chose to provide a Class I recommendation for upfront combination therapy in adults with confirmed hypertension, in agreement with 2018 ESC recommendations.

The major four drug classes (ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide or thiazide-like diuretics) are recommended as first-line BP-lowering medications, either alone or in combination.<sup><a href="javascript:;" reveal-id="ehae178-B122" data-open="ehae178-B122" class="link link-ref link-reveal xref-bibr">122</a>,<a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a>,<a href="javascript:;" reveal-id="ehae178-B484" data-open="ehae178-B484" class="link link-ref link-reveal xref-bibr">484</a>,<a href="javascript:;" reveal-id="ehae178-B497" data-open="ehae178-B497" class="link link-ref link-reveal xref-bibr">497</a></sup> An exception is the combination of two RAS blockers, which is not recommended.<sup><a href="javascript:;" reveal-id="ehae178-B498 ehae178-B499 ehae178-B500" data-open="ehae178-B498 ehae178-B499 ehae178-B500" class="link link-ref link-reveal xref-bibr">498–500</a></sup> For most hypertensive patients, a single-pill combination, initially containing two of these major drug classes, and initially at low dose, is recommended.<sup><a href="javascript:;" reveal-id="ehae178-B489" data-open="ehae178-B489" class="link link-ref link-reveal xref-bibr">489</a>,<a href="javascript:;" reveal-id="ehae178-B501" data-open="ehae178-B501" class="link link-ref link-reveal xref-bibr">501</a>,<a href="javascript:;" reveal-id="ehae178-B502" data-open="ehae178-B502" class="link link-ref link-reveal xref-bibr">502</a></sup> Doses of BP-lowering drugs are presented in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S7](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S8](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

When BP is still uncontrolled under maximally tolerated triple-combination (RAS blocker, CCB, and diuretic) therapy, and after adherence is assessed, the patient should be considered resistant and referred to an expert centre for appropriate work-up (see _Section [7.5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.5)_). At the same time, the addition of spironolactone should be considered.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> If spironolactone is not tolerated, eplerenone or other MRA, or beta-blockers (if not already indicated), should be considered. Eplerenone may need to be dosed higher (50–200 mg) for effective BP lowering. In a meta-analysis, eplerenone 25 mg did not lower BP.<sup><a href="javascript:;" reveal-id="ehae178-B503" data-open="ehae178-B503" class="link link-ref link-reveal xref-bibr">503</a></sup> Due to the shorter time of action than spironolactone, eplerenone may need to be administered twice daily for treating hypertension. An alternative to MRA as fourth-line treatment for BP lowering is the use of beta-blockers for persons who do not already have a compelling indication. A vasodilating beta-blocker (e.g. labetalol, carvedilol, or nebivolol) is preferred when a beta-blocker is chosen.<sup><a href="javascript:;" reveal-id="ehae178-B504" data-open="ehae178-B504" class="link link-ref link-reveal xref-bibr">504</a></sup> However, we note that the BP-lowering effects of beta-blockade appears to be less potent than spironolactone in the setting of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup>

Only thereafter should hydralazine, other potassium-sparing diuretics (amiloride and triamterene), centrally acting BP-lowering medications, or alpha-blockers be considered. Given multiple side-effects, minoxidil should only be considered if all other pharmacological agents prove ineffective in resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B505" data-open="ehae178-B505" class="link link-ref link-reveal xref-bibr">505</a></sup>

As noted above, polypills combining fixed doses of BP-lowering treatment, lipid-lowering therapy and, if indicated, aspirin are effective in more general CVD prevention.<sup><a href="javascript:;" reveal-id="ehae178-B496" data-open="ehae178-B496" class="link link-ref link-reveal xref-bibr">496</a>,<a href="javascript:;" reveal-id="ehae178-B506 ehae178-B507 ehae178-B508 ehae178-B509" data-open="ehae178-B506 ehae178-B507 ehae178-B508 ehae178-B509" class="link link-ref link-reveal xref-bibr">506–509</a></sup> However, the polypill is not available for routine clinical use in many European countries.

#### 8.3.5. A practical algorithm for intensive, effective, and tolerable blood pressure lowering with drug therapy, including considerations around single-pill combinations

The aim of the algorithm in _[Figure 18](javascript:;)_ is to introduce a low-dose double- and then triple-combination strategy while monitoring tolerance among patients with hypertension, and only afterwards to start up-titrating doses to maximum amounts.

![Practical algorithm for pharmacological blood pressure lowering.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f18.jpeg?Expires=1728462844&Signature=2KNQj2adxGPNI4m7Wd7obTBu~7FiQKHjXH4QXA~CNK6Ti5-6LClOzNzRxeYkYyJSXzNaUZTgPHTqzAvG0HBHNu4AUEFMyzr0o1dVksavHjM9ghT4Fh3FRX4Xanrd089OevO4D4gHSeTKyWC70gReY~YvIeLQTnOIjWusnBGYzzeIK3Sr0bWF5kRMxRUmBidBeKSLShN-q6heN7FxkrtpsO1RfzZnCh3k2hiOy-Xy~iqFmROG~2TqcRoF7gNyFXiunNRkD1lrKDMSwXsJYxNnctNmdwG~jiY4LxAng5EYg51~RKbnjwP7~n~Q1Fvk1UmvyvzbaZJ~mLtiUlOdnbC~TA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 18

Practical algorithm for pharmacological blood pressure lowering.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; FU, follow-up.

[Open in new tab](https://academic.oup.com/view-large/figure/479375988/ehae178f18.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f18.jpeg?Expires=1728462844&Signature=D1cS58AvkVl5PygtESQNf48sL9GEtPql442uHFhLTTsfJCMjZDZf19T0riidIgbJ0czQ0-hAGxGOprBhxjLiFX4BSQJoV78AjLGq4XoHrS3F7zW7EH3b6zl7qvBg9g4bLUvTOMgdYRUggYC8xNQ-S7LrSXVtHa3jMxuvwbkRGbtBYxqN2V-adSJb5zRh~ff3sF4Idlkv9XDJD5gyAWQpHvnQVx14PS9WNT6mT8APqGfHuw-ZvXmPqnE6F~INGQvVv8Uu0vUaS4hk4J-eYFlx5UdxtRDOi0UyZvB4cFAP~W3HwBPEfZFzzJGo8K~ypYpKrmDsqvRV4rO7RE9kRWo2Ng__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375988&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Initiation with monotherapy, slower up-titration, and lower dosing should be considered in the setting of elevated BP and increased CVD risk, or in moderate-to-severe frailty, limited life expectancy, symptomatic orthostatic hypotension, or older people (aged ≥85 years). Ideally, BP should be treated to target within 3 months to retain the confidence of the patient, to ensure long-term adherence, and to reduce CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B71" data-open="ehae178-B71" class="link link-ref link-reveal xref-bibr">71</a></sup>

An overview of the recommended approach to BP management in all adult patients is provided in _[Figure 19](javascript:;)_ (Central Illustration). Also, of note, teleconsultation, multidisciplinary or nurse-led care, or patient self-monitoring can help with achieving BP control in certain healthcare systems.<sup><a href="javascript:;" reveal-id="ehae178-B75" data-open="ehae178-B75" class="link link-ref link-reveal xref-bibr">75</a>,<a href="javascript:;" reveal-id="ehae178-B510" data-open="ehae178-B510" class="link link-ref link-reveal xref-bibr">510</a>,<a href="javascript:;" reveal-id="ehae178-B511" data-open="ehae178-B511" class="link link-ref link-reveal xref-bibr">511</a></sup>

![Central Illustration.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f19.jpeg?Expires=1728462844&Signature=fd2UxUVZPjy4yRnbvL2bRZY4mgexTYvU3f2WaEzqqxv~0aOljojNaQse4~stOMrvj-lMLOp02gLntJA3kPHEFjTs6t-5e0PlLHxEw6OorZSVwU~ncyl9u2MixNGvuaLQuEVHWndnFAwnb1ZgOawzy1qnMsUMqdKl7UDd-PReKwcxSdlCj8zt1iXbXWu8pqZjMT6cwjvTWFpJHe3T9lnyJgO~0zb~SqTgMuQ-3T1NeEpAy1rA0z4ZH0-19QFcyaEbzz~F7NL-HTfhs-rwB8KmD-yqoJxBx-d4kDIRenkVzUGhVSqyRa6ipinFUZn~4-HlQG14IG14tuVvnULqW2wDVQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 19

Central Illustration.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; OH, orthostatic hypotension; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic COronary Risk Evaluation 2–Older Persons. Summary algorithm for BP classification and management. See _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_ for recommendations on out-of-office confirmation of the three BP categories. <sup>a</sup>Adults with type 2 diabetes mellitus only and younger than 60 years should be considered for SCORE2-Diabetes assessment. <sup>b</sup>Though scientific data demonstrate that, under research conditions, the optimal target BP is ≤120/70 mmHg, the target BP recommended by these guidelines in routine practice is 120–129/70–79 mmHg. If achieving this target is not possible, or if treatment is not well tolerated, then BP should be treated to as low as reasonably achievable. For persons with elevated BP, treatment with lifestyle measures for 3 months is first recommended, prior to considering medications.

[Open in new tab](https://academic.oup.com/view-large/figure/479375991/ehae178f19.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f19.jpeg?Expires=1728462844&Signature=u9oN6lnEXVtVytTsdCC6LW2Gs-PsiynaW0LqD1wvCEJGXchoM3wNZtJQpZd6A9QWb3IPA3SXogMzFAahiXWuxurcHDsQhZNN9EhTTKbZlNt-xAOdBSJJGNuDvWYN~ra90ZHPenOxZq4mcm5hoGLWT0o6tCOawAhCBgK7Tv1Pk1XgfDOfc~w1FSSMsyJjlhhJQeabGh~0KjuXMZpN8ge2DeiLaPyK3D8CZiM1vn3OWk6nVDRFAYWbW2r0oK8-heGIzCkL-7OtYw8x~7cRCvogWM4ZjYNK6WMun60gSbs2lbATSwZmuI8GHgVyVISRiaUgPlYnyvhCO~1uRfuY~adv7w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479375991&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 8.3.6. Timing of blood pressure-lowering drug treatment

Current evidence does not show benefit of diurnal timing of BP-lowering drug administration on major CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B512" data-open="ehae178-B512" class="link link-ref link-reveal xref-bibr">512</a></sup> It is important that medication is taken at the most convenient time of day to improve adherence. Patients should also be encouraged to take medications at the same time each day and in a consistent setting, to help ensure adherence.<sup><a href="javascript:;" reveal-id="ehae178-B246" data-open="ehae178-B246" class="link link-ref link-reveal xref-bibr">246</a>,<a href="javascript:;" reveal-id="ehae178-B513" data-open="ehae178-B513" class="link link-ref link-reveal xref-bibr">513</a></sup>

Recommendation Table 16

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479375994)

Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29)

![Recommendations for pharmacological treatment of hypertension (see Evidence Tables 27, 28, and 29)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt16.jpeg?Expires=1728462844&Signature=llkC13seG1jrw3kgayghPjoH6eJ2rDa~Ms5IsN5HPJoGg~lVh9Ijo6mZaQugbUV5j4J3b8M5ghkTM7yQ4lTotbh8HdseAKPyma6etpW7iFp2jzaNWi8~jAxEKI2PZ~Bz6n2yTwhmvhBZDYr4864QnYmnokLTNrsZxhA6b9DuFnntkl8RtnJIX6znnbi1AJ3PMuMeGLKBe5XMGuu0vExzE4ZHUMO-Tn~UBXLUlxrlK7EJXOXaeWl9qyBCW9rE0ts5Y~xRgn0iy6A42kCg~nMbnYVj1mc-nLv~clnufzgqT382LqobbEoOV~WPneGHlLMKttywUHhjLv1Fk646grgCYw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.4. Selecting patients for pharmacological blood pressure-lowering treatment

Commencement of BP-lowering treatment is often decided based on office BP measurements but, where possible, the present guidelines strongly recommend using out-of-office BP measurement for confirming elevated BP and hypertension (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4))_. As detailed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, an office BP of <120/70 mmHg is categorized in these guidelines as non-elevated BP.

When a patient is diagnosed with confirmed hypertension (sustained BP ≥ 140/90 mmHg), starting BP-lowering treatment is recommended irrespective of CVD risk, which should consist of a simultaneous combination of lifestyle interventions and pharmacological therapy. Lifestyle interventions are crucial as an initial treatment step, and must be strongly emphasized with the patient, but concurrent pharmacological therapy is recommended. This concurrent initiation of lifestyle and pharmacological therapy should not give patients the impression that lifestyle changes are of lesser importance, and the patient should be counselled that these lifestyle changes may allow subsequent discontinuation or down-titration of medication, which can be used as motivation to persist with lifestyle changes. After treatment initiation, the patient should be seen frequently (e.g. every 1–3 months with a GP or specialist) until BP is controlled. BP should be controlled, preferably within 3 months (see also _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and algorithm _[Figure 18](javascript:;)_). If lifestyle changes are effective in BP lowering, pharmacological treatments may subsequently be down-titrated or stopped as appropriate.

When office BP is 120–139/70–89 mmHg, the patient is considered as having elevated BP, and further CVD risk stratification is recommended to guide therapy (_[Table 14](javascript:;)_).

-   In patients with elevated BP who are not at increased risk for CVD (10-year CVD risk <10%) and do not have other high-risk conditions or risk modifiers, BP-lowering lifestyle measures are recommended. While there are not enough outcomes data for a drug recommendation in lower CVD risk adults with elevated BP, there is some evidence to suggest that relative treatment effects of BP lowering are similar across a wide range of predicted risk categories, including among those with a <10% risk.<sup><a href="javascript:;" reveal-id="ehae178-B518" data-open="ehae178-B518" class="link link-ref link-reveal xref-bibr">518</a></sup> Therefore, while we do not provide a formal recommendation for this, if initial lifestyle measures are not successful after 6–12 months, drug treatment might be discussed on an individual basis among lower CVD-risk adults when BP is between 130/80 and <140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B518" data-open="ehae178-B518" class="link link-ref link-reveal xref-bibr">518</a></sup>
    
-   In patients with elevated BP (office BP of 120–139/70–89 mmHg) who are at sufficiently high risk for CVD (e.g. 10-year CVD risk ≥ 10%) or in the presence of high-risk conditions or borderline 10-year CVD risk (5% - <10%) combined with risk modifiers or abnormal risk tool tests, BP-lowering lifestyle measures should be initiated for 3 months. Following this, pharmacological therapy is recommended for persons with confirmed BP of ≥130/80 mmHg, when these lifestyle changes have not worked or are not being implemented (_Section [8.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.2)_) Prompt addition of pharmacological therapy, if needed by 3 months, should be emphasized, to avoid therapeutic inertia.<sup><a href="javascript:;" reveal-id="ehae178-B519" data-open="ehae178-B519" class="link link-ref link-reveal xref-bibr">519</a></sup> For those with BP of 120–129/70–79 mmHg, ongoing and intensified lifestyle intervention is preferred.
    

The above recommendations apply to all individuals with elevated BP, irrespective of age. However, recognizing the lack of conclusive evidence and added risk of side effects among certain subgroups, the task force also recommends that, among patients with elevated BP, BP-lowering treatment should always be started based on individual clinical judgment and shared decision-making.

Table 14

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376001)

Initiation of blood pressure-lowering treatment based on confirmed blood pressure category and cardiovascular disease risk

| Blood pressure (mmHg) | Non-elevated BP (<120/70) | Elevated BP (120/70 to 139/89) | Hypertension (≥140/90) |
| --- | --- | --- | --- |
| **Risk** |  | 
-   All adults with SBP 120–129 mmHg
    
-   SBP 130–139 AND 10-year estimated CVD risk <10% AND no high-risk conditions or risk modifiers or abnormal risk tool tests
    

 | 

-   SBP 130–139 AND high-risk conditions (e.g. established CVD, diabetes mellitus, CKD, FH or HMOD)
    
-   SBP 130–139 AND 10-year estimated CVD risk ≥10%
    
-   SBP 130–139 AND 10-year estimated CVD risk 5% - <10% AND risk modifiers or abnormal risk tool tests
    

 | Assumed all at sufficiently high risk to benefit from pharmacological treatment |
| **Treatment** | Lifestyle measures for prevention  
Screen BP and CVD risk opportunistically | Lifestyle measures for treatment  
Monitor BP and CVD risk yearly | Lifestyle measures and pharmacological treatment (after 3-month delay).  
Monitor BP yearly once treatment control is established | Lifestyle measures and pharmacological treatment (immediate)  
Monitor BP yearly once treatment control is established |
| **Target (mmHg)** | **Maintain BP <120/70** | **Aim BP 120–129/70–79**  **mmHg**<sup><a href="javascript:;" reveal-id="tblfn126" data-open="tblfn126" class="link link-ref link-reveal xref-fn js-xref-fn">a</a></sup> |

BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; FH, familial hypercholesterolaemia; HMOD, hypertension-mediated organ damage; SBP, systolic blood pressure.

<sup>a</sup>Caution in adults with orthostatic hypotension, moderate-to-severe frailty, limited life expectancy, and older patients (aged ≥85 years).

© ESC 2024

In addition, consideration of BP-lowering drug treatment should be deferred until BP is >140/90 mmHg in the following settings: pre-treatment symptomatic orthostatic hypotension, age ≥85 years, clinically significant moderate-to-severe frailty, and/or limited predicted lifespan (<3 years) due to high competing risk (including eGFR < 30 mL/min/1.73 m<sup>2</sup>). Patients with elevated BP in these settings are less likely to obtain sufficient net benefit from BP-lowering drug therapy or to tolerate intensive drug therapy. _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_ contains more information on the treatment of specific subgroups, including older and frail adults.

Recommendation Table 17

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376003)

Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32)

![Recommendations for initiating blood pressure-lowering treatment (see Evidence Tables 30–32)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt17.jpeg?Expires=1728462844&Signature=NRCozzD2Em0XBN28BWV9wq2mJfESjiKzfzw5-XJo6TorVZG81stKRWzKg4RJzsfwLBJlQkrzGCm7dy5LL6z680cbEsb6SW72n3fKaxifeUFGMSOZwa93sMchm81z6ndTIm5mh296ouxy3W0gh-XduC02Gxy3M7rVB145mDPqBOFXhYxukq5m2INVZFSMnUBptEosNI0PS8KXcSuMSt-XdKIEs9K6vtODOVuCMoWpSnpUFaOKrrGLmNgehcOMLeiJpi5Kqk7jo6et3og1dPuyjyWCGtekxmsAzwrQ446pukDYbJoqVxg9~Ms9PDYCl0WJwadHiMpeklsO-2tN29kKpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.5. Intensity of blood pressure-lowering therapy and ideal treatment targets

#### 8.5.1. Expected degree of blood pressure reduction with approved drugs

The magnitude of BP reduction achieved with the main classes of BP-lowering medications (ACE inhibitors, ARBs, dihydropyridine CCBs, diuretics, and beta-blockers) as monotherapy is similar overall.<sup><a href="javascript:;" reveal-id="ehae178-B528" data-open="ehae178-B528" class="link link-ref link-reveal xref-bibr">528</a>,<a href="javascript:;" reveal-id="ehae178-B529" data-open="ehae178-B529" class="link link-ref link-reveal xref-bibr">529</a></sup> BP reduction with standard doses of any of these five classes can be expected to be approximately 9/5 mmHg with office BP and 5/3 mmHg with ABPM.<sup><a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a></sup> These BP-lowering effects may attenuate over time.<sup><a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> Combination therapy (e.g. with three drugs at half standard dose) over the short term can lower office BP by up to 20/11 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a>,<a href="javascript:;" reveal-id="ehae178-B531" data-open="ehae178-B531" class="link link-ref link-reveal xref-bibr">531</a></sup> The reason why beta-blockers are not considered first-line BP-lowering medications (outside of compelling indications) is not because of inferior BP-lowering properties (particularly for vasodilating beta-blockers),<sup><a href="javascript:;" reveal-id="ehae178-B532" data-open="ehae178-B532" class="link link-ref link-reveal xref-bibr">532</a></sup> but because of inferior efficacy in reducing CVD events (particularly stroke) among patients with hypertension, and tolerance issues.<sup><a href="javascript:;" reveal-id="ehae178-B533 ehae178-B534 ehae178-B535 ehae178-B536" data-open="ehae178-B533 ehae178-B534 ehae178-B535 ehae178-B536" class="link link-ref link-reveal xref-bibr">533–536</a></sup>

The BP-lowering effect of each BP medication class generally increases with the dose administered, though this relationship is not linear.<sup><a href="javascript:;" reveal-id="ehae178-B537" data-open="ehae178-B537" class="link link-ref link-reveal xref-bibr">537</a></sup> Effects of each medication can also vary at the individual level, sometimes requiring personalization by matching the patient with the best medication for them.<sup><a href="javascript:;" reveal-id="ehae178-B490" data-open="ehae178-B490" class="link link-ref link-reveal xref-bibr">490</a></sup> The magnitude of BP reduction for any BP-lowering medication may increase as a function of the pre-treatment BP, which is also known as Wilders principle.<sup><a href="javascript:;" reveal-id="ehae178-B538" data-open="ehae178-B538" class="link link-ref link-reveal xref-bibr">538</a>,<a href="javascript:;" reveal-id="ehae178-B539" data-open="ehae178-B539" class="link link-ref link-reveal xref-bibr">539</a></sup>

The BP-lowering effect of pharmacological therapy is typically evident after 1–2 weeks of treatment,<sup><a href="javascript:;" reveal-id="ehae178-B540" data-open="ehae178-B540" class="link link-ref link-reveal xref-bibr">540</a></sup> but the maximum effect might take longer to manifest. Therefore, the advised follow-up after 1–3 months (1 month preferred with a GP or specialist) allows for assessment of tolerance/safety, but also allows enough time to gauge the full BP-lowering effect of each drug titration (see _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)_).

#### 8.5.2. The ideal target of blood pressure-lowering treatment

As discussed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_, optimal control of BP translates into CVD risk reduction, thereby reducing morbidity and mortality in the population.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B478" data-open="ehae178-B478" class="link link-ref link-reveal xref-bibr">478</a>,<a href="javascript:;" reveal-id="ehae178-B541" data-open="ehae178-B541" class="link link-ref link-reveal xref-bibr">541</a></sup>

BP threshold is defined as the BP at which BP-lowering treatment is initiated, while BP target is the BP goal with treatment.

The BP threshold to initiate BP-lowering therapy is not necessarily the same as the recommended BP target once therapy is commenced (in other words, treatment threshold and treatment target may not be the same for a given patient). Specifically, for hypertensive patients in whom BP-lowering treatment is recommended above a baseline BP of ≥140/90 mmHg, the recommended target of BP-lowering therapy is 120–129/70–79 mmHg, provided treatment is well tolerated (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). Persons with elevated BP who receive treatment are also recommended to achieve a target of 120–129/70–79 mmHg.

Therefore, the treatment target in the 2024 Guidelines is always 120–129/70–79 mmHg (but only if treatment is tolerated and with certain exceptions where more lenient targets are advised). In contrast, the treatment threshold may differ based on CVD risk, specifically in the elevated BP category. For example, in addition to hypertensive adults with BP ≥140/90 mmHg, there are individuals with an office systolic BP of 130–139 mmHg and/or diastolic BP of 80–89 mmHg who have sufficiently high CVD risk to recommend BP-lowering drug treatment.

The BP target range of 120–129/70–79 mmHg recommended in these guidelines reflects the most current evidence from contemporaneous RCTs<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B542 ehae178-B543 ehae178-B544 ehae178-B545" data-open="ehae178-B542 ehae178-B543 ehae178-B544 ehae178-B545" class="link link-ref link-reveal xref-bibr">542–545</a></sup> and from meta-analyses of RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Of note, this treatment target reduces CVD events in older adults<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a></sup> with evidence for efficacy of more intensive BP-lowering treatment targets established up to age 85 years.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Furthermore, research data indicate that, to optimally reduce CVD risk, achieving an on-treatment BP of 120/70 mmHg is the best point on the BP target range provided in our guideline recommendations (_[Figure 20](javascript:;)_). However, while we strongly considered recommending a treatment target of exactly 120/70 mmHg with out-of-office BP confirmation, we instead chose a target range of 120–129/70–79 mmHg (preferably with out-of-office BP confirmation but also allowing for office BP) for the following reasons: providing flexibility to patients and clinicians; feedback from external peer review; feedback from patients that lifestyle is preferred to medication unless BP is in the hypertensive range; the knowledge that contemporary treat-to-target intensive BP trials included only persons with baseline systolic BP of ≥130 mmHg; and a recognition that the BP values recorded under research conditions using systematic approaches to measurement (while strongly recommended by these guidelines) are not always the same as BP values recorded under routine clinical care, which can be 5–10 mmHg higher.<sup><a href="javascript:;" reveal-id="ehae178-B65" data-open="ehae178-B65" class="link link-ref link-reveal xref-bibr">65</a>,<a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a></sup>

![Systolic blood pressure categories and treatment target range.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f20.jpeg?Expires=1728462844&Signature=rAGjE9GaQ0GOmcIGO17jBPs1Q93~5J0BLxR8C6w2Rsva~~~ff3GqfOwh6GGA9g4YlIgJr~fh8Pmsv40MryNB7L5uJGrOsDJCdc-V4xWe-vPes8fQWpWKSpbkj93p7WYBnYNf74dRpj9NzWbQVW17wWaICnETKy2d1MOkkeivCipKOa4ZJvkgoe6u2r45y3ZNGbyXIvsB13hoJevf6AB4t-lUQ6zN2Ff07KL8evLHrvYx59T7-1CUwn6QoNZFojIPDrG6IHNtmEEGXP0JjLaBHj-b8ld33fC6zZVYRFfRXoLKHQPy1seJTPX0Hi9YTHvpI2fql92ErN1xT3u6SoI0mg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 20

Systolic blood pressure categories and treatment target range.

BP, blood pressure; SBP, systolic blood pressure.

[Open in new tab](https://academic.oup.com/view-large/figure/479376015/ehae178f20.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f20.jpeg?Expires=1728462844&Signature=bz6qU4ADGHuhjQd9LrqDBoPDRSDjAfLzeJjvgY1F7d6fTXhfm~P85mn5Dcifz~LZJAGfPx5y3YiZxXTC7OL6xNjBRGjCYL5eutUThNlmVAXJ206y1MVh~HZvrhP8yk5i2daMYH4XuG~qZGYUvkfz1~gIOg9xgMRcc0Vv68lMfd86dyFXmGELXn-XfTG~qUINW6B8OL5zxln51kqUucL7a80xzH0jKP8fcQpWmdYrObgW9nIlmnO2IqtTZbTwBWUa9WctB0SEEot1g-pvYECWo5V6gdD-lRca74ElFhhrSOSvLWRmKy~QOooEFjpv-afSSWCColKbhCvsYBFk0kAz5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376015&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

In addition, the trial data confirming efficacy for our recommended treatment target of 120–129/70–79 mmHg do not necessarily apply to moderately-to-severely frail adults who were generally excluded from trials. Furthermore, the data supporting this BP target among adults aged >85 years are inconclusive.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> Frailty can occur at different ages and is, together with tolerability of BP-lowering treatment, an important characteristic when considering the BP target for a given patient. Accordingly, personalized BP-lowering treatment should be instituted in people aged ≥85 years and/or those with significant frailty. Recommended indicators of frailty in guiding BP-lowering treatment are given in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_.

Several important nuances are highlighted and warrant consideration prior to implementing the new BP target of 120–129/70–79 mmHg among patients receiving BP-lowering therapy:

-   Evidence for a systolic BP-lowering treatment target of 120–129 mmHg is strong (Class I, level of evidence A).
    
-   Evidence for a specific diastolic BP-lowering treatment target is less strong in those who are treated to a systolic target of 120–129 mmHg. While most adults treated to a systolic BP target of 120–129 mmHg will also achieve a diastolic BP of 70–79 mmHg, not all will.<sup><a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B546" data-open="ehae178-B546" class="link link-ref link-reveal xref-bibr">546</a></sup> Furthermore, adults who achieve systolic BP control are generally at low relative risk for CVD, even when diastolic BP is 70–90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B547" data-open="ehae178-B547" class="link link-ref link-reveal xref-bibr">547</a>,<a href="javascript:;" reveal-id="ehae178-B548" data-open="ehae178-B548" class="link link-ref link-reveal xref-bibr">548</a></sup> Nonetheless, due in part to the known higher risk of isolated diastolic hypertension among younger adults,<sup><a href="javascript:;" reveal-id="ehae178-B549" data-open="ehae178-B549" class="link link-ref link-reveal xref-bibr">549</a></sup> the task force agreed that it is reasonable to target an on-treatment diastolic BP of 70–79 mmHg among patients with diastolic BP of ≥80 mmHg who are already at the systolic BP target of 120–129 mmHg (Class IIb, level of evidence C).
    
-   The task force acknowledges the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice,<sup><a href="javascript:;" reveal-id="ehae178-B170" data-open="ehae178-B170" class="link link-ref link-reveal xref-bibr">170</a></sup> which take a stepwise approach to their recommendations for BP-lowering treatment. The 2021 Guidelines recommended an on-treatment systolic BP target of 130–139 mmHg as the first step and then—based on patient preferences, risk, and frailty—to aim for a target on-treatment systolic BP of <130 mmHg as the second step. While we recognize the potential value of this two-step approach, which many clinicians may choose to follow, the current guidelines emphasize one on-treatment BP target (120–129/70–79 mmHg, provided treatment is tolerated). This one-step approach is based on the evidence, and motivated to discourage therapeutic inertia around BP lowering. As an illustrative example of the latter concern for therapeutic inertia, an on-treatment systolic BP of 135 mmHg (office) may be considered reasonable when reviewing the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice but, we hope, will not be considered reasonable to those who follow the updated 2024 ESC Guidelines presented here. Specifically, it is well established that an on-treatment systolic BP of 135 mmHg is not optimal relative to more intensive control.<sup><a href="javascript:;" reveal-id="ehae178-B116" data-open="ehae178-B116" class="link link-ref link-reveal xref-bibr">116</a>,<a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a>,<a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B542" data-open="ehae178-B542" class="link link-ref link-reveal xref-bibr">542</a>,<a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup>
    
-   We acknowledge that the results from RCTs cannot always be extrapolated to routine clinical care. In addition, we recognize the increased risk of side effects among patients receiving more intensive BP-lowering treatments, compared with traditional BP targets.<sup><a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a>,<a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> Accordingly, an important caveat to our treatment target of 120–129/70–79 mmHg is the recommendation to pursue this target only when treatment is well tolerated. In cases where BP-lowering treatment is not well tolerated and a target of 120–129/70–79 mmHg is not possible, it is recommended to follow the ‘as low as reasonably achievable’ (ALARA) principle, by targeting treatment to a BP that is as low as reasonably achievable.
    
-   In addition to adults with significant frailty and/or who are ≥85 years of age, the evidence for a BP-lowering treatment target of 120–129/70–79 mmHg may also not generalize to patients with: (i) pre-treatment symptomatic orthostatic hypotension, (ii) limited predicted lifespan (e.g. <3 years),<sup><a href="javascript:;" reveal-id="ehae178-B527" data-open="ehae178-B527" class="link link-ref link-reveal xref-bibr">527</a></sup> and/or (iii) high levels of competing risk for non-CVD death including CKD with eGFR < 30 mL/min/1.73 m<sup>2</sup>) (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_).
    

Finally, as outlined in _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_, these guidelines endorse a ‘trust but verify’ approach to office BP measurements, and, where possible, confirming BP with accurate out-of-office BP measurements (ABPM, HBPM) is recommended prior to starting treatment, to monitor the treatment effect of BP-lowering medication.

Recommendation Table 18

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376020)

Recommendations for blood pressure targets with treatment (see Evidence Table 34)

![Recommendations for blood pressure targets with treatment (see Evidence Table 34)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt18.jpeg?Expires=1728462844&Signature=vYRXnZ2Vzot~aQGC8adEzUhe4je5RYwSX2lWlkx6hqxzfS4QersEWdItthIeLcQt1r24IR5qW~l-7PqjtLb09VkEdqOIMgiYqnEV3m1RAdVeDwcJKxZHzGJmrsE0E1KbclVu8HoxLpdjIFzybdVF8vD5LSOskbUqXvqj1G03KRj~AgDvESHgmcUP1otSgEDV~dkJzFLMOlwdLm1hXMDmw5WNnlF9N4MS~z97TkJYKRRNeyDUg~V63fz-R8zPyRity9tTvG~9DMU7r0CYVDb3L9takHGfR~CIMN3cCI5WH2d3Dee6GedbR-EGgsDJoliSFRiZ3eZpq-wcikEne3bsFQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.5.3. Personalizing treatment strategies

Though promising, there is little to no evidence to date from CVD outcome trials to use novel biomarkers for individualizing BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B551" data-open="ehae178-B551" class="link link-ref link-reveal xref-bibr">551</a>,<a href="javascript:;" reveal-id="ehae178-B552" data-open="ehae178-B552" class="link link-ref link-reveal xref-bibr">552</a></sup> Nonetheless, different patient groups can be identified, and medication initiation can be tailored to pre-existing conditions, such as diabetes mellitus, CKD, AF, post-myocardial infarction, heart failure, metabolic syndrome, and proteinuria/albuminuria (_Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_). History of previous side effects and possible and compelling indications also need to be considered when selecting treatment (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Tables S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_ and _[S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). Cardioselective beta-blockers may be used in low dose in chronic asthma,<sup><a href="javascript:;" reveal-id="ehae178-B553" data-open="ehae178-B553" class="link link-ref link-reveal xref-bibr">553</a>,<a href="javascript:;" reveal-id="ehae178-B554" data-open="ehae178-B554" class="link link-ref link-reveal xref-bibr">554</a></sup> in line with their use in patients with heart failure with chronic asthma.

For considerations of BP-lowering treatment among specific patient populations of interest, including different racial/ethnic populations, see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_.

#### 8.5.4. Duration and monitoring of drug therapy

BP-lowering treatment is usually chronic, often lifelong. This raises the question of long-term efficiency, long-term side effects, adherence, and persistence with therapy. While BP-lowering therapies typically provide an overall durable effect, some attenuation of effect may be seen over time.<sup><a href="javascript:;" reveal-id="ehae178-B66" data-open="ehae178-B66" class="link link-ref link-reveal xref-bibr">66</a>,<a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> First-line BP-lowering medication classes appear to be safe for long-term use.<sup><a href="javascript:;" reveal-id="ehae178-B555 ehae178-B556 ehae178-B557" data-open="ehae178-B555 ehae178-B556 ehae178-B557" class="link link-ref link-reveal xref-bibr">555–557</a></sup> Once BP is controlled, at least a yearly follow-up is advised. Because of the known temporal variability in BP<sup><a href="javascript:;" reveal-id="ehae178-B558" data-open="ehae178-B558" class="link link-ref link-reveal xref-bibr">558</a>,<a href="javascript:;" reveal-id="ehae178-B559" data-open="ehae178-B559" class="link link-ref link-reveal xref-bibr">559</a></sup> and medication efficacy in the long term,<sup><a href="javascript:;" reveal-id="ehae178-B530" data-open="ehae178-B530" class="link link-ref link-reveal xref-bibr">530</a></sup> medication changes may be necessary over time (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

Recommendation Table 19

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376026)

Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33)

![Recommendations for follow-up in patients with treated hypertension (see Evidence Table 33)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt19.jpeg?Expires=1728462844&Signature=UlndsEzarvniwN4EcFsmPdndKI19K2t96wKGbIcxrFqnESCYiuJB5Lre7n~ku8isms6V~VsHpYOXkR9meI4N53YNu7TxM4YsVBXMb8FL8Xdja6mPu9yXZ6ojDYjA4POS3V6e8Dn3DnU6aFYMDWTnj6330xkDzk60G53AWkXIoUphGS0iGeb54S0xe1ZgXemiTceKnQUdNoEagal35UMK1mqkz2jI8nPZYzA~xUqKPfsMaL0YbF7I~4q5-uhZUvcpthpZKZCsUZmcG08gR4QdMo5y8P-d0BfrVMV-k71eMDO1DsHtczWuuY-HD1TRQmurNkqe-tTmVKLmpw~0ZyTy5Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 8.6. Device-based blood pressure lowering

Several device-based therapies designed to lower BP have been investigated.<sup><a href="javascript:;" reveal-id="ehae178-B560" data-open="ehae178-B560" class="link link-ref link-reveal xref-bibr">560</a>,<a href="javascript:;" reveal-id="ehae178-B561" data-open="ehae178-B561" class="link link-ref link-reveal xref-bibr">561</a></sup> To date, the best evidence exists for catheter-based renal denervation.

#### 8.6.1. Catheter-based renal denervation

Sympathetic nervous system overactivity contributes to the development and progression of hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B562" data-open="ehae178-B562" class="link link-ref link-reveal xref-bibr">562</a></sup> Renal denervation aims to interrupt afferent and efferent sympathetic nerves in the adventitia and perivascular tissue of the renal arteries.<sup><a href="javascript:;" reveal-id="ehae178-B563" data-open="ehae178-B563" class="link link-ref link-reveal xref-bibr">563</a></sup> The 2018 ESC/ESH Guidelines on the management of arterial hypertension did not recommend the use of device-based therapies for routine treatment of hypertension, unless in the context of clinical studies and RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> This was based on negative data using first-generation radiofrequency catheters (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

More recent data from sham-controlled trials investigating second-generation radiofrequency and ultrasound catheters demonstrated a BP-lowering efficacy in a broad range of patients, with and without concomitant BP-lowering medications, including those with resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B564 ehae178-B565 ehae178-B566 ehae178-B567 ehae178-B568" data-open="ehae178-B564 ehae178-B565 ehae178-B566 ehae178-B567 ehae178-B568" class="link link-ref link-reveal xref-bibr">564–568</a></sup> Long-term, non-randomized, follow-up data from the Global Symplicity Registry,<sup><a href="javascript:;" reveal-id="ehae178-B569" data-open="ehae178-B569" class="link link-ref link-reveal xref-bibr">569</a></sup> Symplicity HTN-3 trial,<sup><a href="javascript:;" reveal-id="ehae178-B570" data-open="ehae178-B570" class="link link-ref link-reveal xref-bibr">570</a></sup> Spyral HTN-ON MED pilot trial,<sup><a href="javascript:;" reveal-id="ehae178-B571" data-open="ehae178-B571" class="link link-ref link-reveal xref-bibr">571</a></sup> and A Study of the Recor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN) SOLO trial<sup><a href="javascript:;" reveal-id="ehae178-B572" data-open="ehae178-B572" class="link link-ref link-reveal xref-bibr">572</a></sup> indicate a sustained BP-lowering effect for up to 3 years. A single-centre open-label study suggested sustained BP reductions up to 10 years.<sup><a href="javascript:;" reveal-id="ehae178-B573" data-open="ehae178-B573" class="link link-ref link-reveal xref-bibr">573</a></sup> These data also highlight a potentially important advantage of renal denervation, namely that the BP-lowering effect of this intervention might be ‘always on’, making this approach attractive for patients with suboptimal medication adherence.<sup><a href="javascript:;" reveal-id="ehae178-B254" data-open="ehae178-B254" class="link link-ref link-reveal xref-bibr">254</a></sup> Some patients may prefer a one-off procedure rather than taking daily medications chronically and may request renal denervation.

Of significance, there are no reported procedure-related serious safety signals in the first- and second-generation trials beyond the usual risk of femoral arterial access procedures (noting that most trials to date were not powered for safety outcomes and that the task force could find no published meta-analysis data on exact rates of major bleeding and major femoral artery vascular access complications after renal denervation procedures). However, the rate of major bleeding and major femoral artery vascular access complications for coronary angiography using a femoral approach is typically reported as 1%–4%<sup><a href="javascript:;" reveal-id="ehae178-B574" data-open="ehae178-B574" class="link link-ref link-reveal xref-bibr">574</a>,<a href="javascript:;" reveal-id="ehae178-B575" data-open="ehae178-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> but has been reported as 5%–10% in some studies.<sup><a href="javascript:;" reveal-id="ehae178-B575" data-open="ehae178-B575" class="link link-ref link-reveal xref-bibr">575</a></sup> Trials investigating radial access for renal denervation are currently ongoing ([ClinicalTrials.gov](https://ClinicalTrials.gov) identifier: NCT05234788). After renal denervation, there is a 0.25%–0.5% rate of renal artery stenosis/dissection requiring stenting.<sup><a href="javascript:;" reveal-id="ehae178-B576" data-open="ehae178-B576" class="link link-ref link-reveal xref-bibr">576</a></sup> Long-term follow-up data up to 3 years have not suggested worsening of renal function beyond the expected rates in patients with hypertension with mildly-to-moderately reduced renal function.<sup><a href="javascript:;" reveal-id="ehae178-B569" data-open="ehae178-B569" class="link link-ref link-reveal xref-bibr">569</a>,<a href="javascript:;" reveal-id="ehae178-B577" data-open="ehae178-B577" class="link link-ref link-reveal xref-bibr">577</a></sup> Of note, sham-controlled trials to date excluded patients with severely reduced kidney function at baseline.<sup><a href="javascript:;" reveal-id="ehae178-B564" data-open="ehae178-B564" class="link link-ref link-reveal xref-bibr">564</a>,<a href="javascript:;" reveal-id="ehae178-B566 ehae178-B567 ehae178-B568" data-open="ehae178-B566 ehae178-B567 ehae178-B568" class="link link-ref link-reveal xref-bibr">566–568</a></sup>

Despite the clear promise of renal denervation in reducing BP, there are some concerns that warrant consideration, as we indicate in the recommendations. First, the effect of current renal denervation catheter technologies on BP lowering is relatively modest for an invasive procedure (meta-analyses report placebo-corrected systolic BP lowering of approximately 6 mmHg on office BP assessment and 4 mmHg on 24 h ABPM).<sup><a href="javascript:;" reveal-id="ehae178-B578" data-open="ehae178-B578" class="link link-ref link-reveal xref-bibr">578</a></sup> As such, the average BP-lowering effect of renal denervation appears no more than for one standard BP-lowering medication. Accordingly, many adults undergoing renal denervation will likely require ongoing, post-procedural, BP-lowering drugs.

Second, the cost-effectiveness of renal denervation has not been fully established. Since effects of current renal denervation technologies are similar to that of one standard BP-lowering medication, most of which are generic, it is difficult to see a scenario where renal denervation could be proven cost-effective for most patients. An exception might be patients who are at very high risk of CVD events and who have uncontrolled BP due to resistant hypertension (with or without non-adherence).<sup><a href="javascript:;" reveal-id="ehae178-B579" data-open="ehae178-B579" class="link link-ref link-reveal xref-bibr">579</a>,<a href="javascript:;" reveal-id="ehae178-B580" data-open="ehae178-B580" class="link link-ref link-reveal xref-bibr">580</a></sup>

Third, there are no adequately powered outcomes trials demonstrating that renal denervation reduces CVD events and is safe in the long term. While observational reports have suggested associations between renal denervation and reduced risk for CVD events,<sup><a href="javascript:;" reveal-id="ehae178-B581" data-open="ehae178-B581" class="link link-ref link-reveal xref-bibr">581</a>,<a href="javascript:;" reveal-id="ehae178-B582" data-open="ehae178-B582" class="link link-ref link-reveal xref-bibr">582</a></sup> these observational data have major inferential limitations including a significant potential for confounding. While BP lowering is typically a good surrogate for CVD benefit, there is no guarantee that this is true with renal denervation and, furthermore, off-target effects independent of BP could influence CVD and other adverse-event rates after the procedure. Because of the lack of outcomes trials, renal denervation cannot reach the Class I indication threshold set by this task force. Arguments that outcomes trials will not be funded are insufficient to influence guideline recommendations. However, it is hoped that the position of these guidelines will motivate industry to sponsor the necessary renal denervation outcomes trials.

Fourth, related to the lack of outcomes data, the potentially ‘always on’ effect of renal denervation could backfire if late complications emerge. Medications causing complications or side effects can simply be stopped and replaced with alternative medications when such problems emerge; this is not true with renal denervation.

Fifth, the impact of scaling up renal denervation on usual cardiac department catheterization laboratory workflows is of some concern. Specifically, it is important that renal denervation procedures do not delay timely access to other elective procedures with proven efficacy in reducing CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B583" data-open="ehae178-B583" class="link link-ref link-reveal xref-bibr">583</a></sup>

Sixth, there is still no direct evidence to gauge whether renal denervation procedures are successful and that the kidneys are denervated and do not reinnervate over time.<sup><a href="javascript:;" reveal-id="ehae178-B584" data-open="ehae178-B584" class="link link-ref link-reveal xref-bibr">584</a></sup> Relatedly, the concept of responders and non-responders to renal denervation (and the hypothesis that predictors of response might be found to help identify patients most suitable for the procedure) is questioned. Medical interventions, including drugs, are naturally subject to inter-individual variability in response.<sup><a href="javascript:;" reveal-id="ehae178-B567" data-open="ehae178-B567" class="link link-ref link-reveal xref-bibr">567</a></sup> Additionally, there are few examples in medicine of consistent and clinically useful predictors of treatment response for medical conditions that have complex genetic and environmental underpinnings (i.e. conditions like hypertension).

A multidisciplinary hypertension team, including experts in hypertension and percutaneous cardiovascular interventions, is recommended to evaluate the indication and to perform the procedure.<sup><a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> Based on the available evidence, renal denervation may be considered for patients who have uncontrolled, true resistant hypertension with a three-drug combination and who express a preference to undergo renal denervation.<sup><a href="javascript:;" reveal-id="ehae178-B566" data-open="ehae178-B566" class="link link-ref link-reveal xref-bibr">566</a>,<a href="javascript:;" reveal-id="ehae178-B568" data-open="ehae178-B568" class="link link-ref link-reveal xref-bibr">568</a>,<a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> This recommendation is informed, in part, by the higher risk of CVD events in this subgroup, which represents a major unmet clinical need and which also means that cost-effectiveness considerations are likely to be optimal in this setting. In patients who are non-adherent or intolerant to multiple BP-lowering medications, particularly first-line agents, and who have high predicted CVD risk and a BP that is not at target, renal denervation may, for the same reasons, be considered if the patients express a preference to undergo renal denervation after a tailored shared decision-making process. The shared decision-making process requires that the patients are fully informed about the benefits, limitations, and risks associated with renal denervation.

Recommendation Table 20

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376040)

Recommendations for device-based treatment of hypertension (see Evidence Table 35)

![Recommendations for device-based treatment of hypertension (see Evidence Table 35)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt20.jpeg?Expires=1728462844&Signature=Ez3ME3JRivuUZ4tGO8L4ZoLmiEQ-vfkYAXDZ6pF6wkFQLBRZ9FHzN0uK0Hmt~xVPW8tQpzSqCwXbj7PjbdH866TjkQBGahxH5~v9cOHdchLJi70hYpifpJB-fPUOK-rxfLZbEhzb-JJiTrljGufuyzFADtKHXDXcl628cVrDN4vFoXEm6wBJIvnj3ObkFzo5YL46~LEE29I-ICjheXn7KTIL-FgcemmWDAumNwmTdNoTf8tshsAKOI4Tig5oRyIGvaL29xpTc1SyXJvWHHS-WCDAwUpH-lxiHSZvotjTp69HdPtMso5i8EiuK4B8zims3Sy4-UceGWbUg6ddCA2Wvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 8.6.2. Other devices

Most device-based therapies investigated for BP-lowering therapy in hypertension have been aimed at modulating the autonomic nervous system activity (baroreflex activation therapy, endovascular baroreflex amplification therapy, and carotid body ablation).<sup><a href="javascript:;" reveal-id="ehae178-B560" data-open="ehae178-B560" class="link link-ref link-reveal xref-bibr">560</a></sup> Cardiac neuromodulation therapy aims to lower left ventricular preload by variably altering the atrioventricular interval using a dual-chamber, rate-responsive, implantable pulse generator in patients indicated for implantation or replacement of a dual-chamber pacemaker.<sup><a href="javascript:;" reveal-id="ehae178-B591" data-open="ehae178-B591" class="link link-ref link-reveal xref-bibr">591</a>,<a href="javascript:;" reveal-id="ehae178-B592" data-open="ehae178-B592" class="link link-ref link-reveal xref-bibr">592</a></sup> Some, though not all, of these devices have shown promising results in non-randomized, single-arm studies. A sham-controlled trial investigating central iliac arteriovenous stent anastomosis was terminated early after longer-term follow-up data indicated an increase in heart failure in the stent group.<sup><a href="javascript:;" reveal-id="ehae178-B561" data-open="ehae178-B561" class="link link-ref link-reveal xref-bibr">561</a></sup> Therefore, the use of these device-based therapies is not recommended for routinely treating hypertension until further evidence regarding their safety and efficacy becomes available (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).

### 8.7. Unintended and potentially harmful consequences of blood pressure lowering and implications for treatment targets

#### 8.7.1. Adverse effects of blood pressure-lowering medications

##### 8.7.1.1. Symptomatic adverse effects

BP-lowering medications have multiple side effects, which may be more common in females.<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B593" data-open="ehae178-B593" class="link link-ref link-reveal xref-bibr">593</a>,<a href="javascript:;" reveal-id="ehae178-B594" data-open="ehae178-B594" class="link link-ref link-reveal xref-bibr">594</a></sup> Although generally well tolerated, common side effects include headaches, cough, dizziness or light-headedness, diarrhoea or constipation, fatigue, ankle swelling, and erectile problems, depending on the drug class (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S9](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a>,<a href="javascript:;" reveal-id="ehae178-B593 ehae178-B594 ehae178-B595 ehae178-B596 ehae178-B597" data-open="ehae178-B593 ehae178-B594 ehae178-B595 ehae178-B596 ehae178-B597" class="link link-ref link-reveal xref-bibr">593–597</a></sup>

In randomized trials of adults aged >60 years, the overall rate of symptomatic BP-lowering drug withdrawal was higher than the rate of placebo withdrawal (approximately 15% vs. 5%).<sup><a href="javascript:;" reveal-id="ehae178-B593" data-open="ehae178-B593" class="link link-ref link-reveal xref-bibr">593</a></sup> A systematic review, which included 280 638 participants in 58 RCTs, reported no evidence for an increased relative risk of falls in those taking BP-lowering drugs.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> There was, however, an increased relative risk of mild hyperkalaemia, acute kidney injury, hypotension, and syncope. Furthermore, very frail adults were excluded from BP-lowering trials, which is relevant because such patients are more prone to adverse effects and polypharmacy (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a></sup>

##### 8.7.1.2. Renal effects

A systematic review reported an increased risk of acute kidney injury and hyperkalaemia associated with BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> Analyses of outcomes by specific drug class showed that drugs affecting the RAAS were more likely to be associated with acute kidney injury and hyperkalaemia.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup>

Patients with significant CKD tend to be excluded from RCTs.<sup><a href="javascript:;" reveal-id="ehae178-B137" data-open="ehae178-B137" class="link link-ref link-reveal xref-bibr">137</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a>,<a href="javascript:;" reveal-id="ehae178-B598" data-open="ehae178-B598" class="link link-ref link-reveal xref-bibr">598</a></sup> It is important to remember these exclusion criteria, and that patients with CKD are more likely to suffer from resistant hypertension, when extrapolating the results of more intensive BP lowering to patients with moderate-to-severe CKD (see _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_).<sup><a href="javascript:;" reveal-id="ehae178-B599" data-open="ehae178-B599" class="link link-ref link-reveal xref-bibr">599</a></sup>

##### 8.7.1.3. Erectile dysfunction

Older classes of BP-lowering drugs (including diuretics, beta-blockers, and centrally acting medications) are associated with erectile dysfunction.<sup><a href="javascript:;" reveal-id="ehae178-B600" data-open="ehae178-B600" class="link link-ref link-reveal xref-bibr">600</a></sup> However, newer classes have neutral effects.<sup><a href="javascript:;" reveal-id="ehae178-B601" data-open="ehae178-B601" class="link link-ref link-reveal xref-bibr">601</a></sup> Angiotensin receptor antagonists may have beneficial effect on erectile function.<sup><a href="javascript:;" reveal-id="ehae178-B602" data-open="ehae178-B602" class="link link-ref link-reveal xref-bibr">602</a></sup>

#### 8.7.2. Pill burden and non-adherence

More intensive treatment of elevated BP and hypertension may be associated with an increased risk of polypharmacy and pill burden, which are themselves associated with non-adherence.<sup><a href="javascript:;" reveal-id="ehae178-B603" data-open="ehae178-B603" class="link link-ref link-reveal xref-bibr">603</a>,<a href="javascript:;" reveal-id="ehae178-B604" data-open="ehae178-B604" class="link link-ref link-reveal xref-bibr">604</a></sup> Single-pill, fixed-dose drug combinations can help to reduce pill burden and are recommended to improve adherence (refer to _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)_).

Increased intensity of BP lowering (while ultimately cost reducing in terms of CVD reduction)<sup><a href="javascript:;" reveal-id="ehae178-B605" data-open="ehae178-B605" class="link link-ref link-reveal xref-bibr">605</a></sup> can also result in higher upfront direct and indirect healthcare costs, with more people requiring medication and higher demand for technology-based adherence strategies, which can be challenging to implement, especially in resource-poor settings.<sup><a href="javascript:;" reveal-id="ehae178-B604" data-open="ehae178-B604" class="link link-ref link-reveal xref-bibr">604</a></sup>

#### 8.7.3. Potentially harmful consequences of blood pressure lowering for frail older people

Unintended consequences of BP lowering (hypotension, syncope, falls) can be hazardous for frail older people in particular.<sup><a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a></sup> Retrospective studies have shown that adults aged >75 years from the general population, who would have met the criteria for inclusion in the Systolic Blood Pressure Intervention Trial (SPRINT), had a rate of injurious falls and syncope that was nearly five times that of the standard care group in the trial. This suggests that healthy participant bias may have contributed to the findings of SPRINT and other similar BP-lowering trials, and that the results may not fully generalize to older adults in more routine clinical care.<sup><a href="javascript:;" reveal-id="ehae178-B607" data-open="ehae178-B607" class="link link-ref link-reveal xref-bibr">607</a></sup>

Patients’ functional ability should be considered in addition to age to help negate any unintended consequences of BP lowering in a frailer cohort. Despite their chronological age, older patients with hypertension who are fit and can independently carry out activities of daily living will benefit from guideline-directed treatment similar to younger cohorts.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> However, tailoring treatment targets and treatment plans for frail older patients is necessary to avoid unintended consequences. This should include assessing frailty, including cognitive status, risk of falls, propensity for symptomatic orthostatic hypotension, polypharmacy, and other comorbid conditions.<sup><a href="javascript:;" reveal-id="ehae178-B608" data-open="ehae178-B608" class="link link-ref link-reveal xref-bibr">608</a>,<a href="javascript:;" reveal-id="ehae178-B609" data-open="ehae178-B609" class="link link-ref link-reveal xref-bibr">609</a></sup> Of note, and as detailed in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_, some data indicate a benefit of more intensive BP-lowering on cognitive function.<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> For those with loss of function but preserved activities of daily living, a more detailed geriatric assessment is required to explore the risks and benefits of treatment, as well as considerations for tailoring therapeutic strategies where appropriate. For patients who are both functionally impaired and unable to carry out activities of daily living, the therapeutic goals of hypertension treatment should be personalized, and medications discontinued where appropriate (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a></sup>

#### 8.7.4. Clinical inertia in blood pressure lowering

The fear of serious adverse events with BP-lowering medications is often cited as a reason for clinical inertia, although the evidence to date from meta-analyses of RCTs suggests these side-effect concerns may be exaggerated.<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a>,<a href="javascript:;" reveal-id="ehae178-B612" data-open="ehae178-B612" class="link link-ref link-reveal xref-bibr">612</a></sup> However, RCTs often select populations with less frailty and multimorbidity who are more likely to tolerate treatment.<sup><a href="javascript:;" reveal-id="ehae178-B613" data-open="ehae178-B613" class="link link-ref link-reveal xref-bibr">613</a></sup> Consequently, fewer adverse effects might be reported than would be expected in the general population. It remains up to individual clinicians to initiate shared decision-making with each patient, especially patients in vulnerable groups and those who have experienced previous adverse events, weighing up potential benefits against risks of treatment.<sup><a href="javascript:;" reveal-id="ehae178-B614" data-open="ehae178-B614" class="link link-ref link-reveal xref-bibr">614</a>,<a href="javascript:;" reveal-id="ehae178-B615" data-open="ehae178-B615" class="link link-ref link-reveal xref-bibr">615</a></sup>

## 9\. Managing specific patient groups or circumstances

### 9.1. Young adulthood (18–40 years)

#### 9.1.1. Definition and epidemiology

In the present guidelines ‘young adulthood’ is defined as age 18–40 years. The prevalence of hypertension in young adults is increasing in men and women.<sup><a href="javascript:;" reveal-id="ehae178-B616 ehae178-B617 ehae178-B618" data-open="ehae178-B616 ehae178-B617 ehae178-B618" class="link link-ref link-reveal xref-bibr">616–618</a></sup> Unhealthy lifestyle, gender, obesity, and socio-economic factors contribute.<sup><a href="javascript:;" reveal-id="ehae178-B617" data-open="ehae178-B617" class="link link-ref link-reveal xref-bibr">617</a>,<a href="javascript:;" reveal-id="ehae178-B619 ehae178-B620 ehae178-B621" data-open="ehae178-B619 ehae178-B620 ehae178-B621" class="link link-ref link-reveal xref-bibr">619–621</a></sup> Hypertension-attributable CVD burden in young adults, evaluated as mortality or years of living with disability, has increased in the last decades, especially in low- and middle-income countries and in men.<sup><a href="javascript:;" reveal-id="ehae178-B622" data-open="ehae178-B622" class="link link-ref link-reveal xref-bibr">622</a></sup> Hypertension awareness, treatment, and control in young adults is lower than in other age categories, a result driven by worse control in young men.<sup><a href="javascript:;" reveal-id="ehae178-B623" data-open="ehae178-B623" class="link link-ref link-reveal xref-bibr">623</a></sup>

Systolic and diastolic hypertension and isolated diastolic hypertension are associated with increased CVD risk in the young (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462844&Signature=RzVKZRpv5q3mGk4M9L4Ivrfp8m9rFPlE-geJwhkJ64GXYDedmSHLDLoU~f5vP9vsPar6q4v8PbVftmAjXtRwKYsTT-dDKDf~4PKP10DWpyzSi-cw~M9ZJ1awg3YfRhri7BpklXRiRifR-E1HAwO3hMZlfnQ2g~WKkkfY-SMDcsxYvBVO~jbEUE3f0soS8XWDyYlGE5rtYp7U80Rerrcp7vKGhhyxbrQfTS4zpHZNWEG3W-N-bHrNSGJmp3AKrxLoqCxvx07jDx9bykk03x~fK22yVuUGfVsOoMD1-n2~zrvJJqWQhFqoHLpGRLlXCU9gXWXq3663GVSv5EPF4qAdbQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B624" data-open="ehae178-B624" class="link link-ref link-reveal xref-bibr">624</a></sup> Isolated systolic hypertension in the young is discussed in _Section [9.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.4)._

#### 9.1.2. Secondary hypertension in young adulthood

Secondary hypertension is more frequent in younger than in later-onset hypertension, with a prevalence of 15%–30% in hypertensive young adults reported from some referral centres.<sup><a href="javascript:;" reveal-id="ehae178-B625" data-open="ehae178-B625" class="link link-ref link-reveal xref-bibr">625</a>,<a href="javascript:;" reveal-id="ehae178-B626" data-open="ehae178-B626" class="link link-ref link-reveal xref-bibr">626</a></sup> Major causes of secondary hypertension include drug-induced hypertension (e.g. oestrogen-progesterone oral contraceptives; cold medication) and primary aldosteronism. The use of recreational drugs/substances, as well as supplements and energy drinks should be investigated (see _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_).

Combined oestrogen-progesterone contraceptives are among the most common causes of drug-induced hypertension in young women,<sup><a href="javascript:;" reveal-id="ehae178-B627" data-open="ehae178-B627" class="link link-ref link-reveal xref-bibr">627</a>,<a href="javascript:;" reveal-id="ehae178-B628" data-open="ehae178-B628" class="link link-ref link-reveal xref-bibr">628</a></sup> and should not be used in hypertensive women unless there is no other method available or acceptable to the patient.<sup><a href="javascript:;" reveal-id="ehae178-B629" data-open="ehae178-B629" class="link link-ref link-reveal xref-bibr">629</a></sup> Conversely, progestin-only contraceptives are generally considered safe in women with hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B630" data-open="ehae178-B630" class="link link-ref link-reveal xref-bibr">630</a>,<a href="javascript:;" reveal-id="ehae178-B631" data-open="ehae178-B631" class="link link-ref link-reveal xref-bibr">631</a></sup> Fibromuscular dysplasia should be considered as a cause of secondary hypertension in young women,<sup><a href="javascript:;" reveal-id="ehae178-B626" data-open="ehae178-B626" class="link link-ref link-reveal xref-bibr">626</a>,<a href="javascript:;" reveal-id="ehae178-B632" data-open="ehae178-B632" class="link link-ref link-reveal xref-bibr">632</a></sup> whereas primary aldosteronism, the most common form of secondary hypertension, is equally common in different age classes.<sup><a href="javascript:;" reveal-id="ehae178-B316" data-open="ehae178-B316" class="link link-ref link-reveal xref-bibr">316</a></sup> Screening for secondary hypertension is thus recommended in young adults with hypertension. However, in obese young adults, primary hypertension is more common, though OSAS should also be considered in this instance.<sup><a href="javascript:;" reveal-id="ehae178-B633" data-open="ehae178-B633" class="link link-ref link-reveal xref-bibr">633</a></sup>

#### 9.1.3. Measurement and management of blood pressure in young adults

Out-of-office BP measurement is recommended in young adults for confirming diagnosis, since the white-coat phenomenon occurs in the young.<sup><a href="javascript:;" reveal-id="ehae178-B634" data-open="ehae178-B634" class="link link-ref link-reveal xref-bibr">634</a></sup> Because of the lower absolute CVD risk in this age category compared with older adults, hard-endpoint randomized trials of BP lowering in young adults have not been performed. However, since relative risk reduction by BP-lowering treatment is homogeneous in any age group, including those <55 years old,<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> young adults with suitable indications are also expected to benefit from BP-lowering therapy. The hypertension management algorithm based on CVD risk proposed in _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ is not fully applicable in young adults, since SCORE2 has not been validated for individuals <40 years old. Even risk stratification based on lifetime risk assessment does not apply to very young adults (e.g. 20–30 years of age).<sup><a href="javascript:;" reveal-id="ehae178-B128" data-open="ehae178-B128" class="link link-ref link-reveal xref-bibr">128</a></sup> In the absence of established CVD, diabetes mellitus, familial hypercholesterolaemia, and moderate or severe CKD a BP-lowering treatment initiation threshold of office 140/90 mmHg is appropriate in most young adults. However, HMOD assessment may be considered in patients aged <40 years to stratify individuals with elevated BP into a higher risk category. For example, arterial stiffness better reclassifies CVD risk in individuals aged <50 years than in older individuals.<sup><a href="javascript:;" reveal-id="ehae178-B28" data-open="ehae178-B28" class="link link-ref link-reveal xref-bibr">28</a>,<a href="javascript:;" reveal-id="ehae178-B215" data-open="ehae178-B215" class="link link-ref link-reveal xref-bibr">215</a></sup> Echocardiographic left ventricular mass also maintains its added reclassification and discrimination on top of risk scores in young adults (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ for discussion of risk modifiers).<sup><a href="javascript:;" reveal-id="ehae178-B289" data-open="ehae178-B289" class="link link-ref link-reveal xref-bibr">289</a></sup>

Irrespective of cardiovascular risk, all young adults with elevated BP are recommended to follow lifestyle guidance for BP lowering. A discussion about family planning should be taken with young women of childbearing potential at each visit.<sup><a href="javascript:;" reveal-id="ehae178-B635" data-open="ehae178-B635" class="link link-ref link-reveal xref-bibr">635</a>,<a href="javascript:;" reveal-id="ehae178-B636" data-open="ehae178-B636" class="link link-ref link-reveal xref-bibr">636</a></sup>

Adherence to treatment is low in young adults, <50% in some studies.<sup><a href="javascript:;" reveal-id="ehae178-B251" data-open="ehae178-B251" class="link link-ref link-reveal xref-bibr">251</a></sup> Therefore, communicating the importance of adherence, education, and follow-up clinics is important. (see _Sections [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_ and _[11](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s10)_).

Recommendation Table 21

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376073)

Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37)

![Recommendations for managing hypertension in young adults (see Evidence Tables 36 and 37)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt21.jpeg?Expires=1728462844&Signature=IbGHsT7m26h6J0O1EWY7rinCj-Zyv3mRLTYG1nX88vx4JYMLE4qjXLCHa6o-aeXUL0LPXO7VNrSF5SZGO4mN05eyAm4x4fhhvHhKcLfTRTfHxxnZ7~piDOM~~weFdOsBBUFxPanPmzsIVkwY9xSD72KxUfzvp8-ajpmMEK5DxH7E~mj~MX8lL6xKvDSM8s4f7EKH4M87LzagY8S5VsNsREskSlVwSR5~dJl4RxkRRUISObpayk1yA1GLmt9TJqbYF-H~vMU6XCJnhgCq2rI1tV26vW1niex1frPbPgacfntd1PzDAiCombYodzT4a-RWLZShWnLdojSe40Lkv09zkA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.2. Pregnancy

#### 9.2.1. Definition and epidemiology

Hypertension in pregnancy is typically defined as systolic BP of ≥140 mmHg and/or diastolic BP of ≥90 mmHg, measured using repeated BP readings in the office or hospital on two separate occasions or ≥15 min apart in severe hypertension (≥160/110 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a>,<a href="javascript:;" reveal-id="ehae178-B638" data-open="ehae178-B638" class="link link-ref link-reveal xref-bibr">638</a></sup>

Hypertension in pregnancy is the second leading cause of maternal death after maternal peri-partum haemorrhage.<sup><a href="javascript:;" reveal-id="ehae178-B639" data-open="ehae178-B639" class="link link-ref link-reveal xref-bibr">639</a></sup> Approximately 7% of pregnancies are complicated by hypertension, of which 3% are due to pre-eclampsia and around 1% are chronic or pre-existing hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B640" data-open="ehae178-B640" class="link link-ref link-reveal xref-bibr">640</a></sup> Women with a history of hypertensive disorders during pregnancy are at increased risk of subsequent hypertension and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B640 ehae178-B641 ehae178-B642" data-open="ehae178-B640 ehae178-B641 ehae178-B642" class="link link-ref link-reveal xref-bibr">640–642</a></sup>

#### 9.2.2. Classifying hypertension in pregnancy

Hypertension in pregnancy includes:

-   **Chronic hypertension:** precedes pregnancy, develops before 20 weeks of gestation, persists for >6 weeks post-partum, and may be associated with proteinuria.
    
-   **Gestational hypertension:** develops after 20 weeks of gestation and usually resolves within 6 weeks post-partum.
    
-   **Antenatally unclassifiable hypertension:** BP is first recorded after 20 weeks of gestation, and hypertension is diagnosed but it is unclear if chronic or not; reassessment is necessary 6 weeks post-partum.
    
-   **Pre-eclampsia:** gestational hypertension accompanied by new-onset: (i) proteinuria (>0.3 g/day or ≥30 mg/mmol ACR), (ii) other maternal organ dysfunction, including acute kidney injury (serum creatinine ≥ 1 mg/dL), liver dysfunction (elevated transaminases > 40 UI/L with or without right upper quadrant or epigastric abdominal pain), neurological complications (convulsions, altered mental status, blindness, stroke, severe headaches, and persistent visual scotomata), or haematological complications (platelet count < 150 000/µL, disseminated intravascular coagulation, haemolysis), or (iii) uteroplacental dysfunction (such as foetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or stillbirth).<sup><a href="javascript:;" reveal-id="ehae178-B643" data-open="ehae178-B643" class="link link-ref link-reveal xref-bibr">643</a></sup> The only cure for pre-eclampsia is delivery, which is recommended at 37 weeks’ gestation, or earlier in high-risk cases. Of note, proteinuria is not mandatory for diagnosing pre-eclampsia but is present in about 70% of cases.<sup><a href="javascript:;" reveal-id="ehae178-B644" data-open="ehae178-B644" class="link link-ref link-reveal xref-bibr">644</a></sup> Also, as proteinuria may be a late manifestation of pre-eclampsia, it should be suspected when _de novo_ hypertension is accompanied by headache, visual disturbances, abdominal pain, or abnormal laboratory tests, specifically low platelets and/or abnormal liver function.
    

Other potential causes for high BP, including pain and anxiety, must be excluded when treating hypertension during pregnancy.

#### 9.2.3. Measuring blood pressure in pregnancy

See _Section [5.5.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.5.1)_ for information on BP measurement approaches in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B645" data-open="ehae178-B645" class="link link-ref link-reveal xref-bibr">645</a></sup> It is important to restate here that oscillometric devices tend to under-estimate the true BP and are unreliable in severe pre-eclampsia; only a few have been validated in pregnancy. Importantly, only the relatively few devices validated for measuring BP in pregnancy and pre-eclampsia should be used ([https://stridebp.org](https://stridebp.org)).

#### 9.2.4. Investigating hypertension in pregnancy

Basic laboratory investigations include urinalysis, blood count, haematocrit, liver enzymes, serum creatinine, and serum uric acid. Serum uric acid is increased in pre-eclampsia and identifies women at increased risk of adverse maternal and foetal outcomes in hypertensive pregnancies.<sup><a href="javascript:;" reveal-id="ehae178-B646" data-open="ehae178-B646" class="link link-ref link-reveal xref-bibr">646</a></sup>

All pregnant women should be assessed for proteinuria in early pregnancy (e.g. 11–14 weeks’ gestation).<sup><a href="javascript:;" reveal-id="ehae178-B647" data-open="ehae178-B647" class="link link-ref link-reveal xref-bibr">647</a></sup> A dipstick test of ≥1+ should prompt further investigations, including ACR, which can be quickly determined in a single spot-urine sample.<sup><a href="javascript:;" reveal-id="ehae178-B648" data-open="ehae178-B648" class="link link-ref link-reveal xref-bibr">648</a></sup> An ACR of <30 mg/mmol (<0.3 mg/mg) can rule out proteinuria.<sup><a href="javascript:;" reveal-id="ehae178-B649" data-open="ehae178-B649" class="link link-ref link-reveal xref-bibr">649</a></sup> Higher values should prompt 24 h urine collection.

In one study, 10% of pregnant women with chronic hypertension had secondary hypertension (estimated to affect 0.24% of all pregnancies).<sup><a href="javascript:;" reveal-id="ehae178-B650" data-open="ehae178-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> Secondary hypertension during pregnancy is associated with an increased risk of adverse outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B650" data-open="ehae178-B650" class="link link-ref link-reveal xref-bibr">650</a></sup> The most common cause of secondary hypertension during pregnancy is CKD. The onset of hypertension during the first trimester, at the peak of human chorionic gonadotropin (HCG) secretion, should prompt consideration of primary aldosteronism.<sup><a href="javascript:;" reveal-id="ehae178-B651" data-open="ehae178-B651" class="link link-ref link-reveal xref-bibr">651</a></sup> Phaeochromocytoma in pregnant women is rare (0.002% of all pregnancies) but highly morbid.<sup><a href="javascript:;" reveal-id="ehae178-B652" data-open="ehae178-B652" class="link link-ref link-reveal xref-bibr">652</a>,<a href="javascript:;" reveal-id="ehae178-B653" data-open="ehae178-B653" class="link link-ref link-reveal xref-bibr">653</a></sup>

#### 9.2.5. Preventing hypertension and pre-eclampsia

Low-to-moderate-intensity exercise, especially if supervised and initiated during the first trimester of pregnancy, decreases the incidence of developing gestational hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B654" data-open="ehae178-B654" class="link link-ref link-reveal xref-bibr">654</a></sup> As such, after consultation with their obstetrician, all pregnant women should participate in physical activity, unless contraindicated.<sup><a href="javascript:;" reveal-id="ehae178-B655" data-open="ehae178-B655" class="link link-ref link-reveal xref-bibr">655</a></sup> Factors indicating risk of pre-eclampsia are discussed in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Women at high or moderate risk of pre-eclampsia should be advised to take 100–150 mg of aspirin daily at bedtime from gestational weeks 12–36.<sup><a href="javascript:;" reveal-id="ehae178-B647" data-open="ehae178-B647" class="link link-ref link-reveal xref-bibr">647</a>,<a href="javascript:;" reveal-id="ehae178-B656" data-open="ehae178-B656" class="link link-ref link-reveal xref-bibr">656</a>,<a href="javascript:;" reveal-id="ehae178-B657" data-open="ehae178-B657" class="link link-ref link-reveal xref-bibr">657</a></sup>

Oral calcium supplementation of 0.5–2 g daily is recommended for preventing pre-eclampsia in women with low dietary intake of calcium (<600 mg daily).<sup><a href="javascript:;" reveal-id="ehae178-B658" data-open="ehae178-B658" class="link link-ref link-reveal xref-bibr">658</a>,<a href="javascript:;" reveal-id="ehae178-B659" data-open="ehae178-B659" class="link link-ref link-reveal xref-bibr">659</a></sup>

#### 9.2.6. Treatment initiation and blood pressure targets

Acute management of BP in pre-eclampsia and eclampsia is detailed in _Section [10.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.4)_.

Meta-analyses have found no evidence for an increased risk for delivering small-for-gestational-age babies in pregnant women with mild hypertension receiving BP-lowering medications.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a></sup> Despite a historical paucity of trial data, previous European guidelines<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> recommended initiating BP-lowering drug treatment (i) in all women with persistently elevated office BP of ≥150/90 mmHg, and (ii) in women with gestational hypertension (with or without proteinuria), pre-existing hypertension with superimposed gestational hypertension, or hypertension with subclinical HMOD, when office BP is >140/90 mmHg.

In the CHAP trial, treating pregnant women with chronic hypertension and BP of ≥140/90 mmHg reduced the occurrence of pre-eclampsia with severe features, and reduced medically indicated pre-term birth <35 weeks, compared with only treating severe hypertension (BP ≥ 160/105 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B88" data-open="ehae178-B88" class="link link-ref link-reveal xref-bibr">88</a></sup> Tight BP control (target diastolic BP < 85 mmHg) compared with less-tight BP control (target diastolic BP < 100 mmHg) reduces the incidence of subsequent severe maternal hypertension (BP ≥ 160/110 mmHg), but not foetal or other maternal outcomes in women with mild hypertension at baseline (diastolic BP of 85–105 mmHg).<sup><a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup>

Treatment with BP-lowering drugs in all pregnant women with confirmed BP of ≥140/90 mmHg is recommended to reduce the progression to severe hypertension and the related risks for adverse pregnancy outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a>,<a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup> In women with pre-existing and gestational hypertension with and without pre-eclampsia, we recommend lowering BP below 140 mmHg for systolic and to 80–90 mmHg for diastolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B661" data-open="ehae178-B661" class="link link-ref link-reveal xref-bibr">661</a></sup> Evidence to support a BP target as low as 120–129/70–79 mmHg is lacking in pregnancy, though such evidence exists for non-pregnant patients receiving BP-lowering medication.

#### 9.2.7. Managing mild hypertension in pregnancy (office blood pressure 140–159/90–109 mmHg)

RAS inhibitors are not recommended in pregnancy due to adverse foetal and neonatal outcomes. The BP-lowering drugs of choice are: beta-blockers (most data are available for labetalol, a non-selective beta-blocker that also acts as an alpha-blocker in higher doses; metoprolol and bisoprolol are also considered safe), dihydropyridine CCBs (most data are available for nifedipine, which is generally considered first choice, also felodipine, nitrendipine, amlodipine, and isradipine can be used), and methyldopa.<sup><a href="javascript:;" reveal-id="ehae178-B662" data-open="ehae178-B662" class="link link-ref link-reveal xref-bibr">662</a>,<a href="javascript:;" reveal-id="ehae178-B663" data-open="ehae178-B663" class="link link-ref link-reveal xref-bibr">663</a></sup> A meta-analysis suggests that beta-blockers and CCBs are more effective than methyldopa in preventing severe hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B660" data-open="ehae178-B660" class="link link-ref link-reveal xref-bibr">660</a></sup> Of note, however, atenolol should be avoided, as it is associated with foetal growth restriction.<sup><a href="javascript:;" reveal-id="ehae178-B664" data-open="ehae178-B664" class="link link-ref link-reveal xref-bibr">664</a>,<a href="javascript:;" reveal-id="ehae178-B665" data-open="ehae178-B665" class="link link-ref link-reveal xref-bibr">665</a></sup> Methyldopa has been associated with an increased risk of post-partum depression and caution is therefore advised both intra-partum and post-partum.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Hydralazine can be particularly effective for severe hypertension in pregnancy and can be administered intravenously in hypertensive admissions (_Section [10](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9)_).<sup><a href="javascript:;" reveal-id="ehae178-B666 ehae178-B667 ehae178-B668" data-open="ehae178-B666 ehae178-B667 ehae178-B668" class="link link-ref link-reveal xref-bibr">666–668</a></sup> While thiazide diuretics in pregnancy have limited safety data and should be used with caution, other diuretics such as furosemide are not contraindicated and may be necessary in some situations (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B669" data-open="ehae178-B669" class="link link-ref link-reveal xref-bibr">669</a></sup>

#### 9.2.8. Managing severe hypertension in pregnancy (>160/110 mmHg)

Acute onset of severe hypertension persisting for more than 15 min is considered a hypertensive emergency in pregnancy and is covered in _Section [10.4.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.4.2)._

#### 9.2.9. Managing blood pressure post-partum

For women with hypertension during pregnancy, BP should be measured within 6 h of delivery and, if possible, daily for at least a week after discharge from the hospital.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Post-partum hypertension is common in the first week and associated with prolonged hospitalization.<sup><a href="javascript:;" reveal-id="ehae178-B670" data-open="ehae178-B670" class="link link-ref link-reveal xref-bibr">670</a></sup>

Women with hypertension in pregnancy are at increased risk of chronic hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B671" data-open="ehae178-B671" class="link link-ref link-reveal xref-bibr">671</a></sup> CKD,<sup><a href="javascript:;" reveal-id="ehae178-B672" data-open="ehae178-B672" class="link link-ref link-reveal xref-bibr">672</a></sup> and CVD.<sup><a href="javascript:;" reveal-id="ehae178-B177" data-open="ehae178-B177" class="link link-ref link-reveal xref-bibr">177</a>,<a href="javascript:;" reveal-id="ehae178-B223" data-open="ehae178-B223" class="link link-ref link-reveal xref-bibr">223</a>,<a href="javascript:;" reveal-id="ehae178-B640" data-open="ehae178-B640" class="link link-ref link-reveal xref-bibr">640</a></sup> The relative risk of chronic hypertension is highest in the first 6 months following delivery, motivating regular screening in these women.<sup><a href="javascript:;" reveal-id="ehae178-B673" data-open="ehae178-B673" class="link link-ref link-reveal xref-bibr">673</a></sup> Women with gestational hypertension, especially those with pre-eclampsia, have higher risk of masked hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B674" data-open="ehae178-B674" class="link link-ref link-reveal xref-bibr">674</a></sup> BP measurements, ideally including out-of-office measurements, urine analyses, and CVD risk assessment, should at least be performed 6–12 weeks, 6 months, and 12 months post-partum and, after that, annually. Recent data indicate the potential utility of self-monitoring of BP during the busy early post-partum period.<sup><a href="javascript:;" reveal-id="ehae178-B675" data-open="ehae178-B675" class="link link-ref link-reveal xref-bibr">675</a></sup>

All BP-lowering drugs are excreted into breast milk.<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup> Except for propranolol, atenolol, acebutolol, and nifedipine, most drugs are excreted in very low concentrations in breast milk (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S11](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup>

#### 9.2.10. Risk of recurrence of hypertensive disorders in a subsequent pregnancy

About 20%–30% of women with hypertensive disorders in a previous pregnancy will experience recurrence in a subsequent pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B676" data-open="ehae178-B676" class="link link-ref link-reveal xref-bibr">676</a>,<a href="javascript:;" reveal-id="ehae178-B677" data-open="ehae178-B677" class="link link-ref link-reveal xref-bibr">677</a></sup> The earlier the onset of hypertension in the first pregnancy, the higher the risk of recurrence in a subsequent pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B677" data-open="ehae178-B677" class="link link-ref link-reveal xref-bibr">677</a></sup>

Further details on managing hypertension and other cardiovascular disorders in pregnancy are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B637" data-open="ehae178-B637" class="link link-ref link-reveal xref-bibr">637</a></sup>

Recommendation Table 22

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376108)

Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40)

![Recommendations for managing hypertension in pregnancy (see Evidence Tables 38–40)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt22.jpeg?Expires=1728462845&Signature=El5Koazz9cNjasY3XqAEjoNmf9LPaVZWenHUIkNkJF28zetFzkHxs1765jImVGwzWSjws~RzWR1FXp1MqAo4d5TwUwLIiU3GRoBjsFx2ihiI6QBgp11JfTnbicouCgjMZk7Wi17-SDnVJpEcqxiJMuJiCnY5L9X4CjuudLasOsH3RYzqv8YGhUi6ORp5hJaYWTDB7BWbXO2Ds~duDAaB-Kk8ZmUm4G2PgnRsvKr4hvAL0VLnl-kYyt50evrqlH77X7N5MCZ-8bqGAdUXCf2qhdtuRRhhqHOzrURZbA96E5qHYH4cqIFNklmHH41A0lk-oMvJyqI1KRpfMjn9VwV1CQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.3. Very old age (≥85 years), frailty, multimorbidity, and polypharmacy

#### 9.3.1. Definition of frailty

The most common definition of frailty is an age-associated, biological syndrome characterized by decreased biological reserves, due to dysregulation of several physiological systems.<sup><a href="javascript:;" reveal-id="ehae178-B682" data-open="ehae178-B682" class="link link-ref link-reveal xref-bibr">682</a></sup> This puts an individual at risk when facing physiological stressors, and is associated with poor outcomes, such as disability, hospitalization, and death.<sup><a href="javascript:;" reveal-id="ehae178-B683" data-open="ehae178-B683" class="link link-ref link-reveal xref-bibr">683</a></sup> The estimated prevalence of frailty in people aged >65 years is 7%–16% and is greater in women than in men.<sup><a href="javascript:;" reveal-id="ehae178-B684" data-open="ehae178-B684" class="link link-ref link-reveal xref-bibr">684</a>,<a href="javascript:;" reveal-id="ehae178-B685" data-open="ehae178-B685" class="link link-ref link-reveal xref-bibr">685</a></sup> Although the main determinant of frailty is age, chronological age must be differentiated from biological age.<sup><a href="javascript:;" reveal-id="ehae178-B686" data-open="ehae178-B686" class="link link-ref link-reveal xref-bibr">686</a></sup> An older patient can be fit and robust while a multimorbid young patient can be frail. Using multiple drugs may have more unpredictable effects on BP in older patients, because of increased competition for underlying mechanisms responsible for their degradation and elimination, and because the ability of the baro-<sup><a href="javascript:;" reveal-id="ehae178-B687" data-open="ehae178-B687" class="link link-ref link-reveal xref-bibr">687</a></sup> and chemo-reflex<sup><a href="javascript:;" reveal-id="ehae178-B688" data-open="ehae178-B688" class="link link-ref link-reveal xref-bibr">688</a></sup> systems in maintaining a steady treated BP level can decline with ageing.

With respect to BP, two issues compound interpretation of the frailty literature. First, frailty on its own is a strong predictor of mortality and cardiovascular complications<sup><a href="javascript:;" reveal-id="ehae178-B689" data-open="ehae178-B689" class="link link-ref link-reveal xref-bibr">689</a></sup> and is accompanied by a decrease in systolic BP.<sup><a href="javascript:;" reveal-id="ehae178-B690" data-open="ehae178-B690" class="link link-ref link-reveal xref-bibr">690</a></sup> This raises the issue of the so-called BP J-curve (see _Section [9.8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.8)_) and reverse causality, with frailty rather than excessive BP lowering being the root cause of adverse health outcomes. Only properly randomized and controlled clinical trials can differentiate between the effects of frailty vs. overly intensive BP-lowering treatment, but unfortunately, few BP-lowering trials have included a substantial proportion of frail patients. Second, there is no consensus on how to grade frailty in day-to-day clinical practice.<sup><a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a></sup> Complex frailty scales exist for application in research,<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B691" data-open="ehae178-B691" class="link link-ref link-reveal xref-bibr">691</a></sup> but unless they are electronically generated,<sup><a href="javascript:;" reveal-id="ehae178-B692" data-open="ehae178-B692" class="link link-ref link-reveal xref-bibr">692</a></sup> they are typically not practical in routine clinical care. Nonetheless, the clinical frailty scale (_[Figure 21](javascript:;)_) is intuitive and easy to administer and has been validated against 5-year risk of death.<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B693" data-open="ehae178-B693" class="link link-ref link-reveal xref-bibr">693</a></sup>

![Frailty assessment in the management of blood pressure.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f21.jpeg?Expires=1728462845&Signature=G~uJ3Zba~oV5w9jc-H-slAdvR76ONw8eMn7eHj0nlGoXsiRp7hwh9PaLV~aj7ne9lYR5S1SFO0l9LLN1WVwn~W-1d0CZH3mF2zJBMe9n1mVq5e~lT4inGBDty9Tubp1j9M74HvTmLUN8YdItdBMEIN3vDlUweOxAA2lTD8L-I4I2LVztBiU10tu~8bEUv3TTyV1U0OscU-dJtL46uGjbfHQ9u0HLJfL8UF~2W6QqFx8q4V4XK8PSiT0~XL52do3UgeCl2U056nNopDXeftkfR9wi4nQ5Lxz5j4SbF3rxc-V4Nt6IvD2NH7PO~BLevCTNYf8zaxkNqF4v71CJtzwkgw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 21

Frailty assessment in the management of blood pressure.

ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; IADLs, independent activities of daily living; OH, orthostatic hypotension. Adapted from Rockwood _et al_.<sup><a href="javascript:;" reveal-id="ehae178-B693" data-open="ehae178-B693" class="link link-ref link-reveal xref-bibr">693</a></sup>

[Open in new tab](https://academic.oup.com/view-large/figure/479376113/ehae178f21.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f21.jpeg?Expires=1728462845&Signature=HjsQxuDErWKqpFc-a9a3KA1wbXKdg5tRqgH5IBdVqQuuQKdrgu10HaQe-sE3k5qGbkx7l7EslTzGesOYFdFgjl-5c0kigTi3WM5w22jTjkEvRhvao40s5AGuyO52mSdFNIeRees~jQgFJ2odiHDxCDLeRAXooYGgQhwnOYgWGWeITpjTHyfkgi1WUeFIm5Xx1HkFN6FAh9M66jXDowVeQ0bq5~4Q-2RTKFL7g~ItEC5mQkz~NCi8LTHOolxbw3j~VkgBFWG4YLn2e9hcRZRpvK82Oyk0lHiPQaWR5MHegfEZHh2bV07RIyLhpxh~JwjlacSHU0yCLq-XYpDT6YqI6w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376113&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

#### 9.3.2. Randomized controlled trials of blood pressure lowering in frail older patients

Few adults aged ≥85 years have been included in trials.<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> In addition, generalizing data from RCTs to very frail patients may not be possible.<sup><a href="javascript:;" reveal-id="ehae178-B692" data-open="ehae178-B692" class="link link-ref link-reveal xref-bibr">692</a>,<a href="javascript:;" reveal-id="ehae178-B694 ehae178-B695 ehae178-B696 ehae178-B697" data-open="ehae178-B694 ehae178-B695 ehae178-B696 ehae178-B697" class="link link-ref link-reveal xref-bibr">694–697</a></sup> However, the currently available evidence from RCTs has not demonstrated weakening of the benefits of BP-lowering treatment (i.e. no effect modification) among frailer patients enrolled in these trials, although these participants likely had no more than mild frailty (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B694" data-open="ehae178-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae178-B698" data-open="ehae178-B698" class="link link-ref link-reveal xref-bibr">698</a></sup>

In the absence of robust randomized evidence, several observational studies have suggested that lowering BP might not be warranted or even be harmful in patients with significant frailty or multimorbidity, particularly when BP is not very high. For instance, a systematic review and meta-analysis of non-randomized studies that investigated associations between BP and risk of mortality in older patients found evidence for interaction by frailty status, suggesting that lowering BP might be harmful in this patient group.<sup><a href="javascript:;" reveal-id="ehae178-B699" data-open="ehae178-B699" class="link link-ref link-reveal xref-bibr">699</a></sup> However, as noted above and in _Section [9.8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.8)_, these observational J-curve findings are unreliable when guiding clinical care, as unidentified biases potentially confound the results. For instance, in addition to reverse causality, stiffness of the large arteries is associated with both low diastolic BP and increased mortality.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> In addition, absolute CVD risk increases with age, indicating that fewer older than younger patients with hypertension may need to be treated to prevent one adverse health outcome.<sup><a href="javascript:;" reveal-id="ehae178-B700" data-open="ehae178-B700" class="link link-ref link-reveal xref-bibr">700</a></sup>

Therefore, given the totality of evidence from clinical trials,<sup><a href="javascript:;" reveal-id="ehae178-B523" data-open="ehae178-B523" class="link link-ref link-reveal xref-bibr">523</a>,<a href="javascript:;" reveal-id="ehae178-B694" data-open="ehae178-B694" class="link link-ref link-reveal xref-bibr">694</a>,<a href="javascript:;" reveal-id="ehae178-B701" data-open="ehae178-B701" class="link link-ref link-reveal xref-bibr">701</a>,<a href="javascript:;" reveal-id="ehae178-B702" data-open="ehae178-B702" class="link link-ref link-reveal xref-bibr">702</a></sup> very old and frail patients with hypertension should not be denied the potential benefits of BP-lowering treatment down to a target of 120–129/70–79 mmHg. However, personalized decision-making should be a priority in the very old and frail. Together with management of BP, a major consideration should also be whether reversible causes of frailty can be addressed,<sup><a href="javascript:;" reveal-id="ehae178-B609" data-open="ehae178-B609" class="link link-ref link-reveal xref-bibr">609</a></sup> e.g. by treating underlying comorbidities or undergoing supervised muscle-strengthening physiotherapy or supervised exercise and co-ordination and balance training.<sup><a href="javascript:;" reveal-id="ehae178-B703" data-open="ehae178-B703" class="link link-ref link-reveal xref-bibr">703</a></sup>

#### 9.3.3. Starting blood pressure-lowering treatment in very old or frail patients

All patients must be fully informed about the benefits and risks of starting BP-lowering treatment, so that their preference is considered. Among 34 hypertension guidelines, 18 recommended 150 mmHg as the systolic goal in frailer and/or older patients, but four endorsed systolic targets <130 mmHg or <120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B704" data-open="ehae178-B704" class="link link-ref link-reveal xref-bibr">704</a></sup> Treatment can be started with a long-acting dihydropyridine calcium channel antagonist.<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> To achieve BP control, an ACE inhibitor, or if contraindicated, an ARB, can also be used. Thereafter, low-dose thiazides or thiazide-like diuretics are preferred unless there is a specific contraindication, such as gout, orthostatic hypotension, or disturbed micturition (including micturition syncope).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> Beta-blockers are less desirable as they reduce heart rate, cause fatigue, and increase the systolic pulse wave amplitude, which is insufficiently buffered in stiff central elastic arteries. Vasodilating beta-blockers and direct vasodilators (e.g. hydralazine and minoxidil) are associated with increased risk of orthostasis. Though data are conflicting,<sup><a href="javascript:;" reveal-id="ehae178-B706" data-open="ehae178-B706" class="link link-ref link-reveal xref-bibr">706</a></sup> alpha-blockers are also considered less desirable as they appear to be associated with an increased risk of orthostasis and falls in very old patients (aged ≥85 years).<sup><a href="javascript:;" reveal-id="ehae178-B707" data-open="ehae178-B707" class="link link-ref link-reveal xref-bibr">707</a>,<a href="javascript:;" reveal-id="ehae178-B708" data-open="ehae178-B708" class="link link-ref link-reveal xref-bibr">708</a></sup> Alpha-1 blockers, such as doxazosin, prazosin, terazosin (also used to treat prostate symptoms), are particularly prone to causing orthostasis.<sup><a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a></sup> Once the appropriate combination is found, a combination tablet with variable composition of two agents may optimize adherence. Starting with combination therapy is not advised in most very old and/or frail patients, unless BP is very high.

#### 9.3.4. Maintaining blood pressure lowering in very old or frail patients

If very old and frail patients tolerate BP-lowering treatment well, there is no automatic need to deprescribe or discontinue treatment; however, this should be kept under review. In the case of progressive frailty, systolic BP tends to drop,<sup><a href="javascript:;" reveal-id="ehae178-B709" data-open="ehae178-B709" class="link link-ref link-reveal xref-bibr">709</a></sup> such that deprescription of a BP-lowering drug might become necessary. To identify candidate drugs for deprescribing, a patient’s current medications should be reviewed to identify BP-lowering drugs that may have become contraindicated due to concomitant prescriptions or newly developed comorbidities.<sup><a href="javascript:;" reveal-id="ehae178-B705" data-open="ehae178-B705" class="link link-ref link-reveal xref-bibr">705</a></sup> To help guide deprescription of BP-lowering agents, ABPM can be used to detect orthostatic hypotension or a highly variable BP not buffered by autonomic nervous reflexes.<sup><a href="javascript:;" reveal-id="ehae178-B687" data-open="ehae178-B687" class="link link-ref link-reveal xref-bibr">687</a>,<a href="javascript:;" reveal-id="ehae178-B688" data-open="ehae178-B688" class="link link-ref link-reveal xref-bibr">688</a></sup>

Recommendation Table 23

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376122)

Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41)

![Recommendations for managing hypertension in patients who are very old or frail (see Evidence Table 41)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt23.jpeg?Expires=1728462845&Signature=V~U2W9wiyBQI9g9QDdcPXmaExuXuX~30UZ6I0NDnAsUXtD0-jbEfcvyPaCZmxNb6omuDVQMuOWt77HoVX7cMcupRJYrrQ1LFpCGR3gY2WOUF2MEwAWIDmk~ppO6NK7CPfiLvn7JWsHp8jwxAbUNwxq51E9Qw8SopEIG0SNz3o1ZNmd6AtBV5odqtrpE8E1XELfh8olLOwFk3wnnHWi1QnKkTwAAblfC33mkRxC835xF6N9tPyPa7DPgbe5-3QDWpWEHgFE8B45hSRB9BczkxjRoICa0j7ZuEcevJsATzywwaR3SUMNSthHF58Wx5vGqa-TiET7JbkXE6IhqTqCPqLQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.4. Isolated systolic and diastolic hypertension

#### 9.4.1. Definition of isolated systolic hypertension

Isolated systolic hypertension is typically defined as systolic BP of ≥140 mmHg with a diastolic BP of <90 mmHg. While isolated systolic hypertension is uncommon in younger patients,<sup><a href="javascript:;" reveal-id="ehae178-B713" data-open="ehae178-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> it is the most common type of hypertension in older patients; >80% of untreated patients with hypertension aged >60 years have isolated systolic hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B714" data-open="ehae178-B714" class="link link-ref link-reveal xref-bibr">714</a></sup>

#### 9.4.2. Isolated systolic hypertension, risk factors, and ageing

Systolic BP increases with age in men and women until the eighth decade of life, while diastolic BP gradually increases up until the fifth or sixth decade of life, after which it either plateaus or decreases. As a result, the pulse pressure (the difference between the systolic and diastolic BP) gradually widens from middle age.<sup><a href="javascript:;" reveal-id="ehae178-B34" data-open="ehae178-B34" class="link link-ref link-reveal xref-bibr">34</a></sup> These BP changes are related to increased aortic stiffening with age.<sup><a href="javascript:;" reveal-id="ehae178-B715" data-open="ehae178-B715" class="link link-ref link-reveal xref-bibr">715</a>,<a href="javascript:;" reveal-id="ehae178-B716" data-open="ehae178-B716" class="link link-ref link-reveal xref-bibr">716</a></sup>

Since most older patients with hypertension have isolated systolic hypertension, and since with advancing age, risk of CVD events is driven by systolic rather than diastolic BP,<sup><a href="javascript:;" reveal-id="ehae178-B717" data-open="ehae178-B717" class="link link-ref link-reveal xref-bibr">717</a></sup> management of isolated systolic hypertension in older adults is broadly in line with that of combined systolic-diastolic hypertension seen in younger adults.<sup><a href="javascript:;" reveal-id="ehae178-B718" data-open="ehae178-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> Early isolated systolic hypertension studies used systolic BP treatment targets of 160 or 150 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B718" data-open="ehae178-B718" class="link link-ref link-reveal xref-bibr">718</a></sup> However, results from the SPRINT and the Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients (STEP) trials (mean BP at study entry of 140/78 mmHg and 146/82 mmHg, respectively, indicating that many of the patients had isolated systolic hypertension) confirm that lower systolic BP targets are effective in reducing CVD events in patients with isolated systolic hypertension (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B135" data-open="ehae178-B135" class="link link-ref link-reveal xref-bibr">135</a>,<a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a></sup>

Since relative risk reduction by BP-lowering treatment is homogeneous in any age group, whereas absolute risk reduction is larger with advancing age,<sup><a href="javascript:;" reveal-id="ehae178-B131" data-open="ehae178-B131" class="link link-ref link-reveal xref-bibr">131</a></sup> therapeutic inertia in older patients with isolated systolic hypertension should be avoided (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_). As noted earlier, beta-blockers should be avoided in patients with isolated systolic hypertension or more generally with arterial stiffness, as they increase stroke volume (given the lower heart rate).<sup><a href="javascript:;" reveal-id="ehae178-B218" data-open="ehae178-B218" class="link link-ref link-reveal xref-bibr">218</a></sup>

#### 9.4.3. Isolated systolic hypertension in young adults

In young adults (<40 years old), the presence of isolated systolic hypertension poses different pathophysiological and clinical considerations. In young patients with isolated systolic hypertension, arterial stiffness<sup><a href="javascript:;" reveal-id="ehae178-B713" data-open="ehae178-B713" class="link link-ref link-reveal xref-bibr">713</a></sup> and relative risk of CVD events<sup><a href="javascript:;" reveal-id="ehae178-B624" data-open="ehae178-B624" class="link link-ref link-reveal xref-bibr">624</a></sup> appear to be similar to those without isolated systolic hypertension and lower than young adults with combined systolic-diastolic hypertension and isolated diastolic hypertension. Indeed, younger patients with isolated systolic hypertension appear to comprise a heterogeneous group.<sup><a href="javascript:;" reveal-id="ehae178-B719" data-open="ehae178-B719" class="link link-ref link-reveal xref-bibr">719</a></sup> For these reasons, it might be reasonable to assess central BP and arterial stiffness in these individuals, as recommended by other scientific societies.<sup><a href="javascript:;" reveal-id="ehae178-B720" data-open="ehae178-B720" class="link link-ref link-reveal xref-bibr">720</a>,<a href="javascript:;" reveal-id="ehae178-B721" data-open="ehae178-B721" class="link link-ref link-reveal xref-bibr">721</a></sup> Out-of-office BP measurement is recommended to exclude white-coat hypertension, which is often associated with isolated systolic hypertension in the young.<sup><a href="javascript:;" reveal-id="ehae178-B634" data-open="ehae178-B634" class="link link-ref link-reveal xref-bibr">634</a></sup>

#### 9.4.4. Isolated diastolic hypertension

Isolated diastolic hypertension is defined as a systolic BP of <140 mmHg with a diastolic BP of ≥90 mmHg. The isolated diastolic hypertension phenotype is more commonly seen in younger adults and, particularly, younger adults with obesity or other metabolic derangements.<sup><a href="javascript:;" reveal-id="ehae178-B722" data-open="ehae178-B722" class="link link-ref link-reveal xref-bibr">722</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup> In older adults with this phenotype, consideration should be given to whether the diastolic BP was accurately measured.<sup><a href="javascript:;" reveal-id="ehae178-B724" data-open="ehae178-B724" class="link link-ref link-reveal xref-bibr">724</a></sup>

Patients with isolated diastolic hypertension appear to have a slightly increased relative risk for CVD of 5%–30%.<sup><a href="javascript:;" reveal-id="ehae178-B548" data-open="ehae178-B548" class="link link-ref link-reveal xref-bibr">548</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a>,<a href="javascript:;" reveal-id="ehae178-B725" data-open="ehae178-B725" class="link link-ref link-reveal xref-bibr">725</a></sup> However, because patients with isolated diastolic hypertension are younger, they tend to have few events, and very large samples are required to show this association. Furthermore, because the absolute risk for CVD among these individuals is low (typically <10% over 10 years), it is less clear if isolated diastolic hypertension should prompt initiation of BP-lowering medication, particularly among persons in whom baseline systolic BP is already at the target of 120–129 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup> Irrespective, patients with isolated diastolic hypertension should be followed up, as they are at increased risk for systolic hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup>

Finally, it is also worth noting that when a patient achieves a target systolic BP of 120–129 mmHg with BP-lowering treatment, there is little to no high-quality trial evidence that further intensifying BP-lowering medication to achieve both systolic BP of <120 mmHg and also diastolic BP of <70 mmHg improves CVD prognosis.<sup><a href="javascript:;" reveal-id="ehae178-B547" data-open="ehae178-B547" class="link link-ref link-reveal xref-bibr">547</a>,<a href="javascript:;" reveal-id="ehae178-B723" data-open="ehae178-B723" class="link link-ref link-reveal xref-bibr">723</a></sup>

### 9.5. Orthostatic hypotension with supine hypertension

Patients with orthostatic hypotension need not be hypotensive and indeed, many have supine elevated BP or supine hypertension. Furthermore, many patients with orthostatic hypotension are asymptomatic. Orthostatic hypotension is present in around 10% of all adults with hypertension and is defined as a drop in BP of ≥20/10 mmHg after rising from either a sitting or lying position to a standing position (see _Section [5.5.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4.5.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a>,<a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> Assessment for orthostatic hypotension should be timed to occur at 1 and/or 3 min after standing. Because seated to standing assessment can lead to under-detection of orthostatic hypotension, it is preferable, where possible, to test for orthostatic hypotension using a supine (lying) to standing assessment (see _Section [5](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s4)_).<sup><a href="javascript:;" reveal-id="ehae178-B56" data-open="ehae178-B56" class="link link-ref link-reveal xref-bibr">56</a>,<a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a>,<a href="javascript:;" reveal-id="ehae178-B726" data-open="ehae178-B726" class="link link-ref link-reveal xref-bibr">726</a></sup>

Assessing for orthostatic hypotension is important in managing adults with elevated BP or hypertension for several reasons. First, findings of trials linking more intensive BP control to improved outcomes may not generalize to patients with orthostatic hypotension, particularly when it is severe in magnitude (standing systolic BP < 110 mmHg<sup><a href="javascript:;" reveal-id="ehae178-B97" data-open="ehae178-B97" class="link link-ref link-reveal xref-bibr">97</a></sup>) and/or symptomatic. Second, orthostatic hypotension may be associated with symptoms that may limit the patient’s tolerability of more intensive BP-lowering approaches. Third, orthostatic hypotension may be associated with an increased risk of adverse effects commonly co-attributed to pharmacological BP lowering (such as hospitalizations for hypotension).<sup><a href="javascript:;" reveal-id="ehae178-B727" data-open="ehae178-B727" class="link link-ref link-reveal xref-bibr">727</a></sup> Fourth, orthostatic hypotension is associated with increased risk for CVD.<sup><a href="javascript:;" reveal-id="ehae178-B728" data-open="ehae178-B728" class="link link-ref link-reveal xref-bibr">728</a></sup>

However, the frequency of orthostatic hypotension is not increased in the more intensive BP-lowering arms of randomized trials compared with the less intensive BP-lowering arms.<sup><a href="javascript:;" reveal-id="ehae178-B726" data-open="ehae178-B726" class="link link-ref link-reveal xref-bibr">726</a>,<a href="javascript:;" reveal-id="ehae178-B727" data-open="ehae178-B727" class="link link-ref link-reveal xref-bibr">727</a>,<a href="javascript:;" reveal-id="ehae178-B729" data-open="ehae178-B729" class="link link-ref link-reveal xref-bibr">729</a>,<a href="javascript:;" reveal-id="ehae178-B730" data-open="ehae178-B730" class="link link-ref link-reveal xref-bibr">730</a></sup> As such, and in contrast to common belief, it does not appear that more intensive treatment of BP (which almost always requires more BP-lowering medication) worsens orthostatic hypotension. In contrast, there is some evidence that more intensive treatment of hypertension may actually reduce the risk of orthostatic hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B730" data-open="ehae178-B730" class="link link-ref link-reveal xref-bibr">730</a>,<a href="javascript:;" reveal-id="ehae178-B731" data-open="ehae178-B731" class="link link-ref link-reveal xref-bibr">731</a></sup>

The aetiology of orthostatic hypotension may be considered as neurogenic or non-neurogenic, with the latter being far more common.<sup><a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> Patients with orthostatic hypotension may have underlying neurodegenerative diseases, diabetes, B12 deficiency,<sup><a href="javascript:;" reveal-id="ehae178-B732" data-open="ehae178-B732" class="link link-ref link-reveal xref-bibr">732</a></sup> renal failure, dehydration, prolonged recumbency, deconditioning, and triggering medications (like alpha-blockers, beta-blockers, diuretics, nitrates, antidepressants, and antipsychotics). Of note, ACE inhibitors, ARBs, and dihydropyridine CCBs are examples of BP-lowering medications that appear to have less impact on orthostatic hypotension, and their adverse impact, if any, on orthostatic hypotension typically occurs in the first 2 weeks or so after starting or intensifying treatment.<sup><a href="javascript:;" reveal-id="ehae178-B733" data-open="ehae178-B733" class="link link-ref link-reveal xref-bibr">733</a></sup>

Managing patients with supine hypertension and orthostatic hypotension is a common clinical conundrum. More detailed reviews on this topic are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B98" data-open="ehae178-B98" class="link link-ref link-reveal xref-bibr">98</a>,<a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> The approach to managing orthostatic hypotension should be non-pharmacological at first. Patients with orthostatic hypotension should be asked to change position slowly, maintain adequate hydration, and avoid alcohol and large meals. Compression stockings, crossing legs while standing, and abdominal binders may also help and should be trialled.<sup><a href="javascript:;" reveal-id="ehae178-B734" data-open="ehae178-B734" class="link link-ref link-reveal xref-bibr">734</a>,<a href="javascript:;" reveal-id="ehae178-B735" data-open="ehae178-B735" class="link link-ref link-reveal xref-bibr">735</a></sup> Abdominal heating pads and a head-up bed position can reduce supine (typically nocturnal) hypertension, which may reduce nocturnal diuresis and daytime orthostatic hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B736" data-open="ehae178-B736" class="link link-ref link-reveal xref-bibr">736</a></sup>

The treatment of orthostatic hypotension among those with supine hypertension is not to automatically down-titrate BP-lowering medications. Rather, reversible causes should be sought and treated (including discontinuation of offending medications), and patients requiring BP-lowering medication should be switched to BP-lowering medications that are less likely to cause orthostatic hypotension. When symptoms are disabling and the above interventions do not help, particularly in neurogenic orthostatic hypotension, the best evidence exists for midodrine to reverse orthostatic hypotension, and this may be given in conjunction with ongoing BP-lowering medications when supine hypertension exists.<sup><a href="javascript:;" reveal-id="ehae178-B99" data-open="ehae178-B99" class="link link-ref link-reveal xref-bibr">99</a></sup> An alternative option to midodrine is droxidopa, though this is less readily available. Specialist referral is prudent when persons with supine hypertension are prescribed these orthostatic hypotension treatments, as these agents can increase supine BP more than standing BP.

Recommendation Table 24

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376143)

Recommendations for managing hypertension in patients with orthostatic hypotension

![Recommendations for managing hypertension in patients with orthostatic hypotension](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt24.jpeg?Expires=1728462845&Signature=FIUs0Z0N6EjwP4ZGKo5j4r6hkGKsJcYKN2JB1PlJ6GixQ~q-UtIwZy~14fXKjKd4RUb5tRNNnq2niOeSpDyQTG5b3sBtJsOjqSBTwF63x2A4ePJ3hfuGzNPATLMNPQW5hLMufUHfwqJHkfj7~lAYhWDImoJOzFzBacn2IbFucf0fZr5g4-JUa3ttmcFnm68kQKgPAWUbIg-mPBuHp-irL1KGyrqSECr~E34-nzFPlyR9CmWNUZ8IH9~dkgSCkKpftlwIMiyiU5KTGsOBZaMVdtPTZZJ-PM2WSMcP56XJusb5w613C~45x9fcBmK4uT9XnyX2FhroyBUi1oElUTfkHw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.6. Diabetes

#### 9.6.1. Diabetes and elevated blood pressure/hypertension

Patients with diabetes (both type 1 and type 2) often have elevated BP or hypertension, and are about twice as likely to suffer a major CVD event over the medium to long term compared with those without diabetes.<sup><a href="javascript:;" reveal-id="ehae178-B737" data-open="ehae178-B737" class="link link-ref link-reveal xref-bibr">737</a></sup> Diabetes is also a major cause of microvascular events, such as retinopathy and nephropathy.<sup><a href="javascript:;" reveal-id="ehae178-B738" data-open="ehae178-B738" class="link link-ref link-reveal xref-bibr">738</a>,<a href="javascript:;" reveal-id="ehae178-B739" data-open="ehae178-B739" class="link link-ref link-reveal xref-bibr">739</a></sup> Although the risk of CVD in patients with diabetes varies by screening and diagnostic methods,<sup><a href="javascript:;" reveal-id="ehae178-B740" data-open="ehae178-B740" class="link link-ref link-reveal xref-bibr">740</a>,<a href="javascript:;" reveal-id="ehae178-B741" data-open="ehae178-B741" class="link link-ref link-reveal xref-bibr">741</a></sup> as well as with the presence of other CVD risk factors,<sup><a href="javascript:;" reveal-id="ehae178-B740" data-open="ehae178-B740" class="link link-ref link-reveal xref-bibr">740</a>,<a href="javascript:;" reveal-id="ehae178-B742" data-open="ehae178-B742" class="link link-ref link-reveal xref-bibr">742</a></sup> on average, patients with diabetes are at ≥10% 10-year risk for CVD. However, formal risk estimation with the use of SCORE2-Diabetes among type 2 diabetes mellitus patients should be considered if they are aged <60 years (see _Section [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_).<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a>,<a href="javascript:;" reveal-id="ehae178-B739" data-open="ehae178-B739" class="link link-ref link-reveal xref-bibr">739</a></sup>

#### 9.6.2. J-shaped curve of blood pressure and risk of cardiovascular disease in patients with diabetes

Evidence on the BP threshold and target for treatment in patients with diabetes has been subject to debate. Reports of a J-shaped association between BP and risk of CVD in diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B743" data-open="ehae178-B743" class="link link-ref link-reveal xref-bibr">743</a></sup> and the lack of a clear benefit of treatment on cardiac outcomes at lower BP in some meta-analyses,<sup><a href="javascript:;" reveal-id="ehae178-B744 ehae178-B745 ehae178-B746" data-open="ehae178-B744 ehae178-B745 ehae178-B746" class="link link-ref link-reveal xref-bibr">744–746</a></sup> has led to some cautious recommendations for intensive treatment in this patient population.

An individual patient data meta-analysis by the Blood Pressure Lowering Treatment Trialists’ Collaboration tested treatment effects in 103 325 patients with diabetes and provided evidence against effect modification by categories of baseline BP down to a systolic BP of 120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a></sup> BP reduction in patients with diabetes is expected to reduce the risk of diabetes-associated complications including retinopathy, vasculopathy, and nephropathy (albuminuria and end-stage renal disease), which adds weight to the importance of reducing BP in these patients (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B745 ehae178-B746 ehae178-B747" data-open="ehae178-B745 ehae178-B746 ehae178-B747" class="link link-ref link-reveal xref-bibr">745–747</a></sup> This task force also considered the fact that a proportion of patients with diabetes have orthostatic hypotension due to diabetic neuropathy,<sup><a href="javascript:;" reveal-id="ehae178-B748" data-open="ehae178-B748" class="link link-ref link-reveal xref-bibr">748</a></sup> which might affect the tolerability of BP lowering.

#### 9.6.3. Managing blood pressure in diabetes

We recommend that all patients with diabetes are offered pharmacological BP-lowering treatment with a BP target of 120–129/70–79 mmHg, if feasible and tolerated.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B747" data-open="ehae178-B747" class="link link-ref link-reveal xref-bibr">747</a>,<a href="javascript:;" reveal-id="ehae178-B749 ehae178-B750 ehae178-B751 ehae178-B752" data-open="ehae178-B749 ehae178-B750 ehae178-B751 ehae178-B752" class="link link-ref link-reveal xref-bibr">749–752</a></sup> The task force further sees no strong evidence for a differential BP treatment targets in patients with diabetes and those without.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B445" data-open="ehae178-B445" class="link link-ref link-reveal xref-bibr">445</a>,<a href="javascript:;" reveal-id="ehae178-B746" data-open="ehae178-B746" class="link link-ref link-reveal xref-bibr">746</a>,<a href="javascript:;" reveal-id="ehae178-B747" data-open="ehae178-B747" class="link link-ref link-reveal xref-bibr">747</a></sup> While the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial reported a null primary endpoint for more intensive BP targets in diabetes, stroke was marginally reduced.<sup><a href="javascript:;" reveal-id="ehae178-B137" data-open="ehae178-B137" class="link link-ref link-reveal xref-bibr">137</a></sup> Furthermore, extended follow-up of ACCORD,<sup><a href="javascript:;" reveal-id="ehae178-B750" data-open="ehae178-B750" class="link link-ref link-reveal xref-bibr">750</a></sup> as well as analyses of intensive BP reduction in those randomized to the standard glycaemic arm,<sup><a href="javascript:;" reveal-id="ehae178-B749" data-open="ehae178-B749" class="link link-ref link-reveal xref-bibr">749</a></sup> provide evidence suggesting benefit consistent with the SPRINT, STEP, and Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT) trials.<sup><a href="javascript:;" reveal-id="ehae178-B136" data-open="ehae178-B136" class="link link-ref link-reveal xref-bibr">136</a>,<a href="javascript:;" reveal-id="ehae178-B146" data-open="ehae178-B146" class="link link-ref link-reveal xref-bibr">146</a>,<a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup> Overall, all major BP-lowering medication classes are effective in preventing CVD in people with or without diabetes. Of note, however, albuminuria is more common in diabetes and, for this reason, ACE inhibitors and ARBs have potential advantages that may warrant consideration for BP-lowering in patients with diabetes (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S10](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B753" data-open="ehae178-B753" class="link link-ref link-reveal xref-bibr">753</a></sup>

Evidence for modifying BP-lowering treatment in patients with pre-diabetes is somewhat limited. Furthermore, the relative effect of BP lowering is relatively consistent across different categories of BMI as a measure of obesity.<sup><a href="javascript:;" reveal-id="ehae178-B754" data-open="ehae178-B754" class="link link-ref link-reveal xref-bibr">754</a>,<a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> It is also noteworthy that elevated BP itself may increase the risk of diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup> emphasizing the potential role of BP lowering in preventing diabetes in addition to preventing CVD. Among the major classes of BP-lowering drugs, ACE inhibitors and ARBs are effective in preventing new-onset diabetes and can be considered in patients at risk of diabetes and who are indicated for BP-lowering therapy.<sup><a href="javascript:;" reveal-id="ehae178-B164" data-open="ehae178-B164" class="link link-ref link-reveal xref-bibr">164</a>,<a href="javascript:;" reveal-id="ehae178-B755" data-open="ehae178-B755" class="link link-ref link-reveal xref-bibr">755</a></sup>

Recommendation Table 25

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376153)

Recommendations for managing hypertension in patients with diabetes

![Recommendations for managing hypertension in patients with diabetes](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt25.jpeg?Expires=1728462845&Signature=TR37BPwlc8GOv6ewiHf5EtVXWRQX2OQq4yam3RxwriAu6ZCIt3TdHCYaCKUHWGaNuGXOUezBHGs7M~d16aywQw9mOHd5zRKDVpFWq4G8ML7Kbt2eUsU1R40juDO3QCyDADdfvtTp6A7SNiSParqbgy3XhiV1AX80y4sC1mHXy5ildeTvYmgrvEnOug6qGJizxnBVVsv0pk3QK~RlwBMs09T8wPUw6vOmvSh-RVAUug3xahtCM-rZQpKrrXOrk4L22eUulIpJgYGwJCHFe~zop1Gw2HMIvrdKV4s1p1XhNnfyHznzPYomEWrW~r7rN4TA-iPuGb2RH8ME8fsNN8WOEw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.7. Chronic kidney disease

#### 9.7.1. Relationship between hypertension and chronic kidney disease

Approximately 850 million people worldwide have CKD, with >80% of them hypertensive, and the prevalence is expected to rise to 1.56 billion by 2025.<sup><a href="javascript:;" reveal-id="ehae178-B756 ehae178-B757 ehae178-B758 ehae178-B759" data-open="ehae178-B756 ehae178-B757 ehae178-B758 ehae178-B759" class="link link-ref link-reveal xref-bibr">756–759</a></sup> The pathogeneses of hypertension and CKD are closely entwined.<sup><a href="javascript:;" reveal-id="ehae178-B760" data-open="ehae178-B760" class="link link-ref link-reveal xref-bibr">760</a></sup> Resistant hypertension, masked hypertension, HMOD, and higher night-time BP are common in patients with CKD.<sup><a href="javascript:;" reveal-id="ehae178-B761" data-open="ehae178-B761" class="link link-ref link-reveal xref-bibr">761</a></sup> CVD is one of the largest contributors to mortality in patients with CKD, with hypertension being a major risk factor.<sup><a href="javascript:;" reveal-id="ehae178-B760" data-open="ehae178-B760" class="link link-ref link-reveal xref-bibr">760</a>,<a href="javascript:;" reveal-id="ehae178-B762" data-open="ehae178-B762" class="link link-ref link-reveal xref-bibr">762</a></sup>

For the purposes of these guidelines, adults with moderate-to-severe CKD and elevated BP are at sufficiently high risk to be considered for BP-lowering drug therapy as outlined in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and the Central Illustration (_[Figure 19](javascript:;)_). We use Kidney Disease: Improving Global Outcomes (KDIGO) categories to define CKD-based risk, and our definition of moderate-to-severe CKD comprises persons with an eGFR of <60 mL/min/1.73 m<sup>2</sup> and/or albuminuria of ≥30 mg/g (≥3 mg/mmol).<sup><a href="javascript:;" reveal-id="ehae178-B19" data-open="ehae178-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> For persons with mild CKD and elevated BP, a CVD risk assessment should be conducted before deciding on BP-lowering treatment.

#### 9.7.2. Blood pressure lowering in chronic kidney disease

BP lowering in patients with CKD is associated with beneficial effect on CVD events and mortality.<sup><a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a>,<a href="javascript:;" reveal-id="ehae178-B763 ehae178-B764 ehae178-B765 ehae178-B766" data-open="ehae178-B763 ehae178-B764 ehae178-B765 ehae178-B766" class="link link-ref link-reveal xref-bibr">763–766</a></sup> BP lowering reduces progression of CKD and the incidence of end-stage renal disease, but this tends to be only in those with significant proteinuria at baseline.<sup><a href="javascript:;" reveal-id="ehae178-B766" data-open="ehae178-B766" class="link link-ref link-reveal xref-bibr">766</a>,<a href="javascript:;" reveal-id="ehae178-B767" data-open="ehae178-B767" class="link link-ref link-reveal xref-bibr">767</a></sup>

#### 9.7.3. Managing blood pressure in chronic kidney disease

Patients with CKD should receive lifestyle advice, especially regarding reducing sodium intake. Dietary potassium supplementation recommendations are provided in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_, with caution required among persons with moderate-to-severe CKD. While exercise appears to have little effect on improving BP in patients with CKD<sup><a href="javascript:;" reveal-id="ehae178-B768" data-open="ehae178-B768" class="link link-ref link-reveal xref-bibr">768</a></sup> or patients on dialysis,<sup><a href="javascript:;" reveal-id="ehae178-B769" data-open="ehae178-B769" class="link link-ref link-reveal xref-bibr">769</a></sup> those with CKD on ACE inhibitor monotherapy have protection against adverse kidney outcomes, CVD events, cardiovascular death, and all-cause death.<sup><a href="javascript:;" reveal-id="ehae178-B770" data-open="ehae178-B770" class="link link-ref link-reveal xref-bibr">770</a>,<a href="javascript:;" reveal-id="ehae178-B771" data-open="ehae178-B771" class="link link-ref link-reveal xref-bibr">771</a></sup> Both ACE inhibitors and ARBs reduce the risk of CVD events and kidney failure compared with placebo; however, ACE inhibitors appear to do so with higher probability than ARBs.<sup><a href="javascript:;" reveal-id="ehae178-B772" data-open="ehae178-B772" class="link link-ref link-reveal xref-bibr">772</a>,<a href="javascript:;" reveal-id="ehae178-B773" data-open="ehae178-B773" class="link link-ref link-reveal xref-bibr">773</a></sup> Patients with CKD usually require combination therapy, and this should be initiated as a combination of a RAS inhibitor and a CCB or diuretic. In patients with eGFR < 30 mL/min/1.73 m<sup>2</sup>, an adequately up-titrated loop diuretic is necessary to define resistant hypertension. Chlorthalidone, typically added to a loop diuretic, also effectively lowers BP and reduces microalbuminuria in patients with resistant hypertension with stage 4 CKD (eGFR of 15–30 mL/min/1.73 m<sup>2</sup>).<sup><a href="javascript:;" reveal-id="ehae178-B774" data-open="ehae178-B774" class="link link-ref link-reveal xref-bibr">774</a></sup> The combination of an ACE inhibitor and an ARB is not recommended in CKD or any other BP-treatment scenario.

#### 9.7.4. Blood pressure targets in chronic kidney disease

Evidence regarding BP targets in patients with CKD is complex and controversial. The 2021 KDIGO Guideline suggested that adults with elevated BP and CKD be treated to a target systolic BP of <120 mmHg, when tolerated, using standardized office BP measurement (Class of Recommendation IIb).<sup><a href="javascript:;" reveal-id="ehae178-B19" data-open="ehae178-B19" class="link link-ref link-reveal xref-bibr">19</a></sup> This suggestion was based, in part, on the SPRINT trial.<sup><a href="javascript:;" reveal-id="ehae178-B545" data-open="ehae178-B545" class="link link-ref link-reveal xref-bibr">545</a></sup> It should be noted that patients with 24 h urine protein excretion ≥ 1 g/day or eGFR < 20 mL/min/1.73 m<sup>2</sup> were excluded from SPRINT. In patients with CKD, after a median follow-up of 3.3 years, the hazard ratio for the primary composite cardiovascular outcome was 0.81 (95% CI 0.63–1.05) and for all-cause death it was 0.72 (95% CI 0.53–0.99). Although intensive BP lowering in SPRINT resulted in greater early decline in eGFR, there was no evidence that this reduction in eGFR attenuated the beneficial effects of the SPRINT intervention on CVD events or death.<sup><a href="javascript:;" reveal-id="ehae178-B775" data-open="ehae178-B775" class="link link-ref link-reveal xref-bibr">775</a></sup>

Several systematic reviews have examined the benefit of intensive BP control in patients with CKD (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)). Some have shown no benefit of intensive BP control on renal outcomes,<sup><a href="javascript:;" reveal-id="ehae178-B764" data-open="ehae178-B764" class="link link-ref link-reveal xref-bibr">764</a>,<a href="javascript:;" reveal-id="ehae178-B767" data-open="ehae178-B767" class="link link-ref link-reveal xref-bibr">767</a></sup> while others showed lower mortality in intensively treated vs. non-intensively treated patients.<sup><a href="javascript:;" reveal-id="ehae178-B275" data-open="ehae178-B275" class="link link-ref link-reveal xref-bibr">275</a></sup> Highlighting the beneficial effects of SGLT2 inhibitors in persons with CKD<sup><a href="javascript:;" reveal-id="ehae178-B776" data-open="ehae178-B776" class="link link-ref link-reveal xref-bibr">776</a>,<a href="javascript:;" reveal-id="ehae178-B777" data-open="ehae178-B777" class="link link-ref link-reveal xref-bibr">777</a></sup> and finerenone in persons with CKD and diabetes<sup><a href="javascript:;" reveal-id="ehae178-B460 ehae178-B461 ehae178-B462" data-open="ehae178-B460 ehae178-B461 ehae178-B462" class="link link-ref link-reveal xref-bibr">460–462</a>,<a href="javascript:;" reveal-id="ehae178-B778" data-open="ehae178-B778" class="link link-ref link-reveal xref-bibr">778</a></sup> is relevant, though these drugs are not currently marketed for BP-lowering effects alone.

Recommendation Table 26

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376165)

Recommendations for managing hypertension in patients with chronic kidney disease

![Recommendations for managing hypertension in patients with chronic kidney disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt26.jpeg?Expires=1728462845&Signature=UkG1cXnSAloECwecmVKGguhQMdkXwvSzpIwWD4~FbZmLDB0C4yR7H0XecSW-gA96xLZctEx-uPLPpI-9pcKREoBOnZeKiBxWxLlk9wnyolv-UEUoZhl-nQz~xDGmHMUTDG5tpbbDfwXUwMWuRwSHncFTktJcCzdoWmCNKZOrIPRgv9ZVdSj~pYrygCHAWm8XSfZUGXooiqASb1tdq2WogXLOmGlPcGgymVu39mLiyYM42pn8Av-1D5BNai9Lq94t3jZDLEyH8xsH8aCRW9QjitKfWIwV6bOQx2yKL4lZEPUNjLl4MI10LUTmQnoOK5lgAdV64BmXIQr9UWZPnQUnfQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.8. Cardiac disease

#### 9.8.1. Blood pressure thresholds and targets in patients with cardiac disease

Recommended BP thresholds for initiating BP-lowering therapy and recommended BP targets in patients receiving therapy are provided in _Sections [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and _[8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_. All patients with a history of CVD (including coronary artery disease) are at increased risk of recurrent CVD. As such, these patients are recommended to be treated with BP-lowering therapy for confirmed baseline BP of ≥130/80 mmHg and the recommended treatment target BP of 120–129/70–79 mmHg, provided treatment is tolerated (see _Sections [6](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s5)_ and _[8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_). As stated in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_, it should be remembered that a systolic BP of 120 mmHg (especially by out-of-office assessment) is likely the optimal point in the target range recommended in these guidelines. In addition to considering patients with known CVD at sufficiently high risk for more intensive BP treatment targets, the task force considers patients with both severe valvular heart disease and symptomatic heart failure to also be at sufficiently high risk. We also note that, whether used for angina control or BP control, a beta-blocker should not be combined with a non-dihydropyridine CCB.

#### 9.8.2. Coronary artery disease with particular reference to the blood pressure J-curve

Important considerations in patients with coronary artery disease are: (i) the BP J-curve (an observation suggesting that over-intensive BP lowering may increase CVD risk in some patients), and (ii) compelling indications for specific classes of BP-lowering medications.

The J-curve phenomenon describes increased risk for CVD observed among patients with the lowest and highest BP in the dataset, with the best CVD outcome rates typically observed among those with BP in the normal range (e.g. systolic BP of 100–120 mmHg and diastolic BP of 60–80 mmHg). For this reason, the J-curve is sometimes also called the U-curve, with both terms typically used interchangeably.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a>,<a href="javascript:;" reveal-id="ehae178-B783" data-open="ehae178-B783" class="link link-ref link-reveal xref-bibr">783</a>,<a href="javascript:;" reveal-id="ehae178-B784" data-open="ehae178-B784" class="link link-ref link-reveal xref-bibr">784</a></sup>

However, observational data do not consistently demonstrate a BP J-curve with CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> It is more commonly observed among patients with established clinical CVD, such as those with coronary artery disease, or in secondary prevention cohorts.<sup><a href="javascript:;" reveal-id="ehae178-B785" data-open="ehae178-B785" class="link link-ref link-reveal xref-bibr">785</a>,<a href="javascript:;" reveal-id="ehae178-B786" data-open="ehae178-B786" class="link link-ref link-reveal xref-bibr">786</a></sup> Furthermore, the J-curve is more commonly observed when analysing diastolic BP values vs. systolic BP values, though it has been described for both.<sup><a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a></sup> This stronger relationship with diastolic BP has informed the hypothesis that the J-curve may be caused by reduced perfusion of major organs at low BP, which is particularly operative for diastolic BP in the coronary vasculature when considering ischaemic heart disease events (since coronary blood flow is largely confined to diastole).<sup><a href="javascript:;" reveal-id="ehae178-B786" data-open="ehae178-B786" class="link link-ref link-reveal xref-bibr">786</a>,<a href="javascript:;" reveal-id="ehae178-B787" data-open="ehae178-B787" class="link link-ref link-reveal xref-bibr">787</a></sup>

If excessive lowering of BP causes CVD events, this needs to be addressed in treatment recommendations provided by BP management guidelines. The 2018 ESC/ESH Guidelines on the management of arterial hypertension introduced, for the first time, lower bounds of BP-lowering treatment targets, implying that treatment be de-intensified for patients with on-treatment BP below these bounds (i.e. <120 mmHg systolic or <70 mmHg diastolic).<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a></sup> The 2023 ESH document also makes this argument.<sup><a href="javascript:;" reveal-id="ehae178-B788" data-open="ehae178-B788" class="link link-ref link-reveal xref-bibr">788</a></sup>

However, since 2018, compelling evidence has demonstrated that the BP J-curve evident in observational datasets is highly unlikely to reflect a causal process and can instead be attributed to residual confounding and/or reverse causation.<sup><a href="javascript:;" reveal-id="ehae178-B33" data-open="ehae178-B33" class="link link-ref link-reveal xref-bibr">33</a>,<a href="javascript:;" reveal-id="ehae178-B114" data-open="ehae178-B114" class="link link-ref link-reveal xref-bibr">114</a>,<a href="javascript:;" reveal-id="ehae178-B115" data-open="ehae178-B115" class="link link-ref link-reveal xref-bibr">115</a>,<a href="javascript:;" reveal-id="ehae178-B546" data-open="ehae178-B546" class="link link-ref link-reveal xref-bibr">546</a>,<a href="javascript:;" reveal-id="ehae178-B697" data-open="ehae178-B697" class="link link-ref link-reveal xref-bibr">697</a>,<a href="javascript:;" reveal-id="ehae178-B789 ehae178-B790 ehae178-B791 ehae178-B792 ehae178-B793" data-open="ehae178-B789 ehae178-B790 ehae178-B791 ehae178-B792 ehae178-B793" class="link link-ref link-reveal xref-bibr">789–793</a></sup>

Accordingly, while low BP can indicate a high-risk state, particularly among older adults and those with comorbidities, there is no evidence that this is a causal phenomenon. Indeed, if there is another indication for BP-lowering therapy (e.g. in a patient with wide pulse pressure and a baseline systolic BP of >140 mmHg but diastolic BP of <60 mmHg), the evidence suggests that such therapy should be provided if tolerated to reduce CVD risk.

There is a limit to how low BP can be treated without potentially tipping the scales in favour of CVD harm vs. CVD benefit. However, it is not clear what that limit is and how much it differs based on comorbidities. Currently, the data do not suggest that risk for CVD can be causally increased by treating any patient to the recommended intensive BP target outlined in these guidelines of as low as 120/70 mmHg. We also do not recommend stopping or de-intensifying BP-lowering medication among asymptomatic patients with on-treatment BP of <120/70 mmHg. It should be recognized, though, that there are no robust data demonstrating that an on-treatment systolic BP of <90 mmHg or an on-treatment diastolic BP of <50 mmHg is safe from a CVD perspective and there is clear potential for harm. Furthermore, it must be emphasized that the above discussion of the BP J-curve relates solely to CVD risk and does not consider the known non-CVD side effects of BP-lowering drugs, like, e.g. orthostatic hypotension, syncope, and renal injury. We do know that patients treated to a more intensive BP target of 120/70 mmHg are at increased risk for these side effects,<sup><a href="javascript:;" reveal-id="ehae178-B550" data-open="ehae178-B550" class="link link-ref link-reveal xref-bibr">550</a></sup> which is why these guidelines stress that this more intensive target should only be pursued among those in whom treatment is being tolerated (_Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_).

The second consideration in managing BP in patients with coronary artery disease is the recommended use of BP-lowering medications with compelling indications based on outcomes trials that demonstrated CVD outcomes benefits in the setting of coronary artery disease. These recommendations are provided in the recommendation table below.

#### 9.8.3. Valvular heart disease

Most patients with both severe heart valve disease and heart failure, defined by the 2021 ESC/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular heart disease,<sup><a href="javascript:;" reveal-id="ehae178-B794" data-open="ehae178-B794" class="link link-ref link-reveal xref-bibr">794</a></sup> can be considered at increased risk of CVD. Accordingly, it is recommended they are treated with BP-lowering therapy for confirmed baseline BP of >130/80 mmHg, and their recommended target of treatment is BP of 120–129/70–79 mmHg, provided treatment is tolerated. Persons with mild-to-moderate heart valve disease should have a CVD risk assessment prior to deciding their BP-lowering treatment threshold and target.

Vasodilating ARBs/ACE inhibitors are preferable over vasodilating dihydropyridine CCBs because of the link between valvular heart disease and subsequent heart failure and given the stronger efficacy evidence for ARBs/ACE inhibitors in the setting of heart failure once manifested.<sup><a href="javascript:;" reveal-id="ehae178-B795" data-open="ehae178-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> In aortic valve stenosis, concomitant hypertension influences both the aortic root, the aortic valve, and the left ventricular structure and function.<sup><a href="javascript:;" reveal-id="ehae178-B796" data-open="ehae178-B796" class="link link-ref link-reveal xref-bibr">796</a></sup> In this subgroup, treatment preferably with ARBs/ACE inhibitors should be considered. A beta-blocker may be added if BP remains >140/90 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B796" data-open="ehae178-B796" class="link link-ref link-reveal xref-bibr">796</a>,<a href="javascript:;" reveal-id="ehae178-B797" data-open="ehae178-B797" class="link link-ref link-reveal xref-bibr">797</a></sup>

#### 9.8.4. Heart failure

Patients with symptomatic heart failure are at increased risk of CVD. Therefore, it is recommended that these patients are treated with BP-lowering therapy for confirmed baseline BP of >130/80 mmHg and their recommended treatment target is BP of 120–129/70–79 mmHg, provided treatment is tolerated and with out-of-office confirmation of on-treatment BP. Of note, many patients with systolic heart failure on maximal heart failure therapies have BP of <120/70 mmHg, and we do not recommend de-intensifying such treatment unless indicated by symptomatic side effects. Besides referencing the new evidence for ARNi and SGLT2 inhibitor therapies,<sup><a href="javascript:;" reveal-id="ehae178-B795" data-open="ehae178-B795" class="link link-ref link-reveal xref-bibr">795</a></sup> our 2024 recommendations for heart failure are largely unchanged from the 2018 ESC/ESH Guidelines on the management of arterial hypertension. Non-dihydropyridine CCBs should not be used in heart failure. Frailty and hypotension risk should be assessed in older heart failure patients being considered for ARNi and SGLT2 inhibitor therapies, and older patients should be closely followed to ensure they are tolerating such treatments. For more information on the management of heart failure, we direct readers to the latest ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.<sup><a href="javascript:;" reveal-id="ehae178-B798" data-open="ehae178-B798" class="link link-ref link-reveal xref-bibr">798</a></sup>

Recommendation Table 27

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376183)

Recommendations for managing hypertension in patients with cardiac disease

![Recommendations for managing hypertension in patients with cardiac disease](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt27.jpeg?Expires=1728462845&Signature=PXN488r7QdNycrDlLxqejc9WKBGaQxqLiqUCIImj~8ymfRfIHkH64RaUV9XmTQX7KPAEtJ534y9bdy~AM05NgrG8o~BST0B-aFus9yNJcm3hZS2lv~LWE4v62HZC5DgxCiFW2qWRle1Whjq7TGRtfzwU0cknYPhyp1EyhlWOF5p15IVfmneOUZqxs87q9FsqZIlqrRSnALJnELpfKXCzvNtWiDtJCY-9Lb-P6oRkiCzvKHGWOInU~Mr2Fg-VrMYtWwPYUBrfvI12BQXw4iCmoVaxhZam7a4Q6tZXzPPgWJgW7QR54z4CwFxBbauKL7P664eyz6aMIlljCdWucLB5kg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.8.5. Heart rhythm disease (including AF)

Not all patients with heart rhythm disease, including those with AF, are at increased risk for CVD and, as such, the management of BP among patients with heart rhythm disease should be the same as for the general adult population.<sup><a href="javascript:;" reveal-id="ehae178-B443" data-open="ehae178-B443" class="link link-ref link-reveal xref-bibr">443</a></sup> However, there is a close relationship between increased BP and AF risk, hence, ensuring good BP control is important.<sup><a href="javascript:;" reveal-id="ehae178-B801" data-open="ehae178-B801" class="link link-ref link-reveal xref-bibr">801</a>,<a href="javascript:;" reveal-id="ehae178-B802" data-open="ehae178-B802" class="link link-ref link-reveal xref-bibr">802</a></sup> Management of heart rhythm disorders should follow recommendations in guidelines specific to these conditions.<sup><a href="javascript:;" reveal-id="ehae178-B803" data-open="ehae178-B803" class="link link-ref link-reveal xref-bibr">803</a></sup>

### 9.9. Chronic cerebrovascular disease and/or cognitive impairment

#### 9.9.1. Role of hypertension in chronic cerebrovascular disease

Hypertension is a risk factor for chronic cerebrovascular disease through its direct effects on brain structure and microvasculature. This manifests as transient ischaemic attack (TIA) and stroke in the acute setting, but chronic hypertension can lead to covert stroke and white-matter ischaemic change over time, resulting in cognitive decline and progressive vascular dementia.<sup><a href="javascript:;" reveal-id="ehae178-B804 ehae178-B805 ehae178-B806 ehae178-B807 ehae178-B808" data-open="ehae178-B804 ehae178-B805 ehae178-B806 ehae178-B807 ehae178-B808" class="link link-ref link-reveal xref-bibr">804–808</a></sup> Hypertension is also associated with increased risk of Alzheimer’s disease,<sup><a href="javascript:;" reveal-id="ehae178-B809" data-open="ehae178-B809" class="link link-ref link-reveal xref-bibr">809</a></sup> and is a risk factor for developing AF, heart failure, and CKD, all of which are associated with increased risk of developing cognitive impairment and dementia.<sup><a href="javascript:;" reveal-id="ehae178-B810 ehae178-B811 ehae178-B812 ehae178-B813" data-open="ehae178-B810 ehae178-B811 ehae178-B812 ehae178-B813" class="link link-ref link-reveal xref-bibr">810–813</a></sup> For the purposes of these guidelines, adults with a history of stroke or TIA and elevated BP are considered at sufficiently high risk to be considered for BP-lowering drug therapy as outlined in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_ and the Central Illustration (_[Figure 19](javascript:;)_).

#### 9.9.2. Treatment in patients with history of prior stroke or transient ischaemic attack

In patients with a prior history of TIA and ischaemic stroke, BP-lowering treatment reduces the risk of any recurrent stroke by 20%.<sup><a href="javascript:;" reveal-id="ehae178-B814 ehae178-B815 ehae178-B816 ehae178-B817" data-open="ehae178-B814 ehae178-B815 ehae178-B816 ehae178-B817" class="link link-ref link-reveal xref-bibr">814–817</a></sup> The aetiology of stroke can affect the degree of risk reduction with pharmacological treatment, with greater reductions observed for intracerebral haemorrhage and lacunar ischaemic stroke syndromes.<sup><a href="javascript:;" reveal-id="ehae178-B818 ehae178-B819 ehae178-B820" data-open="ehae178-B818 ehae178-B819 ehae178-B820" class="link link-ref link-reveal xref-bibr">818–820</a></sup>

Most prior guidelines recommend an intensive BP target in patients with a prior history of stroke, typically using combination treatment (ACE inhibitor/ARB plus either a calcium channel antagonist or a thiazide/thiazide-like diuretic), with therapy commencing immediately after TIA and within a few days of ischaemic stroke (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and see _Section [10.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s9.3)_ for acute BP management during hospitalization for stroke).<sup><a href="javascript:;" reveal-id="ehae178-B814" data-open="ehae178-B814" class="link link-ref link-reveal xref-bibr">814</a>,<a href="javascript:;" reveal-id="ehae178-B815" data-open="ehae178-B815" class="link link-ref link-reveal xref-bibr">815</a>,<a href="javascript:;" reveal-id="ehae178-B821 ehae178-B822 ehae178-B823 ehae178-B824" data-open="ehae178-B821 ehae178-B822 ehae178-B823 ehae178-B824" class="link link-ref link-reveal xref-bibr">821–824</a></sup>

Regimens containing an ACE inhibitor and thiazide/thiazide-like diuretic may be superior to beta-blockers in terms of stroke risk reduction.<sup><a href="javascript:;" reveal-id="ehae178-B825" data-open="ehae178-B825" class="link link-ref link-reveal xref-bibr">825</a>,<a href="javascript:;" reveal-id="ehae178-B826" data-open="ehae178-B826" class="link link-ref link-reveal xref-bibr">826</a></sup> Regarding intensive BP control after stroke, typically targeting a systolic BP of <130 mmHg, individual trials were somewhat inconclusive, but a meta-analysis showed a reduced risk of recurrent stroke of 22% in the intensive treatment group randomized to a target systolic BP as low as 120 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B543" data-open="ehae178-B543" class="link link-ref link-reveal xref-bibr">543</a>,<a href="javascript:;" reveal-id="ehae178-B824" data-open="ehae178-B824" class="link link-ref link-reveal xref-bibr">824</a>,<a href="javascript:;" reveal-id="ehae178-B827" data-open="ehae178-B827" class="link link-ref link-reveal xref-bibr">827</a>,<a href="javascript:;" reveal-id="ehae178-B828" data-open="ehae178-B828" class="link link-ref link-reveal xref-bibr">828</a></sup> Caveats to this recommendation would be for frail patients, who have a much higher rate of stroke and recurrent stroke than the general population, and who are more sensitive to adverse effects of BP-lowering agents (see _Section [9.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.3)_).<sup><a href="javascript:;" reveal-id="ehae178-B596" data-open="ehae178-B596" class="link link-ref link-reveal xref-bibr">596</a>,<a href="javascript:;" reveal-id="ehae178-B606" data-open="ehae178-B606" class="link link-ref link-reveal xref-bibr">606</a>,<a href="javascript:;" reveal-id="ehae178-B607" data-open="ehae178-B607" class="link link-ref link-reveal xref-bibr">607</a>,<a href="javascript:;" reveal-id="ehae178-B829" data-open="ehae178-B829" class="link link-ref link-reveal xref-bibr">829</a></sup>

#### 9.9.3. Treatment in patients with chronic cerebrovascular disease and cognitive impairment

Treatment of hypertension represents a key mechanism for reducing the global burden of dementia at the population level.<sup><a href="javascript:;" reveal-id="ehae178-B830" data-open="ehae178-B830" class="link link-ref link-reveal xref-bibr">830</a></sup> Epidemiological studies have reported associations between mid-life hypertension and development of cognitive decline in later life, with, e.g. mid-life hypertension increasing relative risk of lifetime dementia by 20%–54%.<sup><a href="javascript:;" reveal-id="ehae178-B831 ehae178-B832 ehae178-B833 ehae178-B834 ehae178-B835 ehae178-B836 ehae178-B837" data-open="ehae178-B831 ehae178-B832 ehae178-B833 ehae178-B834 ehae178-B835 ehae178-B836 ehae178-B837" class="link link-ref link-reveal xref-bibr">831–837</a></sup> In one observational meta-analysis, an increased risk for dementia emerged with systolic BP of >130 mmHg.<sup><a href="javascript:;" reveal-id="ehae178-B831" data-open="ehae178-B831" class="link link-ref link-reveal xref-bibr">831</a></sup>

Evidence for lowering BP to reduce the risk of dementia is limited due to heterogeneity in populations studied, cognitive testing methods used, and the varied use of dementia or cognitive impairment or both as a primary outcome.<sup><a href="javascript:;" reveal-id="ehae178-B838" data-open="ehae178-B838" class="link link-ref link-reveal xref-bibr">838</a>,<a href="javascript:;" reveal-id="ehae178-B839" data-open="ehae178-B839" class="link link-ref link-reveal xref-bibr">839</a></sup> Findings from individual studies have mixed results (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)).<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a>,<a href="javascript:;" reveal-id="ehae178-B839 ehae178-B840 ehae178-B841 ehae178-B842 ehae178-B843" data-open="ehae178-B839 ehae178-B840 ehae178-B841 ehae178-B842 ehae178-B843" class="link link-ref link-reveal xref-bibr">839–843</a></sup> Studies on effects of BP-lowering treatment on white-matter intensities concluded that patients in the intensive-control arm had less white-matter intensity accumulation than in the standard-treatment arm.<sup><a href="javascript:;" reveal-id="ehae178-B841" data-open="ehae178-B841" class="link link-ref link-reveal xref-bibr">841</a>,<a href="javascript:;" reveal-id="ehae178-B844" data-open="ehae178-B844" class="link link-ref link-reveal xref-bibr">844</a></sup> Studies in which people with stroke and TIA were included reported a reduced risk of dementia and cognitive decline for the active-treatment group, but a mixed signal for dementia alone.<sup><a href="javascript:;" reveal-id="ehae178-B841" data-open="ehae178-B841" class="link link-ref link-reveal xref-bibr">841</a>,<a href="javascript:;" reveal-id="ehae178-B845" data-open="ehae178-B845" class="link link-ref link-reveal xref-bibr">845</a></sup> However, individual studies may have been under-powered and more recent meta-analyses do convincingly support efficacy in reducing dementia with BP-lowering treatment.<sup><a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> Indeed, these meta-analyses reported a reduced risk of incident dementia or cognitive impairment with BP lowering of 7%–13%.<sup><a href="javascript:;" reveal-id="ehae178-B610" data-open="ehae178-B610" class="link link-ref link-reveal xref-bibr">610</a>,<a href="javascript:;" reveal-id="ehae178-B611" data-open="ehae178-B611" class="link link-ref link-reveal xref-bibr">611</a></sup> While one trial suggested superiority of long-acting CCBs,<sup><a href="javascript:;" reveal-id="ehae178-B264" data-open="ehae178-B264" class="link link-ref link-reveal xref-bibr">264</a></sup> it is unclear if any first-line BP-lowering agent is preferable for preventing dementia and cognitive impairment.<sup><a href="javascript:;" reveal-id="ehae178-B846" data-open="ehae178-B846" class="link link-ref link-reveal xref-bibr">846</a>,<a href="javascript:;" reveal-id="ehae178-B847" data-open="ehae178-B847" class="link link-ref link-reveal xref-bibr">847</a></sup>

The role of competing risk mechanisms including orthostatic hypotension<sup><a href="javascript:;" reveal-id="ehae178-B848" data-open="ehae178-B848" class="link link-ref link-reveal xref-bibr">848</a></sup> and BP variability<sup><a href="javascript:;" reveal-id="ehae178-B849" data-open="ehae178-B849" class="link link-ref link-reveal xref-bibr">849</a></sup> may be important factors in treatment decisions for people with frailty, multimorbidity, and/or chronic cerebrovascular disease.

Recommendation Table 28

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376197)

Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment

![Recommendations for managing hypertension in patients with chronic cerebrovascular disease and cognitive impairment](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt28.jpeg?Expires=1728462845&Signature=DeD2m2mfYbkBRkIZDg4ZxItUdfhPe1a1Y5zGYkp3LVLZn9Qr5O7Ox~MSnRy1D9z2VL6KRB9JLHmJJ8WqPU~kwKcJ1lKiQeEw2PlwqQ7SsDKyeM6f0aO4IVf3K4tfu6Gf5PdhDB0lYxBs6khLrCL1Pof04x4sNEjClOYPv9zUgQCqgOPnHGHZQUarmDcbfDpmOrgcKSqY-C8lej-zpR9pcipaMlBAUAQC1WT4SxGLZULivnKHGfRiGMaDQNQFCy~N5EJkNqPYgI5daVFcHqyUoyBWppLyorlB4dUjUthSRYVt0iOBye-vMY~TG5QTwwYP5wrGW6IyoQieoNnHmSGkww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.10. Aortopathy

#### 9.10.1. Coarctation of the aorta

Aortic coarctation is associated with CVD in the long term, even following early surgical or percutaneous treatment. The most common complications are associated with hypertension, which is common in aortic coarctation. When aortic coarctation is not treated, patients often develop severe hypertension and HMOD (especially LVH and left ventricular dysfunction, aortopathy, and cerebrovascular complications).<sup><a href="javascript:;" reveal-id="ehae178-B850 ehae178-B851 ehae178-B852" data-open="ehae178-B850 ehae178-B851 ehae178-B852" class="link link-ref link-reveal xref-bibr">850–852</a></sup> No formal RCTs to define optimal medical treatment of hypertension in aortic coarctation have been conducted, therefore, patients not suitable for, or having undergone, intervention should be treated for hypertension following the core algorithm for the general population.

#### 9.10.2. Bicuspid aortic valve-related aortopathy

Bicuspid aortic valve is the most common congenital heart disease and is sometimes associated with aortopathy or aortic coarctation. Bicuspid aortic valve disease is associated with an increased risk of valve malfunction and adverse aortic events.<sup><a href="javascript:;" reveal-id="ehae178-B853" data-open="ehae178-B853" class="link link-ref link-reveal xref-bibr">853</a>,<a href="javascript:;" reveal-id="ehae178-B854" data-open="ehae178-B854" class="link link-ref link-reveal xref-bibr">854</a></sup> This risk is exacerbated by hypertension.

Beyond aortic dilation and aneurysm formation, bicuspid aortic valve disease is also a risk factor for aortic dissection and rupture.<sup><a href="javascript:;" reveal-id="ehae178-B855" data-open="ehae178-B855" class="link link-ref link-reveal xref-bibr">855</a></sup> Blood pressure should be carefully monitored and controlled.<sup><a href="javascript:;" reveal-id="ehae178-B856" data-open="ehae178-B856" class="link link-ref link-reveal xref-bibr">856</a></sup>

#### 9.10.3. Preventing aortic dilation and dissection in high-risk patients

A modest dilatation of the ascending aorta or aortic root is often associated with chronic hypertension and HMOD. An additional cause of aortopathy (bicuspid valve, coarctation, Marfan or other syndromes) should be considered in more severe cases.<sup><a href="javascript:;" reveal-id="ehae178-B857" data-open="ehae178-B857" class="link link-ref link-reveal xref-bibr">857</a></sup> Patients with aortic dilatation should have their BP optimally controlled following the core algorithm for the general hypertension population.

In patients with Marfan syndrome, prophylactic use of ARBs, ACE inhibitors, or beta-blockers may reduce complications or progression of aortic dilation.<sup><a href="javascript:;" reveal-id="ehae178-B857 ehae178-B858 ehae178-B859 ehae178-B860" data-open="ehae178-B857 ehae178-B858 ehae178-B859 ehae178-B860" class="link link-ref link-reveal xref-bibr">857–860</a></sup> More information is available in the 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases.<sup><a href="javascript:;" reveal-id="ehae178-B861" data-open="ehae178-B861" class="link link-ref link-reveal xref-bibr">861</a></sup>

### 9.11. Different ethnic groups

Influx and settlement of migrant populations in Europe have contributed to regional population growth and changes in its composition.<sup><a href="javascript:;" reveal-id="ehae178-B862" data-open="ehae178-B862" class="link link-ref link-reveal xref-bibr">862</a></sup> Ethnic minority populations are disproportionally affected by hypertension and hypertension-mediated complications, compared with historically native Europeans, with data suggesting migrant women are particularly vulnerable.<sup><a href="javascript:;" reveal-id="ehae178-B536" data-open="ehae178-B536" class="link link-ref link-reveal xref-bibr">536</a>,<a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> In particular, hypertension is more prevalent in those of African descent.<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a>,<a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a></sup> The predominant group of European black ethnicity originates from sub-Saharan Africa,<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a></sup> but specific studies on the management and control of hypertension in this population are lacking, and data are often extrapolated from studies in the African American population.<sup><a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a></sup> This assumption requires caution, as differences likely exist between these populations in terms of CVD risk, economic, and sociological status,<sup><a href="javascript:;" reveal-id="ehae178-B865" data-open="ehae178-B865" class="link link-ref link-reveal xref-bibr">865</a>,<a href="javascript:;" reveal-id="ehae178-B866" data-open="ehae178-B866" class="link link-ref link-reveal xref-bibr">866</a></sup> as well as responses to BP-lowering drugs.<sup><a href="javascript:;" reveal-id="ehae178-B867" data-open="ehae178-B867" class="link link-ref link-reveal xref-bibr">867</a></sup>

Black patients have a greater prevalence of low-renin, salt-sensitive hypertension and may be more predisposed to HMOD than white patients, possibly in part due to increased vascular stiffness.<sup><a href="javascript:;" reveal-id="ehae178-B864" data-open="ehae178-B864" class="link link-ref link-reveal xref-bibr">864</a>,<a href="javascript:;" reveal-id="ehae178-B868" data-open="ehae178-B868" class="link link-ref link-reveal xref-bibr">868</a>,<a href="javascript:;" reveal-id="ehae178-B869" data-open="ehae178-B869" class="link link-ref link-reveal xref-bibr">869</a></sup> Salt restriction, thiazide or thiazide-like diuretics, and CCBs appear particularly useful in black patients with hypertension, whereas RAS blocker monotherapy may be less effective.<sup><a href="javascript:;" reveal-id="ehae178-B870 ehae178-B871 ehae178-B872 ehae178-B873" data-open="ehae178-B870 ehae178-B871 ehae178-B872 ehae178-B873" class="link link-ref link-reveal xref-bibr">870–873</a></sup> If combination therapy is needed, in a recent RCT conducted in sub-Saharan African countries, amlodipine plus either hydrochlorothiazide or perindopril proved to be equally effective and superior, respectively, to hydrochlorothiazide plus perindopril.<sup><a href="javascript:;" reveal-id="ehae178-B874" data-open="ehae178-B874" class="link link-ref link-reveal xref-bibr">874</a></sup> When RAS blockers are used in combination therapy, ARBs may be preferable to ACE inhibitors, as angioedema appears more common with ACE inhibitors in black patients.

Despite some recent progress,<sup><a href="javascript:;" reveal-id="ehae178-B875" data-open="ehae178-B875" class="link link-ref link-reveal xref-bibr">875</a></sup> data on hypertension epidemiology and management in European immigrant patients are still lacking.<sup><a href="javascript:;" reveal-id="ehae178-B863" data-open="ehae178-B863" class="link link-ref link-reveal xref-bibr">863</a>,<a href="javascript:;" reveal-id="ehae178-B875 ehae178-B876 ehae178-B877" data-open="ehae178-B875 ehae178-B876 ehae178-B877" class="link link-ref link-reveal xref-bibr">875–877</a></sup>

Recommendation Table 29

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376211)

Recommendations for managing hypertension in different ethnic groups

![Recommendations for managing hypertension in different ethnic groups](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt29.jpeg?Expires=1728462845&Signature=o6G~JjEmKWjI5lgD0SJh6blI6oYFQcASr7vLKJzu47rgkmAbV6oxALu-O88lieu~6pjyClCLTzAGTkpFNRDnlLo6S~RUgzY8g99ZIPMkUbKiAPy3EVMV2KCBLGu9xTuaORAz5mtq-8CXEaqB~Isco7giMcTXpseHD64M0~7WerwOfrfkyjGz3u0Z5W8UDwWNvvdITJKUG3hkTMlEhLmVMjdBm2eU0AKhAA3ZFbQ85e9wtd9e~XN-rTDyQ737cJNugJn2oD5mXg3GZ1oG3F46YJ1jxleujYtyHMtHA7I~YTyI~-CROECg-sZwkwqhemdOm4OCxamfZoNYv~2TYo0exw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.12. Nocturnal hypertension

#### 9.12.1. Definition

Nocturnal hypertension is defined as night-time BP of >120 mmHg systolic and/or >70 mmHg diastolic by 24 h ABPM. Nocturnal hypertension can occur as day–night sustained hypertension or isolated nocturnal hypertension (daytime BP < 135/85 mmHg on 24 h ABPM). Physiologically, BP is expected to decrease during sleep by 10%–20% relative to daytime BP.<sup><a href="javascript:;" reveal-id="ehae178-B878" data-open="ehae178-B878" class="link link-ref link-reveal xref-bibr">878</a></sup> Night-time dipping patterns are classified into four groups:<sup><a href="javascript:;" reveal-id="ehae178-B879" data-open="ehae178-B879" class="link link-ref link-reveal xref-bibr">879</a>,<a href="javascript:;" reveal-id="ehae178-B880" data-open="ehae178-B880" class="link link-ref link-reveal xref-bibr">880</a></sup>

-   **Inverse dipping (riser):** nocturnal increase in BP (night-to-day ratio of >1.0).
    
-   **Non-dipper:** reduced night-time BP dip of <10% (or night-to-day ratio of >0.9 and ≤1.0).
    
-   **Normal dipping:** fall in night-time BP of >10% and <20% (or night-to-day ratio of 0.8 to 0.9).
    
-   **Extreme dipping:** marked fall in night-time BP of >20% (or night-to-day ratio of <0.8).
    

Patients with nocturnal hypertension may be dippers or non-dippers. Of note, the long-term reproducibility of dipping patterns appears to be low.<sup><a href="javascript:;" reveal-id="ehae178-B881" data-open="ehae178-B881" class="link link-ref link-reveal xref-bibr">881</a>,<a href="javascript:;" reveal-id="ehae178-B882" data-open="ehae178-B882" class="link link-ref link-reveal xref-bibr">882</a></sup>

#### 9.12.2. Epidemiology

Nocturnal hypertension has been observed in up to half of patients with hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B883 ehae178-B884 ehae178-B885 ehae178-B886" data-open="ehae178-B883 ehae178-B884 ehae178-B885 ehae178-B886" class="link link-ref link-reveal xref-bibr">883–886</a></sup> and is associated with increased HMOD,<sup><a href="javascript:;" reveal-id="ehae178-B883" data-open="ehae178-B883" class="link link-ref link-reveal xref-bibr">883</a></sup> impaired renal function, and diabetes mellitus.<sup><a href="javascript:;" reveal-id="ehae178-B887" data-open="ehae178-B887" class="link link-ref link-reveal xref-bibr">887</a></sup> Nocturnal hypertension appears to be more prevalent in black<sup><a href="javascript:;" reveal-id="ehae178-B888 ehae178-B889 ehae178-B890" data-open="ehae178-B888 ehae178-B889 ehae178-B890" class="link link-ref link-reveal xref-bibr">888–890</a></sup> and Asian<sup><a href="javascript:;" reveal-id="ehae178-B891" data-open="ehae178-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae178-B892" data-open="ehae178-B892" class="link link-ref link-reveal xref-bibr">892</a></sup> populations. Masked uncontrolled hypertension, which occurs in 30% of patients treated for hypertension, is more often due to poorly controlled nocturnal BP than daytime BP on ABPM.<sup><a href="javascript:;" reveal-id="ehae178-B893" data-open="ehae178-B893" class="link link-ref link-reveal xref-bibr">893</a></sup>

Environmental factors, including sleep duration and higher humidity,<sup><a href="javascript:;" reveal-id="ehae178-B894" data-open="ehae178-B894" class="link link-ref link-reveal xref-bibr">894</a></sup> nocturia,<sup><a href="javascript:;" reveal-id="ehae178-B895" data-open="ehae178-B895" class="link link-ref link-reveal xref-bibr">895</a></sup> OSAS,<sup><a href="javascript:;" reveal-id="ehae178-B896" data-open="ehae178-B896" class="link link-ref link-reveal xref-bibr">896</a></sup> obesity, high salt intake in salt-sensitive patients,<sup><a href="javascript:;" reveal-id="ehae178-B897" data-open="ehae178-B897" class="link link-ref link-reveal xref-bibr">897</a></sup> orthostatic hypotension, autonomic dysfunction, CKD,<sup><a href="javascript:;" reveal-id="ehae178-B898 ehae178-B899 ehae178-B900" data-open="ehae178-B898 ehae178-B899 ehae178-B900" class="link link-ref link-reveal xref-bibr">898–900</a></sup> diabetic neuropathy/diabetes,<sup><a href="javascript:;" reveal-id="ehae178-B901" data-open="ehae178-B901" class="link link-ref link-reveal xref-bibr">901</a></sup> and old age<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a></sup> are associated with non-dipping. Moreover, nocturnal hypertension and absent night-time dipping pattern are more common in secondary hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B902" data-open="ehae178-B902" class="link link-ref link-reveal xref-bibr">902</a>,<a href="javascript:;" reveal-id="ehae178-B903" data-open="ehae178-B903" class="link link-ref link-reveal xref-bibr">903</a></sup>

#### 9.12.3. Night-time blood pressure as a cardiovascular disease risk factor

Nocturnal hypertension is a risk factor for adverse CVD events,<sup><a href="javascript:;" reveal-id="ehae178-B904" data-open="ehae178-B904" class="link link-ref link-reveal xref-bibr">904</a></sup> cerebrovascular disease, including stroke,<sup><a href="javascript:;" reveal-id="ehae178-B905" data-open="ehae178-B905" class="link link-ref link-reveal xref-bibr">905</a></sup> and cardiovascular mortality.<sup><a href="javascript:;" reveal-id="ehae178-B891" data-open="ehae178-B891" class="link link-ref link-reveal xref-bibr">891</a>,<a href="javascript:;" reveal-id="ehae178-B906" data-open="ehae178-B906" class="link link-ref link-reveal xref-bibr">906</a>,<a href="javascript:;" reveal-id="ehae178-B907" data-open="ehae178-B907" class="link link-ref link-reveal xref-bibr">907</a></sup> Night-time BP may provide more prognostic information than daytime BP, perhaps as it is less dependent on physical activities. Non-dipping<sup><a href="javascript:;" reveal-id="ehae178-B908 ehae178-B909 ehae178-B910" data-open="ehae178-B908 ehae178-B909 ehae178-B910" class="link link-ref link-reveal xref-bibr">908–910</a></sup> and reverse dipping (nocturnal rise in BP) may also be associated with increased CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B62" data-open="ehae178-B62" class="link link-ref link-reveal xref-bibr">62</a>,<a href="javascript:;" reveal-id="ehae178-B910 ehae178-B911 ehae178-B912 ehae178-B913" data-open="ehae178-B910 ehae178-B911 ehae178-B912 ehae178-B913" class="link link-ref link-reveal xref-bibr">910–913</a></sup> A nocturnal rise in BP is associated with an increased risk of dementia and Alzheimer’s disease in older men.<sup><a href="javascript:;" reveal-id="ehae178-B914" data-open="ehae178-B914" class="link link-ref link-reveal xref-bibr">914</a></sup> There is also some evidence that extreme dipping, particularly in untreated patients, is associated with an increased risk for CVD events.<sup><a href="javascript:;" reveal-id="ehae178-B35" data-open="ehae178-B35" class="link link-ref link-reveal xref-bibr">35</a>,<a href="javascript:;" reveal-id="ehae178-B886" data-open="ehae178-B886" class="link link-ref link-reveal xref-bibr">886</a></sup>

#### 9.12.4. Treatment of nocturnal hypertension

There is no reliable evidence that BP-lowering medication should be routinely dosed at bedtime. The diurnal timing of drug administration is discussed in _Section [8.3.4](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.3.4)._ In patients with secondary hypertension, the underlying cause (OSAS, primary aldosteronism) should be treated as discussed in _Section [9.14](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8.14)_.

### 9.13. Resistant hypertension

#### 9.13.1. Definition of resistant hypertension

Resistant hypertension is defined as BP remaining above goal despite three or more BP-lowering drugs of different classes at maximally tolerated doses, of which one is a diuretic (_[Table 11](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B915" data-open="ehae178-B915" class="link link-ref link-reveal xref-bibr">915</a></sup> Resistant hypertension should be managed at specialized centres with the expertise and resources to exclude pseudo-resistant hypertension (adherence testing) and causes of secondary hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B916" data-open="ehae178-B916" class="link link-ref link-reveal xref-bibr">916</a></sup>

#### 9.13.2. Non-pharmacological interventions

The Treating Resistant Hypertension Using Lifestyle Modification to Promote Health (TRIUMPH) trial demonstrated significant clinic and ambulatory BP reductions in patients with resistant hypertension participating in a 4-month lifestyle intervention comprising diet and exercise interventions delivered within a cardiac rehabilitation programme.<sup><a href="javascript:;" reveal-id="ehae178-B917" data-open="ehae178-B917" class="link link-ref link-reveal xref-bibr">917</a></sup>

#### 9.13.3. Pharmacological interventions

BP-lowering treatment of resistant hypertension with single-pill combinations is recommended to reduce the pill burden, thereby increasing drug adherence and persistence.<sup><a href="javascript:;" reveal-id="ehae178-B492" data-open="ehae178-B492" class="link link-ref link-reveal xref-bibr">492</a></sup>

As resistant hypertension often, and especially in CKD,<sup><a href="javascript:;" reveal-id="ehae178-B918" data-open="ehae178-B918" class="link link-ref link-reveal xref-bibr">918</a></sup> represents a state of salt retention and volume expansion secondary to relative aldosterone excess,<sup><a href="javascript:;" reveal-id="ehae178-B516" data-open="ehae178-B516" class="link link-ref link-reveal xref-bibr">516</a>,<a href="javascript:;" reveal-id="ehae178-B919" data-open="ehae178-B919" class="link link-ref link-reveal xref-bibr">919</a>,<a href="javascript:;" reveal-id="ehae178-B920" data-open="ehae178-B920" class="link link-ref link-reveal xref-bibr">920</a></sup> BP control may be improved by switching hydrochlorothiazide to long-acting thiazide-like diuretics, such as chlorthalidone.<sup><a href="javascript:;" reveal-id="ehae178-B921" data-open="ehae178-B921" class="link link-ref link-reveal xref-bibr">921</a>,<a href="javascript:;" reveal-id="ehae178-B922" data-open="ehae178-B922" class="link link-ref link-reveal xref-bibr">922</a></sup> However, a recent trial of chlorthalidone vs. hydrochlorothiazide—which probably included a sizeable proportion of adults with resistant hypertension—did not demonstrate any difference in systolic BP or CVD outcomes between the two medications. In the subgroup of patients with prior CVD, there was a strong trend of benefit with chlorthalidone on CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> Of note, the risk of hypokalaemia was higher in the chlorthalidone group than in the hydrochlorothiazide group.<sup><a href="javascript:;" reveal-id="ehae178-B447" data-open="ehae178-B447" class="link link-ref link-reveal xref-bibr">447</a></sup> In patients with eGFR < 30 mL/min/1.73 m<sup>2</sup>, an adequately up-titrated loop diuretic is necessary to define resistant hypertension.

Most patients with resistant hypertension require the addition of non-first-line BP-lowering drugs (_[Figure 22](javascript:;)_). Of these, low-dose spironolactone (25–50 mg daily) should be considered first.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a>,<a href="javascript:;" reveal-id="ehae178-B515" data-open="ehae178-B515" class="link link-ref link-reveal xref-bibr">515</a>,<a href="javascript:;" reveal-id="ehae178-B923 ehae178-B924 ehae178-B925" data-open="ehae178-B923 ehae178-B924 ehae178-B925" class="link link-ref link-reveal xref-bibr">923–925</a></sup> In patients with resistant hypertension and type 2 diabetes, spironolactone (25–50 mg daily) reduced BP and albuminuria.<sup><a href="javascript:;" reveal-id="ehae178-B926" data-open="ehae178-B926" class="link link-ref link-reveal xref-bibr">926</a></sup> The use of spironolactone can be precluded by limited tolerability due to anti-androgenic side effects resulting in breast tenderness or gynaecomastia (in about 6%), impotence in men, and menstrual irregularities in women.<sup><a href="javascript:;" reveal-id="ehae178-B927" data-open="ehae178-B927" class="link link-ref link-reveal xref-bibr">927</a></sup> The efficacy and safety of spironolactone for treating resistant hypertension have not yet been established in patients with significant renal impairment. Moreover, spironolactone, especially in addition to RAS inhibitors, increases the risk of hyperkalaemia.<sup><a href="javascript:;" reveal-id="ehae178-B927" data-open="ehae178-B927" class="link link-ref link-reveal xref-bibr">927</a>,<a href="javascript:;" reveal-id="ehae178-B928" data-open="ehae178-B928" class="link link-ref link-reveal xref-bibr">928</a></sup> Therefore, spironolactone should be restricted to patients with an eGFR of ≥30 mL/min/1.73 m<sup>2</sup> and a plasma potassium concentration of ≤4.5 mmol/L.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup> Steroidal MRAs are contraindicated in patients with an eGFR of <30 mL/min/1.73 m<sup>2</sup>. Serum electrolytes and kidney function should be monitored soon after initiation and frequently thereafter. In patients with resistant hypertension and CKD (eGFR of 25–45 mL/min/1.73 m<sup>2</sup>), the oral potassium binder patiromer enabled more patients to continue treatment with spironolactone.<sup><a href="javascript:;" reveal-id="ehae178-B929" data-open="ehae178-B929" class="link link-ref link-reveal xref-bibr">929</a></sup>

![Management of resistant hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f22.jpeg?Expires=1728462845&Signature=5D-GhDgSTuORpFbi~ZKmoKv8Dzhyc0xqTvfLJuRU~DxgUVw9mx-9KyCASuhnE~Eat6EgMbZxCcIh0WCFnnt5n2LMAsWhPFYeufKgrXyUQkLqFqbfzl3x9Q~JL85jUg~rQSlhOF7EusmlTO4MEBwhHjjrWx4Nub6iun-7Ex-ndkU5x6ZVvq0MY7ft-CIn7CfGgvWDPRjM2P7lQIv3dPptd3yqfbaPa1oMF3NjFztg3yQCuiK5o1SjIycsb8k3kvP5fBjERSrbIkS-Y55yXwYIi2MNp7mmxKFKG-53nHQ2uN6RI4NIIdDbSD5YUQrwTnfv4vDc53IBAUel-GvjLJdmlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 22

Management of resistant hypertension.

BP, blood pressure; K<sup>+</sup>, potassium; SPC, single-pill combination.

[Open in new tab](https://academic.oup.com/view-large/figure/479376233/ehae178f22.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f22.jpeg?Expires=1728462845&Signature=wTNZPJhAW4qMYwNroNzc8bPLWQQDdNcJJ1qoUkiJkFkn9lk28iPnF5LCjDDk2QVRuha71PgvgEdsI3QkK~14Ln8s46cjnyRi6zoY-vCYDpcv47yQHVyNhbf-Uu~4zoLnJ1Wl3HnnD8tIORiUswEwcjmvWJuBp~w9m~wMOvRHaj~OresKbekdAOIFvl5aqjdLuVUI-Samu--P1NXwctfK3Ccd9TR5HgW57zhAGDnIzAPd4Jr8w-f3~AFsD966VVpt7RLEn5M9-A8ju-uG86xyMNMRslgZzvFWSgFURODBX0ZZlVaTNbywbXj3jw3wdL4rHcoO55gMpbGhsMPzse~OIg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376233&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

If spironolactone is not tolerated due to anti-androgen side effects, eplerenone may be used. If eplerenone is used, higher doses (i.e. 50–200 mg daily) and twice-daily dosing may be necessary to achieve a BP-lowering effect.<sup><a href="javascript:;" reveal-id="ehae178-B503" data-open="ehae178-B503" class="link link-ref link-reveal xref-bibr">503</a></sup> Of note, eplerenone is not licensed for hypertension treatment in many countries.

When not already prescribed for a compelling indication, beta-blockers should be considered in the treatment of resistant hypertension, though their BP-lowering effects appear to be less potent than spironolactone in the setting of resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B459" data-open="ehae178-B459" class="link link-ref link-reveal xref-bibr">459</a></sup>

Amiloride and clonidine have data suggesting they are as effective as spironolactone for BP lowering, though they lack outcomes data. A non-exhaustive list of additional medications sometimes used for BP-lowering purposes includes other centrally acting BP-lowering medications (e.g. methyldopa), hydralazine, aliskiren, minoxidil, triamterene, and loop diuretics (_[Figure 22](javascript:;)_).<sup><a href="javascript:;" reveal-id="ehae178-B515" data-open="ehae178-B515" class="link link-ref link-reveal xref-bibr">515</a>,<a href="javascript:;" reveal-id="ehae178-B516" data-open="ehae178-B516" class="link link-ref link-reveal xref-bibr">516</a></sup> As noted earlier, minoxidil use is often limited by side effects.

#### 9.13.4. Devices for blood pressure lowering

Several devices have been investigated for treating resistant hypertension. Of these, the most evidence is available for catheter-based renal denervation. As discussed in _Section [8.6.1](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.6.1)_, several randomized, sham-controlled trials have been published, demonstrating a BP-lowering efficacy over 24 h for radiofrequency and ultrasound renal denervation in a broad spectrum of hypertension, including resistant hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B568" data-open="ehae178-B568" class="link link-ref link-reveal xref-bibr">568</a>,<a href="javascript:;" reveal-id="ehae178-B585" data-open="ehae178-B585" class="link link-ref link-reveal xref-bibr">585</a></sup> Other devices are still under investigation and are not recommended for routine use in clinical practice (_Section [8.6.2](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7.6.2)_).

Recommendation Table 30

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376239)

Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43)

![Recommendations for treating resistant hypertension (see Evidence Tables 42 and 43)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt30.jpeg?Expires=1728462845&Signature=087TCPVSKopMosPmKu35MLTJkEDUC-d3P2vKX8T6ULDWIRoC~mbHlZoGqR5u4PxYJ65eQv2wYJL9NlnCGEJBq8a4LpQaqz0iU9sFZHGjS~YAvshZAYgxyZg9ytvjSH7lSfMo3B8udgvYGk-RfrD5Sh6TFoyKiHDJb4n3i611-9VlXhRyfw3EUzvQsG3xHs1J7hADfqorkYyvX7DA2XUrNfwZof-y8j~hqdORkf0dGeAlrHQuUpSiEAovkzpG3frllbcgP-YerDnMyn0votXUaTBfN9y6jx27LNRy5fvnFFnLEf2ZNJ46ITizvxmGB~g8zeyj7GCCQqgJ64CXVWhLbg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 9.14. Management of specific causes of secondary hypertension

#### 9.14.1. General considerations

These guidelines will describe only the general principles of managing the most common forms of secondary hypertension. For the rarer forms of secondary hypertension, patients should be referred to specialized hypertension centres.

By definition, secondary hypertension should be, for the most part, cured when the underlying cause has been unambiguously identified and removed. However, in clinical practice, this is not always the case. Vascular remodelling, a common feature of a delayed diagnosis of secondary hypertension, affects renal function and can account for residual high BP in some patients with secondary hypertension. The rate of cure is higher when the diagnosis is made early in the course of the disease. Most common forms of secondary hypertension are listed in _[Table 13](javascript:;)_.

#### 9.14.2. Primary aldosteronism

Primary aldosteronism (Conn syndrome) is the most common form of secondary hypertension. The management of primary aldosteronism depends on its subtype, particularly on adrenal lesions being unilateral or bilateral, because the unilateral forms are amenable to surgical treatment while the latter require lifelong medical treatment. In sporadic forms, unilateral primary aldosteronism is distinguished from bilateral primary aldosteronism by adrenal vein sampling or functional imaging with radiolabelled tracers.<sup><a href="javascript:;" reveal-id="ehae178-B930 ehae178-B931 ehae178-B932" data-open="ehae178-B930 ehae178-B931 ehae178-B932" class="link link-ref link-reveal xref-bibr">930–932</a></sup> In the much less common familial forms (necessitating a family history be taken), genetic testing for germline mutations is necessary.<sup><a href="javascript:;" reveal-id="ehae178-B933" data-open="ehae178-B933" class="link link-ref link-reveal xref-bibr">933</a></sup>

For unilateral primary aldosteronism, surgical removal of the offending adrenal gland is typically considered, unless the patient is older or has comorbidities of concern. Surgery is not an option for bilateral primary aldosteronism. Medical treatment is currently based on MRAs. Among MRAs, spironolactone is the most widely available. The effective dose, usually 50–100 mg once daily, can be titrated up to 300–400 mg once daily, if necessary. Eplerenone is also used and, despite being less potent than spironolactone and requiring twice-daily administration, it has the advantage of causing less gynaecomastia and erectile dysfunction in men.<sup><a href="javascript:;" reveal-id="ehae178-B934" data-open="ehae178-B934" class="link link-ref link-reveal xref-bibr">934</a></sup> Newer agents, such as the non-steroidal MRAs finerenone and exarenone, and the aldosterone synthase inhibitor baxdrostat, which lower BP in resistant hypertension,<sup><a href="javascript:;" reveal-id="ehae178-B326" data-open="ehae178-B326" class="link link-ref link-reveal xref-bibr">326</a>,<a href="javascript:;" reveal-id="ehae178-B474" data-open="ehae178-B474" class="link link-ref link-reveal xref-bibr">474</a></sup> are also being tested for treating primary aldosteronism. Of the familial forms, only glucocorticoid-remediable primary aldosteronism, now reclassified as familial hyperaldosteronism type 1, can be corrected with dexamethasone,<sup><a href="javascript:;" reveal-id="ehae178-B935" data-open="ehae178-B935" class="link link-ref link-reveal xref-bibr">935</a></sup> usually with low doses that are free of glucocorticoid effects and can be safely used during pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B936" data-open="ehae178-B936" class="link link-ref link-reveal xref-bibr">936</a></sup> For detailed information, readers are referred to the latest primary aldosteronism guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B328" data-open="ehae178-B328" class="link link-ref link-reveal xref-bibr">328</a>,<a href="javascript:;" reveal-id="ehae178-B329" data-open="ehae178-B329" class="link link-ref link-reveal xref-bibr">329</a></sup>

#### 9.14.3. Renovascular hypertension

Patients with RVH should receive medical therapy to reduce BP in the first instance. Percutaneous transluminal renal angioplasty (PTRA) without stenting is the treatment of choice for fibromuscular dysplasia, and can restore renal perfusion pressure and lower BP.<sup><a href="javascript:;" reveal-id="ehae178-B937" data-open="ehae178-B937" class="link link-ref link-reveal xref-bibr">937</a></sup> When this is not feasible, RAS blockers are the drugs of choice for treatment, but they require careful monitoring of renal function over time, as they can cause acute renal failure in those with tight bilateral stenoses or a stenosed solitary functioning kidney. Possible involvement of the carotid, coronary, and other major arteries, possibly leading to dissection if BP is not controlled, should also be considered, as fibromuscular dysplasia is now recognized as a systemic disease affecting multiple vascular beds.

Patients with significant atherosclerotic renal artery stenosis are at very high risk of CVD and renal events. It is recommended that PTRA and stenting are performed in experienced centres due to the high risk of restenosis. Unfortunately, though these studies did not solely recruit patients with true significant atherosclerotic RVH, publication of some null trials<sup><a href="javascript:;" reveal-id="ehae178-B938" data-open="ehae178-B938" class="link link-ref link-reveal xref-bibr">938</a>,<a href="javascript:;" reveal-id="ehae178-B939" data-open="ehae178-B939" class="link link-ref link-reveal xref-bibr">939</a></sup> have decreased the enthusiasm for investigating atherosclerotic renal artery stenosis. This could result in more uncontrolled hypertension, recurrent flash pulmonary oedema (Pickering syndrome), and worsening renal function ultimately leading to end-stage renal disease.<sup><a href="javascript:;" reveal-id="ehae178-B940" data-open="ehae178-B940" class="link link-ref link-reveal xref-bibr">940</a></sup>

Recommendation Table 31

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376250)

Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45)

![Recommendations for managing hypertension in patients with renovascular hypertension (see Evidence Tables 44 and 45)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt31.jpeg?Expires=1728462845&Signature=lrYGgtVc~D4zTE9SDPzBJHTsPqBw0SBjpJiTS3VHzEByvMiGeAIhf6lKtBZVEPLtxrOxTW9p5uBQJJqrEjC0C6DrpBgRaQNLueb4mw~YRFoLGZOPSuSTR-1WUVR-vEzMnNOQxsqskaTqP5sgGDI2lS2t3pVQZtZ8icjza5rJNk8wRG4YHksnEDsX6Rt~yHu09x75Yi~1NkmcX-lNp~~4tKtUmZUOpKbbP1lU5-0SmRubLodKFFPpfYiORp3WYizp37PzO9pGqwJA0ZVvaSuUCv3YFqM7LURwZsvOg~2nOVd9XaXKNeP8oADuAO8SeyHf3Qv3EzwzI2EgEyvTC8Tgnw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

#### 9.14.4. Phaeochromocytoma/paraganglioma

Phaeochromocytomas are rare adrenal tumours that secrete catecholamines and are present in <0.2% of patients with hypertension. A small percentage (<10%) of catecholamine-producing tumours are extra-adrenal and are derived from sympathetic and non-sympathetic nerves. More than 35% of the non-syndromic PPGLs are due to germline mutations.<sup><a href="javascript:;" reveal-id="ehae178-B338" data-open="ehae178-B338" class="link link-ref link-reveal xref-bibr">338</a></sup> These mutations should be screened for because, when found, they can drive management of the proband and the family and also inform the choice of functional imaging. Moreover, some germline mutations, such as those involving succinate dehydrogenase B, carry a risk of malignant adrenal tumours.<sup><a href="javascript:;" reveal-id="ehae178-B301" data-open="ehae178-B301" class="link link-ref link-reveal xref-bibr">301</a>,<a href="javascript:;" reveal-id="ehae178-B336" data-open="ehae178-B336" class="link link-ref link-reveal xref-bibr">336</a></sup>

Sympathetic PPGLs are usually secreting and present with chronic, episodic, or labile hypertension. Adrenergic crises cause hypertensive emergencies and should be treated with an intravenous (i.v.) alpha-1-blocker, such as phentolamine, doxazosin or terazosin, or labetalol. When given i.v. (1–2 mg/kg) twice weekly as a bolus over 1 min followed by a continuous infusion, labetalol also has alpha-blocker properties and has the advantage of allowing titration of the infusion based on the BP response, and avoids tachycardia via beta-blockade.

Identifying a single tumour mandates surgical excision after adequate pharmacological preparation, because secreting PPGLs can cause fatal events with no warning. Administering doxazosin or terazosin, followed by a beta-blocker, usually controls BP and adrenergic crises. As PPGLs are associated with a redistribution of volume from the periphery to the cardiopulmonary system,<sup><a href="javascript:;" reveal-id="ehae178-B944" data-open="ehae178-B944" class="link link-ref link-reveal xref-bibr">944</a></sup> patients with PPGLs have peripheral hypovolaemia that exposes them to the risk of profound hypotension, particularly right after tumour excision. Therefore, adequate fluid administration should be carefully managed.

#### 9.14.5. Obstructive sleep apnoea syndrome

The management of this prevalent condition should be driven by the result of a polysomnography study, which should provide the value of the AHI (the average number of episodes per hour) and the sleep position in which apnoeic–hypopnoeic episodes occur. For mild OSAS (AHI < 15), weight loss and advice on sleep hygiene are usually sufficient. For moderate (AHI of 15–30) and severe (AHI > 30) OSAS, continuous positive airway pressure (CPAP) is indicated and usually improves BP control and helps to resolve resistant hypertension. If CPAP is not tolerated, the site of upper airway obstruction should be determined by an Ear, Nose, and Throat evaluation with drug-induced sleep endoscopy as a potential step to corrective surgery.

#### 9.14.6. Drug-induced hypertension

Over-the-counter medications, prescribed drugs, and drug abuse (recreational substances and misuse of drugs) can cause hypertension ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

##### 9.14.6.1. Anticancer drug-induced hypertension

Growing evidence indicates that, while contemporary anticancer and anti-angiogenic drugs improve cancer survival, they can also cause hypertension ([Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S4](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_). This is especially evident in patients treated with vascular endothelial growth factor inhibitors, in whom BP increases in 80%–90%.<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a></sup> Tyrosine kinase inhibitors and proteasome inhibitors also increase BP, as do adjuvant therapies (corticosteroids, calcineurin inhibitors, non-steroidal anti-inflammatory drugs, and anti-androgen hormone therapy). Hypertension caused by anticancer drugs is often dose limiting and may be reversible after therapy interruption or discontinuation. Evidence-based clinical trials specifically addressing patients who develop hypertension due to cancer therapy are lacking. It is recommended that management of hypertension in these patients follows that for the general population.<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a>,<a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup> Managing these complex patients requires multidisciplinary healthcare involving oncologists, hypertension specialists, cardiologists, and nephrologists,<sup><a href="javascript:;" reveal-id="ehae178-B945" data-open="ehae178-B945" class="link link-ref link-reveal xref-bibr">945</a>,<a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup> as highlighted in the 2022 ESC Guidelines on cardio-oncology.<sup><a href="javascript:;" reveal-id="ehae178-B946" data-open="ehae178-B946" class="link link-ref link-reveal xref-bibr">946</a></sup>

#### 9.14.7. Other forms of secondary hypertension

Other forms of secondary hypertension, such as genetic causes of hypertension (Liddle’s syndrome, glucocorticoid-remediable aldosteronism), excess liquorice, Cushing’s syndrome, thyroid disease, hyperparathyroidism, aortic coarctation, and acromegaly are rare. Affected patients should be referred to specialized centres for treatment.

## 10\. Acute and short-term lowering of blood pressure

### 10.1. Acute blood pressure management in hypertensive emergencies

#### 10.1.1. Definition and characteristics of hypertensive emergencies

Hypertensive emergency is defined as BP of ≥180/110 mmHg (see _[Figure 10](javascript:;)_) associated with acute HMOD, often in the presence of symptoms. Hypertensive emergencies are potentially life-threatening and require immediate and careful intervention to reduce BP, often with i.v. therapy.

Symptoms of hypertensive emergency depend on the organs affected but may include headache, visual disturbances, chest pain, shortness of breath, dizziness, and other neurological deficits. In patients with hypertensive encephalopathy, somnolence, lethargy, tonic–clonic seizures, and cortical blindness may precede a loss of consciousness; however, focal neurological lesions are rare and should raise the suspicion of stroke.

As outlined in _Section [7](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6)_, we define HMOD among patients with chronically elevated BP or hypertension as the presence of specific cardiac, vascular, and renal alterations.<sup><a href="javascript:;" reveal-id="ehae178-B31" data-open="ehae178-B31" class="link link-ref link-reveal xref-bibr">31</a>,<a href="javascript:;" reveal-id="ehae178-B159" data-open="ehae178-B159" class="link link-ref link-reveal xref-bibr">159</a></sup> However, in the setting of hypertensive emergency, more acute manifestations of organ damage are relevant for management.

Acute manifestations of organ damage include:

-   Patients with severe acute hypertension associated with other clinical conditions likely to require urgent reduction in BP, e.g. acute onset of aortic dissection, myocardial ischaemia, eclampsia, or heart failure.
    
-   Malignant hypertension, defined as extreme BP elevations and acute microvascular damage (microangiopathy) affecting various organs.<sup><a href="javascript:;" reveal-id="ehae178-B947" data-open="ehae178-B947" class="link link-ref link-reveal xref-bibr">947</a></sup> The hallmark of this condition is small-artery fibrinoid necrosis in the kidneys, retina, and brain. The acute microangiopathy is typically characterized clinically by retinopathy (flame haemorrhages, cotton wool spots, and/or papilloedema). Other manifestations of microangiopathy include disseminated intravascular coagulation, encephalopathy (in about 15% of cases), acute heart failure, and acute deterioration in renal function.
    
-   Patients with sudden severe hypertension due to phaeochromocytoma, which can result in severe acute organ damage.
    

The term ‘hypertension urgency’ describes severe hypertension in patients without clinical evidence of acute organ damage. While these patients require BP reduction, they do not usually require admission to hospital, and BP reduction is best achieved with oral medication according to the drug treatment algorithm presented in _Section [8](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s7)_. However, these patients may require more urgent outpatient review to ensure that their BP is controlled.

Acute and severe increases in BP can sometimes be precipitated by sympathomimetics such as methamphetamine or cocaine, when caution around beta-blocker use is also needed. Many patients in an emergency department with acute pain or distress may have acutely elevated BP that will normalize when the pain and distress are relieved, rather than requiring any specific intervention to lower BP.

A diagnostic work-up is necessary for patients with a suspected hypertensive emergency (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S12](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).

#### 10.1.2. Acute management of hypertensive emergencies

Key considerations in defining treatment are:

1.  Establishing the affected target organ(s) and whether they require any specific interventions other than BP lowering.
    
2.  Determining whether there is a precipitating cause for the acute rise in BP and/or another concomitant health condition present that might affect the treatment plan (e.g. pregnancy).
    
3.  The recommended timing and magnitude of BP lowering required for safe BP reduction.
    

These considerations will inform the type of BP-lowering treatment required. Regarding BP-lowering drugs, i.v. treatment using a short half-life drug is typically ideal to allow careful titration of the BP response to treatment. This requires a higher dependency clinical area with facilities for continuous or near-continuous haemodynamic monitoring. Recommended drug treatments for specific hypertensive emergencies are provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S13](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.

Rapid and uncontrolled or excessive BP lowering is not recommended in hypertensive emergency as this can lead to further complications. Although i.v. drug administration is recommended for most hypertensive emergencies, oral therapy with ACE inhibitors, ARBs, or beta-blockers (shorter-acting formulations like captopril or metoprolol) can also be effective. However, low initial doses should be used because these patients can be very sensitive to these agents, and treatment should take place in hospital. Further comprehensive details on the clinical management of hypertensive emergencies are available elsewhere.<sup><a href="javascript:;" reveal-id="ehae178-B242" data-open="ehae178-B242" class="link link-ref link-reveal xref-bibr">242</a></sup>

#### 10.1.3. Prognosis and follow-up

The survival of patients with hypertensive emergencies has improved over the past few decades, but these patients remain at high risk and should be screened for secondary hypertension.

### 10.2. Acute blood pressure management in acute intracerebral haemorrhage

In acute intracerebral haemorrhage, an increased BP is common and is associated with a greater risk of haematoma expansion and death, and a worse prognosis for neurological recovery. In trials testing immediate BP lowering (within <6 h) to a systolic target of <140 mmHg, the achieved systolic BP in the intervention group was typically 140–160 mmHg and was reported to reduce the risk of haematoma expansion.<sup><a href="javascript:;" reveal-id="ehae178-B948" data-open="ehae178-B948" class="link link-ref link-reveal xref-bibr">948</a>,<a href="javascript:;" reveal-id="ehae178-B949" data-open="ehae178-B949" class="link link-ref link-reveal xref-bibr">949</a></sup> Excessive acute drops in systolic BP (>70 mmHg) may be associated with acute renal injury and early neurological deterioration and should be avoided.<sup><a href="javascript:;" reveal-id="ehae178-B950" data-open="ehae178-B950" class="link link-ref link-reveal xref-bibr">950</a>,<a href="javascript:;" reveal-id="ehae178-B951" data-open="ehae178-B951" class="link link-ref link-reveal xref-bibr">951</a></sup>

### 10.3. Acute blood pressure management in acute ischaemic stroke

The beneficial effects of BP reduction in acute ischaemic stroke remain unclear. In patients not receiving i.v. thrombolysis or mechanical thrombectomy, there is no evidence for actively lowering BP unless it is extremely high (e.g. >220/120 mmHg). If BP is extremely high, an initial moderate relative reduction of 10%–15% over a period of hours may be considered.<sup><a href="javascript:;" reveal-id="ehae178-B952" data-open="ehae178-B952" class="link link-ref link-reveal xref-bibr">952</a></sup> The reason for a more conservative approach to acute BP management is that cerebral autoregulation may be impaired in acute stroke, and maintaining cerebral perfusion relies on systemic BP.

In contrast, patients who are treated with i.v. thrombolysis or mechanical thrombectomy (or both) should have more proactive management of severe hypertension, because they have an increased risk of reperfusion injury and intracranial haemorrhage. In patients undergoing treatment with i.v. thrombolysis, BP should be lowered to <185/110 mmHg prior to thrombolysis and then maintained at <180/105 mmHg over the following 24 h.<sup><a href="javascript:;" reveal-id="ehae178-B953" data-open="ehae178-B953" class="link link-ref link-reveal xref-bibr">953</a></sup> In patients undergoing treatment with mechanical thrombectomy (with or without i.v. thrombolysis) there is limited evidence from clinical trials, but BP should also be lowered to <180/105 mmHg prior to thrombectomy and maintained over the next 24 h.<sup><a href="javascript:;" reveal-id="ehae178-B953" data-open="ehae178-B953" class="link link-ref link-reveal xref-bibr">953</a>,<a href="javascript:;" reveal-id="ehae178-B954" data-open="ehae178-B954" class="link link-ref link-reveal xref-bibr">954</a></sup> Therefore, patients with acute ischaemic stroke and a BP of <180/105 mmHg in the first 72 h after stroke do not seem to benefit from the introduction or reintroduction of BP-lowering medication.<sup><a href="javascript:;" reveal-id="ehae178-B955" data-open="ehae178-B955" class="link link-ref link-reveal xref-bibr">955</a></sup> For stable patients who remain hypertensive (≥140/90 mmHg) ≥3 days after an acute ischaemic stroke, initiation or reintroduction of BP-lowering medication is recommended.

Recommendation Table 32

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376286)

Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke

![Recommendations for acutely managing blood pressure in patients with intracerebral haemorrhage or acute ischaemic stroke](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt32.jpeg?Expires=1728462845&Signature=qxUJKSkIxrAdZQ~2RuYFr6qPWPDIOqE2psxRHeMvc5a7ZfD7O51IMcjpo~88mXyCs0qMW5Na2HuLYx4UlcBW8gYYqjq2~-JyXsLJ3ZTWs5GPj0fDvbtxq8RJU73OGIV6Vriiw05ANAAnEmIReEL9Pe2eqSM7ZMV2Z0q89gYpezrRAxpH8AASlknTQ4qOzRmjWt2txRFnG6iSWrd3LkIfmtYBSt0RvENwCXT-2cqryae7R4Cx87upuqbxH7B4dSMdGjgqc6ev9RG-TxMWN0nP9jzaaLEEHwNRsNI3xagL15hPynRnzT-KPPYLEkb8fAlkeCY~U4mS5~fm6v9aiwyfNA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.4. Acute blood pressure management in pre-eclampsia and severe hypertension in pregnancy

#### 10.4.1. Pre-eclampsia

Pre-eclampsia is discussed in _Section [9](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s8)_. Here we focus on its management in the acute setting. Pre-eclampsia is cured by delivery. Most international societies, including the ESC, recommend an intensive approach to BP lowering in pre-eclampsia.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B964" data-open="ehae178-B964" class="link link-ref link-reveal xref-bibr">964</a>,<a href="javascript:;" reveal-id="ehae178-B965" data-open="ehae178-B965" class="link link-ref link-reveal xref-bibr">965</a></sup> In women with pre-eclampsia and severe hypertension, immediately reducing systolic BP to <160 mmHg and diastolic BP to <105 mmHg using i.v. labetalol or nicardipine (with administration of magnesium sulfate if appropriate and consideration of delivery if appropriate) was recommended in the 2018 ESC/ESH Guidelines on the management of arterial hypertension and the 2022 ESC Guidelines for management of cardiovascular disease in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B1" data-open="ehae178-B1" class="link link-ref link-reveal xref-bibr">1</a>,<a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a></sup> The objective of treatment is to lower BP within 150–180 min.

Magnesium sulfate \[4 g i.v. over 5 min, then 1 g/h i.v.; or 5 g intramuscularly (i.m.) into each buttock, then 5 g i.m. every 4 h\] is recommended for eclampsia treatment but also for women with pre-eclampsia who have severe hypertension and proteinuria or hypertension and neurological symptoms or signs.<sup><a href="javascript:;" reveal-id="ehae178-B966" data-open="ehae178-B966" class="link link-ref link-reveal xref-bibr">966</a></sup> There is a risk of hypotension when magnesium is given concomitantly with nifedipine.<sup><a href="javascript:;" reveal-id="ehae178-B967" data-open="ehae178-B967" class="link link-ref link-reveal xref-bibr">967</a></sup> If BP control is not achieved by 360 min despite two medications, consulting critical care is recommended for intensive care unit admission, stabilization, and delivery (if appropriate).<sup><a href="javascript:;" reveal-id="ehae178-B966" data-open="ehae178-B966" class="link link-ref link-reveal xref-bibr">966</a></sup> Since plasma volume is reduced in pre-eclampsia, diuretic therapy should be avoided.

#### 10.4.2. Severe acute hypertension in pregnancy

Severe hypertension in pregnancy (without pre-eclampsia) may necessitate acute BP-lowering therapies. Severe hypertension in pregnancy is defined in general as systolic BP of >160 mmHg and diastolic BP of >110 mmHg and is associated with adverse maternal and peri-natal outcomes independent of pre-eclampsia and potentially of the same magnitude as eclampsia itself.<sup><a href="javascript:;" reveal-id="ehae178-B89" data-open="ehae178-B89" class="link link-ref link-reveal xref-bibr">89</a>,<a href="javascript:;" reveal-id="ehae178-B968" data-open="ehae178-B968" class="link link-ref link-reveal xref-bibr">968</a></sup>

There are differences in rate of BP control between i.v. labetalol and i.v. hydralazine in severe hypertension in pregnancy.<sup><a href="javascript:;" reveal-id="ehae178-B969" data-open="ehae178-B969" class="link link-ref link-reveal xref-bibr">969</a></sup> While evidence is conflicting,<sup><a href="javascript:;" reveal-id="ehae178-B667" data-open="ehae178-B667" class="link link-ref link-reveal xref-bibr">667</a>,<a href="javascript:;" reveal-id="ehae178-B668" data-open="ehae178-B668" class="link link-ref link-reveal xref-bibr">668</a></sup> hydralazine may be associated with more peri-natal adverse events than other drugs.<sup><a href="javascript:;" reveal-id="ehae178-B970" data-open="ehae178-B970" class="link link-ref link-reveal xref-bibr">970</a></sup> Nifedipine seems to provide lower BP with lower rates of neonatal complications than labetalol.<sup><a href="javascript:;" reveal-id="ehae178-B971" data-open="ehae178-B971" class="link link-ref link-reveal xref-bibr">971</a></sup>

Recommendation Table 33

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376294)

Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46)

![Recommendations for acutely managing blood pressure in patients with severe hypertension in pregnancy and pre-eclampsia (see Evidence Table 46)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt33.jpeg?Expires=1728462845&Signature=ctKbHxZ16lwmyeQJVoyZRDzTBPfzRHRdaoQ4tQOQw-wdsTA4i8Xg1eKsbdOgwnLjUFw7-ruZJ55MooUWMJf-Uy5BPYV9jDjzjNsNTuk5XkaHJmle2rh8VjrEYeUlyp8jXSBgVB6R5Z9xFa8-Qqo7Q6ZubrwX9x-fr2TkUQFfDTnZflNt9en5JaVIBd~43dYK3br6DKdVMn3lXt25VOPk74HUC-uZaUlc3-rGp92MjEoBF4WSvShtnavBneSBcIx5K18~6qs5YGqySaI6b5eoXJtRJdRbS8JcDTm4GYpMTn92CtVjDbDRQ5eRB5d1-238QljQ92q1LhUef3kOPiETNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 10.5. Peri-operative acute management of elevated blood pressure

Details are provided in the ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.<sup><a href="javascript:;" reveal-id="ehae178-B972" data-open="ehae178-B972" class="link link-ref link-reveal xref-bibr">972</a></sup> Peri-operative hypertension, hypotension, and BP variability are associated with haemodynamic instability and poor clinical outcomes for patients undergoing surgery.<sup><a href="javascript:;" reveal-id="ehae178-B973" data-open="ehae178-B973" class="link link-ref link-reveal xref-bibr">973</a></sup> Pre-operative risk assessment for BP management, therefore, should involve assessing for underlying end-organ damage and comorbidities.<sup><a href="javascript:;" reveal-id="ehae178-B974" data-open="ehae178-B974" class="link link-ref link-reveal xref-bibr">974</a></sup> Postponing necessary non-cardiac surgery is not usually warranted for patients with minor or moderate elevations in BP, as they are not at higher CVD risk.<sup><a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a>,<a href="javascript:;" reveal-id="ehae178-B975" data-open="ehae178-B975" class="link link-ref link-reveal xref-bibr">975</a></sup>

Avoiding large fluctuations in BP in the peri-operative course is important, and planning a strategy for a patient should account for the baseline office BP.<sup><a href="javascript:;" reveal-id="ehae178-B974 ehae178-B975 ehae178-B976 ehae178-B977" data-open="ehae178-B974 ehae178-B975 ehae178-B976 ehae178-B977" class="link link-ref link-reveal xref-bibr">974–977</a></sup>

There is insufficient evidence for reduced or increased peri-operative BP targets compared to usual care BP targets to lower peri-operative events.<sup><a href="javascript:;" reveal-id="ehae178-B978" data-open="ehae178-B978" class="link link-ref link-reveal xref-bibr">978</a></sup> No specific measure of BP appears better than any other for predicting risk of peri-operative events.<sup><a href="javascript:;" reveal-id="ehae178-B975" data-open="ehae178-B975" class="link link-ref link-reveal xref-bibr">975</a></sup>

#### 10.5.1. Blood pressure-lowering drugs in the peri-operative phase

Routine initiation of a beta-blocker peri-operatively is not necessary.<sup><a href="javascript:;" reveal-id="ehae178-B979" data-open="ehae178-B979" class="link link-ref link-reveal xref-bibr">979</a></sup>

Pre-operative initiation of beta-blockers in advance of high-risk, non-cardiac surgery may be considered in patients who have known coronary artery disease or myocardial ischaemia<sup><a href="javascript:;" reveal-id="ehae178-B980" data-open="ehae178-B980" class="link link-ref link-reveal xref-bibr">980</a></sup> or two or more significantly elevated clinical risk factors in order to reduce the incidence of peri-operative myocardial infarction.<sup><a href="javascript:;" reveal-id="ehae178-B979" data-open="ehae178-B979" class="link link-ref link-reveal xref-bibr">979</a></sup> Peri-operative continuation of beta-blockers is recommended for patients currently taking beta-blockers.<sup><a href="javascript:;" reveal-id="ehae178-B981" data-open="ehae178-B981" class="link link-ref link-reveal xref-bibr">981</a></sup>

Some studies suggest that continued use of ACE inhibitors is associated with a higher risk of peri-operative hypotension and subsequent end-organ damage including kidney injury, myocardial infarction, and stroke.<sup><a href="javascript:;" reveal-id="ehae178-B982" data-open="ehae178-B982" class="link link-ref link-reveal xref-bibr">982</a></sup> In the Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI) trial, transient pre-operative interruption of ACE inhibitor therapy was associated with a decreased risk of intra-operative hypotension.<sup><a href="javascript:;" reveal-id="ehae178-B983" data-open="ehae178-B983" class="link link-ref link-reveal xref-bibr">983</a></sup> A subsequent systematic review also showed a decreased risk of intra-operative hypotension with withholding ACE inhibitors/ARBs before surgery, but no association with decreased mortality or CVD outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B984" data-open="ehae178-B984" class="link link-ref link-reveal xref-bibr">984</a></sup> On the other hand, vigilance is needed because withholding ACE inhibitors has also been shown to increase post-operative hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B985" data-open="ehae178-B985" class="link link-ref link-reveal xref-bibr">985</a></sup> In patients with heart failure, loop diuretics can be continued in patients prone to volume overload.<sup><a href="javascript:;" reveal-id="ehae178-B986" data-open="ehae178-B986" class="link link-ref link-reveal xref-bibr">986</a></sup> CCBs are generally considered safe pre-operatively.

## 11\. Patient-centred care in hypertension

### 11.1. Definition

Patient-centred care is defined as an attitude of the healthcare professional that closely aligns with the patient’s preferences and needs.<sup><a href="javascript:;" reveal-id="ehae178-B987" data-open="ehae178-B987" class="link link-ref link-reveal xref-bibr">987</a></sup> In the patient-centred approach (_[Figure 23](javascript:;)_), patients are viewed as active participants in health services, who work as partners alongside healthcare professionals. A patient-centred approach is associated with higher satisfaction rates, better adherence to recommendations and prescriptions, and better treatment, particularly in the management of chronic illness, such as hypertension.<sup><a href="javascript:;" reveal-id="ehae178-B988" data-open="ehae178-B988" class="link link-ref link-reveal xref-bibr">988</a></sup> While there is limited evidence for the efficacy and effectiveness of specific shared decision-making intervention strategies in hypertension care,<sup><a href="javascript:;" reveal-id="ehae178-B989" data-open="ehae178-B989" class="link link-ref link-reveal xref-bibr">989</a></sup> it is viewed as an ethical imperative in healthcare practice and health policy, and in clinical guidelines.<sup><a href="javascript:;" reveal-id="ehae178-B130" data-open="ehae178-B130" class="link link-ref link-reveal xref-bibr">130</a></sup>

![Patient-centred care.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f23.jpeg?Expires=1728462845&Signature=EZmvrP45p6HG7YGYrAB6dJKrvueypQWi16k~t6z1To5nwlcgVXUT7DU1DfZr7t898YDLhv8GoCFhRvbPCKu4Dmkaei320h9N-ouwor~Eej1nGpeFn5OAnWo2-~CU~ecwGI6yqClyA9bFzYtouwVx0C9ZYTFoEGKCaNiu~xY2aSEJP1BceFLovx9Ge9sXfV3-XMJj2lPd2P~PSUtCco89X5EzJD7YB9UEZPBpc8Fr8f6MHwqI-WV2Oh2IKlXEIBEn-7j89FwHX0ZkLN8Q-SmeOfSqsvCTGch3Q27iyOBBxFvSWM-~n9FRmpBAcVqu2eThAmK7PRRrZaAAhYtdnBBrlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 23

Patient-centred care.

[Open in new tab](https://academic.oup.com/view-large/figure/479376306/ehae178f23.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f23.jpeg?Expires=1728462845&Signature=oSy2SEpfjDeOFgC8w0m9HqS1fZ3gfTowv9eBQaQcakD-PBtF9FN1I~ZuhXNGr2GZpNjT3NjA6wzSgczv~3bw8hK7ukTBzDQwBwf3WwAFOoqE5mI6GWUzT5nCje4z7hp3FTr6s4vp7qnUDuSEcNYZmNu3N8qXfHu1PvFAIsNbzIz8eeI67hr6ZtCKgynFJ0KkOS6JVJixz2Y9Bqn2Jy6q4lTaXy-pXZJm0OrjKu-RcGiURea9QvU17MZ4UBJ25-pXJOSazi7gn9RQiFmRGjCeXa~I37O94eZ-05cNX6CGCKZ0DuYiVn2wryxjT--bIMIK3uipvRddEZB~mIhfyIHQyw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376306&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

### 11.2. Communicating consequences of treatment

In line with patient-centred care, it is important to assess whether patients understand their hypertension-related risk, the rationale for any hypertension treatment, the benefits and harms of hypertension treatment, and that the treatment plan is also centrally guided by what matters most to the patient. Risk communication is challenging, and providers need to be led by the individual’s preferences when presenting more detailed numeric and visual representations of risk and the likely benefits and harms of hypertension treatment. Socio-demographic differences in healthcare need to be considered in patient–provider communication.<sup><a href="javascript:;" reveal-id="ehae178-B990" data-open="ehae178-B990" class="link link-ref link-reveal xref-bibr">990</a>,<a href="javascript:;" reveal-id="ehae178-B991" data-open="ehae178-B991" class="link link-ref link-reveal xref-bibr">991</a></sup>

Standard approaches to communicate consequences of treatment can involve 10-year risk of a CVD event with SCORE2 or SCORE2-OP. Alternatively, individual risk and risk reduction can be communicated in terms of ‘risk age’ or ‘heart age’ (_Section [7.3](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false#ehae178-s6.3)_).

Recommendation Table 34

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376310)

Recommendations for communicating consequences of treatment (see Evidence Table 47)

![Recommendations for communicating consequences of treatment (see Evidence Table 47)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt34.jpeg?Expires=1728462845&Signature=qrKHz6qNnRe9qAepGdaagbr5s6Zh0ioqmcevQf9qZUXAQENOL3l-UfNRkewvDNGdbL1qxAE5dLl-5mqRh6DRSt~GEnEbPoA9F6Vh~KCAi7CJmUGVmPtxXhFAH0Y5P5xWVTl7G7tIC51FF6-Bc4tmZ8cnk0T~Fg8e9zHfD68o0Usz-JllP5HN6ReRlypmXsGaZhdnOcatuAuCfT6eMYdruDSo1uXZsP-0~0opFadfS9kthVcQF7xvSPW9hCr-pMNOz8TT-bJkBnMDQ9dtNFF0ceIwRlRKAz2rO6YUpiqKKxddHO8T9uqVqXZESkPjQS7q4vrGHD5vx6NYStCktUSZ4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 11.3. Self-measuring and monitoring

Self-care refers to individual responsibility for healthy lifestyle behaviours, as well as the actions required to cope with health conditions.<sup><a href="javascript:;" reveal-id="ehae178-B996" data-open="ehae178-B996" class="link link-ref link-reveal xref-bibr">996</a>,<a href="javascript:;" reveal-id="ehae178-B997" data-open="ehae178-B997" class="link link-ref link-reveal xref-bibr">997</a></sup> In the context of hypertension, it also includes self-management and self-measurement of BP.

Self-management includes lifestyle behaviour (diet, exercise, smoking, alcohol), co-management of medical treatments, and support for adhering to prescribed medication.<sup><a href="javascript:;" reveal-id="ehae178-B998" data-open="ehae178-B998" class="link link-ref link-reveal xref-bibr">998</a></sup> Self-monitoring allows high BP to be detected early,<sup><a href="javascript:;" reveal-id="ehae178-B999" data-open="ehae178-B999" class="link link-ref link-reveal xref-bibr">999</a></sup> and enables patients to co-manage medications with their healthcare provider.<sup><a href="javascript:;" reveal-id="ehae178-B1000" data-open="ehae178-B1000" class="link link-ref link-reveal xref-bibr">1000</a>,<a href="javascript:;" reveal-id="ehae178-B1001" data-open="ehae178-B1001" class="link link-ref link-reveal xref-bibr">1001</a></sup> Suitably validated and correctly used digital devices have the potential to support co-management,<sup><a href="javascript:;" reveal-id="ehae178-B1002" data-open="ehae178-B1002" class="link link-ref link-reveal xref-bibr">1002</a>,<a href="javascript:;" reveal-id="ehae178-B1003" data-open="ehae178-B1003" class="link link-ref link-reveal xref-bibr">1003</a></sup> and facilitate remote monitoring of BP.<sup><a href="javascript:;" reveal-id="ehae178-B76" data-open="ehae178-B76" class="link link-ref link-reveal xref-bibr">76</a>,<a href="javascript:;" reveal-id="ehae178-B81" data-open="ehae178-B81" class="link link-ref link-reveal xref-bibr">81</a>,<a href="javascript:;" reveal-id="ehae178-B1004" data-open="ehae178-B1004" class="link link-ref link-reveal xref-bibr">1004</a></sup>

Recommendation Table 35

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376314)

Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48)

![Recommendations for self-measuring and monitoring blood pressure (see Evidence Table 48)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt35.jpeg?Expires=1728462845&Signature=yDXb7ivuBeH4fvFf206DEvS4jVzre1RRs1QEn3KltdFW~fikmD1nMXokphVHgAk42jSwQrynliQMSQUlqYb7Dc83qIhiRdIlKGpKUzR8eUqvrabcB0Mhpr8QrsHmWfvmxTgJq05Sb7~lmFjBh1rDD88hB9NXwpfESLz8HSSvY2FvY7xrZhUECdu0SYpK3JjqFK94jLJ~XiPVkDZjFRf~n~MuFoN6RVGzLCCxZg7FWU7XJDxQlIkuivnHSTsQaNiu1XnJa0AfFA8gfgFB5dD~2xteidpCvdugnifHgT0x4NlyBge~KzDnXfVDjzqBsOkNlNTsA6cwLuxvIBqipOjuBg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

### 11.4. Facilitating medication adherence and persistence

Adherence (_[Figure 24](javascript:;)_) to BP-lowering drug regimens in clinical practice is almost always lower than seen in clinical trials.<sup><a href="javascript:;" reveal-id="ehae178-B1007" data-open="ehae178-B1007" class="link link-ref link-reveal xref-bibr">1007</a></sup> Most apparent treatment-resistant hypertension is accounted for by non-adherence.<sup><a href="javascript:;" reveal-id="ehae178-B1008" data-open="ehae178-B1008" class="link link-ref link-reveal xref-bibr">1008</a></sup> Adherence should always be assessed with a no-blame approach. Various methods are available to assess adherence and, along with details on barriers to adherence, are described in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) and _[Table S14](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_.<sup><a href="javascript:;" reveal-id="ehae178-B1009" data-open="ehae178-B1009" class="link link-ref link-reveal xref-bibr">1009</a></sup>

![The five dimensions of adherence (WHO, 2003) applied to hypertension.](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178f24.jpeg?Expires=1728462845&Signature=vYLCBfntJuKwk~iU-GCYRiemEtXqUJyg34wynLkd8oQ1tnXvCsaKojwLUsENVArhC1~2cqDDd6W9qq27gMNSF3eQWxgI2CpcUCQQUfPRagZcwXQK8u6M2Xa0kISQbWDtuKNcrx5Abplf5mCdCs2Rq0pjq7qQsruebWlFidSjOsHi~lShN2dSFr3qum~DjxlhtUGui8YEd3Zaf9QSFmGez8jJ21keqAFN-6~-CiqOVlR6-7DYDSmZ5uW9U~spHoguEnuQWdCjZFOSssu1q6LRGAmNgtEdR39JQUY1FpKPsrGUpQYQO70LEtyDvO-JDv3QcRf93bjMoRYYQFyanXcgAA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

Figure 24

The five dimensions of adherence (WHO, 2003) applied to hypertension.

[Open in new tab](https://academic.oup.com/view-large/figure/479376317/ehae178f24.jpg)[Download slide](https://academic.oup.com/DownloadFile/DownloadImage.aspx?image=https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178f24.jpeg?Expires=1728462845&Signature=b6lUTmKGA1K~5lzKsSPQw1YE89edoDWvGi8ubUS3YFzfWcg-QB-EWh8LXMZiK4YAyUoTcsXACTes4NtOWnNdKFPRuzf4vXSCqYzyOGhzboq9EqsWIyv9nzwaLra1p3T5taxUyng0w0ujUAewsHPdel4AAvegwUo-g3nornm5Q0iX1pxomANzSPRH0Q85fDEM1ZPIVE3QEvQn26woXKcm6qqkZJv7KOZBJ1XON~rv4bCFJXhvAnpF8lXzEkvvDr1ZnbJk5QnhDVG-3N2sYkqECPu5VPTWlxq1EBma8RTvfkKVO4PvsTHV5ZdVaQ8rUusmiyYi4HYUET72oCBHfvluvw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=479376317&ar=7741010&xsltPath=~/UI/app/XSLT&imagename=&siteId=5375)

Adherence may also be facilitated by an optimal therapeutic regimen, which can be achieved by medication reviews carried out at appropriate intervals. Several factors should be considered: (i) identifying drug-related adverse events and appropriate dosing levels, (ii) using long-acting drugs that require once-daily dosing (preferably drugs that are long-acting due to pharmacokinetic properties rather than galenic formulation), (iii) avoiding complex dosing schedules, (iv) using single-pill combinations whenever feasible, (v) taking into account the financial capacity of the patient to pay for a given regimen in the longer term, if relevant, or other pertinent aspects of the local or national healthcare systems, and (vi) enlisting support of a family member or other social support to facilitate medication adherence and persistence (see [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), _[Table S15](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)_).<sup><a href="javascript:;" reveal-id="ehae178-B1010" data-open="ehae178-B1010" class="link link-ref link-reveal xref-bibr">1010</a></sup>

While there have been advancements in digital tools to support self-management of chronic illness including hypertension, there is little efficacy evidence evaluating these interventions. Therefore, it is premature to make recommendations about specific digital tools.

### 11.5. Multidisciplinary management

A collaborative approach to managing hypertension, using team-based care among physicians, nurses, pharmacists, dietitians, and physiotherapists, offers significant benefits over physician-only care. Multidisciplinary care is intended to be collaborative and complementary to regular medical care<sup><a href="javascript:;" reveal-id="ehae178-B1011" data-open="ehae178-B1011" class="link link-ref link-reveal xref-bibr">1011</a></sup> and is associated with lower systolic and diastolic BP<sup><a href="javascript:;" reveal-id="ehae178-B227" data-open="ehae178-B227" class="link link-ref link-reveal xref-bibr">227</a>,<a href="javascript:;" reveal-id="ehae178-B229" data-open="ehae178-B229" class="link link-ref link-reveal xref-bibr">229</a>,<a href="javascript:;" reveal-id="ehae178-B1012" data-open="ehae178-B1012" class="link link-ref link-reveal xref-bibr">1012</a>,<a href="javascript:;" reveal-id="ehae178-B1013" data-open="ehae178-B1013" class="link link-ref link-reveal xref-bibr">1013</a></sup> and improved outcomes.<sup><a href="javascript:;" reveal-id="ehae178-B230" data-open="ehae178-B230" class="link link-ref link-reveal xref-bibr">230</a>,<a href="javascript:;" reveal-id="ehae178-B1014" data-open="ehae178-B1014" class="link link-ref link-reveal xref-bibr">1014</a></sup> Task-shifting away from physicians is necessary to meet the huge need for the management of elevated BP and hypertension in the population.<sup><a href="javascript:;" reveal-id="ehae178-B1015" data-open="ehae178-B1015" class="link link-ref link-reveal xref-bibr">1015</a></sup> Prescribing remains a physician duty, but prescribing can be conducted under collaborative practice agreements with the multidisciplinary team in many countries.

Further details on patient-centred care in hypertension is provided in the [Supplementary data online](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA).

Recommendation Table 36

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376323)

Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49)

![Recommendations for multi/interdisciplinary blood pressure management (see Evidence Table 49)](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178ilt36.jpeg?Expires=1728462845&Signature=P~-R8x9DR-AeWMnnteTDD8rIuJ~0RnpKYSufxKuW1-XCmftA6xInPxM8yl0lseySh0PX2Jm~PJxWN5KZDhp3cVAgLJra1D6cfV-lAQTCTr0lQZ7yf9mHBbBhMx7VkCJFW0B1CFvEXPIUoDDZB~Cj0XYGvBej69uBuWF7oIj76RHhPQ-C1rCBIP1BA7oJxs0r1PJA0h65tJCRJyWudi2Wi6cBw~U82cGByWWTaGxhxBDUknCiBopRCgayXZ6ZbrH3quW3qx8XgIs6GhiaTk7OMffdhDwf2pAIdsjClO0-UOgEkcTvuaKc4qI-tUmV7uMoQ9oSpRNLfhOeSVkbEyyRkQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 12\. Key messages

1.  Given the demographic transition and the worldwide ageing of populations, the number of individuals with elevated BP or hypertension is increasing worldwide.
    
2.  The trajectory of BP control appears to be worsening in North America, in some (but not all) European countries, and elsewhere around the world.
    
3.  The risk for CVD attributable to BP is on a continuous log-linear exposure variable scale, not a binary scale of normotension vs. hypertension.
    
4.  BP-lowering drugs can reduce CVD risk even among individuals not traditionally classified as hypertensive. Accordingly, a new BP category called ‘elevated BP’ is introduced. Elevated BP is defined as an office systolic BP of 120–139 mmHg or diastolic BP of 70–89 mmHg. Hypertension remains defined as office BP of ≥140/90 mmHg.
    
5.  Hypertension in women is under-studied in basic, clinical, and population research.
    
6.  HMOD suggests long-standing or severe hypertension and is associated with increased CVD risk.
    
7.  Absolute CVD risk must be considered when assessing and managing elevated BP.
    
8.  Despite the growing number of hypertension guidelines, the rates of diagnosis, treatment, and control of hypertension (and elevated BP) remain suboptimal. A major factor underlying this is poor implementation of evidence-based guidelines in real-world clinical practice.
    
9.  One of the most important changes in the 2024 Guidelines is the focus on evidence related to CVD outcomes of BP-lowering interventions rather than BP lowering alone.
    
10.  Irrespective of the threshold BP above which BP-lowering treatment (lifestyle or pharmacological or other treatment) is recommended, the on-treatment BP target is 120–129/70–79 mmHg for all adults, provided this treatment is well tolerated. There are several important exceptions to these targets and individualized decision-making is always the most important priority.
    

## 13\. Gaps in the evidence

1.  Drivers of worsening trajectories of BP control in women and men.
    
2.  Need for sex-specific data on epidemiology, risk factors, and pathophysiology of hypertension. Need for more prospective studies to assess women’s and men’s specific CVD risk factors pertinent to adults with elevated BP and hypertension, due to biological and socio-cultural conditions. This includes sex-specific weighting of traditional risk factors, as well as inclusion of sex-dependent, non-traditional, vascular risk factors such as stress, socio-economic conditions, and others.<sup><a href="javascript:;" reveal-id="ehae178-B1017" data-open="ehae178-B1017" class="link link-ref link-reveal xref-bibr">1017</a>,<a href="javascript:;" reveal-id="ehae178-B1018" data-open="ehae178-B1018" class="link link-ref link-reveal xref-bibr">1018</a></sup> We are also lacking data on sex-specific hormonal and genetic mechanisms and pathophysiology in the human.<sup><a href="javascript:;" reveal-id="ehae178-B1019" data-open="ehae178-B1019" class="link link-ref link-reveal xref-bibr">1019</a></sup> Another important area in need of investigation is a better understanding of the role of gender in the management of elevated BP and hypertension (including gender-driven barriers in accessing medical care and adherence).
    
3.  More widespread validation of home BP measuring devices. Validation protocols for cuffless BP measurement devices have just recently been proposed and need to be tested.
    
4.  Clinical effectiveness of HMOD in directing intensity of care and personalized approaches in managing elevated BP and hypertension.
    
5.  Best practice to screen and manage primary aldosteronism.
    
6.  Clinical benefits of treating low CVD-risk individuals with elevated BP and further data strengthening the use of BP-lowering medication among high-risk persons with baseline systolic BP of 120–129 mmHg.
    
7.  Need for more data on the sex-specific optimal dosing, effects, and adverse effects of BP-lowering drugs,<sup><a href="javascript:;" reveal-id="ehae178-B1020" data-open="ehae178-B1020" class="link link-ref link-reveal xref-bibr">1020</a></sup> in particular from specifically planned prospective randomized trials.
    
8.  More consideration for overall CVD outcomes of BP-lowering interventions.
    
9.  More European data (RCTs, real life) about the beneficial effect of treating patients with elevated BP and hypertension with polypills (inclusive of non-BP lowering medications).
    
10.  CVD outcomes-based data on MRAs as add-on therapy solely for resistant hypertension.
    
11.  Trials on the BP-lowering effects of newer antidiabetic drugs (such as SGLT2 inhibitors and GLP-1 receptor agonists) or drugs that now have indications for other conditions, such as finerenone or sacubitril-valsartan.
    
12.  Beneficial BP and CVD effects of increasing dietary potassium intake and other lifestyle interventions. Studies to disentangle the effect of sodium reduction vs. the effect of potassium supplementation on BP control and CVD outcomes.
    
13.  RCTs comparing single-pill combination therapy with fixed doses vs. multiple monotherapies and their effects on CVD outcomes.
    
14.  Cardiovascular outcomes trials of renal denervation.
    
15.  BP-lowering treatment RCTs on different ethnic and migrant groups established in Europe.
    
16.  Pharmacological BP management in young adults (aged <40 years) and better data on the efficacy of a life-course approach for the drug management of BP.<sup><a href="javascript:;" reveal-id="ehae178-B1021" data-open="ehae178-B1021" class="link link-ref link-reveal xref-bibr">1021</a></sup>
    
17.  CVD outcomes in moderately to severely frail and/or very elderly persons where BP medications have been deprescribed, and the impact of competing risks.
    
18.  Management of renal artery disease with haemodynamically stable but severe stenosis (i.e. without high-risk features).
    
19.  Need for clinical trials on managing hypertension in patients treated with anticancer drugs or anti-rejection drugs in recipients of an allograft transplant.
    
20.  Hypertension management in the setting of climate changes, global warming, air and other forms of pollution, pandemics, war zones, and in the context of drug restrictions experienced in some low-to-middle-income countries.
    
21.  Need to improve implementation of guidelines by healthcare providers.
    
22.  How to develop sustainable hypertension care at the intersection of growing numbers of patients and limited resources.
    
23.  Treat-to-target trials specifically testing BP-lowering drugs among drug-naïve persons with baseline BP of 120–129 mmHg and increased CVD risk.
    

## 14\. ‘What to do’ and ‘what not to do’ messages from the guidelines

A selected sample of the main messages from these guidelines are provided in _[Table 15](javascript:;)_.

Table 15

[Open in new tab](https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae178/7741010?login=false
                                /view-large/479376330)

What to do and what not to do

![What to do and what not to do](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178t15.jpeg?Expires=1728462845&Signature=X5Z5w42Fcpl2D1m5W7Vei8KhvtCt~lUObpzltVjZzug4NTfGK5HGcNwLWMm3Zqg7a6GrTNPWynqOb7TRkkN7jHBzKkZC0Vyo7o4Z97Zt7HvCR5QmMTX7kh3dWWORDJZq4Esl~bT5DuTYbMMQsU3udrNef~DfaYhLK~Xk0ROTvsqIavifhiRiWupERcxDVEBUcC2NNbkhi076Wh~TqujHNsrBJwy7s4x~gENaGA07mmAQbBItKagW5U1OkTP57GnnIJpsju42yg3qBlsuUo8EgN7GG-502HCu8PARf3J9Tr9x52jDCkrLMICMfJTdKqUXIsJEP2njXpfVyNEjSmwVhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)

## 15\. Evidence tables

[Evidence tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/2024_hypertension_guidelines_evidence_tables.pdf?Expires=1728462845&Signature=ouEM5I5CibCYM3GqloI7s9~JI00H8MfD81BoIcnVDVsDGQivmOCeLZtur9zJTFeWYqCcClqeEMk6Pu0FKutcCpA3bCVfHIEHxBgecDL8vuHWpTPZVNGaxkfDYObx8AXhAa4H9qrnjxJWbz-oz-o97M3f-IAMk7bfizdl2eplf2-SW9UvRMVT1zsx7sRR0mqQlsBgWq6v9Jq5FRHMKEx5ze25J0xci6V8Z0qKuOBP7BOT0TWXLf6qonytosxqeN4Jx4lAYEpH6O2JNn94hfqMt0kU3e5tmelGvUXUu2Hz8zROsR8n-lHF9BVUo9oWq4O5G4iKmeQyJ~CWvk9ITlriNg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) are available at _European Heart Journal_ online.

## 16\. Data availability statement

No new data were generated or analysed in support of this research.

## 17\. Author information

**Author/task force Member Affiliations: Cian P. McCarthy**, Cardiovascular Division Massachusetts General Hospital and Harvard Medical School Boston, MA, United States of America; **Rosa Maria Bruno**, PARCC, Université Paris Cité, Inserm, Paris, France, and Pharmacology & Hypertension, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; **Sofie Brouwers**, Cardiovascular Center Aalst, Department of Cardiology, OLV Clinic Aalst, Aalst, Belgium, and Department of Experimental Pharmacology, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium; **Michelle D. Canavan**, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland, and Department of Geriatric Medicine, University Hospital Galway, Saolta Hospitals Group, Galway, Ireland; **Claudio Ceconi**, Motusmed Clinic, Brescia, Italy; **Ruxandra Maria Christodorescu**, Department V Internal Medicine, University of Medicine and Pharmacy V Babes, Timisoara, Romania, and Research Center, Institute of Cardiovascular Diseases, Timisoara, Romania; **Stella S. Daskalopoulou**, Medicine Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; **Charles J. Ferro**, Department of Renal Medicine, University Hospitals Birmingham, Birmingham, United Kingdom, and Institute of Cardiovascular Sciences University of Birmingham, Birmingham, United Kingdom; **Eva Gerdts**, Department of Clinical Science, University of Bergen, Bergen, Norway, and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; **Henner Hanssen**, Department Sport, Exercise and Health, Medical Faculty, University of Basel, Basel, Switzerland; **Julie Harris** (United Kingdom), ESC Patient Forum, Sophia Antipolis, France; **Lucas Lauder**, Department of cardiology, University hospital Basel, Basel, Switzerland, and Department of internal medicine III, Cardiology, Angiology, and Intensive Care Medicine, Saarland university medical center, Homburg, Germany; **Richard J. McManus**, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; **Gerard J. Molloy**, School of Psychology, University of Galway, Galway, Ireland; **Kazem Rahimi**, Deep Medicine, Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, United Kingdom; **Vera Regitz-Zagrosek**, Charite, University Medicine Berlin, Gender in Medicine, Berlin, Germany; **Gian Paolo Rossi**, Department of Medicine, DIMED, University of Padua, Padua, Italy; **Else Charlotte Sandset**, Department of Neurology, Oslo University Hospital, Oslo, Norway, The Norwegian Air Ambulance Foundation, Oslo, Norway, and Institute of Clinical Medicine University of Oslo, Oslo, Norway; **Bart Scheenaerts** (Belgium), ESC Patient Forum, Sophia Antipolis, France; **Jan A. Staessen**, Non-Profit Research Association Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium, and Biomedical Research Group, Faculty of Medicine, University of Leuven, Leuven, Belgium; **Izabella Uchmanowicz**, Department of Nursing and Obstetrics, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland; and **Maurizio Volterrani**, Exercise Science and Medicine San Raffaele Open University, Rome, Italy, and Cardiopulmonary Department, IRCCS San Raffaele, Rome, Italy.

### 18\. Appendix

**ESC Scientific Document Group**

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:** Ana Abreu (CPG Review Co-ordinator) (Portugal), Michael Hecht Olsen (CPG Review Co-ordinator) (Denmark), Marco Ambrosetti (Italy), Emmanuel Androulakis (United Kingdom), Lia Evi Bang (Denmark), Jesper Nørgaard Bech (Denmark), Michael A. Borger (Germany), Pierre Boutouyrie (France), Luís Bronze (Portugal), Sergio Buccheri (Sweden), Regina Dalmau (Spain), Maria Carmen De Pablo Zarzosa (Spain), Christian Delles (United Kingdom), Maria Manuela Fiuza (Portugal), Rahima Gabulova (Azerbaijan), Bjørn Olav Haugen (Norway), Christian Heiss (United Kingdom), Borja Ibanez (Spain), Stefan James (Sweden), Vikas Kapil (United Kingdom), Meral Kayikçioglu (Turkey), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Emanuela Teresa Locati (Italy), Sharon MacDonald (United Kingdom), Anastasia S. Mihailidou (Australia), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom) Martin Bodtker Mortensen (Denmark), Sandor Nardai (Hungary), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Peter M. Nilsson (Sweden), Agnes A. Pasquet (Belgium), Mónica Mendes Pedro (Portugal), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Ernst Rietzschel (Belgium), Bianca Rocca (Italy), Xavier Rossello (Spain), Jean-Paul Schmid (Switzerland), Eduard Shantsila (United Kingdom), Isabella Sudano (Switzerland), Ana Teresa Timóteo (Portugal), Georgios Tsivgoulis (Greece), Andrea Ungar (Italy), Ilonca Vaartjes (Netherlands), Frank Visseren (Netherlands), Heinz Voeller (Germany), Christiaan Vrints (Belgium), Adam Witkowski (Poland), Maria-Christina Zennaro (France), and Katja Zeppenfeld (Netherlands).

**ESC National Cardiac Societies actively involved in the review process of the 2024 ESC Guidelines for the management of elevated blood pressure and hypertension:**

**Albania:** Albanian Society of Cardiology, Naltin Shuka; **Algeria:** Algerian Society of Cardiology, Nadia Laredj; **Austria:** Austrian Society of Cardiology, Noemi Pavo; **Azerbaijan:** Azerbaijan Society of Cardiology, Ulvi Mirzoyev; **Belgium:** Belgian Society of Cardiology, Philippe van de Borne; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia and Herzegovina, Šekib Sokolović; **Bulgaria:** Bulgarian Society of Cardiology, Arman Postadzhiyan; **Croatia:** Croatian Cardiac Society, Jure Samardzic; **Cyprus:** Cyprus Society of Cardiology, Petros Agathangelou; **Czechia:** Czech Society of Cardiology, Jiri Widimsky; **Denmark:** Danish Society of Cardiology, Michael Hecht Olsen; **Egypt:** Egyptian Society of Cardiology, Wael M. El-Kilany; **Estonia:** Estonian Society of Cardiology, Priit Pauklin; **Finland:** Finnish Cardiac Society, Jari A. Laukkanen; **France:** French Society of Cardiology, Romain Boulestreau; **Georgia:** Georgian Society of Cardiology, Bezhan Tsinamdzgvrishvili; **Germany:** German Cardiac Society, Ulrich Kintscher; **Greece:** Hellenic Society of Cardiology, Maria Marketou; **Hungary:** Hungarian Society of Cardiology, Dénes Páll; **Iceland:** Icelandic Society of Cardiology, Þórdís Jóna Hrafnkelsdóttir; **Ireland:** Irish Cardiac Society, Eamon Dolan; **Israel:** Israel Heart Society, Talya Wolak; **Italy:** Italian Federation of Cardiology, Grzegorz Bilo; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Meiramgul Kapsimetovna Tundybayeva; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Erkin Mirrakhimov, **Latvia:** Latvian Society of Cardiology, Karlis Trusinskis; **Lebanon:** Lebanese Society of Cardiology, Ghassan Kiwan; **Libya:** Libyan Cardiac Society, Omar Msalem; **Lithuania:** Lithuanian Society of Cardiology, Jolita Badarienė; **Luxembourg:** Luxembourg Society of Cardiology, Cristiana-Astra Banu; **Malta:** Maltese Cardiac Society, Matthew Mercieca Balbi; **Moldova (Republic of):** Moldavian Society of Cardiology, Alexandru Caraus; **Montenegro:** Montenegro Society of Cardiology, Aneta Boskovic; **Morocco:** Moroccan Society of Cardiology, Najat Mouine; **Netherlands:** Netherlands Society of Cardiology, Tom Vromen; **North Macedonia:** National Society of Cardiology of North Macedonia, Marijan Bosevski; **Norway:** Norwegian Society of Cardiology, Helga B. Midtbø; **Poland:** Polish Cardiac Society, Adrian Doroszko; **Portugal:** Portuguese Society of Cardiology, Hélder Dores; **Romania:** Romanian Society of Cardiology, Elisabeta Badila; **San Marino:** San Marino Society of Cardiology, Roberto Bini; **Serbia:** Cardiology Society of Serbia, Dragan Vojislav Simić; **Slovenia:** Slovenian Society of Cardiology, Zlatko Fras; **Spain:** Spanish Society of Cardiology, Pilar Mazón; **Sweden:** Swedish Society of Cardiology, Jonas Spaak; **Switzerland:** Swiss Society of Cardiology, Thilo Burkard; **Syrian Arab Republic:** Syrian Cardiovascular Association, Elias Barakat; **Tunisia:** Tunisian Society of Cardiology and Cardiovascular Surgery, Salem Abdessalem; **Türkiye:** Turkish Society of Cardiology, Yilmaz Gunes; **Ukraine:** Ukrainian Association of Cardiology, Yurij M. Sirenko; **United Kingdom of Great Britain and Northern Ireland:** British Cardiovascular Society, Adrian J. B. Brady; and **Uzbekistan:** Association of Cardiologists of Uzbekistan, Gulnoz Abdusattarovna Khamidullaeva.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).


##19. References
1	Williams   B, Mancia   G, Spiering   W, Rosei   EA, Azizi   M, Burnier   M, et al.   2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J  2018;39:3021–104. https://doi.org/10.1093/eurheartj/ehy339
   
2	Murray   CJL, Aravkin   AY, Zheng   P, Abbafati   C, Abbas   KM, Abbasi-Kangevari   M, et al.   Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet  2020;396:1223–49. https://doi.org/10.1016/S0140-6736(20)30752-2
   
3	Mensah   GA, Fuster   V, Murray   CJL, Roth   GA, Mensah   GA, Abate   YH, et al.   Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol  2023;82:2350–473. https://doi.org/10.1016/j.jacc.2023.11.007
   
4	Johnson   JL, Greaves   L, Repta   R. Better science with sex and gender: facilitating the use of a sex and gender-based analysis in health research. Int J Equity Health  2009;8:14. https://doi.org/10.1186/1475-9276-8-14
   
5	Mauvais-Jarvis   F, Bairey Merz   N, Barnes   PJ, Brinton   RD, Carrero   J-J, DeMeo   DL, et al.   Sex and gender: modifiers of health, disease, and medicine. Lancet  2020;396:565–82. https://doi.org/10.1016/s0140-6736(20)31561-0
   
6	Camm   AJ, Lüscher   TF, Maurer   G, Serruys   PW (eds). The ESC Textbook of Cardiovascular Medicine. Oxford University Press, 2018.
Google ScholarGoogle PreviewWorldCatCOPAC 
7	Mayfield   SK, Foti   K, Moran   AE, Blakeman   DE, Frieden   TR. Hypertension call to action: will we respond to the call with action?  Am J Hypertens  2022;35:214–6. https://doi.org/10.1093/ajh/hpab191
   
8	Muntner   P. The continuing challenge of low rates of blood pressure control among US adults. Am J Hypertens  2022;35:839–41. https://doi.org/10.1093/ajh/hpac075
   
9	Reuter   H, Jordan   J. Status of hypertension in Europe. Curr Opin Cardiol  2019;34:342–9. https://doi.org/10.1097/hco.0000000000000642
   
10	Brown   JM, Siddiqui   M, Calhoun   DA, Carey   RM, Hopkins   PN, Williams   GH, et al.   The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med  2020;173:10–20. https://doi.org/10.7326/m20-0065
   
11	Oparil   S, Acelajado   MC, Bakris   GL, Berlowitz   DR, Cífková   R, Dominiczak   AF, et al.   Hypertension. Nat Rev Dis Primers  2018;4:18014. https://doi.org/10.1038/nrdp.2018.14
   
12	Navaneethabalakrishnan   S, Smith   HL, Arenaz   CM, Goodlett   BL, McDermott   JG, Mitchell   BM. Update on immune mechanisms in hypertension. Am J Hypertens  2022;35:842–51. https://doi.org/10.1093/ajh/hpac077
   
13	Levy   D, Garrison   RJ, Savage   DD, Kannel   WB, Castelli   WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med  1990;322:1561–6. https://doi.org/10.1056/nejm199005313222203
   
14	Devereux   RB, Wachtell   K, Gerdts   E, Boman   K, Nieminen   MS, Papademetriou   V, et al.   Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA  2004;292:2350–6. https://doi.org/10.1001/jama.292.19.2350
   
15	de Simone   G, Gottdiener   JS, Chinali   M, Maurer   MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the cardiovascular health study. Eur Heart J  2008;29:741–7. https://doi.org/10.1093/eurheartj/ehm605
   
16	Verdecchia   P, Porcellati   C, Reboldi   G, Gattobigio   R, Borgioni   C, Pearson   TA, et al.   Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation  2001;104:2039–44. https://doi.org/10.1161/hc4201.097944
   
17	Hijazi   Z, Verdecchia   P, Oldgren   J, Andersson   U, Reboldi   G, Di Pasquale   G, et al.   Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RE-LY trial. J Am Heart Assoc  2019;8:e010107. https://doi.org/10.1161/jaha.118.010107
   
18	Siedlinski   M, Carnevale   L, Xu   X, Carnevale   D, Evangelou   E, Caulfield   MJ, et al.   Genetic analyses identify brain structures related to cognitive impairment associated with elevated blood pressure. Eur Heart J  2023;44:2114–25. https://doi.org/10.1093/eurheartj/ehad101
   
19	Cheung   AK, Chang   TI, Cushman   WC, Furth   SL, Hou   FF, Ix   JH, et al.   KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International  2021;99:S1–87. https://doi.org/10.1016/j.kint.2020.11.003
   
20	Subbiah   A, Bhowmik   D. KDIGO recommendations on blood pressure management in chronic kidney disease. Kidney Int  2022;101:1299. https://doi.org/10.1016/j.kint.2022.02.036
   
21	Cheung   CY, Biousse   V, Keane   PA, Schiffrin   EL, Wong   TY. Hypertensive eye disease. Nat Rev Dis Primers  2022;8:14. https://doi.org/10.1038/s41572-022-00342-0
   
22	Lewington   S, Clarke   R, Qizilbash   N, Peto   R, Collins   R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet  2002;360:1903–13. https://doi.org/10.1016/s0140-6736(02)11911-8
Google ScholarPubMedWorldCat 
23	O’Rourke   MF, Safar   ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension  2005;46:200–4. https://doi.org/10.1161/01.Hyp.0000168052.00426.65
   
24	Gerdts   E, Izzo   R, Mancusi   C, Losi   MA, Manzi   MV, Canciello   G, et al.   Left ventricular hypertrophy offsets the sex difference in cardiovascular risk (the Campania Salute Network). Int J Cardiol  2018;258:257–61. https://doi.org/10.1016/j.ijcard.2017.12.086
   
25	Gerdts   E, Okin   PM, de Simone   G, Cramariuc   D, Wachtell   K, Boman   K, et al.   Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan intervention for endpoint reduction in hypertension study. Hypertension  2008;51:1109–14. https://doi.org/10.1161/hypertensionaha.107.107474
   
26	Gerdts   E, Wachtell   K, Omvik   P, Otterstad   JE, Oikarinen   L, Boman   K, et al.   Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan Intervention for Endpoint Reduction in Hypertension Trial. Hypertension  2007;49:311–6. https://doi.org/10.1161/01.Hyp.0000254322.96189.85
   
27	Park   JB, Schiffrin   EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens  2001;19:921–30. https://doi.org/10.1097/00004872-200105000-00013
   
28	Vasan   RS, Pan   S, Xanthakis   V, Beiser   A, Larson   MG, Seshadri   S, et al.   Arterial stiffness and long-term risk of health outcomes: the Framingham heart study. Hypertension  2022;79:1045–56. https://doi.org/10.1161/hypertensionaha.121.18776
   
29	Piskorz   D. Hypertensive mediated organ damage and hypertension management. How to assess beneficial effects of antihypertensive treatments?  High Blood Press Cardiovasc Prev  2020;27:9–17. https://doi.org/10.1007/s40292-020-00361-6
   
30	Vallelonga   F, Cesareo   M, Menon   L, Airale   L, Leone   D, Astarita   A, et al.   Cardiovascular hypertension-mediated organ damage in hypertensive urgencies and hypertensive outpatients. Front Cardiovasc Med  2022;9:889554. https://doi.org/10.3389/fcvm.2022.889554
   
31	Vasan   RS, Song   RJ, Xanthakis   V, Beiser   A, DeCarli   C, Mitchell   GF, et al.   Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community. Hypertension  2022;79:505–15. https://doi.org/10.1161/hypertensionaha.121.18502
   
32	Rapsomaniki   E, Timmis   A, George   J, Pujades-Rodriguez   M, Shah   AD, Denaxas   S, et al.   Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet  2014;383:1899–911. https://doi.org/10.1016/s0140-6736(14)60685-1
   
33	Malik   R, Georgakis   MK, Vujkovic   M, Damrauer   SM, Elliott   P, Karhunen   V, et al.   Relationship between blood pressure and incident cardiovascular disease: linear and nonlinear Mendelian randomization analyses. Hypertension  2021;77:2004–13. https://doi.org/10.1161/hypertensionaha.120.16534
   
34	Ji   H, Kim   A, Ebinger   JE, Niiranen   TJ, Claggett   BL, Bairey Merz   CN, et al.   Sex differences in blood pressure trajectories over the life course. JAMA Cardiol  2020;5:19–26. https://doi.org/10.1001/jamacardio.2019.5306
   
35	Salles   GF, Reboldi   G, Fagard   RH, Cardoso   CRL, Pierdomenico   SD, Verdecchia   P, et al.   Prognostic effect of the nocturnal blood pressure fall in hypertensive patients: the ambulatory blood pressure collaboration in patients with hypertension (ABC-H) meta-analysis. Hypertension  2016;67:693–700. https://doi.org/10.1161/hypertensionaha.115.06981
   
36	Verdecchia   P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension  2000;35:844–51. https://doi.org/10.1161/01.hyp.35.3.844
   
37	Mauck   GW, Smith   CR, Geddes   LA, Bourland   JD. The meaning of the point of maximum oscillations in cuff pressure in the indirect measurement of blood pressure—part ii. J Biomech Eng  1980;102:28–33. https://doi.org/10.1115/1.3138195
   
38	Clark   CE, Warren   FC, Boddy   K, McDonagh   STJ, Moore   SF, Goddard   J, et al.   Associations between systolic interarm differences in blood pressure and cardiovascular disease outcomes and mortality: individual participant data meta-analysis, development and validation of a prognostic algorithm: the INTERPRESS-IPD collaboration. Hypertension  2021;77:650–61. https://doi.org/10.1161/hypertensionaha.120.15997
   
39	Picone   DS, Deshpande   RA, Schultz   MG, Fonseca   R, Campbell   NRC, Delles   C, et al.   Nonvalidated home blood pressure devices dominate the online marketplace in Australia: major implications for cardiovascular risk management. Hypertension  2020;75:1593–9. https://doi.org/10.1161/hypertensionaha.120.14719
   
40	Picone   DS, Campbell   NRC, Schutte   AE, Olsen   MH, Ordunez   P, Whelton   PK, et al.   Validation status of blood pressure measuring devices sold globally. JAMA  2022;327:680–1. https://doi.org/10.1001/jama.2021.24464
   
41	Stergiou   GS, O’Brien   E, Myers   M, Palatini   P, Parati   G, Kollias   A, et al.   STRIDE BP international initiative for accurate blood pressure measurement: systematic review of published validation studies of blood pressure measuring devices. J Clin Hypertens (Greenwich)  2019;21:1616–22. https://doi.org/10.1111/jch.13710
   
42	Stergiou   GS, Alpert   B, Mieke   S, Asmar   R, Atkins   N, Eckert   S, et al.   A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) collaboration statement. Hypertension  2018;71:368–74. https://doi.org/10.1161/hypertensionaha.117.10237
   
43	Stergiou   GS, Mukkamala   R, Avolio   A, Kyriakoulis   KG, Mieke   S, Murray   A, et al.   Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension working group on blood pressure monitoring and cardiovascular variability. J Hypertens  2022;40:1449–60. https://doi.org/10.1097/hjh.0000000000003224
   
44	Stergiou   GS, Avolio   AP, Palatini   P, Kyriakoulis   KG, Schutte   AE, Mieke   S, et al.   European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens  2023;41:2074–87. https://doi.org/10.1097/hjh.0000000000003483
   
45	McAlister   FA, Straus   SE. Evidence based treatment of hypertension. Measurement of blood pressure: an evidence based review. BMJ  2001;322:908–11. https://doi.org/10.1136/bmj.322.7291.908
   
46	Fagius   J, Karhuvaara   S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension  1989;14:511–7. https://doi.org/10.1161/01.hyp.14.5.511
   
47	Stergiou   GS, Kyriakoulis   KG, Stambolliu   E, Destounis   A, Karpettas   N, Kalogeropoulos   P, et al.   Blood pressure measurement in atrial fibrillation: review and meta-analysis of evidence on accuracy and clinical relevance. J Hypertens  2019;37:2430–41. https://doi.org/10.1097/hjh.0000000000002201
   
48	Clark   CE, McDonagh   STJ, McManus   RJ. Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: systematic review and meta-analysis. J Hum Hypertens  2019;33:352–64. https://doi.org/10.1038/s41371-018-0153-z
   
49	Verberk   WJ, Omboni   S, Kollias   A, Stergiou   GS. Screening for atrial fibrillation with automated blood pressure measurement: research evidence and practice recommendations. Int J Cardiol  2016;203:465–73. https://doi.org/10.1016/j.ijcard.2015.10.182
   
50	Manning   DM, Kuchirka   C, Kaminski   J. Miscuffing: inappropriate blood pressure cuff application. Circulation  1983;68:763–6. https://doi.org/10.1161/01.cir.68.4.763
   
51	Irving   G, Holden   J, Stevens   R, McManus   RJ. Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: a diagnostic accuracy review. BMJ Open  2016;6:e012429. https://doi.org/10.1136/bmjopen-2016-012429
   
52	Keeley   EC, Villanueva   M, Chen   YE, Gong   Y, Handberg   EM, Smith   SM, et al.   Attended vs unattended systolic blood pressure measurement: a randomized comparison in patients with cardiovascular disease. J Clin Hypertens (Greenwich)  2020;22:1987–92. https://doi.org/10.1111/jch.14037
   
53	Myers   MG, Godwin   M, Dawes   M, Kiss   A, Tobe   SW, Grant   FC, et al.   Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ  2011;342:d286. https://doi.org/10.1136/bmj.d286
   
54	Clark   CE. Inter-arm blood pressure difference, when is it a useful risk marker for cardiovascular events?  J Hum Hypertens  2022;36:117–9. https://doi.org/10.1038/s41371-021-00629-x
   
55	Clark   CE, Steele   AM, Taylor   RS, Shore   AC, Ukoumunne   OC, Campbell   JL. Interarm blood pressure difference in people with diabetes: measurement and vascular and mortality implications: a cohort study. Diabetes Care  2014;37:1613–20. https://doi.org/10.2337/dc13-1576
   
56	Juraschek   SP, Appel   LJ, Mitchell   CM, Mukamal   KJ, Lipsitz   LA, Blackford   AL, et al.   Comparison of supine and seated orthostatic hypotension assessments and their association with falls and orthostatic symptoms. J Am Geriatr Soc  2022;70:2310–9. https://doi.org/10.1111/jgs.17804
   
57	Stergiou   GS, Palatini   P, Parati   G, O’Brien   E, Januszewicz   A, Lurbe   E, et al.   European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens  2021;39:1293–302. https://doi.org/10.1097/hjh.0000000000002843
   
58	Parati   G, Stergiou   GS, Bilo   G, Kollias   A, Pengo   M, Ochoa   J, et al.   Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the working group on blood pressure monitoring and cardiovascular variability of the European Society of Hypertension. J Hypertens  2021;39:1742–67. https://doi.org/10.1097/hjh.0000000000002922
   
59	Bradley   CK, Choi   E, Abdalla   M, Mizuno   H, Lam   M, Cepeda   M, et al.   Use of different blood pressure thresholds to reduce the number of home blood pressure monitoring days needed for detecting hypertension. Hypertension  2023;80:2169–77. https://doi.org/10.1161/hypertensionaha.123.21118
   
60	Hodgkinson   JA, Lee   MM, Milner   S, Bradburn   P, Stevens   R, Hobbs   FDR, et al.   Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. Br J Gen Pract  2020;70:e548–54. https://doi.org/10.3399/bjgp20X710381
   
61	Niiranen   TJ, Asayama   K, Thijs   L, Johansson   JK, Ohkubo   T, Kikuya   M, et al.   Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome. Hypertension  2013;61:27–34. https://doi.org/10.1161/hypertensionaha.111.00100
   
62	Parati   G, Stergiou   G, O’Brien   E, Asmar   R, Beilin   L, Bilo   G, et al.   European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens  2014;32:1359–66. https://doi.org/10.1097/hjh.0000000000000221
   
63	Yang   WY, Thijs   L, Zhang   ZY, Asayama   K, Boggia   J, Hansen   TW, et al.   Evidence-based proposal for the number of ambulatory readings required for assessing blood pressure level in research settings: an analysis of the IDACO database. Blood Press  2018;27:341–50. https://doi.org/10.1080/08037051.2018.1476057
   
64	Asayama   K, Stolarz-Skrzypek   K, Yang   WY, Hansen   TW, Brguljan-Hitij   J, Odili   AN, et al.   What did we learn from the international databases on ambulatory and home blood pressure in relation to cardiovascular outcome?  Hypertens Res  2023;46:934–49. https://doi.org/10.1038/s41440-023-01191-4
   
65	Drawz   PE, Agarwal   A, Dwyer   JP, Horwitz   E, Lash   J, Lenoir   K, et al.   Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice. JAMA Intern Med  2020;180:1655–63. https://doi.org/10.1001/jamainternmed.2020.5028
   
66	Jaeger   BC, Bress   AP, Bundy   JD, Cheung   AK, Cushman   WC, Drawz   PE, et al.   Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol  2022;7:1138–46. https://doi.org/10.1001/jamacardio.2022.3345
   
67	Ntineri   A, Niiranen   TJ, McManus   RJ, Lindroos   A, Jula   A, Schwartz   C, et al.   Ambulatory versus home blood pressure monitoring: frequency and determinants of blood pressure difference and diagnostic disagreement. J Hypertens  2019;37:1974–81. https://doi.org/10.1097/hjh.0000000000002148
   
68	Sheppard   JP, Fletcher   B, Gill   P, Martin   U, Roberts   N, McManus   RJ. Predictors of the home-clinic blood pressure difference: a systematic review and meta-analysis. Am J Hypertens  2016;29:614–25. https://doi.org/10.1093/ajh/hpv157
   
69	Franklin   SS, Thijs   L, Li   Y, Hansen   TW, Boggia   J, Liu   Y, et al.   Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension  2013;61:964–71. https://doi.org/10.1161/hypertensionaha.111.00289
   
70	Guirguis-Blake   JM, Evans   CV, Webber   EM, Coppola   EL, Perdue   LA, Weyrich   MS. Screening for hypertension in adults: updated evidence report and systematic review for the US preventive services task force. JAMA  2021;325:1657–69. https://doi.org/10.1001/jama.2020.21669
   
71	Xu   W, Goldberg   SI, Shubina   M, Turchin   A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ  2015;350:h158. https://doi.org/10.1136/bmj.h158
   
72	Antza   C, Farmakis   I, Doundoulakis   I, Akrivos   E, Stalikas   N, Zafeiropoulos   S, et al.   Reproducibility of masked hypertension and office-based hypertension: a systematic review and meta-analysis. J Hypertens  2022;40:1053–9. https://doi.org/10.1097/hjh.0000000000003111
   
73	Uhlig   K, Patel   K, Ip   S, Kitsios   GD, Balk   EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med  2013;159:185–94. https://doi.org/10.7326/0003-4819-159-3-201308060-00008
   
74	Tucker   KL, Sheppard   JP, Stevens   R, Bosworth   HB, Bove   A, Bray   EP, et al.   Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med  2017;14:e1002389. https://doi.org/10.1371/journal.pmed.1002389
   
75	McManus   RJ, Mant   J, Franssen   M, Nickless   A, Schwartz   C, Hodgkinson   J, et al.   Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet  2018;391:949–59. https://doi.org/10.1016/s0140-6736(18)30309-x
   
76	McManus   RJ, Little   P, Stuart   B, Morton   K, Raftery   J, Kelly   J, et al.   Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ  2021;372:m4858. https://doi.org/10.1136/bmj.m4858
Google ScholarPubMedWorldCat 
77	Li   R, Liang   N, Bu   F, Hesketh   T. The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis. JMIR Mhealth Uhealth  2020;8:e17776. https://doi.org/10.2196/17776
   
78	Acharya   S, Neupane   G, Seals   A, Madhav   KC, Giustini   D, Sharma   S, et al.   Self-measured blood pressure-guided pharmacotherapy: a systematic review and meta-analysis of US-based telemedicine trials. Hypertension  2024;81:648–57. https://doi.org/10.1161/hypertensionaha.123.22109
   
79	Monahan   M, Jowett   S, Nickless   A, Franssen   M, Grant   S, Greenfield   S, et al.   Cost-effectiveness of telemonitoring and self-monitoring of blood pressure for antihypertensive titration in primary care (TASMINH4). Hypertension  2019;73:1231–9. https://doi.org/10.1161/hypertensionaha.118.12415
   
80	Wood   S, Greenfield   SM, Sayeed Haque   M, Martin   U, Gill   PS, Mant   J, et al.   Influence of ethnicity on acceptability of method of blood pressure monitoring: a cross-sectional study in primary care. Br J Gen Pract  2016;66:e577–586. https://doi.org/10.3399/bjgp16X685717
   
81	Stergiou   GS, Karpettas   N, Destounis   A, Tzamouranis   D, Nasothimiou   E, Kollias   A, et al.   Home blood pressure monitoring alone vs. combined clinic and ambulatory measurements in following treatment-induced changes in blood pressure and organ damage. Am J Hypertens  2014;27:184–92. https://doi.org/10.1093/ajh/hpt206
   
82	Staessen   JA, Byttebier   G, Buntinx   F, Celis   H, O’Brien   ET, Fagard   R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory blood pressure monitoring and treatment of hypertension investigators. JAMA  1997;278:1065–72. https://doi.org/10.1001/jama.1997.03550130039034
   
83	McEvoy   JW, Leahy   N, Parati   G. The apples and oranges of blood pressure variability. Hypertension  2023;80:2556–8. https://doi.org/10.1161/hypertensionaha.123.21927
   
84	Ishikuro   M, Obara   T, Metoki   H, Ohkubo   T, Yamamoto   M, Akutsu   K, et al.   Blood pressure measured in the clinic and at home during pregnancy among nulliparous and multiparous women: the BOSHI study. Am J Hypertens  2013;26:141–8. https://doi.org/10.1093/ajh/hps002
   
85	Bello   NA, Woolley   JJ, Cleary   KL, Falzon   L, Alpert   BS, Oparil   S, et al.   Accuracy of blood pressure measurement devices in pregnancy: a systematic review of validation studies. Hypertension  2018;71:326–35. https://doi.org/10.1161/hypertensionaha.117.10295
   
86	Tucker   KL, Mort   S, Yu   LM, Campbell   H, Rivero-Arias   O, Wilson   HM, et al.   Effect of self-monitoring of blood pressure on diagnosis of hypertension during higher-risk pregnancy: the BUMP 1 randomized clinical trial. JAMA  2022;327:1656–65. https://doi.org/10.1001/jama.2022.4712
   
87	Chappell   LC, Tucker   KL, Galal   U, Yu   L-M, Campbell   H, Rivero-Arias   O, et al.   Effect of self-monitoring of blood pressure on blood pressure control in pregnant individuals with chronic or gestational hypertension: the BUMP 2 randomized clinical trial. JAMA  2022;327:1666–78. https://doi.org/10.1001/jama.2022.4726
   
88	Tita   AT, Szychowski   JM, Boggess   K, Dugoff   L, Sibai   B, Lawrence   K, et al.   Treatment for mild chronic hypertension during pregnancy. N Engl J Med  2022;386:1781–92. https://doi.org/10.1056/NEJMoa2201295
   
89	Regitz-Zagrosek   V, Roos-Hesselink   JW, Bauersachs   J, Blomström-Lundqvist   C, Cífková   R, De Bonis   M, et al.   2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J  2018;39:3165–241. https://doi.org/10.1093/eurheartj/ehy340
   
90	Tikhonoff   V, Kuznetsova   T, Thijs   L, Cauwenberghs   N, Stolarz-Skrzypek   K, Seidlerová   J, et al.   Ambulatory blood pressure and long-term risk for atrial fibrillation. Heart  2018;104:1263–70. https://doi.org/10.1136/heartjnl-2017-312488
   
91	Lip   GYH, Coca   A, Kahan   T, Boriani   G, Manolis   AS, Olsen   MH, et al.   Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace  2017;19:891–911. https://doi.org/10.1093/europace/eux091
   
92	Šelmytė-Besusparė   A, Barysienė   J, Petrikonytė   D, Aidietis   A, Marinskis   G, Laucevičius   A. Auscultatory versus oscillometric blood pressure measurement in patients with atrial fibrillation and arterial hypertension. BMC Cardiovasc Disord  2017;17:87. https://doi.org/10.1186/s12872-017-0521-6
   
93	Omboni   S, Ballatore   T, Rizzi   F, Tomassini   F, Campolo   L, Panzeri   E, et al.   24-Hour ambulatory blood pressure telemonitoring in patients at risk of atrial fibrillation: results from the TEMPLAR project. Hypertens Res  2022;45:1486–95. https://doi.org/10.1038/s41440-022-00932-1
   
94	Seccia   TM, Letizia   C, Muiesan   ML, Lerco   S, Cesari   M, Bisogni   V, et al.   Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J Hypertens  2020;38:332–9. https://doi.org/10.1097/hjh.0000000000002250
   
95	McDonagh   STJ, Mejzner   N, Clark   CE. Prevalence of postural hypotension in primary, community and institutional care: a systematic review and meta-analysis. BMC Fam Pract  2021;22:1. https://doi.org/10.1186/s12875-020-01313-8
   
96	Tran   J, Hillebrand   SL, Meskers   CGM, Iseli   RK, Maier   AB. Prevalence of initial orthostatic hypotension in older adults: a systematic review and meta-analysis. Age Ageing  2021;50:1520–8. https://doi.org/10.1093/ageing/afab090
   
97	Juraschek   SP, Hu   JR, Cluett   JL, Ishak   AM, Mita   C, Lipsitz   LA, et al.   Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis. JAMA  2023;330:1459–71. https://doi.org/10.1001/jama.2023.18497
   
98	Juraschek   SP, Cortez   MM, Flack   JM, Ghazi   L, Kenny   RA, Rahman   M, et al.   Orthostatic hypotension in adults with hypertension: a scientific statement from the American Heart Association. Hypertension  2024;81:e16–30. https://doi.org/10.1161/hyp.0000000000000236
   
99	Raber   I, Belanger   MJ, Farahmand   R, Aggarwal   R, Chiu   N, Al Rifai   M, et al.   Orthostatic hypotension in hypertensive adults: Harry Goldblatt award for early career investigators 2021. Hypertension  2022;79:2388–96. https://doi.org/10.1161/hypertensionaha.122.18557
   
100	Wieling   W, Kaufmann   H, Claydon   VE, van Wijnen   VK, Harms   MPM, Juraschek   SP, et al.   Diagnosis and treatment of orthostatic hypotension. Lancet Neurol  2022;21:735–46. https://doi.org/10.1016/s1474-4422(22)00169-7
   
101	Juraschek   SP, Daya   N, Rawlings   AM, Appel   LJ, Miller   ER, Windham   BG, et al.   Association of history of dizziness and long-term adverse outcomes with early vs later orthostatic hypotension assessment times in middle-aged adults. JAMA Intern Med  2017;177:1316–23. https://doi.org/10.1001/jamainternmed.2017.2937
   
102	Brignole   M, Moya   A, de Lange   FJ, Deharo   J-C, Elliott   PM, Fanciulli   A, et al.   Practical instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J  2018;39:e43–80. https://doi.org/10.1093/eurheartj/ehy071
   
103	Rivasi   G, Groppelli   A, Brignole   M, Soranna   D, Zambon   A, Bilo   G, et al.   Association between hypotension during 24 h ambulatory blood pressure monitoring and reflex syncope: the SynABPM 1 study. Eur Heart J  2022;43:3765–76. https://doi.org/10.1093/eurheartj/ehac347
   
104	Smith   TO, Sillito   JA, Goh   CH, Abdel-Fattah   A-R, Einarsson   A, Soiza   RL, et al.   Association between different methods of assessing blood pressure variability and incident cardiovascular disease, cardiovascular mortality and all-cause mortality: a systematic review. Age Ageing  2020;49:184–92. https://doi.org/10.1093/ageing/afz178
   
105	Kim   S, Xiao   X, Chen   J. Advances in photoplethysmography for personalized cardiovascular monitoring. Biosensors (Basel)  2022;12:863. https://doi.org/10.3390/bios12100863
   
106	Dagamseh   A, Qananwah   Q, Al Quran   H, Shaker Ibrahim   K. Towards a portable-noninvasive blood pressure monitoring system utilizing the photoplethysmogram signal. Biomed Opt Express  2021;12:7732–51. https://doi.org/10.1364/boe.444535
   
107	Sharman   JE, Avolio   AP, Baulmann   J, Benetos   A, Blacher   J, Blizzard   CL, et al.   Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. Eur Heart J  2017;38:2805–12. https://doi.org/10.1093/eurheartj/ehw632
   
108	Sharman   JE, O’Brien   E, Alpert   B, Schutte   AE, Delles   C, Hecht Olsen   M, et al.   Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. J Hypertens  2020;38:21–9. https://doi.org/10.1097/hjh.0000000000002246
   
109	Lunardi   M, Muhammad   F, Shahzad   A, Nadeem   A, Combe   L, Simpkin   AJ, et al.   Performance of wearable watch-type home blood pressure measurement devices in a real-world clinical sample. Clin Res Cardiol. 2023. https://doi.org/10.1007/s00392-023-02353-7
Google ScholarWorldCat 
110	Clark   CE, Warren   FC, Boddy   K, McDonagh   STJ, Moore   SF, Teresa Alzamora   M, et al.   Higher arm versus lower arm systolic blood pressure and cardiovascular outcomes: a meta-analysis of individual participant data from the INTERPRESS-IPD collaboration. Hypertension  2022;79:2328–35. https://doi.org/10.1161/hypertensionaha.121.18921
   
111	Margolis   KL, Dehmer   SP, Sperl-Hillen   J, O’Connor   PJ, Asche   SE, Bergdall   AR, et al.   Cardiovascular events and costs with home blood pressure telemonitoring and pharmacist management for uncontrolled hypertension. Hypertension  2020;76:1097–103. https://doi.org/10.1161/hypertensionaha.120.15492
   
112	Sheppard   JP, Tucker   KL, Davison   WJ, Stevens   R, Aekplakorn   W, Bosworth   H B, et al.   Self-monitoring of blood pressure in patients with hypertension-related multi-morbidity: systematic review and individual patient data meta-analysis. Am J Hypertens  2020;33:243–51. https://doi.org/10.1093/ajh/hpz182
   
113	Cooke   G, Doust   J, Sanders   S. Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract  2006;55:130–4.
Google ScholarPubMedWorldCat 
114	Arvanitis   M, Qi   G, Bhatt   DL, Post   WS, Chatterjee   N, Battle   A, et al.   Linear and nonlinear Mendelian randomization analyses of the association between diastolic blood pressure and cardiovascular events: the J-curve revisited. Circulation  2021;143:895–906. https://doi.org/10.1161/circulationaha.120.049819
   
115	Whelton   SP, McEvoy   JW, Shaw   L, Psaty   BM, Lima   JAC, Budoff   M, et al.   Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiol  2020;5:1011–8. https://doi.org/10.1001/jamacardio.2020.1731
   
116	Rahimi   K, Bidel   Z, Nazarzadeh   M, Copland   E, Canoy   D, Ramakrishnan   R, et al.   Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet  2021;397:1625–36. https://doi.org/10.1016/S0140-6736(21)00590-0
   
117	Ji   H, Niiranen   TJ, Rader   F, Henglin   M, Kim   A, Ebinger   JE, et al.   Sex differences in blood pressure associations with cardiovascular outcomes. Circulation  2021;143:761–3. https://doi.org/10.1161/circulationaha.120.049360
   
118	Kringeland   E, Tell   GS, Midtbø   H, Igland   J, Haugsgjerd   TR, Gerdts   E. Stage 1 hypertension, sex, and acute coronary syndromes during midlife: the Hordaland health study. Eur J Prev Cardiol  2022;29:147–54. https://doi.org/10.1093/eurjpc/zwab068
   
119	Appel   LJ, Moore   TJ, Obarzanek   E, Vollmer   WM, Svetkey   LP, Sacks   FM, et al.   A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N Engl J Med  1997;336:1117–24. https://doi.org/10.1056/nejm199704173361601
   
120	Toledo   E, Hu   FB, Estruch   R, Buil-Cosiales   P, Corella   D, Salas-Salvadó   J, et al.   Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med  2013;11:207. https://doi.org/10.1186/1741-7015-11-207
   
121	Sundström   J, Arima   H, Jackson   R, Turnbull   F, Rahimi   K, Chalmers   J, et al.   Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med  2015;162:184–91. https://doi.org/10.7326/m14-0773
   
122	Ettehad   D, Emdin   CA, Kiran   A, Anderson   SG, Callender   T, Emberson   J, et al.   Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet  2016;387:957–67. https://doi.org/10.1016/s0140-6736(15)01225-8
   
123	Muntner   P, Whelton   PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol  2017;69:2446–56. https://doi.org/10.1016/j.jacc.2017.02.066
   
124	Herrett   E, Strongman   H, Gadd   S, Tomlinson   L, Nitsch   D, Bhaskaran   K, et al.   The importance of blood pressure thresholds versus predicted cardiovascular risk on subsequent rates of cardiovascular disease: a cohort study in English primary care. Lancet Healthy Longev  2022;3:e22–30. https://doi.org/10.1016/s2666-7568(21)00281-6
   
125	Navar   AM, Pencina   MJ, Peterson   ED. Assessing cardiovascular risk to guide hypertension diagnosis and treatment. JAMA Cardiol  2016;1:864–71. https://doi.org/10.1001/jamacardio.2016.2861
   
126	Kovell   LC, Ahmed   HM, Misra   S, Whelton   SP, Prokopowicz   GP, Blumenthal   RS, et al.   US hypertension management guidelines: a review of the recent past and recommendations for the future. J Am Heart Assoc  2015;4:e002315. https://doi.org/10.1161/jaha.115.002315
   
127	McEvoy   JW, Martin   SS, Dardari   ZA, Miedema   MD, Sandfort   V, Yeboah   J, et al.   Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation  2017;135:153–65. https://doi.org/10.1161/circulationaha.116.025471
   
128	Rossello   X, Dorresteijn   JA, Janssen   A, Lambrinou   E, Scherrenberg   M, Bonnefoy-Cudraz   E, et al.   Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol  2019;26:1534–44. https://doi.org/10.1177/2047487319846715
   
129	Ioannidis   JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA  2018;319:115–6. https://doi.org/10.1001/jama.2017.19672
   
130	Whelton   PK, Carey   RM, Aronow   WS, Casey   DE, Collins   KJ, Dennison Himmelfarb   C, et al.   2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation  2018;138:e484–594. https://doi.org/10.1161/cir.0000000000000596
Google ScholarPubMedWorldCat 
131	Rahimi   K, Bidel   Z, Nazarzadeh   M, Copland   E, Canoy   D, Wamil   M, et al.   Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet  2021;398:1053–64. https://doi.org/10.1016/S0140-6736(21)01921-8
   
132	Brunström   M, Carlberg   B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med  2018;178:28–36. https://doi.org/10.1001/jamainternmed.2017.6015
   
133	Arguedas   JA, Leiva   V, Wright   JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev  2020;12:CD004349. https://doi.org/10.1002/14651858.CD004349.pub3
Google ScholarPubMedWorldCat 
134	Saiz   LC, Gorricho   J, Garjón   J, Celaya   MC, Erviti   J, Leache   L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev  2022;11:CD010315. https://doi.org/10.1002/14651858.CD010315.pub5
Google ScholarPubMedWorldCat 
135	Wright   JT  Jr, Williamson   JD, Whelton   PK, Snyder   JK, Sink   KM, Rocco   MV, et al.   A randomized trial of intensive versus standard blood-pressure control. N Engl J Med  2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939
Google ScholarPubMedWorldCat 
136	Zhang   W, Zhang   S, Deng   Y, Wu   S, Ren   J, Sun   G, et al.   Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med  2021;385:1268–79. https://doi.org/10.1056/NEJMoa2111437
   
137	Cushman   WC, Evans   GW, Byington   RP, Goff   DC  Jr, Grimm   RH  Jr, Cutler   JA, et al.   Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med  2010;362:1575–85. https://doi.org/10.1056/NEJMoa1001286
Google ScholarPubMedWorldCat 
138	Ferrucci   L, Furberg   CD, Penninx   BW, DiBari   M, Williamson   JD, Guralnik   JM, et al.   Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation  2001;104:1923–6. https://doi.org/10.1161/hc4101.097520
   
139	Leening   MJ, Ferket   BS, Steyerberg   EW, Kavousi   M, Deckers   JW, Nieboer   D, et al.   Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ  2014;349:g5992. https://doi.org/10.1136/bmj.g5992
   
140	Ference   BA, Bhatt   DL, Catapano   AL, Packard   CJ, Graham   I, Kaptoge   S, et al.   Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA  2019;322:1381–91. https://doi.org/10.1001/jama.2019.14120
   
141	Kannel   WB. Risk stratification in hypertension: new insights from the Framingham study. Am J Hypertens  2000;13:S3–10. https://doi.org/10.1016/s0895-7061(99)00252-6
   
142	Weycker   D, Nichols   GA, O’Keeffe-Rosetti   M, Edelsberg   J, Khan   Z, Kaura   S, et al.   Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens  2007;20:599–607. https://doi.org/10.1016/j.amjhyper.2006.10.013
   
143	Constanti   M, Floyd   CN, Glover   M, Boffa   R, Wierzbicki   AS, McManus   RJ. Cost-effectiveness of initiating pharmacological treatment in stage one hypertension based on 10-year cardiovascular disease risk: a Markov modeling study. Hypertension  2021;77:682–91. https://doi.org/10.1161/hypertensionaha.120.14913
   
144	Forouzanfar   MH, Liu   P, Roth   GA, Ng   M, Biryukov   S, Marczak   L, et al.   Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA  2017;317:165–82. https://doi.org/10.1001/jama.2016.19043
   
145	Karmali   KN, Ning   H, Goff   DC, Lloyd-Jones   DM. Identifying individuals at risk for cardiovascular events across the spectrum of blood pressure levels. J Am Heart Assoc  2015;4:e002126. https://doi.org/10.1161/jaha.115.002126
   
146	Liu   J, Li   Y, Ge   J, Yan   X, Zhang   H, Zheng   X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet  2024;404:245–55. https://doi.org/10.1016/S0140-6736(24)01028-6
   
147	Wilson   PW, D’Agostino   RB, Levy   D, Belanger   AM, Silbershatz   H, Kannel   WB. Prediction of coronary heart disease using risk factor categories. Circulation  1998;97:1837–47. https://doi.org/10.1161/01.cir.97.18.1837
   
148	Sussman   J, Vijan   S, Hayward   R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation  2013;128:2309–17. https://doi.org/10.1161/circulationaha.113.002290
   
149	Karmali   KN, Lloyd-Jones   DM, van der Leeuw   J, Goff   DC, Yusuf   S, Zanchetti   A, et al.   Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med  2018;15:e1002538. https://doi.org/10.1371/journal.pmed.1002538
   
150	Gaziano   TA, Steyn   K, Cohen   DJ, Weinstein   MC, Opie   LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation  2005;112:3569–76. https://doi.org/10.1161/circulationaha.105.535922
   
151	Basu   S, Sussman   JB, Hayward   RA. Black-white cardiovascular disease disparities after target-based versus personalized benefit-based lipid and blood pressure treatment. MDM Policy Pract  2017;2:2381468317725741. https://doi.org/10.1177/2381468317725741
Google ScholarWorldCat 
152	Go   AS, Chertow   GM, Fan   D, McCulloch   CE, Hsu   CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med  2004;351:1296–305. https://doi.org/10.1056/NEJMoa041031
   
153	Klooster   CCV, Bhatt   DL, Steg   PG, Massaro   JM, Dorresteijn   JAN, Westerink   J, et al.   Predicting 10-year risk of recurrent cardiovascular events andcardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int J Cardiol  2021;325:140–8. https://doi.org/10.1016/j.ijcard.2020.09.053
   
154	Kaasenbrood   L, Boekholdt   SM, van der Graaf   Y, Ray   KK, Peters   RJG, Kastelein   JJP, et al.   Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation  2016;134:1419–29. https://doi.org/10.1161/circulationaha.116.021314
   
155	Eisen   A, Bhatt   DL, Steg   PG, Eagle   KA, Goto   S, Guo   J, et al.   Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. J Am Heart Assoc  2016;5:e004080. https://doi.org/10.1161/jaha.116.004080
   
156	Taylor   CJ, Roalfe   AK, Iles   R, Hobbs   FD. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail  2012;14:176–84. https://doi.org/10.1093/eurjhf/hfr170
   
157	Shah   KS, Xu   H, Matsouaka   RA, Bhatt   DL, Heidenreich   PA, Hernandez   AF, et al.   Heart failure with preserved, borderline, and reduced ejection fraction: 5–year outcomes. J Am Coll Cardiol  2017;70:2476–86. https://doi.org/10.1016/j.jacc.2017.08.074
   
158	Benjamin   EJ, Wolf   PA, D’Agostino   RB, Silbershatz   H, Kannel   WB, Levy   D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation  1998;98:946–52. https://doi.org/10.1161/01.cir.98.10.946
   
159	Pandey   A, Patel   KV, Vongpatanasin   W, Ayers   C, Berry   JD, Mentz   RJ, et al.   Incorporation of biomarkers into risk assessment for allocation of antihypertensive medication according to the 2017 ACC/AHA high blood pressure guideline: a pooled cohort analysis. Circulation  2019;140:2076–88. https://doi.org/10.1161/circulationaha.119.043337
   
160	Mulnier   HE, Seaman   HE, Raleigh   VS, Soedamah-Muthu   SS, Colhoun   HM, Lawrenson   RA, et al.   Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the general practice research database. Diabetologia  2008;51:1639–45. https://doi.org/10.1007/s00125-008-1076-y
   
161	Soedamah-Muthu   SS, Fuller   JH, Mulnier   HE, Raleigh   VS, Lawrenson   RA, Colhoun   HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care  2006;29:798–804. https://doi.org/10.2337/diacare.29.04.06.dc05-1433
   
162	Wong   ND, Glovaci   D, Wong   K, Malik   S, Franklin   SS, Wygant   G, et al.   Global cardiovascular disease risk assessment in United States adults with diabetes. Diab Vasc Dis Res  2012;9:146–52. https://doi.org/10.1177/1479164112436403
   
163	Paquette   M, Bernard   S, Cariou   B, Hegele   RA, Genest   J, Trinder   M, et al.   Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol  2021;41:2632–40. https://doi.org/10.1161/atvbaha.121.316106
   
164	SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J  2023;44:2544–56. https://doi.org/10.1093/eurheartj/ehad260
CrossrefPubMedWorldCat 
165	SCORE Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J  2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309
CrossrefPubMedWorldCat 
166	SCORE OP working group and ESC Cardiovascular Risk Collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J  2021;42:2455–67. https://doi.org/10.1093/eurheartj/ehab312
CrossrefPubMedWorldCat 
167	Pignone   M, Phillips   CJ, Elasy   TA, Fernandez   A. Physicians’ ability to predict the risk of coronary heart disease. BMC Health Serv Res  2003;3:13. https://doi.org/10.1186/1472-6963-3-13
   
168	Grover   SA, Lowensteyn   I, Esrey   KL, Steinert   Y, Joseph   L, Abrahamowicz   M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ  1995;310:975–8. https://doi.org/10.1136/bmj.310.6985.975
   
169	Friedmann   PD, Brett   AS, Mayo-Smith   MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med  1996;124:414–21. https://doi.org/10.7326/0003-4819-124-4-199602150-00005
   
170	Visseren   FLJ, Mach   F, Smulders   YM, Carballo   D, Koskinas   KC, Bäck   M, et al.   ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J  2021;42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
   
171	Xie   X, Atkins   E, Lv   J, Bennett   A, Neal   B, Ninomiya   T, et al.   Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet  2016;387:435–43. https://doi.org/10.1016/s0140-6736(15)00805-3
   
172	Herrett   E, Gadd   S, Jackson   R, Bhaskaran   K, Williamson   E, van Staa   T, et al.   Eligibility and subsequent burden of cardiovascular disease of four strategies for blood pressure-lowering treatment: a retrospective cohort study. Lancet  2019;394:663–71. https://doi.org/10.1016/s0140-6736(19)31359-5
   
173	Matsushita   K, Kaptoge   S, Hageman   SHJ, Sang   Y, Ballew   SH, Grams   ME, et al.   Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur J Prev Cardiol  2023;30:8–16. https://doi.org/10.1093/eurjpc/zwac176
   
174	Gerdts   E, Sudano   I, Brouwers   S, Borghi   C, Bruno   RM, Ceconi   C, et al.   Sex differences in arterial hypertension. Eur Heart J  2022;43:4777–88. https://doi.org/10.1093/eurheartj/ehac470
   
175	Brown   MC, Best   KE, Pearce   MS, Waugh   J, Robson   SC, Bell   R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol  2013;28:1–19. https://doi.org/10.1007/s10654-013-9762-6
   
176	Honigberg   MC, Zekavat   SM, Aragam   K, Klarin   D, Bhatt   DL, Scott   NS, et al.   Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol  2019;74:2743–54. https://doi.org/10.1016/j.jacc.2019.09.052
   
177	Leon   LJ, McCarthy   FP, Direk   K, Gonzalez-Izquierdo   A, Prieto-Merino   D, Casas   JP, et al.   Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records: a CALIBER study. Circulation  2019;140:1050–60. https://doi.org/10.1161/circulationaha.118.038080
   
178	Haug   EB, Horn   J, Markovitz   AR, Fraser   A, Klykken   B, Dalen   H, et al.   Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Trøndelag health study. JAMA Cardiol  2019;4:628–35. https://doi.org/10.1001/jamacardio.2019.1746
   
179	Wu   P, Haththotuwa   R, Kwok   CS, Babu   A, Kotronias   RA, Rushton   C, et al.   Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes  2017;10:e003497. https://doi.org/10.1161/circoutcomes.116.003497
   
180	Kramer   CK, Campbell   S, Retnakaran   R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia  2019;62:905–14. https://doi.org/10.1007/s00125-019-4840-2
   
181	Kyriacou   H, Al-Mohammad   A, Muehlschlegel   C, Foster-Davies   L, Bruco   MEF, Legard   C, et al.   The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis. Eur Heart J Open  2022;2:oeac065. https://doi.org/10.1093/ehjopen/oeac065
   
182	Kessous   R, Shoham-Vardi   I, Pariente   G, Holcberg   G, Sheiner   E. An association between preterm delivery and long-term maternal cardiovascular morbidity. Am J Obstet Gynecol  2013;209:368.e1–8. https://doi.org/10.1016/j.ajog.2013.05.041
   
183	Markovitz   AR, Stuart   JJ, Horn   J, Williams   PL, Rimm   EB, Missmer   SA, et al.   Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. Eur Heart J  2019;40:1113–20. https://doi.org/10.1093/eurheartj/ehy863
   
184	Saei Ghare Naz   M, Sheidaei   A, Aflatounian   A, Azizi   F, Ramezani Tehrani   F. Does adding adverse pregnancy outcomes improve the Framingham cardiovascular risk score in women? Data from the Tehran Lipid and Glucose Study. J Am Heart Assoc  2022;11:e022349. https://doi.org/10.1161/jaha.121.022349
   
185	Gladstone   RA, Pudwell   J, Nerenberg   KA, Grover   SA, Smith   GN. Cardiovascular risk assessment and follow-up of women after hypertensive disorders of pregnancy: a prospective cohort study. J Obstet Gynaecol Can  2019;41:1157–67.e1. https://doi.org/10.1016/j.jogc.2018.10.024
   
186	Patel   AP, Wang   M, Kartoun   U, Ng   K, Khera   AV. Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among South Asian individuals: results from the UK Biobank prospective cohort study. Circulation  2021;144:410–22. https://doi.org/10.1161/circulationaha.120.052430
   
187	Tillin   T, Hughes   AD, Whincup   P, Mayet   J, Sattar   N, McKeigue   PM, et al.   Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE—Southall And Brent REvisited). Heart  2014;100:60–7. https://doi.org/10.1136/heartjnl-2013-304474
   
188	Rabanal   KS, Igland   J, Tell   GS, Jenum   AK, Klemsdal   TO, Ariansen   I, et al.   Validation of the cardiovascular risk model NORRISK 2 in South Asians and people with diabetes. Scand Cardiovasc J  2021;55:56–62. https://doi.org/10.1080/14017431.2020.1821909
   
189	Veronesi   G, Gianfagna   F, Giampaoli   S, Chambless   LE, Mancia   G, Cesana   G, et al.   Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. Prev Med  2014;64:75–80. https://doi.org/10.1016/j.ypmed.2014.04.007
   
190	Sivapalaratnam   S, Boekholdt   SM, Trip   MD, Sandhu   MS, Luben   R, Kastelein   JJP, et al.   Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart  2010;96:1985–9. https://doi.org/10.1136/hrt.2010.210740
   
191	Kimenai   DM, Pirondini   L, Gregson   J, Prieto   D, Pocock   SJ, Perel   P, et al.   Socioeconomic deprivation: an important, largely unrecognized risk factor in primary prevention of cardiovascular disease. Circulation  2022;146:240–8. https://doi.org/10.1161/circulationaha.122.060042
   
192	Avina-Zubieta   JA, Thomas   J, Sadatsafavi   M, Lehman   AJ, Lacaille   D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis  2012;71:1524–9. https://doi.org/10.1136/annrheumdis-2011-200726
   
193	Crowson   CS, Matteson   EL, Roger   VL, Therneau   TM, Gabriel   SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol  2012;110:420–4. https://doi.org/10.1016/j.amjcard.2012.03.044
   
194	Arts   EE, Popa   C, Den Broeder   AA, Semb   A G, Toms   T, Kitas   G D, et al.   Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis  2015;74:668–74. https://doi.org/10.1136/annrheumdis-2013-204024
   
195	Arts   EE, Popa   CD, Den Broeder   AA, Donders   R, Sandoo   A, Toms   T, et al.   Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis  2016;75:674–80. https://doi.org/10.1136/annrheumdis-2014-206879
   
196	Gelfand   JM, Neimann   AL, Shin   DB, Wang   X, Margolis   DJ, Troxel   AB. Risk of myocardial infarction in patients with psoriasis. JAMA  2006;296:1735–41. https://doi.org/10.1001/jama.296.14.1735
   
197	Miller   IM, Ellervik   C, Yazdanyar   S, Jemec   GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol  2013;69:1014–24. https://doi.org/10.1016/j.jaad.2013.06.053
   
198	Eder   L, Chandran   V, Gladman   DD. The Framingham risk score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis  2014;73:1990–6. https://doi.org/10.1136/annrheumdis-2013-203433
   
199	Armstrong   EJ, Harskamp   CT, Armstrong   AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc  2013;2:e000062. https://doi.org/10.1161/jaha.113.000062
   
200	Elmets   CA, Leonardi   CL, Davis   DMR, Gelfand   JM, Lichten   J, Mehta   NN, et al.   Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol  2019;80:1073–113. https://doi.org/10.1016/j.jaad.2018.11.058
   
201	Lu   X, Wang   Y, Zhang   J, Pu   D, Hu   N, Luo   J, et al.   Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol  2021;94:107466. https://doi.org/10.1016/j.intimp.2021.107466
   
202	Drosos   GC, Konstantonis   G, Sfikakis   PP, Tektonidou   MG. Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. Eur J Prev Cardiol. 2020. https://doi.org/10.1177/2047487320906650
Google ScholarWorldCat 
203	Shah   ASV, Stelzle   D, Lee   KK, Beck   EJ, Alam   S, Clifford   S, et al.   Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation  2018;138:1100–12. https://doi.org/10.1161/circulationaha.117.033369
   
204	Triant   VA, Perez   J, Regan   S, Massaro   JM, Meigs   JB, Grinspoon   SK, et al.   Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation  2018;137:2203–14. https://doi.org/10.1161/circulationaha.117.028975
   
205	Triant VA, Lyass A, Hurley LB, Borowsky LH, Ehrbar RQ, H W, et al.   Cardiovascular Risk Estimation Is Suboptimal in People With HIV. J Am Heart Assoc.  2024;13:e029228. https://doi.org/10.1161/JAHA.123.029228
CrossrefPubMedWorldCat 
206	Correll   CU, Solmi   M, Veronese   N, Bortolato   B, Rosson   S, Santonastaso   P, et al.   Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry  2017;16:163–80. https://doi.org/10.1002/wps.20420
   
207	Lambert   AM, Parretti   HM, Pearce   E, Price   MJ, Riley   M, Ryan   R, et al.   Temporal trends in associations between severe mental illness and risk of cardiovascular disease: a systematic review and meta-analysis. PLoS Med  2022;19:e1003960. https://doi.org/10.1371/journal.pmed.1003960
   
208	Cunningham   R, Poppe   K, Peterson   D, Every-Palmer   S, Soosay   I, Jackson   R. Prediction of cardiovascular disease risk among people with severe mental illness: a cohort study. PLoS One  2019;14:e0221521. https://doi.org/10.1371/journal.pone.0221521
   
209	Yeboah   J, Young   R, McClelland   RL, Delaney   JC, Polonsky   TS, Dawood   FZ, et al.   Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol  2016;67:139–47. https://doi.org/10.1016/j.jacc.2015.10.058
   
210	Akintoye   E, Afonso   L, Bengaluru Jayanna   M, Bao   W, Briasoulis   A, Robinson   J, et al.   Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC/AHA multisociety cholesterol treatment guidelines over the pooled cohort equation: insights from 3 large prospective cohorts. J Am Heart Assoc  2021;10:e019589. https://doi.org/10.1161/jaha.120.019589
   
211	Peters   SA, den Ruijter   HM, Bots   ML, Moons   KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart  2012;98:177–84. https://doi.org/10.1136/heartjnl-2011-300747
   
212	Nicolaides   AN, Panayiotou   AG, Griffin   M, Tyllis   T, Bond   D, Georgiou   N, et al.   Arterial ultrasound testing to predict atherosclerotic cardiovascular events. J Am Coll Cardiol  2022;79:1969–82. https://doi.org/10.1016/j.jacc.2022.03.352
   
213	Laclaustra   M, Casasnovas   JA, Fernández-Ortiz   A, Fuster   V, León-Latre   M, Jiménez-Borreguero   LJ, et al.   Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol  2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056
   
214	López-Melgar   B, Fernández-Friera   L, Oliva   B, García-Ruiz   JM, Peñalvo   JL, Gómez-Talavera   S, et al.   Subclinical atherosclerosis burden by 3D ultrasound in mid-life: the PESA study. J Am Coll Cardiol  2017;70:301–13. https://doi.org/10.1016/j.jacc.2017.05.033
   
215	Ben-Shlomo   Y, Spears   M, Boustred   C, May   M, Anderson   SG, Benjamin   EJ, et al.   Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol  2014;63:636–46. https://doi.org/10.1016/j.jacc.2013.09.063
   
216	Ohkuma   T, Ninomiya   T, Tomiyama   H, Kario   K, Hoshide   S, Kita   Y, et al.   Brachial-Ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension  2017;69:1045–52. https://doi.org/10.1161/hypertensionaha.117.09097
   
217	Stone   K, Veerasingam   D, Meyer   ML, Heffernan   KS, Higgins   S, Maria Bruno   R, et al.   Reimagining the value of brachial-ankle pulse wave velocity as a biomarker of cardiovascular disease risk-a call to action on behalf of VascAgeNet. Hypertension  2023;80:1980–92. https://doi.org/10.1161/hypertensionaha.123.21314
   
218	An   DW, Hansen   TW, Aparicio   LS, Chori   B, Huang   Q-F, Wei   F-F, et al.   Derivation of an outcome-driven threshold for aortic pulse wave velocity: an individual-participant meta-analysis. Hypertension  2023;80:1949–59. https://doi.org/10.1161/hypertensionaha.123.21318
   
219	de Lemos   JA, Ayers   CR, Levine   BD, deFilippi   CR, Wang   TJ, Hundley   W, et al.   Multimodality strategy for cardiovascular risk assessment: performance in 2 population-based cohorts. Circulation  2017;135:2119–32. https://doi.org/10.1161/circulationaha.117.027272
   
220	Hageman   SHJ, Petitjean   C, Pennells   L, Kaptoge   S, Pajouheshnia   R, Tillmann   T, et al.   Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol  2023;30:1705–14. https://doi.org/10.1093/eurjpc/zwad187
   
221	McEvoy   JW, Chen   Y, Nambi   V, Ballantyne   CM, Sharrett   AR, Appel   LJ, et al.   High-sensitivity cardiac troponin T and risk of hypertension. Circulation  2015;132:825–33. https://doi.org/10.1161/circulationaha.114.014364
   
222	Hussain   A, Sun   W, Deswal   A, de Lemos   JA, McEvoy   JW, Hoogeveen   RC, et al.   Association of NT-ProBNP, blood pressure, and cardiovascular events: the ARIC study. J Am Coll Cardiol  2021;77:559–71. https://doi.org/10.1016/j.jacc.2020.11.063
   
223	Stuart   JJ, Tanz   LJ, Cook   NR, Spiegelman   D, Missmer   SA, Rimm   EB, et al.   Hypertensive disorders of pregnancy and 10-year cardiovascular risk prediction. J Am Coll Cardiol  2018;72:1252–63. https://doi.org/10.1016/j.jacc.2018.05.077
   
224	Timpka   S, Fraser   A, Schyman   T, Stuart   JJ, Åsvold   BO, Mogren   I, et al.   The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. Eur J Epidemiol  2018;33:1003–10. https://doi.org/10.1007/s10654-018-0429-1
   
225	Blankenberg   S, Salomaa   V, Makarova   N, Ojeda   F, Wild   P, Lackner   KJ, et al.   Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J  2016;37:2428–37. https://doi.org/10.1093/eurheartj/ehw172
   
226	Zeller   T, Tunstall-Pedoe   H, Saarela   O, Ojeda   F, Schnabel   RB, Tuovinen   T, et al.   High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM biomarker project Scottish cohort. Eur Heart J  2014;35:271–81. https://doi.org/10.1093/eurheartj/eht406
   
227	Schoenthaler   AM, Lancaster   KJ, Chaplin   W, Butler   M, Forsyth   J, Ogedegbe   G, et al.   Cluster randomized clinical trial of FAITH (faith-based approaches in the treatment of hypertension) in blacks. Circ Cardiovasc Qual Outcomes  2018;11:e004691. https://doi.org/10.1161/circoutcomes.118.004691
   
228	Beaney   T, Schutte   AE, Stergiou   GS, Borghi   C, Burger   D, Charchar   F, et al.   May Measurement Month 2019: the global blood pressure screening campaign of the international society of Hypertension. Hypertension  2020;76:333–41. https://doi.org/10.1161/hypertensionaha.120.14874
   
229	Victor   RG, Lynch   K, Li   N, Blyler   C, Muhammad   E, Handler   J, et al.   A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med  2018;378:1291–301. https://doi.org/10.1056/NEJMoa1717250
   
230	Sun   Y, Mu   J, Wang   DW, Ouyang   N, Xing   L, Guo   X, et al.   A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet  2022;399:1964–75. https://doi.org/10.1016/s0140-6736(22)00325-7
   
231	Schmidt   BM, Durao   S, Toews   I, Bavuma   CM, Hohlfeld   A, Nury   E, et al.   Screening strategies for hypertension. Cochrane Database Syst Rev  2020;5:CD013212. https://doi.org/10.1002/14651858.CD013212.pub2
Google ScholarPubMedWorldCat 
232	Kaczorowski   J, Chambers   LW, Dolovich   L, Paterson   JM, Karwalajtys   T, Gierman   T, et al.   Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). BMJ  2011;342:d442. https://doi.org/10.1136/bmj.d442
   
233	Lindholt   JS, Søgaard   R, Rasmussen   LM, Mejldal   A, Lambrechtsen   J, Steffensen   FH, et al.   Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med  2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681
   
234	Sheppard   JP, Schwartz   CL, Tucker   KL, McManus   RJ. Modern management and diagnosis of hypertension in the United Kingdom: home care and self-care. Ann Glob Health  2016;82:274–87. https://doi.org/10.1016/j.aogh.2016.02.005
   
235	Andersson   H, Hedström   L, Bergman   S, Bergh   H. The outcome of two-step blood pressure screening in dental healthcare. Scand J Public Health  2018;46:623–9. https://doi.org/10.1177/1403494818759840
   
236	Zhang   H, Thijs   L, Kuznetsova   T, Fagard   RH, Li   X, Staessen   JA. Progression to hypertension in the non-hypertensive participants in the Flemish study on environment, genes and health outcomes. J Hypertens  2006;24:1719–27. https://doi.org/10.1097/01.hjh.0000242395.07473.92
   
237	Conen   D, Aeschbacher   S, Thijs   L, Li   Y, Boggia   J, Asayama   K, et al.   Age-specific differences between conventional and ambulatory daytime blood pressure values. Hypertension  2014;64:1073–9. https://doi.org/10.1161/hypertensionaha.114.03957
   
238	Karnjanapiboonwong   A, Anothaisintawee   T, Chaikledkaew   U, Dejthevaporn   C, Attia   J, Thakkinstian   A. Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord  2020;20:491. https://doi.org/10.1186/s12872-020-01736-2
   
239	Viera   AJ, Yano   Y, Lin   FC, Simel   DL, Yun   J, Dave   G, et al.   Does this adult patient have hypertension?: The rational clinical examination systematic review. JAMA  2021;326:339–47. https://doi.org/10.1001/jama.2021.4533
   
240	Green   BB, Anderson   ML, Cook   AJ, Ehrlich   K, Hall   YN, Hsu   C, et al.   Clinic, home, and kiosk blood pressure measurements for diagnosing hypertension: a randomized diagnostic study. J Gen Intern Med  2022;37:2948–56. https://doi.org/10.1007/s11606-022-07400-z
   
241	Kim   JS, Rhee   MY, Kim   CH, Kim   YR, Do   U, Kim   J-H, et al.   Algorithm for diagnosing hypertension using out-of-office blood pressure measurements. J Clin Hypertens (Greenwich)  2021;23:1965–74. https://doi.org/10.1111/jch.14382
   
242	van den Born   BH, Lip   GYH, Brguljan-Hitij   J, Cremer   A, Segura   J, Morales   E, et al.   ESC Council on Hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother  2019;5:37–46. https://doi.org/10.1093/ehjcvp/pvy032
   
243	Ross   S, Walker   A, MacLeod   MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens  2004;18:607–13. https://doi.org/10.1038/sj.jhh.1001721
   
244	Hagger   MS, Koch   S, Chatzisarantis   NLD, Orbell   S. The common sense model of self-regulation: meta-analysis and test of a process model. Psychol Bull  2017;143:1117–54. https://doi.org/10.1037/bul0000118
   
245	Meyer   D, Leventhal   H, Gutmann   M. Common-sense models of illness: the example of hypertension. Health Psychol  1985;4:115–35. https://doi.org/10.1037//0278-6133.4.2.115
   
246	O’Carroll   RE, Chambers   JA, Dennis   M, Sudlow   C, Johnston   M. Improving adherence to medication in stroke survivors: a pilot randomised controlled trial. Ann Behav Med  2013;46:358–68. https://doi.org/10.1007/s12160-013-9515-5
   
247	Hollands   GJ, Usher-Smith   JA, Hasan   R, Alexander   F, Clarke   N, Griffin   SJ. Visualising health risks with medical imaging for changing recipients’ health behaviours and risk factors: systematic review with meta-analysis. PLoS Med  2022;19:e1003920. https://doi.org/10.1371/journal.pmed.1003920
   
248	Burnier   M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens  2006;19:1190–6. https://doi.org/10.1016/j.amjhyper.2006.04.006
   
249	Parati   G, Goncalves   A, Soergel   D, Bruno   RM, Caiani   EG, Gerdts   E. New perspectives for hypertension management: progress in methodological and technological developments. Eur J Prev Cardiol  2023;30:48–60. https://doi.org/10.1093/eurjpc/zwac203
   
250	Naderi   SH, Bestwick   JP, Wald   DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med  2012;125:882–7.e1. https://doi.org/10.1016/j.amjmed.2011.12.013
   
251	Chang   TE, Ritchey   MD, Park   S, Chang   A, Odom   EC, Durthaler   J, et al.   National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension  2019;74:1324–32. https://doi.org/10.1161/hypertensionaha.119.13616
   
252	Qvarnström   M, Kahan   T, Kieler   H, Brandt   L, Hasselström   J, Bengtsson Boström   K, et al.   Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol  2013;69:1955–64. https://doi.org/10.1007/s00228-013-1555-z
   
253	Burnier   M, Egan   BM. Adherence in hypertension. Circ Res  2019;124:1124–40. https://doi.org/10.1161/circresaha.118.313220
   
254	Curneen   JMG, Rabbitt   L, Browne   D, O’Donoghue   DF, Alansari   Y, Harhen   B, et al.   Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: a prospective study in a tertiary-referral hypertension clinic. Br J Clin Pharmacol  2022;89:1948–55. https://doi.org/10.1111/bcp.15292
   
255	Corrao   G, Parodi   A, Nicotra   F, Zambon   A, Merlino   L, Cesana   G, et al.   Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens  2011;29:610–8. https://doi.org/10.1097/HJH.0b013e328342ca97
   
256	Kim   S, Shin   DW, Yun   JM, Hwang   Y, Park   SK, Ko   Y-J, et al.   Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension  2016;67:506–12. https://doi.org/10.1161/hypertensionaha.115.06731
   
257	Lane   D, Lawson   A, Burns   A, Azizi   M, Burnier   M, Jones   DJL, et al.   Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension  2022;79:12–23. https://doi.org/10.1161/hypertensionaha.121.17596
   
258	Marshall   IJ, Wolfe   CD, McKevitt   C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ  2012;345:e3953. https://doi.org/10.1136/bmj.e3953
   
259	Schoenthaler   A, Knafl   GJ, Fiscella   K, Ogedegbe   G. Addressing the social needs of hypertensive patients: the role of patient–provider communication as a predictor of medication adherence. Circ Cardiovasc Qual Outcomes  2017;10:e003659. https://doi.org/10.1161/circoutcomes.117.003659
   
260	Schmieder   RE, Wassmann   S, Predel   HG, Weisser   B, Blettenberg   J, Gillessen   A, et al.   Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study. Hypertension  2023;80:1127–35. https://doi.org/10.1161/hypertensionaha.122.20810
   
261	Ruzicka   M, Leenen   FHH, Ramsay   T, Bugeja   A, Edwards   C, McCormick   B, et al.   Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med  2019;179:1433–4. https://doi.org/10.1001/jamainternmed.2019.1455
   
262	Pio-Abreu   A, Trani-Ferreira   F, Silva   GV, Bortolotto   LA, Drager   LF. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart  2022;108:1952–6. https://doi.org/10.1136/heartjnl-2022-320802
   
263	Tomaszewski   M, White   C, Patel   P, Masca   N, Damani   R, Hepworth   J, et al.   High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart  2014;100:855–61. https://doi.org/10.1136/heartjnl-2013-305063
   
264	Forette   F, Seux   ML, Staessen   JA, et al.   The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med  2002;162:2046–52. https://doi.org/10.1001/archinte.162.18.2046
   
265	Näslund   U, Ng   N, Lundgren   A, Fhärm   E, Grönlund   C, Johansson   H, et al.   Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet  2019;393:133–42. https://doi.org/10.1016/s0140-6736(18)32818-6
   
266	Bengtsson   A, Norberg   M, Ng   N, Carlberg   B, Grönlund   C, Hultdin   J, et al.   The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: results from the VIPVIZA randomized clinical trial. Am J Prev Cardiol  2021;7:100199. https://doi.org/10.1016/j.ajpc.2021.100199
   
267	Sjölander   M, Carlberg   B, Norberg   M, Näslund   U, Ng   N. Prescription of lipid-lowering and antihypertensive drugs following pictorial information about subclinical atherosclerosis: a secondary outcome of a randomized clinical trial. JAMA Netw Open  2021;4:e2121683. https://doi.org/10.1001/jamanetworkopen.2021.21683
   
268	Muiesan   ML, Salvetti   M, Monteduro   C, Bonzi   B, Paini   A, Viola   S, et al.   Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension  2004;43:731–8. https://doi.org/10.1161/01.HYP.0000121223.44837.de
   
269	Guerin   AP, Blacher   J, Pannier   B, Marchais   SJ, Safar   ME, London   GM, et al.   Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation  2001;103:987–92. https://doi.org/10.1161/01.cir.103.7.987
   
270	Cardoso   CRL, Salles   GF. Prognostic value of changes in aortic stiffness for cardiovascular outcomes and mortality in resistant hypertension: a cohort study. Hypertension  2022;79:447–56. https://doi.org/10.1161/hypertensionaha.121.18498
   
271	Laurent   S, Chatellier   G, Azizi   M, Calvet   D, Choukroun   G, Danchin   N, et al.   SPARTE study: normalization of arterial stiffness and cardiovascular events in patients with hypertension at medium to very high risk. Hypertension  2021;78:983–95. https://doi.org/10.1161/hypertensionaha.121.17579
   
272	Levin   A, Stevens   PE, Bilous   RW, Coresh   J, De Francisco   ALM, De Jong   PE, et al.   Summary of recommendation statements. Kidney Int Suppl (2011)  2013;3:5–14. https://doi.org/10.1038/kisup.2012.77
Google ScholarPubMedWorldCat 
273	Matsushita   K, Coresh   J, Sang   Y, Chalmers   J, Fox   C, Guallar   E, et al.   Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol  2015;3:514–25. https://doi.org/10.1016/s2213-8587(15)00040-6
   
274	Cheung   AK, Rahman   M, Reboussin   DM, Craven   TE, Greene   T, Kimmel   PL, et al.   Effects of intensive BP control in CKD. J Am Soc Nephrol  2017;28:2812–23. https://doi.org/10.1681/asn.2017020148
   
275	Malhotra   R, Nguyen   HA, Benavente   O, Mete   M, Howard   BV, Mant   J, et al.   Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med  2017;177:1498–505. https://doi.org/10.1001/jamainternmed.2017.4377
   
276	Stevens   PE, Levin   A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med  2013;158:825–30. https://doi.org/10.7326/0003-4819-158-11-201306040-00007
   
277	Aboyans   V, Ricco   JB, Bartelink   MEL, Björck   M, Brodmann   M, Cohnert   T, et al.   2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J  2018;39:763–816. https://doi.org/10.1093/eurheartj/ehx095
   
278	Iribarren   C, Round   AD, Lu   M, Okin   PM, McNulty   EJ. Cohort study of ECG left ventricular hypertrophy trajectories: ethnic disparities, associations with cardiovascular outcomes, and clinical utility. J Am Heart Assoc  2017;6:e004954. https://doi.org/10.1161/jaha.116.004954
   
279	Okin   PM, Devereux   RB, Jern   S, Kjeldsen   SE, Julius   S, Dahlöf   B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Hypertension  2000;36:766–73. https://doi.org/10.1161/01.hyp.36.5.766
   
280	Okin   PM, Oikarinen   L, Viitasalo   M, Toivonen   L, Kjeldsen   SE, Nieminen   MS, et al.   Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-point reduction in hypertension study (LIFE). Circulation  2009;119:1883–91. https://doi.org/10.1161/circulationaha.108.812313
   
281	Lehtonen   AO, Puukka   P, Varis   J, Porthan   K, Tikkanen   JT, Nieminen   MS, et al.   Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens  2016;34:959–66. https://doi.org/10.1097/hjh.0000000000000882
   
282	Pewsner   D, Jüni   P, Egger   M, Battaglia   M, Sundström   J, Bachmann   LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ  2007;335:711. https://doi.org/10.1136/bmj.39276.636354.AE
   
283	Kuznetsova   T, Thijs   L, Knez   J, Cauwenberghs   N, Petit   T, Gu   Y-M. Longitudinal changes in left ventricular diastolic function in a general population. Circ Cardiovasc Imaging  2015;8:e002882. https://doi.org/10.1161/circimaging.114.002882
   
284	Zhao   L, Zierath   R, Claggett   B, Dorbala   P, Matsushita   K, Kitzman   D. Longitudinal changes in left ventricular diastolic function in late life: the ARIC study. JACC Cardiovasc Imaging  2023;16:1133–45. https://doi.org/10.1016/j.jcmg.2023.02.022
   
285	Redfield   MM, Jacobsen   SJ, Burnett   JC  Jr, Mahoney   DW, Bailey   KR, Rodeheffer   RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA  2003;289:194–202. https://doi.org/10.1001/jama.289.2.194
   
286	Sundström   J, Lind   L, Arnlöv   J, Zethelius   B, Andrén   B, Lithell   HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation  2001;103:2346–51. https://doi.org/10.1161/01.cir.103.19.2346
   
287	Seko   Y, Kato   T, Yamaji   Y, Haruna   Y, Nakane   E, Haruna   T, et al.   Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes. Open Heart  2021;8:e001765. https://doi.org/10.1136/openhrt-2021-001765
   
288	Modin   D, Biering-Sørensen   SR, Mogelvang   R, Landler   N, Jensen   JS, Biering-Sørensen   T. Prognostic value of echocardiography in hypertensive versus nonhypertensive participants from the general population. Hypertension  2018;71:742–51. https://doi.org/10.1161/hypertensionaha.117.10674
   
289	Armstrong   AC, Jacobs   DR  Jr, Gidding   SS, Colangelo   LA, Gjesdal   O, Lewis   CE, et al.   Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol  2014;172:350–5. https://doi.org/10.1016/j.ijcard.2014.01.003
   
290	Kuznetsova   T, Thijs   L, Knez   J, Herbots   L, Zhang   Z, Staessen   JA. Prognostic value of left ventricular diastolic dysfunction in a general population. J Am Heart Assoc  2014;3:e000789. https://doi.org/10.1161/jaha.114.000789
   
291	Marwick   TH, Gillebert   TC, Aurigemma   G, et al.   Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging  2015;16:577–605. https://doi.org/10.1093/ehjci/jev076
Google ScholarPubMedWorldCat 
292	Douglas   PS, Garcia   MJ, Haines   DE, Lai   WW, Manning   WJ, Patel   AR, et al.   ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation appropriate use criteria task force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr  2011;24:229–67. https://doi.org/10.1016/j.echo.2010.12.008
Google ScholarPubMedWorldCat 
293	van Rosendael   AR, Bax   AM, Smit   JM, van den Hoogen   IJ, Ma   X, Al’Aref   S, et al.   Clinical risk factors and atherosclerotic plaque extent to define risk for major events in patients without obstructive coronary artery disease: the long-term coronary computed tomography angiography CONFIRM registry. Eur Heart J Cardiovasc Imaging  2020;21:479–88. https://doi.org/10.1093/ehjci/jez322
   
294	Mehta   A, Pandey   A, Ayers   CR, Khera   A, Sperling   LS, Szklo   M, et al.   Predictive value of coronary artery calcium score categories for coronary events versus strokes: impact of sex and race: MESA and DHS. Circ Cardiovasc Imaging  2020;13:e010153. https://doi.org/10.1161/circimaging.119.010153
   
295	Bengtsson   A, Lindvall   K, Norberg   M, Fhärm   E. Increased knowledge makes a difference!—general practitioners’ experiences of pictorial information about subclinical atherosclerosis for primary prevention: an interview study from the VIPVIZA trial. Scand J Prim Health Care  2021;39:77–84. https://doi.org/10.1080/02813432.2021.1882083
   
296	Ibanez   B, Fernández-Ortiz   A, Fernández-Friera   L, García-Lunar   I, Andrés   V, Fuster   V. Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8. J Am Coll Cardiol  2021;78:156–79. https://doi.org/10.1016/j.jacc.2021.05.011
   
297	Den Ruijter   HM, Peters   SA, Anderson   TJ, Britton   AR, Dekker   JM, Eijkemans   MJ. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA  2012;308:796–803. https://doi.org/10.1001/jama.2012.9630
   
298	Downie   LE, Hodgson   LA, DSylva   C, McIntosh   RL, Rogers   SL, Connell   P, et al.   Hypertensive retinopathy: comparing the Keith-Wagener-Barker to a simplified classification. J Hypertens  2013;31:960–5. https://doi.org/10.1097/HJH.0b013e32835efea3
   
299	Liew   G, Xie   J, Nguyen   H, Keay   L, Kamran Ikram   M, McGeechan   K, et al.   Hypertensive retinopathy and cardiovascular disease risk: 6 population-based cohorts meta-analysis. Int J Cardiol Cardiovasc Risk Prev  2023;17:200180. https://doi.org/10.1016/j.ijcrp.2023.200180
Google ScholarPubMedWorldCat 
300	Padmanabhan   S, Caulfield   M, Dominiczak   AF. Genetic and molecular aspects of hypertension. Circ Res  2015;116:937–59. https://doi.org/10.1161/circresaha.116.303647
   
301	Casey   R, Neumann   HPH, Maher   ER. Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine. Hum Mol Genet  2020;29:R128–137. https://doi.org/10.1093/hmg/ddaa201
   
302	Rossi   GP, Ceolotto   G, Caroccia   B, Lenzini   L. Genetic screening in arterial hypertension. Nat Rev Endocrinol  2017;13:289–98. https://doi.org/10.1038/nrendo.2016.196
   
303	Cascón   A, Calsina   B, Monteagudo   M, Mellid   S, Díaz-Talavera   A, Currás-Freixes   M, et al.   Genetic bases of pheochromocytoma and paraganglioma. J Mol Endocrinol  2023;70:e220167. https://doi.org/10.1530/jme-22-0167
   
304	Staessen   JA, Wang   J, Bianchi   G, Birkenhäger   WH. Essential hypertension. Lancet  2003;361:1629–41. https://doi.org/10.1016/s0140-6736(03)13302-8
   
305	Lenders   JW, Duh   QY, Eisenhofer   G, Gimenez-Roqueplo   A-P, Grebe   SKG, Murad   MH, et al.   Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab  2014;99:1915–42. https://doi.org/10.1210/jc.2014-1498
   
306	Poulter   NR, Prabhakaran   D, Caulfield   M. Hypertension. Lancet  2015;386:801–12. https://doi.org/10.1016/s0140-6736(14)61468-9
   
307	Mills   KT, Bundy   JD, Kelly   TN, Reed   JE, Kearney   PM, Reynolds   K, et al.   Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation  2016;134:441–50. https://doi.org/10.1161/circulationaha.115.018912
   
308	Wei   FF, Zhang   ZY, Huang   QF, Staessen   JA. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol  2018;14:428–41. https://doi.org/10.1038/s41581-018-0006-6
   
309	Carey   RM, Calhoun   DA, Bakris   GL, Brook   RD, Daugherty   SL, Dennison-Himmelfarb Cheryl   R, et al.   Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension  2018;72:e53–90. https://doi.org/10.1161/hyp.0000000000000084
   
310	Carey   RM, Sakhuja   S, Calhoun   DA, Whelton   PK, Muntner   P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension  2019;73:424–31. https://doi.org/10.1161/hypertensionaha.118.12191
   
311	Vongpatanasin   W. Resistant hypertension: a review of diagnosis and management. JAMA  2014;311:2216–24. https://doi.org/10.1001/jama.2014.5180
   
312	Azizi   M, Sapoval   M, Gosse   P, Monge   M, Bobrie   G, Delsart   P, et al.   Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet  2015;385:1957–65. https://doi.org/10.1016/s0140-6736(14)61942-5
   
313	Rossi   GP, Bernini   G, Caliumi   C, Desideri   G, Fabris   B, Ferri   C, et al.   A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol  2006;48:2293–300. https://doi.org/10.1016/j.jacc.2006.07.059
   
314	Pedrosa   RP, Drager   LF, Gonzaga   CC, Sousa   MG, de Paula   LKG, Amaro   ACS, et al.   Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension  2011;58:811–7. https://doi.org/10.1161/hypertensionaha.111.179788
   
315	Douma   S, Petidis   K, Doumas   M, Papaefthimiou   P, Triantafyllou   A, Kartali   N, et al.   Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet  2008;371:1921–6. https://doi.org/10.1016/s0140-6736(08)60834-x
   
316	Monticone   S, Burrello   J, Tizzani   D, Bertello   C, Viola   A, Buffolo   F, et al.   Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol  2017;69:1811–20. https://doi.org/10.1016/j.jacc.2017.01.052
   
317	Käyser   SC, Deinum   J, de Grauw   WJ, Schalk   BWM, Bor   HJHJ, Lenders   JWM, et al.   Prevalence of primary aldosteronism in primary care: a cross-sectional study. Br J Gen Pract  2018;68:e114–22. https://doi.org/10.3399/bjgp18X694589
   
318	Rimoldi   SF, Scherrer   U, Messerli   FH. Secondary arterial hypertension: when, who, and how to screen?  Eur Heart J  2014;35:1245–54. https://doi.org/10.1093/eurheartj/eht534
   
319	Rossi   GP, Bisogni   V, Rossitto   G, Maiolino   G, Cesari   M, Zhu   R, et al.   Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension. High Blood Press Cardiovasc Prev  2020;27:547–60. https://doi.org/10.1007/s40292-020-00415-9
   
320	Calhoun   DA, Nishizaka   MK, Zaman   MA, Thakkar   RB, Weissmann   P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension  2002;40:892–6. https://doi.org/10.1161/01.hyp.0000040261.30455.b6
   
321	Jaffe   G, Gray   Z, Krishnan   G, Stedman   M, Zheng   Y, Han   J, et al.   Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension  2020;75:650–9. https://doi.org/10.1161/hypertensionaha.119.14359
   
322	Hundemer   GL, Imsirovic   H, Vaidya   A, Yozamp   N, Goupil   R, Madore   F, et al.   Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension  2022;79:178–86. https://doi.org/10.1161/hypertensionaha.121.18118
   
323	Monticone   S, D’Ascenzo   F, Moretti   C, Williams   TA, Veglio   F, Gaita   F, et al.   Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol  2018;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4
   
324	Savard   S, Amar   L, Plouin   PF, Steichen   O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension  2013;62:331–6. https://doi.org/10.1161/hypertensionaha.113.01060
   
325	Hiramatsu   K, Yamada   T, Yukimura   Y, Komiya   I, Ichikawa   K, Ishihara   M, et al.   A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med  1981;141:1589–93. https://doi.org/10.1001/archinte.1981.00340130033011
   
326	Rossi   GP. Primary aldosteronism: JACC state-of-the-art review. J Am Coll Cardiol  2019;74:2799–811. https://doi.org/10.1016/j.jacc.2019.09.057
   
327	Rossi   GP, Ceolotto   G, Rossitto   G, Maiolino   G, Cesari   M, Seccia   TM. Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism—the EMIRA study. J Clin Endocrinol Metab  2020;105:2060–7. https://doi.org/10.1210/clinem/dgaa080
   
328	Rossi   GP, Bisogni   V, Bacca   AV, Bacca   AV, Belfiore   A, Cesari   M, et al.   The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens  2020;5:100029. https://doi.org/10.1016/j.ijchy.2020.100029
   
329	Faconti   L, Kulkarni   S, Delles   C, Kapil   V, Lewis   P, Glover   M, et al.   Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society. J Hum Hypertens  2024;38:8–18. https://doi.org/10.1038/s41371-023-00875-1
   
330	Olin   JW, Gornik   HL, Bacharach   JM, Biller   J, Fine   LJ, Gray   BH, et al.   Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation  2014;129:1048–78. https://doi.org/10.1161/01.cir.0000442577.96802.8c
   
331	Faconti   L, Morselli   F, Sinha   M, Chrysochou   C, Chowienczyk   PJ. Fibromuscular dysplasia and hypertension—a statement on behalf of the British and Irish Hypertension Society. J Hum Hypertens  2021;35:1051–3. https://doi.org/10.1038/s41371-020-00456-6
   
332	Gornik   HL, Persu   A, Adlam   D, Aparicio   LS, Azizi   M, Boulanger   M, et al.   First international consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens  2019;37:229–52. https://doi.org/10.1097/hjh.0000000000002019
   
333	Abrishami   A, Khajehdehi   A, Chung   F. A systematic review of screening questionnaires for obstructive sleep apnea. Can J Anaesth  2010;57:423–38. https://doi.org/10.1007/s12630-010-9280-x
   
334	Chai-Coetzer   CL, Antic   NA, Hamilton   GS, McArdle   N, Wong   K, Yee   BJ, et al.   Physician decision making and clinical outcomes with laboratory polysomnography or limited-channel sleep studies for obstructive sleep apnea: a randomized trial. Ann Intern Med  2017;166:332–40. https://doi.org/10.7326/m16-1301
   
335	Lenders   JW, Eisenhofer   G, Mannelli   M, Pacak   K. Phaeochromocytoma. Lancet  2005;366:665–75. https://doi.org/10.1016/s0140-6736(05)67139-5
   
336	Lenders   JWM, Kerstens   MN, Amar   L, Prejbisz   A, Robledo   M, Taieb   D, et al.   Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens  2020;38:1443–56. https://doi.org/10.1097/hjh.0000000000002438
   
337	Mannelli   M, Ianni   L, Cilotti   A, Conti   A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol  1999;141:619–24. https://doi.org/10.1530/eje.0.1410619
Google ScholarPubMedWorldCat 
338	Neumann   HPH, Young   WF  Jr, Eng   C. Pheochromocytoma and paraganglioma. N Engl J Med  2019;381:552–65. https://doi.org/10.1056/NEJMra1806651
   
339	Hundemer   GL, Curhan   GC, Yozamp   N, Wang   M, Vaidya   A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol  2018;6:51–9. https://doi.org/10.1016/s2213-8587(17)30367-4
   
340	Jackson   R, Lawes   CM, Bennett   DA, Milne   RJ, Rodgers   A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet  2005;365:434–41.
   
341	Yang   L, Sun   J, Zhao   M, Liang   Y, Bovet   P, Xi   B. Elevated blood pressure in childhood and hypertension risk in adulthood: a systematic review and meta-analysis. J Hypertens  2020;38:2346–55. https://doi.org/10.1097/hjh.0000000000002550
   
342	Allen   NB, Krefman   AE, Labarthe   D, Greenland   P, Juonala   M, Kähönen   M, et al.   Cardiovascular health trajectories from childhood through middle age and their association with subclinical atherosclerosis. JAMA Cardiol  2020;5:557–66. https://doi.org/10.1001/jamacardio.2020.0140
   
343	de Simone   G, Mancusi   C, Hanssen   H, Genovesi   S, Lurbe   E, Parati   G, et al.   Hypertension in children and adolescents. Eur Heart J  2022;43:3290–301. https://doi.org/10.1093/eurheartj/ehac328
   
344	Falkstedt   D, Koupil   I, Hemmingsson   T. Blood pressure in late adolescence and early incidence of coronary heart disease and stroke in the Swedish 1969 conscription cohort. J Hypertens  2008;26:1313–20. https://doi.org/10.1097/HJH.0b013e3282ffb17e
   
345	Jacobs   DR  Jr, Woo   JG, Sinaiko   AR, Daniels   SR, Ikonen   J, Juonala   M, et al.   Childhood cardiovascular risk factors and adult cardiovascular events. N Engl J Med  2022;386:1877–88. https://doi.org/10.1056/NEJMoa2109191
   
346	Oikonen   M, Nuotio   J, Magnussen   CG, Viikari   JSA, Taittonen   L, Laitinen   T, et al.   Repeated blood pressure measurements in childhood in prediction of hypertension in adulthood. Hypertension  2016;67:41–7. https://doi.org/10.1161/hypertensionaha.115.06395
   
347	Garcia-Lunar   I, van der Ploeg   HP, Fernández Alvira   JM, van Nassau   F, Castellano Vázquez   JM, van der Beek   AJ, et al.   Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial. Eur Heart J  2022;43:3732–45. https://doi.org/10.1093/eurheartj/ehac378
   
348	Neal   B, Wu   Y, Feng   X, Zhang   R, Zhang   Y, Shi   J, et al.   Effect of salt substitution on cardiovascular events and death. N Engl J Med  2021;385:1067–77. https://doi.org/10.1056/NEJMoa2105675
   
349	He   FJ, Tan   M, Ma   Y, MacGregor   GA. Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol  2020;75:632–47. https://doi.org/10.1016/j.jacc.2019.11.055
   
350	Ma   Y, He   FJ, Sun   Q, Yuan   C, Kieneker   LM, Curhan   GC, et al.   24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med  2022;386:252–63. https://doi.org/10.1056/NEJMoa2109794
   
351	Ma   H, Xue   Q, Wang   X, Li   X, Franco   OH, Li   Y, et al.   Adding salt to foods and hazard of premature mortality. Eur Heart J  2022;43:2878–88. https://doi.org/10.1093/eurheartj/ehac208
   
352	Huang   L, Trieu   K, Yoshimura   S, M  Woodward, N  Campbell, D  Lackland, et al.   Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ  2020;368:m315. https://doi.org/10.1136/bmj.m315
Google ScholarPubMedWorldCat 
353	Graudal   N, Hubeck-Graudal   T, Jürgens   G, Taylor   RS. Dose-response relation between dietary sodium and blood pressure: a meta-regression analysis of 133 randomized controlled trials. Am J Clin Nutr  2019;109:1273–8. https://doi.org/10.1093/ajcn/nqy384
   
354	Graudal   NA, Hubeck-Graudal   T, Jurgens   G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev  2020;12:CD004022. https://doi.org/10.1002/14651858.CD004022.pub5
Google ScholarPubMedWorldCat 
355	Filippini   T, Malavolti   M, Whelton   PK, Naska   A, Orsini   N, Vinceti   M. Blood pressure effects of sodium reduction: dose–response meta-analysis of experimental studies. Circulation  2021;143:1542–67. https://doi.org/10.1161/circulationaha.120.050371
   
356	Gupta   DK, Lewis   CE, Varady   KA, Su   YR, Madhur   MS, Lackland   DT, et al.   Effect of dietary sodium on blood pressure: a crossover trial. JAMA  2023;330:2258 . https://doi.org/10.1001/jama.2023.23651
   
357	He   J, Gu   D, Chen   J, Jaquish   CE, Rao   DC, Hixson   JE, et al.   Gender difference in blood pressure responses to dietary sodium intervention in the GenSalt study. J Hypertens  2009;27:48–54. https://doi.org/10.1097/hjh.0b013e328316bb87
   
358	Sacks   FM, Svetkey   LP, Vollmer   WM, Appel   LJ, Bray   GA, Harsha   D, et al.   Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med  2001;344:3–10. https://doi.org/10.1056/nejm200101043440101
   
359	MacGregor   GA, Markandu   ND, Sagnella   GA, Singer   DR, Cappuccio   FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet  1989;2:1244–7. https://doi.org/10.1016/s0140-6736(89)91852-7
Google ScholarPubMedWorldCat 
360	Whelton   PK, Appel   LJ, Espeland   MA, Applegate   WB, Ettinger   WH  Jr, Kostis   JB, et al.   Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA  1998;279:839–46. https://doi.org/10.1001/jama.279.11.839
   
361	He   FJ, Li   J, Macgregor   GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ  2013;346:f1325. https://doi.org/10.1136/bmj.f1325
   
362	Stolarz-Skrzypek   K, Kuznetsova   T, Thijs   L, Tikhonoff   V, Seidlerová   J, Richart   T, et al.   Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA  2011;305:1777–85. https://doi.org/10.1001/jama.2011.574
   
363	Messerli   FH, Hofstetter   L, Syrogiannouli   L, Rexhaj   E, Siontis   GCM, Seiler   C, et al.   Sodium intake, life expectancy, and all-cause mortality. Eur Heart J  2021;42:2103–12. https://doi.org/10.1093/eurheartj/ehaa947
   
364	Mente   A, O’Donnell   M, Rangarajan   S, McQueen   M, Dagenais   G, Wielgosz   A, et al.   Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet  2018;392:496–506. https://doi.org/10.1016/s0140-6736(18)31376-x
   
365	Au Yeung   SL, Schooling   CM. Impact of urinary sodium on cardiovascular disease and risk factors: a 2 sample Mendelian randomization study. Clin Nutr  2021;40:1990–6. https://doi.org/10.1016/j.clnu.2020.09.018
   
366	Zanetti   D, Bergman   H, Burgess   S, Assimes   TL, Bhalla   V, Ingelsson   E. Urinary albumin, sodium, and potassium and cardiovascular outcomes in the UK Biobank: observational and Mendelian randomization analyses. Hypertension  2020;75:714–22. https://doi.org/10.1161/hypertensionaha.119.14028
   
367	Nolan   P, McEvoy   JW. Salt restriction for treatment of hypertension—current state and future directions. Curr Opin Cardiol  2024;39:61–7. https://doi.org/10.1097/hco.0000000000001098
   
368	Yuan   Y, Jin   A, Neal   B, Feng   X, Qiao   Q, Wang   H, et al.   Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med  2023;29:973–81. https://doi.org/10.1038/s41591-023-02286-8
   
369	Lechner   K, Schunkert   H. Recommendations on sodium intake for cardiovascular health: conviction or evidence?  Eur Heart J  2020;41:3374–5. https://doi.org/10.1093/eurheartj/ehaa545
   
370	O’Donnell   M, Mente   A, Alderman   MH, Brady   AJB, Diaz   R, Gupta   R, et al.   Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. Eur Heart J  2020;41:3363–73. https://doi.org/10.1093/eurheartj/ehaa586
   
371	Aburto   NJ, Hanson   S, Gutierrez   H, Hooper   L, Elliott   P, Cappuccio   FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ  2013;346:f1378. https://doi.org/10.1136/bmj.f1378
   
372	O’Donnell   M, Mente   A, Rangarajan   S, McQueen   MJ, Wang   X, Liu   L, et al.   Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med  2014;371:612–23. https://doi.org/10.1056/NEJMoa1311889
   
373	Wouda   RD, Boekholdt   SM, Khaw   KT, Wareham   NJ, de Borst   MH, Hoorn   EJ, et al.   Sex-specific associations between potassium intake, blood pressure, and cardiovascular outcomes: the EPIC-Norfolk study. Eur Heart J  2022;43:2867–75. https://doi.org/10.1093/eurheartj/ehac313
   
374	Filippini   T, Naska   A, Kasdagli   MI, Torres   D, Lopes   C, Carvalho   C, et al.   Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc  2020;9:e015719. https://doi.org/10.1161/jaha.119.015719
   
375	O’Donnell   M, Yusuf   S, Vogt   L, Mente   A, Messerli   FH. Potassium intake: the Cinderella electrolyte. Eur Heart J  2023;44:4925–34. https://doi.org/10.1093/eurheartj/ehad628
   
376	Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis  2004;43:S1–290. https://doi.org/10.1053/j.ajkd.2004.03.006
PubMedWorldCat 
377	Ndanuko   RN, Ibrahim   R, Hapsari   RA, Neale   EP, Raubenheimer   D, Charlton   KE. Association between the urinary sodium to potassium ratio and blood pressure in adults: a systematic review and meta-analysis. Adv Nutr  2021;12:1751–67. https://doi.org/10.1093/advances/nmab036
   
378	Messerli   FH, O’Donnell   M, Mente   A, Yusuf   S. Settling the controversy of salt substitutes and stroke: sodium reduction or potassium increase?  Eur Heart J  2022;43:3365–7. https://doi.org/10.1093/eurheartj/ehac160
   
379	Yin   X, Paige   E, Tian   M, Li   Q, Huang   L, Yu   J, et al.   The proportion of dietary salt replaced with potassium-enriched salt in the SSaSS: implications for scale-up. Hypertension  2023;80:956–65. https://doi.org/10.1161/hypertensionaha.122.20115
   
380	Xu   X, Zeng   L, Jha   V, Cobb   LK, Shibuya   K, Appel   LJ, et al.   Potassium-enriched salt substitutes: a review of recommendations in clinical management guidelines. Hypertension  2024;81:400–14. https://doi.org/10.1161/hypertensionaha.123.21343
   
381	Hanssen   H, Boardman   H, Deiseroth   A, Moholdt   T, Simonenko   M, Kränkel   N, et al.   Personalized exercise prescription in the prevention and treatment of arterial hypertension: a consensus document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol  2022;29:205–15. https://doi.org/10.1093/eurjpc/zwaa141
   
382	Van Hoof   R, Hespel   P, Fagard   R, Lijnen   P, Staessen   J, Amery   A. Effect of endurance training on blood pressure at rest, during exercise and during 24 hours in sedentary men. Am J Cardiol  1989;63:945–9. https://doi.org/10.1016/0002-9149(89)90145-8
   
383	MacDonald   HV, Johnson   BT, Huedo-Medina   TB, Livingston   J, Forsyth   KC, Kraemer   WJ, et al.   Dynamic resistance training as stand-alone antihypertensive lifestyle therapy: a meta-analysis. J Am Heart Assoc  2016;5:e003231. https://doi.org/10.1161/jaha.116.003231
   
384	Hansford   HJ, Parmenter   BJ, McLeod   KA, Wewege   MA, Smart   NA, Schutte   AE, et al.   The effectiveness and safety of isometric resistance training for adults with high blood pressure: a systematic review and meta-analysis. Hypertens Res  2021;44:1373–84. https://doi.org/10.1038/s41440-021-00720-3
   
385	Van Hoof   R, Macor   F, Lijnen   P, Staessen   J, Thijs   L, Vanhees   L, et al.   Effect of strength training on blood pressure measured in various conditions in sedentary men. Int J Sports Med  1996;17:415–22. https://doi.org/10.1055/s-2007-972871
   
386	Leal   JM, Galliano   LM, Del Vecchio   FB. Effectiveness of high-intensity interval training versus moderate-intensity continuous training in hypertensive patients: a systematic review and meta-analysis. Curr Hypertens Rep  2020;22:26. https://doi.org/10.1007/s11906-020-1030-z
   
387	Rossi   A, Dikareva   A, Bacon   SL, Daskalopoulou   SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens  2012;30:1277–88. https://doi.org/10.1097/HJH.0b013e3283544669
   
388	Cuspidi   C, Gherbesi   E, Faggiano   A, Sala   C, Carugo   S, Grassi   G, et al.   Masked hypertension and exaggerated blood pressure response to exercise: a review and meta-analysis. Diagnostics (Basel)  2023;13:1005. https://doi.org/10.3390/diagnostics13061005
   
389	Mariampillai   JE, Liestøl   K, Kjeldsen   SE, Prestgaard   EE, Engeseth   K, Bodegard   J, et al.   Exercise systolic blood pressure at moderate workload is linearly associated with coronary disease risk in healthy men. Hypertension  2020;75:44–50. https://doi.org/10.1161/hypertensionaha.119.13528
   
390	Pelliccia   A, Sharma   S, Gati   S, Bäck   M, Börjesson   M, Caselli   S. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J  2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
   
391	Bull   FC, Al-Ansari   SS, Biddle   S, Borodulin   K, Buman   MP, Cardon   G, et al.   World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med  2020;54:1451–62. https://doi.org/10.1136/bjsports-2020-102955
   
392	Saco-Ledo   G, Valenzuela   PL, Ramírez-Jiménez   M, Morales   JS, Castillo-García   A, Blumenthal   JA, et al.   Acute aerobic exercise induces short-term reductions in ambulatory blood pressure in patients with hypertension: a systematic review and meta-analysis. Hypertension  2021;78:1844–58. https://doi.org/10.1161/hypertensionaha.121.18099
   
393	Garber   CE, Blissmer   B, Deschenes   MR, Franklin   BA, Lamonte   MJ, Lee   I-M, et al.   American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc  2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb
   
394	Edwards   JJ, Deenmamode   AHP, Griffiths   M, Arnold   O, Cooper   NJ, Wiles   JD, et al.   Exercise training and resting blood pressure: a large-scale pairwise and network meta-analysis of randomised controlled trials. Br J Sports Med  2023;57:1317–26. https://doi.org/10.1136/bjsports-2022-106503
   
395	Fletcher   GF, Ades   PA, Kligfield   P, Arena   R, Balady   GJ, Bittner   VA, et al.   Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation  2013;128:873–934. https://doi.org/10.1161/CIR.0b013e31829b5b44
   
396	Craft   BB, Carroll   HA, Lustyk   MK. Gender differences in exercise habits and quality of life reports: assessing the moderating effects of reasons for exercise. Int J Lib Arts Soc Sci  2014;2:65–76.
Google ScholarPubMedWorldCat 
397	Mathieu   P, Poirier   P, Pibarot   P, Lemieux   I, Després   JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension  2009;53:577–84. https://doi.org/10.1161/hypertensionaha.108.110320
   
398	Chandra   A, Neeland   IJ, Berry   JD, Ayers   CR, Rohatgi   A, Das   SR, et al.   The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas heart study. J Am Coll Cardiol  2014;64:997–1002. https://doi.org/10.1016/j.jacc.2014.05.057
   
399	Neter   JE, Stam   BE, Kok   FJ, Grobbee   DE, Geleijnse   JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension  2003;42:878–84. https://doi.org/10.1161/01.Hyp.0000094221.86888.Ae
   
400	Haase   CL, Lopes   S, Olsen   AH, Satylganova   A, Schnecke   V, McEwan   P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond)  2021;45:1249–58. https://doi.org/10.1038/s41366-021-00788-4
   
401	Moore   LL, Visioni   AJ, Qureshi   MM, Bradlee   ML, Ellison   RC, D’Agostino   R. Weight loss in overweight adults and the long-term risk of hypertension: the Framingham study. Arch Intern Med  2005;165:1298–303. https://doi.org/10.1001/archinte.165.11.1298
   
402	Zomer   E, Gurusamy   K, Leach   R, Trimmer   C, Lobstein   T, Morris   S, et al.   Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev  2016;17:1001–11. https://doi.org/10.1111/obr.12433
   
403	Wing   RR, Espeland   MA, Clark   JM, Hazuda   HP, Knowler   WC, Pownall   HJ, et al.   Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: the action for health in diabetes (Look AHEAD) clinical trial. Diabetes Care  2016;39:1345–55. https://doi.org/10.2337/dc16-0509
Google ScholarPubMedWorldCat 
404	Ma   C, Avenell   A, Bolland   M, Hudson   J, Stewart   F, Robertson   C, et al.   Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ  2017;359:j4849. https://doi.org/10.1136/bmj.j4849
Google ScholarPubMedWorldCat 
405	Semlitsch   T, Krenn   C, Jeitler   K, Berghold   A, Horvath   K, Siebenhofer   A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev  2021;2:CD008274. https://doi.org/10.1002/14651858.CD008274.pub4
Google ScholarPubMedWorldCat 
406	Wing   RR, Bolin   P, Brancati   FL, Bray   GA, Clark   JM, Coday   M, et al.   Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med  2013;369:145–54. https://doi.org/10.1056/NEJMoa1212914
Google ScholarPubMedWorldCat 
407	Pagidipati   NJ, Phelan   M, Page   C, Clowse   M, Henao   R, Peterson   ED, et al.   The importance of weight stabilization amongst those with overweight or obesity: results from a large health care system. Prev Med Rep  2021;24:101615. https://doi.org/10.1016/j.pmedr.2021.101615
   
408	Estruch   R, Ros   E, Salas-Salvadó   J, Covas   M-I, Corella   D, Arós   F, et al.   Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med  2018;378:e34. https://doi.org/10.1056/NEJMoa1800389
Google ScholarPubMedWorldCat 
409	Delgado-Lista   J, Alcala-Diaz   JF, Torres-Peña   JD, Quintana-Navarro   GM, Fuentes   F, Garcia-Rios   A, et al.   Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet  2022;399:1876–85. https://doi.org/10.1016/s0140-6736(22)00122-2
   
410	Blumenthal   JA, Babyak   MA, Hinderliter   A, Watkins   LL, Craighead   L, Lin   P-H, et al.   Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med  2010;170:126–35. https://doi.org/10.1001/archinternmed.2009.470
   
411	Juraschek   SP, Miller   ER  III, Weaver   CM, Appel   LJ. Effects of sodium reduction and the DASH diet in relation to baseline blood pressure. J Am Coll Cardiol  2017;70:2841–8. https://doi.org/10.1016/j.jacc.2017.10.011
   
412	Gay   HC, Rao   SG, Vaccarino   V, Ali   MK. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension  2016;67:733–9. https://doi.org/10.1161/hypertensionaha.115.06853
   
413	Siebenhofer   A, Winterholer   S, Jeitler   K, Horvath   K, Berghold   A, Krenn   C, et al.   Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev  2021;1:CD007654. https://doi.org/10.1002/14651858.CD007654.pub5
Google ScholarPubMedWorldCat 
414	Müller   TD, Blüher   M, Tschöp   MH, DiMarchi   RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov  2022;21:201–23. https://doi.org/10.1038/s41573-021-00337-8
   
415	Wilding   JPH, Batterham   RL, Calanna   S, Davies   M, Van Gaal   LF, Lingvay   I, et al.   Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med  2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
   
416	Davies   M, Færch   L, Jeppesen   OK, Pakseresht   A, Pedersen   SD, Perreault   L, et al.   Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet  2021;397:971–84. https://doi.org/10.1016/s0140-6736(21)00213-0
   
417	Tasnim   S, Tang   C, Musini   VM, Wright   JM. Effect of alcohol on blood pressure. Cochrane Database Syst Rev  2020;7:CD012787. https://doi.org/10.1002/14651858.CD012787.pub2
Google ScholarPubMedWorldCat 
418	Liu   F, Liu   Y, Sun   X, Yin   Z, Li   H, Deng   K, et al.   Race- and sex-specific association between alcohol consumption and hypertension in 22 cohort studies: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis  2020;30:1249–59. https://doi.org/10.1016/j.numecd.2020.03.018
   
419	Griswold   MG, Fullman   N, Hawley   C, Arian   N, Zimsen   SRM, Tymeson   HD, et al.   Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet  2018;392:1015–35. https://doi.org/10.1016/s0140-6736(18)31310-2
   
420	D’Elia   L, La Fata   E, Galletti   F, Scalfi   L, Strazzullo   P. Coffee consumption and risk of hypertension: a dose–response meta-analysis of prospective studies. Eur J Nutr  2019;58:271–80. https://doi.org/10.1007/s00394-017-1591-z
   
421	Hodgson   JM, Puddey   IB, Woodman   RJ, Mulder   TPJ, Fuchs   D, Scott   K, et al.   Effects of black tea on blood pressure: a randomized controlled trial. Arch Intern Med  2012;172:186–8. https://doi.org/10.1001/archinte.172.2.186
   
422	Shah   SA, Chu   BW, Lacey   CS, Riddock   IC, Lee   M, Dargush   AE. Impact of acute energy drink consumption on blood pressure parameters: a meta-analysis. Ann Pharmacother  2016;50:808–15. https://doi.org/10.1177/1060028016656433
   
423	Shah   SA, Szeto   AH, Farewell   R, Shek   A, Fan   D, Quach   KN, et al.   Impact of high volume energy drink consumption on electrocardiographic and blood pressure parameters: a randomized trial. J Am Heart Assoc  2019;8:e011318. https://doi.org/10.1161/jaha.118.011318
   
424	Basrai   M, Schweinlin   A, Menzel   J, Mielke   H, Weikert   C, Dusemund   B, et al.   Energy drinks induce acute cardiovascular and metabolic changes pointing to potential risks for young adults: a randomized controlled trial. J Nutr  2019;149:441–50. https://doi.org/10.1093/jn/nxy303
   
425	Fung   TT, Malik   V, Rexrode   KM, Manson   JE, Willett   WC, Hu   FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr  2009;89:1037–42. https://doi.org/10.3945/ajcn.2008.27140
   
426	Mullee   A, Romaguera   D, Pearson-Stuttard   J, Viallon   V, Stepien   M, Freisling   H, et al.   Association between soft drink consumption and mortality in 10 European countries. JAMA Intern Med  2019;179:1479–90. https://doi.org/10.1001/jamainternmed.2019.2478
   
427	Farhangi   MA, Nikniaz   L, Khodarahmi   M. Sugar-sweetened beverages increases the risk of hypertension among children and adolescence: a systematic review and dose–response meta-analysis. J Transl Med  2020;18:344. https://doi.org/10.1186/s12967-020-02511-9
   
428	Critchley   JA, Capewell   S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA  2003;290:86–97. https://doi.org/10.1001/jama.290.1.86
   
429	Anthonisen   NR, Skeans   MA, Wise   RA, Manfreda   J, Kanner   RE, Connett   JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med  2005;142:233–9. https://doi.org/10.7326/0003-4819-142-4-200502150-00005
   
430	Thomson   B, Emberson   J, Lacey   B, Lewington   S, Peto   R, Jemal   A. Association between smoking, smoking cessation, and mortality by race, ethnicity, and sex among US adults. JAMA Netw Open  2022;5:e2231480. https://doi.org/10.1001/jamanetworkopen.2022.31480
   
431	Yang   JJ, Yu   D, Shu   XO, Wen   W, Rahman   S, Abe   S. Reduction in total and major cause-specific mortality from tobacco smoking cessation: a pooled analysis of 16 population-based cohort studies in Asia. Int J Epidemiol  2022;50:2070–81. https://doi.org/10.1093/ije/dyab087
   
432	Martinez-Morata   I, Sanchez   TR, Shimbo   D, Navas-Acien   A. Electronic cigarette use and blood pressure endpoints: a systematic review. Curr Hypertens Rep  2020;23:2. https://doi.org/10.1007/s11906-020-01119-0
   
433	Kim   SY, Jeong   SH, Joo   HJ, Park   M, Park   E-C, Kim   JH, et al.   High prevalence of hypertension among smokers of conventional and e-cigarette: using the nationally representative community dwelling survey. Front Public Health  2022;10:919585. https://doi.org/10.3389/fpubh.2022.919585
   
434	Groppelli   A, Giorgi   DM, Omboni   S, Parati   G, Mancia   G. Persistent blood pressure increase induced by heavy smoking. J Hypertens  1992;10:495–9. https://doi.org/10.1097/00004872-199205000-00014
   
435	Primatesta   P, Falaschetti   E, Gupta   S, Marmot   MG, Poulter   NR. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension  2001;37:187–93. https://doi.org/10.1161/01.hyp.37.2.187
   
436	Stead   LF, Buitrago   D, Preciado   N, Sanchez   G, Hartmann-Boyce   J, Lancaster   T. Physician advice for smoking cessation. Cochrane Database Syst Rev  2013;2013:CD000165. https://doi.org/10.1002/14651858.CD000165.pub4
Google ScholarPubMedWorldCat 
437	Rasmussen   M, Lauridsen   SV, Pedersen   B, Backer   V, Tønnesen   H. Intensive versus short face-to-face smoking cessation interventions: a meta-analysis. Eur Respir Rev  2022;31:220063. https://doi.org/10.1183/16000617.0063-2022
   
438	Filippou   CD, Thomopoulos   CG, Kouremeti   MM, Sotiropoulou   LI, Nihoyannopoulos   PI, Tousoulis   DM, et al.   Mediterranean diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr  2021;40:3191–200. https://doi.org/10.1016/j.clnu.2021.01.030
   
439	Cowell   OR, Mistry   N, Deighton   K, Matu   J, Griffiths   A, Minihane   AM, et al.   Effects of a Mediterranean diet on blood pressure: a systematic review and meta-analysis of randomized controlled trials and observational studies. J Hypertens  2021;39:729–39. https://doi.org/10.1097/hjh.0000000000002667
   
440	Roerecke   M, Tobe   SW, Kaczorowski   J, Bacon   SL, Vafaei   A, Hasan   OSM, et al.   Sex-specific associations between alcohol consumption and incidence of hypertension: a systematic review and meta-analysis of cohort studies. J Am Heart Assoc  2018;7:e008202. https://doi.org/10.1161/jaha.117.008202
   
441	Ding   C, O’Neill   D, Bell   S, Stamatakis   E, Britton   A. Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women. BMC Med  2021;19:167. https://doi.org/10.1186/s12916-021-02040-2
   
442	Marklund   M, Singh   G, Greer   R, Cudhea   F, Matsushita   K, Micha   R, et al.   Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study. BMJ  2020;369:m824. https://doi.org/10.1136/bmj.m824
Google ScholarPubMedWorldCat 
443	Pinho-Gomes   AC, Azevedo   L, Copland   E, Canoy   D, Nazarzadeh   M, Ramakrishnan   R, et al.   Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis. PLoS Med  2021;18:e1003599. https://doi.org/10.1371/journal.pmed.1003599
   
444	Bidel   Z, Nazarzadeh   M, Canoy   D, Copland   E, Gerdts   E, Woodward   M, et al.   Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension  2023;80:2293–302. https://doi.org/10.1161/hypertensionaha.123.21496
   
445	Nazarzadeh   M, Bidel   Z, Canoy   D, Copland   E, Bennett   DA, Dehghan   A, et al.   Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol  2022;10:645–54. https://doi.org/10.1016/s2213-8587(22)00172-3
   
446	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens  2015;33:195–211. https://doi.org/10.1097/hjh.0000000000000447
   
447	Ishani   A, Cushman   WC, Leatherman   SM, Lew   RA, Woods   P, Glassman   PA, et al.   Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med  2022;387:2401–10. https://doi.org/10.1056/NEJMoa2212270
   
448	Ziff   OJ, Samra   M, Howard   JP, Bromage   DI, Ruschitzka   F, Francis   DP, et al.   Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med  2020;18:103. https://doi.org/10.1186/s12916-020-01564-3
   
449	Thomopoulos   C, Bazoukis   G, Tsioufis   C, Mancia   G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens  2020;38:1669–81. https://doi.org/10.1097/hjh.0000000000002523
   
450	Mancia   G, Kjeldsen   SE, Kreutz   R, Pathak   A, Grassi   G, Esler   M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension  2022;79:1153–66. https://doi.org/10.1161/hypertensionaha.122.19020
   
451	Bradley   HA, Wiysonge   CS, Volmink   JA, Mayosi   BM, Opie   LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens  2006;24:2131–41. https://doi.org/10.1097/01.hjh.0000249685.58370.28
   
452	Wiysonge   CS, Bradley   HA, Volmink   J, Mayosi   BM, Opie   LH. Beta-blockers for hypertension. Cochrane Database Syst Rev  2017;1:CD002003. https://doi.org/10.1002/14651858.CD002003.pub5
Google ScholarPubMedWorldCat 
453	Elliott   WJ, Meyer   PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet  2007;369:201–7. https://doi.org/10.1016/s0140-6736(07)60108-1
   
454	Bangalore   S, Parkar   S, Grossman   E, Messerli   FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol  2007;100:1254–62. https://doi.org/10.1016/j.amjcard.2007.05.057
   
455	Laurent   S, Briet   M, Boutouyrie   P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension  2009;54:388–92. https://doi.org/10.1161/hypertensionaha.109.133116
   
456	Klingbeil   AU, Schneider   M, Martus   P, Messerli   FH, Schmieder   RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med  2003;115:41–6. https://doi.org/10.1016/s0002-9343(03)00158-x
   
457	Zanchetti   A, Bond   MG, Hennig   M, Neiss   A, Mancia   G, Dal Palù   C, et al.   Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation  2002;106:2422–7. https://doi.org/10.1161/01.cir.0000039288.86470.dd
   
458	Schiffrin   EL, Deng   LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension  1995;25:699–703. https://doi.org/10.1161/01.hyp.25.4.699
   
459	Williams   B, MacDonald   TM, Morant   S, Webb   DJ, Sever   P, McInnes   G, et al.   Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet  2015;386:2059–68. https://doi.org/10.1016/s0140-6736(15)00257-3
   
460	Agarwal   R, Filippatos   G, Pitt   B, Anker   SD, Rossing   P, Joseph   A, et al.   Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J  2022;43:474–84. https://doi.org/10.1093/eurheartj/ehab777
   
461	Agarwal   R, Ruilope   LM, Ruiz-Hurtado   G, Haller   H, Schmieder   RE, Anker   SD, et al.   Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens  2023;41:295–302. https://doi.org/10.1097/hjh.0000000000003330
   
462	Bakris   GL, Agarwal   R, Anker   SD, Pitt   B, Ruilope   LM, Rossing   P, et al.   Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med  2020;383:2219–29. https://doi.org/10.1056/NEJMoa2025845
   
463	The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA  2000;283:1967–75. https://doi.org/10.1001/jama.283.15.1967
CrossrefPubMedWorldCat 
464	Ruilope   LM, Dukat   A, Böhm   M, Lacourcière   Y, Gong   J, Lefkowitz   MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet  2010;375:1255–66. https://doi.org/10.1016/s0140-6736(09)61966-8
   
465	McMurray   JJ, Packer   M, Desai   AS, Gong   J, Lefkowitz   MP, Rizkala   AR, et al.   Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med  2014;371:993–1004. https://doi.org/10.1056/NEJMoa1409077
   
466	Rakugi   H, Kario   K, Yamaguchi   M, Sasajima   T, Gotou   H, Zhang   J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res  2022;45:824–33. https://doi.org/10.1038/s41440-021-00819-7
   
467	Jackson   AM, Jhund   PS, Anand   IS, Düngen   H-D, Lam   CSP, Lefkowitz   MP, et al.   Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J  2021;42:3741–52. https://doi.org/10.1093/eurheartj/ehab499
   
468	Kario   K, Sun   N, Chiang   FT, Supasyndh   O, Baek   SH, Inubushi-Molessa   A, et al.   Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension  2014;63:698–705. https://doi.org/10.1161/hypertensionaha.113.02002
   
469	Williams   B, Cockcroft   JR, Kario   K, Zappe   DH, Brunel   PC, Wang   Q, et al.   Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension  2017;69:411–20. https://doi.org/10.1161/hypertensionaha.116.08556
   
470	Herrington   WG, Savarese   G, Haynes   R, Marx   N, Mellbin   L, Lund   LH, et al.   Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail  2021;23:1260–75. https://doi.org/10.1002/ejhf.2286
   
471	Gupta   R, Maitz   T, Egeler   D, Mehta   A, Nyaeme   M, Hajra   A, et al.   SGLT2 inhibitors in hypertension: role beyond diabetes and heart failure. Trends Cardiovasc Med  2022;33:479–86. https://doi.org/10.1016/j.tcm.2022.05.005
   
472	Kario   K, Ferdinand   KC, Vongpatanasin   W. Are SGLT2 inhibitors new hypertension drugs?  Circulation  2021;143:1750–3. https://doi.org/10.1161/circulationaha.121.053709
   
473	Yan   C, Thijs   L, Cao   Y, Trenson   S, Zhang   Z-Y, Janssens   S, et al.   Opportunities of antidiabetic drugs in cardiovascular medicine: a meta-analysis and perspectives for trial design. Hypertension  2020;76:420–31. https://doi.org/10.1161/hypertensionaha.120.14791
   
474	Freeman   MW, Halvorsen   YD, Marshall   W, Pater   M, Isaacsohn   J, Pearce   C, et al.   Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med  2023;388:395–405. https://doi.org/10.1056/NEJMoa2213169
   
475	Laffin   LJ, Rodman   D, Luther   JM, Vaidya   A, Weir   MR, Rajicic   N, et al.   Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial. JAMA  2023;330:1140–50. https://doi.org/10.1001/jama.2023.16029
   
476	Schlaich   MP, Bellet   M, Weber   MA, Danaietash   P, Bakris   GL, Flack   JM, et al.   Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet  2022;400:1927–37. https://doi.org/10.1016/s0140-6736(22)02034-7
   
477	Desai   AS, Webb   DJ, Taubel   J, Casey   S, Cheng   Y, Robbie   GJ, et al.   Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med  2023;389:228–38. https://doi.org/10.1056/NEJMoa2208391
   
478	Law   MR, Wald   NJ, Morris   JK, Jordan   RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ  2003;326:1427. https://doi.org/10.1136/bmj.326.7404.1427
   
479	Mahmud   A, Feely   J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents—a preliminary report. Hypertension  2007;49:272–5. https://doi.org/10.1161/01.HYP.0000254479.66645.a3
   
480	Wald   DS, Law   M, Morris   JK, Bestwick   JP, Wald   NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med  2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038
   
481	Chow   CK, Thakkar   J, Bennett   A, Hillis   G, Burke   M, Usherwood   T, et al.   Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet  2017;389:1035–42. https://doi.org/10.1016/s0140-6736(17)30260-x
   
482	Chow   CK, Atkins   ER, Hillis   GS, Nelson   MR, Reid   CM, Schlaich   MP, et al.   Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet  2021;398:1043–52. https://doi.org/10.1016/s0140-6736(21)01922-x
   
483	Webster   R, Salam   A, de Silva   HA, Selak   V, Stepien   S, Rajapakse   S, et al.   Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA  2018;320:566–79. https://doi.org/10.1001/jama.2018.10359
   
484	MacDonald   TM, Williams   B, Webb   DJ, Morant   S, Caulfield   M, Cruickshank   JK, et al.   Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc  2017;6:e006986. https://doi.org/10.1161/jaha.117.006986
   
485	Salam   A, Kanukula   R, Atkins   E, Wang   X, Islam   S, Kishore   SP, et al.   Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens  2019;37:1768–74. https://doi.org/10.1097/hjh.0000000000002096
   
486	Zhang   ZY, Yu   YL, Asayama   K, Hansen   TW, Maestre   GE, Staessen   JA. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension—con side of the argument. Hypertension  2021;77:788–98. https://doi.org/10.1161/hypertensionaha.120.12858
   
487	Kahan   T. Low-dose combination of blood pressure-lowering medicines. Lancet  2021;398:1022–3. https://doi.org/10.1016/s0140-6736(21)01964-4
   
488	Rea   F, Corrao   G, Merlino   L, Mancia   G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension  2018;72:846–53. https://doi.org/10.1161/hypertensionaha.118.11308
   
489	Egan   BM, Bandyopadhyay   D, Shaftman   SR, Wagner   CS, Zhao   Y, Yu-Isenberg   KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension  2012;59:1124–31. https://doi.org/10.1161/hypertensionaha.112.194167
   
490	Sundström   J, Lind   L, Nowrouzi   S, Hagström   E, Held   C, Lytsy   P, et al.   Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA  2023;329:1160–9. https://doi.org/10.1001/jama.2023.3322
   
491	Tsioufis   K, Kreutz   R, Sykara   G, van Vugt   J, Hassan   T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens  2020;38:1016–28. https://doi.org/10.1097/hjh.0000000000002381
   
492	Parati   G, Kjeldsen   S, Coca   A, Cushman   WC, Wang   J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension  2021;77:692–705. https://doi.org/10.1161/hypertensionaha.120.15781
   
493	Egan   BM, Kjeldsen   SE, Narkiewicz   K, Kreutz   R, Burnier   M. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Press  2022;31:164–8. https://doi.org/10.1080/08037051.2022.2095254
   
494	Yusuf   S, Joseph   P, Dans   A, Gao   P, Teo   K, Xavier   D, et al.   Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med  2021;384:216–28. https://doi.org/10.1056/NEJMoa2028220
   
495	Roshandel   G, Khoshnia   M, Poustchi   H, Hemming   K, Kamangar   F, Gharavi   A, et al.   Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet  2019;394:672–83. https://doi.org/10.1016/s0140-6736(19)31791-x
   
496	Joseph   P, Roshandel   G, Gao   P, Pais   P, Lonn   E, Xavier   D, et al.   Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet  2021;398:1133–46. https://doi.org/10.1016/s0140-6736(21)01827-4
   
497	van Vark   LC, Bertrand   M, Akkerhuis   KM, Brugts   JJ, Fox   K, Mourad   J-J, et al.   Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J  2012;33:2088–97. https://doi.org/10.1093/eurheartj/ehs075
   
498	Parving   HH, Brenner   BM, McMurray   JJ, de Zeeuw   D, Haffner   SM, Solomon   SD, et al.   Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med  2012;367:2204–13. https://doi.org/10.1056/NEJMoa1208799
   
499	Fried   LF, Emanuele   N, Zhang   JH, Brophy   M, Conner   TA, Duckworth   W, et al.   Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med  2013;369:1892–903. https://doi.org/10.1056/NEJMoa1303154
   
500	Yusuf   S, Teo   KK, Pogue   J, Dyal   L, Copland   I, Schumacher   H, et al.   Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med  2008;358:1547–59. https://doi.org/10.1056/NEJMoa0801317
Google ScholarPubMedWorldCat 
501	Gupta   AK, Arshad   S, Poulter   NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension  2010;55:399–407. https://doi.org/10.1161/hypertensionaha.109.139816
   
502	Gnanenthiran   SR, Wang   N, Di Tanna   GL, Salam   A, Webster   R, de Silva   HA, et al.   Association of low-dose triple combination therapy vs usual care with time at target blood pressure: a secondary analysis of the TRIUMPH randomized clinical trial. JAMA Cardiol  2022;7:645–50. https://doi.org/10.1001/jamacardio.2022.0471
   
503	Tam   TS, Wu   MH, Masson   SC, Tsang   MP, Stabler   SN, Kinkade   A, et al.   Eplerenone for hypertension. Cochrane Database Syst Rev  2017;2:CD008996. https://doi.org/10.1002/14651858.CD008996.pub2
Google ScholarPubMedWorldCat 
504	Pedersen   ME, Cockcroft   JR. The vasodilatory beta-blockers. Curr Hypertens Rep  2007;9:269–77. https://doi.org/10.1007/s11906-007-0050-2
   
505	Sica   DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich)  2004;6:283–7. https://doi.org/10.1111/j.1524-6175.2004.03585.x
   
506	Muñoz   D, Uzoije   P, Reynolds   C, Miller   R, Walkley   D, Pappalardo   S, et al.   Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med  2019;381:1114–23. https://doi.org/10.1056/NEJMoa1815359
   
507	Castellano   JM, Pocock   SJ, Bhatt   DL, Quesada   AJ, Owen   R, Fernandez-Ortiz   A, et al.   Polypill strategy in secondary cardiovascular prevention. N Engl J Med  2022;387:967–77. https://doi.org/10.1056/NEJMoa2208275
   
508	González-Juanatey   JR, Cordero   A, Castellano   JM, Masana   L, Dalmau   R, Ruiz   E, et al.   The CNIC-polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study. Int J Cardiol  2022;361:116–23. https://doi.org/10.1016/j.ijcard.2022.05.015
   
509	Jowett   S, Barton   P, Roalfe   A, Fletcher   K, Hobbs   FDR, McManus   RJ, et al.   Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One  2017;12:e0182625. https://doi.org/10.1371/journal.pone.0182625
   
510	McManus   RJ, Mant   J, Bray   EP, Holder   R, Jones   MI, Greenfield   S, et al.   Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet  2010;376:163–72. https://doi.org/10.1016/s0140-6736(10)60964-6
   
511	Clark   CE, Smith   LF, Taylor   RS, Campbell   JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ  2010;341:c3995. https://doi.org/10.1136/bmj.c3995
   
512	Mackenzie   IS, Rogers   A, Poulter   NR, Williams   B, Brown   MJ, Webb   DJ, et al.   Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet  2022;400:1417–25. https://doi.org/10.1016/s0140-6736(22)01786-x
   
513	Conn   VS, Ruppar   TM, Chase   JA, Enriquez   M, Cooper   PS. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep  2015;17:94. https://doi.org/10.1007/s11906-015-0606-5
   
514	Corrao   G, Parodi   A, Zambon   A, Heiman   F, Filippi   A, Cricelli   C, et al.   Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens  2010;28:1584–90. https://doi.org/10.1097/HJH.0b013e328339f9fa
   
515	Krieger   EM, Drager   LF, Giorgi   DMA, Pereira   AC, Barreto-Filho   JAS, Nogueira   AR, et al.   Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension  2018;71:681–90. https://doi.org/10.1161/hypertensionaha.117.10662
   
516	Williams   B, MacDonald   TM, Morant   SV, Webb   DJ, Sever   P, McInnes   GT, et al.   Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol  2018;6:464–75. https://doi.org/10.1016/s2213-8587(18)30071-8
   
517	Mann   JF, Schmieder   RE, McQueen   M, Dyal   L, Schumacher   H, Pogue   J, et al.   Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet  2008;372:547–53. https://doi.org/10.1016/s0140-6736(08)61236-2
   
518	Jones   DW, Whelton   PK, Allen   N, Clark   D  III, Gidding   SS, Muntner   P, et al.   Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: a scientific statement from the American Heart Association. Hypertension  2021;77:e58–67. https://doi.org/10.1161/hyp.0000000000000195
   
519	Ali   DH, Kiliç   B, Hart   HE, Bots   ML, Biermans   MCJ, Spiering   W, et al.   Therapeutic inertia in the management of hypertension in primary care. J Hypertens  2021;39:1238–45. https://doi.org/10.1097/hjh.0000000000002783
   
520	Appel   LJ, Champagne   CM, Harsha   DW, Cooper   LS, Obarzanek   E, Elmer   PJ, et al.   Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA  2003;289:2083–93. https://doi.org/10.1001/jama.289.16.2083
Google ScholarPubMedWorldCat 
521	Appel   LJ, Sacks   FM, Carey   VJ, Obarzanek   E, Swain   JF, Miller   ER, et al.   Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA  2005;294:2455–64. https://doi.org/10.1001/jama.294.19.2455
   
522	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens  2017;35:2150–60. https://doi.org/10.1097/hjh.0000000000001547
   
523	Williamson   JD, Supiano   MA, Applegate   WB, Berlowitz   DR, Campbell   RC, Chertow   GM, et al.   Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA  2016;315:2673–82. https://doi.org/10.1001/jama.2016.7050
   
524	Beckett   N, Peters   R, Leonetti   G, Duggan   J, Fagard   R, Thijs   L, et al.   Subgroup and per-protocol analyses from the hypertension in the very elderly trial. J Hypertens  2014;32:1478–87; discussion 1487. https://doi.org/10.1097/hjh.0000000000000195
   
525	Jowett   S, Kodabuckus   S, Ford   GA, Hobbs   FDR, Lown   M, Mant   J, et al.   Cost-effectiveness of antihypertensive deprescribing in primary care: a Markov modelling study using data from the OPTiMISE trial. Hypertension  2022;79:1122–31. https://doi.org/10.1161/hypertensionaha.121.18726
   
526	Odden   MC, McClure   LA, Sawaya   BP, White   CL, Peralta   CA, Field   TS, et al.   Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial. Hypertension  2016;67:63–9. https://doi.org/10.1161/hypertensionaha.115.06480
   
527	Chen   T, Shao   F, Chen   K, Wang   Y, Wu   Z, Wang   Y, et al.   Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials. JAMA Intern Med  2022;182:660–7. https://doi.org/10.1001/jamainternmed.2022.1657
   
528	Neaton   JD, Grimm   RH  Jr, Prineas   RJ, Stamler   J, Grandits   GA, Elmer   PJ, et al.   Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA  1993;270:713–24. https://doi.org/10.1001/jama.1993.03510060059034
   
529	Wu   J, Kraja   AT, Oberman   A, Lewis   C, Ellison   R, Arnett   D, et al.   A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens  2005;18:935–42. https://doi.org/10.1016/j.amjhyper.2005.01.011
   
530	Canoy   D, Copland   E, Nazarzadeh   M, Ramakrishnan   R, Pinho-Gomes   A-C, Salam   A, et al.   Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart  2022;108:1281–9. https://doi.org/10.1136/heartjnl-2021-320171
   
531	Paz   MA, de-La-Sierra   A, Sáez   M, Barceló   MA, Rodríguez   JJ, Castro   S, et al.   Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore)  2016;95:e4071. https://doi.org/10.1097/md.0000000000004071
   
532	Morales-Salinas   A, Kones   R. Concerning the degradation of β-blocker use in the 2018 ESC/ESH hypertension guidelines. Eur Heart J  2019;40:2091. https://doi.org/10.1093/eurheartj/ehz125
   
533	Lindholm   LH, Carlberg   B, Samuelsson   O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet  2005;366:1545–53. https://doi.org/10.1016/s0140-6736(05)67573-3
   
534	Larochelle   P, Tobe   SW, Lacourcière   Y. β-Blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol  2014;30:S16–22. https://doi.org/10.1016/j.cjca.2014.02.012
   
535	Reboussin   DM, Allen   NB, Griswold   ME, Guallar   E, Hong   Y, Lackland   DT, et al.   Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension  2018;71:e116–35. https://doi.org/10.1161/hyp.0000000000000067
   
536	Wright   JM, Musini   VM, Gill   R. First-line drugs for hypertension. Cochrane Database Syst Rev  2018;4:CD001841. https://doi.org/10.1002/14651858.CD001841.pub3
Google ScholarPubMedWorldCat 
537	Johnston   GD. Dose-response relationships with antihypertensive drugs. Pharmacol Ther  1992;55:53–93. https://doi.org/10.1016/0163-7258(92)90029-y
   
538	Law   MR, Morris   JK, Wald   NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ  2009;338:b1665. https://doi.org/10.1136/bmj.b1665
   
539	Messerli   FH, Bangalore   S, Schmieder   RE. Wilder’s principle: pre-treatment value determines post-treatment response. Eur Heart J  2015;36:576–9. https://doi.org/10.1093/eurheartj/ehu467
   
540	Lasserson   DS, Buclin   T, Glasziou   P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart  2011;97:1771–5. https://doi.org/10.1136/hrt.2010.221473
   
541	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens  2014;32:2285–95. https://doi.org/10.1097/hjh.0000000000000378
   
542	Verdecchia   P, Staessen   JA, Angeli   F, de Simone   G, Achilli   A, Ganau   A, et al.   Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet  2009;374:525–33. https://doi.org/10.1016/s0140-6736(09)61340-4
   
543	Benavente   OR, Coffey   CS, Conwit   R, Hart   RG, McClure   LA, Pearce   LA, et al.   Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet  2013;382:507–15. https://doi.org/10.1016/s0140-6736(13)60852-1
Google ScholarPubMedWorldCat 
544	Vaduganathan   M, Claggett   BL, Juraschek   SP, Solomon   SD. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol  2020;5:576–81. https://doi.org/10.1001/jamacardio.2019.6192
   
545	Lewis   CE, Fine   LJ, Beddhu   S, Cheung   AK, Cushman   WC, Cutler   JA, et al.   Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med  2021;384:1921–30. https://doi.org/10.1056/NEJMoa1901281
Google ScholarPubMedWorldCat 
546	Beddhu   S, Chertow   GM, Cheung   AK, Cushman   WC, Rahman   M, Greene   T, et al.   Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation  2018;137:134–43. https://doi.org/10.1161/circulationaha.117.030848
   
547	McEvoy   JW, Daya   N, Rahman   F, Hoogeveen   RC, Blumenthal   RS, Shah   AM, et al.   Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA  2020;323:329–38. https://doi.org/10.1001/jama.2019.21402
   
548	Jacobsen   AP, Al Rifai   M, Arps   K, Whelton   SP, Budoff   MJ, Nasir   K, et al.   A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J  2021;42:2119–29. https://doi.org/10.1093/eurheartj/ehab111
   
549	McEvoy   JW, Yang   WY, Thijs   L, Zhang   Z-Y, Melgarejo   JD, Boggia   J, et al.   Isolated diastolic hypertension in the IDACO study: an age-stratified analysis using 24-hour ambulatory blood pressure measurements. Hypertension  2021;78:1222–31. https://doi.org/10.1161/hypertensionaha.121.17766
   
550	Albasri   A, Hattle   M, Koshiaris   C, Dunnigan   A, Paxton   B, Fox   SE, et al.   Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ  2021;372:n189. https://doi.org/10.1136/bmj.n189
Google ScholarPubMedWorldCat 
551	Savoia   C, Volpe   M, Grassi   G, Borghi   C, Agabiti Rosei   E, Touyz   RM, et al.   Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci (Lond)  2017;131:2671–85. https://doi.org/10.1042/cs20160407
   
552	Egan   BM, Basile   JN, Rehman   SU, Davis   PB, Grob   CH 3rd, Riehle   JF, et al.   Plasma renin test–guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens  2009;22:792–801. https://doi.org/10.1038/ajh.2009.63
   
553	Huang   KY, Tseng   PT, Wu   YC, Tu   Y-K, Stubbs   B, Su   K-P, et al.   Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep  2021;11:452. https://doi.org/10.1038/s41598-020-79837-3
   
554	Bennett   M, Chang   CL, Tatley   M, Savage   R, Hancox   RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res  2021;7:00801-2020. https://doi.org/10.1183/23120541.00801-2020
   
555	Assimes   TL, Elstein   E, Langleben   A, Suissa   S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf  2008;17:1039–49. https://doi.org/10.1002/pds.1656
   
556	Zhang   Y, Song   M, Chan   AT, Meyerhardt   JA, Willett   WC, Giovannucci   EL. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study. Br J Cancer  2022;127:1974–82. https://doi.org/10.1038/s41416-022-01975-4
   
557	Grossman   E, Messerli   FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis  2006;49:16–25. https://doi.org/10.1016/j.pcad.2006.06.002
   
558	Parati   G, Stergiou   GS, Dolan   E, Bilo   G. Blood pressure variability: clinical relevance and application. J Clin Hypertens (Greenwich)  2018;20:1133–7. https://doi.org/10.1111/jch.13304
   
559	Schutte   AE, Kollias   A, Stergiou   GS. Blood pressure and its variability: classic and novel measurement techniques. Nat Rev Cardiol  2022;19:643–54. https://doi.org/10.1038/s41569-022-00690-0
   
560	Lauder   L, Azizi   M, Kirtane   AJ, Böhm   M, Mahfoud   F. Device-based therapies for arterial hypertension. Nat Rev Cardiol  2020;17:614–28. https://doi.org/10.1038/s41569-020-0364-1
   
561	Mahfoud   F, Schlaich   MP, Lobo   MD. Device therapy of hypertension. Circ Res  2021;128:1080–99. https://doi.org/10.1161/circresaha.121.318091
   
562	DiBona   GF. Sympathetic nervous system and hypertension. Hypertension  2013;61:556–60. https://doi.org/10.1161/hypertensionaha.111.00633
   
563	DiBona   GF, Esler   M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol  2010;298:R245–253. https://doi.org/10.1152/ajpregu.00647.2009
   
564	Böhm   M, Kario   K, Kandzari   DE, Mahfoud   F, Weber   MA, Schmieder   RE, et al.   Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet  2020;395:1444–51. https://doi.org/10.1016/s0140-6736(20)30554-7
   
565	Weber   MA, Kirtane   AJ, Weir   MR, Radhakrishnan   J, Das   T, Berk   M, et al.   The REDUCE HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. JACC Cardiovasc Interv  2020;13:461–70. https://doi.org/10.1016/j.jcin.2019.10.061
   
566	Kandzari   DE, Böhm   M, Mahfoud   F, Townsend   RR, Weber   MA, Pocock   S, et al.   Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet  2018;391:2346–55. https://doi.org/10.1016/s0140-6736(18)30951-6
   
567	Azizi   M, Schmieder   RE, Mahfoud   F, Weber   MA, Daemen   J, Davies   J, et al.   Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet  2018;391:2335–45. https://doi.org/10.1016/s0140-6736(18)31082-1
   
568	Azizi   M, Sanghvi   K, Saxena   M, Gosse   P, Reilly   JP, Levy   T, et al.   Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet  2021;397:2476–86. https://doi.org/10.1016/s0140-6736(21)00788-1
   
569	Mahfoud   F, Böhm   M, Schmieder   R, Narkiewicz   K, Ewen   S, Ruilope   L, et al.   Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the global SYMPLICITY registry. Eur Heart J  2019;40:3474–82. https://doi.org/10.1093/eurheartj/ehz118
   
570	Bhatt   DL, Vaduganathan   M, Kandzari   DE, Leon   MB, Rocha-Singh   K, Townsend   RR, et al.   Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial. Lancet  2022;400:1405–16. https://doi.org/10.1016/s0140-6736(22)01787-1
   
571	Mahfoud   F, Kandzari   DE, Kario   K, Townsend   RR, Weber   MA, Schmieder   RE, et al.   Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet  2022;399:1401–10. https://doi.org/10.1016/s0140-6736(22)00455-x
   
572	Rader   F, Kirtane   AJ, Wang   Y, Daemen   J, Lurz   P, Sayer   J, et al.   Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention  2022;18:e677–85. https://doi.org/10.4244/eij-d-22-00305
   
573	Al Ghorani   H, Kulenthiran   S, Recktenwald   MJM, Lauder   L, Kunz   M, Götzinger   F, et al.   10-year outcomes of catheter-based renal denervation in patients with resistant hypertension. J Am Coll Cardiol  2023;81:517–9. https://doi.org/10.1016/j.jacc.2022.11.038
   
574	Stone   P, Campbell   J, Thompson   S, Walker   J. A prospective, randomized study comparing ultrasound versus fluoroscopic guided femoral arterial access in noncardiac vascular patients. J Vasc Surg  2020;72:259–67. https://doi.org/10.1016/j.jvs.2019.09.051
   
575	Jolly   SS, Yusuf   S, Cairns   J, Niemelä   K, Xavier   D, Widimsky   P, et al.   Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet  2011;377:1409–20. https://doi.org/10.1016/s0140-6736(11)60404-2
   
576	Townsend   RR, Walton   A, Hettrick   DA, Hickey   GL, Weil   J, Sharp   ASP, et al.   Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention  2020;16:89–96. https://doi.org/10.4244/eij-d-19-00902
   
577	Sanders   MF, Reitsma   JB, Morpey   M, Gremmels   H, Bots   ML, Pisano   A, et al.   Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant  2017;32:1440–7. https://doi.org/10.1093/ndt/gfx088
   
578	Ahmad   Y, Francis   DP, Bhatt   DL, Howard   JP. Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv  2021;14:2614–24. https://doi.org/10.1016/j.jcin.2021.09.020
   
579	Chowdhury   EK, Reid   CM, Zomer   E, Kelly   DJ, Liew   D. Cost-effectiveness of renal denervation therapy for treatment-resistant hypertension: a best case scenario. Am J Hypertens  2018;31:1156–63. https://doi.org/10.1093/ajh/hpy108
   
580	Sharp   ASP, Cao   KN, Esler   MD, Kandzari   DE, Lobo   MD, Schmieder   RE, et al.   Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes  2024:qcae001. https://doi.org/10.1093/ehjqcco/qcae001
Google ScholarWorldCat 
581	Fengler   K, Reimann   P, Rommel   KP, Kresoja   K-P, Blazek   S, Unterhuber   M, et al.   Comparison of long-term outcomes for responders versus non-responders following renal denervation in resistant hypertension. J Am Heart Assoc  2021;10:e022429. https://doi.org/10.1161/jaha.121.022429
   
582	Mahfoud   F, Mancia   G, Schmieder   RE, Ruilope   L, Narkiewicz   K, Schlaich   M, et al.   Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol  2022;80:1871–80. https://doi.org/10.1016/j.jacc.2022.08.802
   
583	Byrne   RA, Rossello   X, Coughlan   JJ, Barbato   E, Berry   C, Chieffo   A, et al.   ESC guidelines for the management of acute coronary syndromes. Eur Heart J  2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191
   
584	Singh   RR, Denton   KM. Renal denervation. Hypertension  2018;72:528–36. https://doi.org/10.1161/hypertensionaha.118.10265
   
585	Barbato   E, Azizi   M, Schmieder   RE, Lauder   L, Böhm   M, Brouwers   S, et al.   Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J  2023;44:1313–30. https://doi.org/10.1093/eurheartj/ehad054
   
586	Bhatt   DL, Kandzari   DE, O’Neill   WW, D’Agostino   R, Flack   JM, Katzen   BT, et al.   A controlled trial of renal denervation for resistant hypertension. N Engl J Med  2014;370:1393–401. https://doi.org/10.1056/NEJMoa1402670
   
587	Desch   S, Okon   T, Heinemann   D, Kulle   K, Röhnert   K, Sonnabend   M, et al.   Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension  2015;65:1202–8. https://doi.org/10.1161/hypertensionaha.115.05283
   
588	Mathiassen   ON, Vase   H, Bech   JN, Christensen   KL, Buus   NH, Schroeder   AP, et al.   Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24–h blood pressure-based trial. J Hypertens  2016;34:1639–47. https://doi.org/10.1097/hjh.0000000000000977
   
589	Townsend   RR, Mahfoud   F, Kandzari   DE, Kario   K, Pocock   S, Weber   MA, et al.   Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet  2017;390:2160–70. https://doi.org/10.1016/s0140-6736(17)32281-x
   
590	Kario   K, Yokoi   Y, Okamura   K, Fujihara   M, Ogoyama   Y, Yamamoto   E, et al.   Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res  2022;45:221–31. https://doi.org/10.1038/s41440-021-00754-7
   
591	Neuzil   P, Merkely   B, Erglis   A, Marinskis   G, de Groot   JR, Schmidinger   H, et al.   Pacemaker-mediated programmable hypertension control therapy. J Am Heart Assoc  2017;6:e006974. https://doi.org/10.1161/jaha.117.006974
   
592	Kalarus   Z, Merkely   B, Neužil   P, Grabowski   M, Mitkowski   P, Marinskis   G, et al.   Pacemaker-based cardiac neuromodulation therapy in patients with hypertension: a pilot study. J Am Heart Assoc  2021;10:e020492. https://doi.org/10.1161/jaha.120.020492
   
593	Musini   VM, Tejani   AM, Bassett   K, Puil   L, Wright   JM. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev  2019;6:CD000028. https://doi.org/10.1002/14651858.CD000028.pub3
Google ScholarPubMedWorldCat 
594	Musini   VM, Gueyffier   F, Puil   L, Salzwedel   DM, Wright   JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev  2017;8:CD008276. https://doi.org/10.1002/14651858.CD008276.pub2
Google ScholarPubMedWorldCat 
595	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens  2016;34:1921–32. https://doi.org/10.1097/hjh.0000000000001052
   
596	Benetos   A, Petrovic   M, Strandberg   T. Hypertension management in older and frail older patients. Circ Res  2019;124:1045–60. https://doi.org/10.1161/circresaha.118.313236
   
597	Frey   L, Gravestock   I, Pichierri   G, Steurer   J, Burgstaller   JM. Serious adverse events in patients with target-oriented blood pressure management: a systematic review. J Hypertens  2019;37:2135–44. https://doi.org/10.1097/hjh.0000000000002176
   
598	Palmer   SC, Sciancalepore   M, Strippoli   GF. Trial quality in nephrology: how are we measuring up?  Am J Kidney Dis  2011;58:335–7. https://doi.org/10.1053/j.ajkd.2011.06.006
   
599	Carriazo   S, Sarafidis   P, Ferro   CJ, Ortiz   A. Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney J  2022;15:845–51. https://doi.org/10.1093/ckj/sfac014
   
600	Kessler   A, Sollie   S, Challacombe   B, Briggs   K, Van Hemelrijck   M. The global prevalence of erectile dysfunction: a review. BJU Int  2019;124:587–99. https://doi.org/10.1111/bju.14813
   
601	Doumas   M, Douma   S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich)  2006;8:359–64. https://doi.org/10.1111/j.1524-6175.2005.05285.x
   
602	Ismail   SB, Noor   NM, Hussain   NHN, Sulaiman   Z, Shamsudin   MA, Irfan   M. Angiotensin receptor blockers for erectile dysfunction in hypertensive men: a brief meta-analysis of randomized control trials. Am J Mens Health  2019;13:1557988319892735. https://doi.org/10.1177/1557988319892735
Google ScholarWorldCat 
603	Lawson   AJ, Hameed   MA, Brown   R, Cappuccio   FP, George   S, Hinton   T, et al.   Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens  2020;38:1165–73. https://doi.org/10.1097/hjh.0000000000002398
   
604	Choudhry   NK, Kronish   IM, Vongpatanasin   W, Ferdinand   KC, Pavlik   VN, Egan   BM, et al.   Medication adherence and blood pressure control: a scientific statement from the American heart association. Hypertension  2022;79:e1–14. https://doi.org/10.1161/hyp.0000000000000203
   
605	Liao   CT, Toh   HS, Sun   L, Yang   C-T, Hu   A, Wei   D, et al.   Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension. JAMA Netw Open  2023;6:e230708. https://doi.org/10.1001/jamanetworkopen.2023.0708
   
606	O’Donoghue   P, O’Halloran   AM, Kenny   RA, Romero-Ortuno   R. Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA). EClinicalMedicine  2022;45:101304. https://doi.org/10.1016/j.eclinm.2022.101304
   
607	Sexton   DJ, Canney   M, O’Connell   MDL, Moore   P, Little   MA, O’Seaghdha   CM, et al.   Injurious falls and syncope in older community-dwelling adults meeting inclusion criteria for SPRINT. JAMA Intern Med  2017;177:1385–7. https://doi.org/10.1001/jamainternmed.2017.2924
   
608	Masoli   JAH, Sheppard   JP, Rajkumar   C. Hypertension management in older patients-are the guideline blood pressure targets appropriate?  Age Ageing  2022;51:afab226. https://doi.org/10.1093/ageing/afab226
   
609	Richter   D, Guasti   L, Walker   D, Lambrinou   E, Lionis   C, Abreu   A, et al.   Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol  2022;29:216–27. https://doi.org/10.1093/eurjpc/zwaa167
   
610	Hughes   D, Judge   C, Murphy   R, Loughlin   E, Costello   M, Whiteley   W, et al.   Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA  2020;323:1934–44. https://doi.org/10.1001/jama.2020.4249
   
611	Peters   R, Xu   Y, Fitzgerald   O, Aung   HL, Beckett   N, Bulpitt   C, et al.   Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J  2022;43:4980–90. https://doi.org/10.1093/eurheartj/ehac584
   
612	Pathak   A, Poulter   NR, Kavanagh   M, Kreutz   R, Burnier   M. Improving the management of hypertension by tackling awareness, adherence, and clinical inertia: a symposium report. Am J Cardiovasc Drugs  2022;22:251–61. https://doi.org/10.1007/s40256-021-00505-6
   
613	Sheppard   JP, Lown   M, Burt   J, Temple   E, Lowe   R, Ashby   H, et al.   Generalizability of blood pressure lowering trials to older patients: cross-sectional analysis. J Am Geriatr Soc  2020;68:2508–15. https://doi.org/10.1111/jgs.16749
   
614	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events—meta-analyses of randomized trials. J Hypertens  2016;34:1451–63. https://doi.org/10.1097/hjh.0000000000000972
   
615	Jordan   J, Tank   J, Reuter   H. Risk-benefit assessment of intense blood pressure lowering. Hypertension  2019;74:1302–4. https://doi.org/10.1161/hypertensionaha.119.13835
   
616	Rietz   H, Pennlert   J, Nordström   P, Brunström   M. Prevalence, time-trends and clinical characteristics of hypertension in young adults: nationwide cross-sectional study of 1.7 million Swedish 18-year-olds, 1969–2010. J Hypertens  2022;40:1231–8. https://doi.org/10.1097/hjh.0000000000003141
   
617	Ostchega   Y, Fryar   CD, Nwankwo   T, Nguyen   DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief  2020;364:1–8.
Google ScholarWorldCat 
618	O’Neil   A, Scovelle   AJ, Milner   AJ, Kavanagh   A. Gender/sex as a social determinant of cardiovascular risk. Circulation  2018;137:854–64. https://doi.org/10.1161/circulationaha.117.028595
   
619	Bruno   RM, Pucci   G, Rosticci   M, Guarino   L, Guglielmo   C, Agabiti Rosei   C, et al.   Association between lifestyle and systemic arterial hypertension in young adults: a national, survey-based, cross-sectional study. High Blood Press Cardiovasc Prev  2016;23:31–40. https://doi.org/10.1007/s40292-016-0135-6
   
620	Suzuki   Y, Kaneko   H, Yano   Y, Okada   A, Itoh   H, Matsuoka   S, et al.   Association of cardiovascular health metrics with risk of transition to hypertension in non-hypertensive young adults. Am J Hypertens  2022;35:858–66. https://doi.org/10.1093/ajh/hpac057
   
621	Haggart   RC, Bartels   CM, Smith   MA, Johnson   HM. Sociodemographics and hypertension control among young adults with incident hypertension: a multidisciplinary group practice observational study. J Hypertens  2018;36:2425–33. https://doi.org/10.1097/hjh.0000000000001872
   
622	Liu   J, Bu   X, Wei   L, Wang   X, Lai   L, Dong   C, et al.   Global burden of cardiovascular diseases attributable to hypertension in young adults from 1990 to 2019. J Hypertens  2021;39:2488–96. https://doi.org/10.1097/hjh.0000000000002958
   
623	Zhang   Y, Moran   AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension  2017;70:736–42. https://doi.org/10.1161/hypertensionaha.117.09801
   
624	Yano   Y, Stamler   J, Garside   DB, Daviglus   ML, Franklin   SS, Carnethon   MR, et al.   Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. J Am Coll Cardiol  2015;65:327–35. https://doi.org/10.1016/j.jacc.2014.10.060
   
625	Noilhan   C, Barigou   M, Bieler   L, Amar   J, Chamontin   B, Bouhanick   B, et al.   Causes of secondary hypertension in the young population: a monocentric study. Ann Cardiol Angeiol (Paris)  2016;65:159–64. https://doi.org/10.1016/j.ancard.2016.04.016
   
626	Jones   ESW, Esack   I, Mangena   P, Rayner   BL. Hypertension in adolescents and young adults referred to a tertiary hypertension clinic in Cape Town, South Africa. Medicine (Baltimore)  2020;99:e23137. https://doi.org/10.1097/md.0000000000023137
   
627	Chasan-Taber   L, Willett   WC, Manson   JE, Spiegelman   D, Hunter   DJ, Curhan   G, et al.   Prospective study of oral contraceptives and hypertension among women in the United States. Circulation  1996;94:483–9. https://doi.org/10.1161/01.cir.94.3.483
   
628	Lubianca   JN, Faccin   CS, Fuchs   FD. Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception  2003;67:19–24. https://doi.org/10.1016/s0010-7824(02)00429-8
   
629	The American College of Obstetricians and Gynecologists. ACOG practice bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol  2019;133:e128–50. https://doi.org/10.1097/aog.0000000000003072
CrossrefPubMedWorldCat 
630	Glisic   M, Shahzad   S, Tsoli   S, Chadni   M, Asllanaj   E, Rojas   LZ, et al.   Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol  2018;25:1042–52. https://doi.org/10.1177/2047487318774847
   
631	Archer   DF, Ahrendt   HJ, Drouin   D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception  2015;92:439–44. https://doi.org/10.1016/j.contraception.2015.07.014
   
632	Pappaccogli   M, Di Monaco   S, Warchoł-Celińska   E, Lorthioir   A, Amar   L, Aparicio   LS, et al.   The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovasc Res  2021;117:950–9. https://doi.org/10.1093/cvr/cvaa102
   
633	Thompson   P, Logan   I, Tomson   C, Sheerin   N, Ellam   T. Obesity, sex, race, and early onset hypertension: implications for a refined investigation strategy. Hypertension  2020;76:859–65. https://doi.org/10.1161/hypertensionaha.120.15557
   
634	Saladini   F, Fania   C, Mos   L, Mazzer   A, Casiglia   E, Palatini   P. Office pulse pressure is a predictor of favorable outcome in young- to middle-aged subjects with stage 1 hypertension. Hypertension  2017;70:537–42. https://doi.org/10.1161/hypertensionaha.117.09516
   
635	Hoeltzenbein   M, Tissen-Diabaté   T, Fietz   AK, Zinke   S, Kayser   A, Meister   R, et al.   Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors—treatment or hypertension related? An observational cohort study. Pregnancy Hypertens  2018;13:65–71. https://doi.org/10.1016/j.preghy.2018.04.022
   
636	Ahmed   B, Tran   DT, Zoega   H, Kennedy   SE, Jorm   LR, Havard   A. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy. Pregnancy Hypertens  2018;14:156–61. https://doi.org/10.1016/j.preghy.2018.09.010
   
637	Cífková   R, Johnson   MR, Kahan   T, Brguljan   J, Williams   B, Coca   A, et al.   Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother  2020;6:384–93. https://doi.org/10.1093/ehjcvp/pvz082
   
638	Magee   LA, Brown   MA, Hall   DR, Gupte   S, Hennessy   A, Karumanchi   SA, et al.   The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens  2022;27:148–69. https://doi.org/10.1016/j.preghy.2021.09.008
   
639	Kassebaum   NJ, Barber   RM, Bhutta   ZA, Dandona   L, Gething   PW, Hay   SI, et al.   Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet  2016;388:1775–812. https://doi.org/10.1016/S0140-6736(16)31470-2
   
640	Garovic   VD, White   WM, Vaughan   L, Saiki   M, Parashuram   S, Garcia-Valencia   O, et al.   Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol  2020;75:2323–34. https://doi.org/10.1016/j.jacc.2020.03.028
   
641	Heida   KY, Franx   A, van Rijn   BB, Eijkemans   MJC, Boer   JMA, Verschuren   MWM, et al.   Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension  2015;66:1116–22. https://doi.org/10.1161/hypertensionaha.115.06005
   
642	Garovic   VD, Bailey   KR, Boerwinkle   E, Hunt   SC, Weder   AB, Curb   D, et al.   Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens  2010;28:826–33. https://doi.org/10.1097/HJH.0b013e328335c29a
   
643	Brown   MA, Magee   LA, Kenny   LC, Karumanchi   SA, McCarthy   FP, Saito   S, et al.   Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension  2018;72:24–43. https://doi.org/10.1161/hypertensionaha.117.10803
   
644	Homer   CS, Brown   MA, Mangos   G, Davis   GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens  2008;26:295–302. https://doi.org/10.1097/HJH.0b013e3282f1a953
   
645	Davis   GK, Roberts   LM, Mangos   GJ, Brown   MA. Comparisons of auscultatory hybrid and automated sphygmomanometers with mercury sphygmomanometry in hypertensive and normotensive pregnant women: parallel validation studies. J Hypertens  2015;33:499–505; discussion 505–496. https://doi.org/10.1097/hjh.0000000000000420
   
646	Schmella   MJ, Clifton   RG, Althouse   AD, Roberts   JM. Uric acid determination in gestational hypertension: is it as effective a delineator of risk as proteinuria in high-risk women?  Reprod Sci  2015;22:1212–9. https://doi.org/10.1177/1933719115572477
   
647	Rolnik   DL, Wright   D, Poon   LC, O’Gorman   N, Syngelaki   A, de Paco Matallana   C, et al.   Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med  2017;377:613–22. https://doi.org/10.1056/NEJMoa1704559
   
648	Chappell   LC, Shennan   AH. Assessment of proteinuria in pregnancy. BMJ  2008;336:968–9. https://doi.org/10.1136/bmj.39540.657928.BE
   
649	Jeon   HR, Jeong   DH, Lee   JY, Woo   EY, Shin   GT, Kim   S-Y. sFlt-1/PlGF ratio as a predictive and prognostic marker for preeclampsia. J Obstet Gynaecol Res  2021;47:2318–23. https://doi.org/10.1111/jog.14815
   
650	Bateman   BT, Bansil   P, Hernandez-Diaz   S, Mhyre   JM, Callaghan   WM, Kuklina   EV. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol  2012;206:134.e1–8. https://doi.org/10.1016/j.ajog.2011.10.878
   
651	Zhou   J, Azizan   EAB, Cabrera   CP, Fernandes-Rosa   FL, Boulkroun   S, Argentesi   G, et al.   Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nat Genet  2021;53:1360–72. https://doi.org/10.1038/s41588-021-00906-y
   
652	Lenders   JWM, Langton   K, Langenhuijsen   JF, Eisenhofer   G. Pheochromocytoma and pregnancy. Endocrinol Metab Clin North Am  2019;48:605–17. https://doi.org/10.1016/j.ecl.2019.05.006
   
653	Bancos   I, Atkinson   E, Eng   C, Young   WF  Jr, Neumann   HPH, Yukina   M, et al.   Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes Endocrinol  2021;9:13–21. https://doi.org/10.1016/s2213-8587(20)30363-6
   
654	Martínez-Vizcaíno   V, Sanabria-Martínez   G, Fernández-Rodríguez   R, Cavero-Redondo   I, Pascual-Morena   C, Álvarez-Bueno   C, et al.   Exercise during pregnancy for preventing gestational diabetes mellitus and hypertensive disorders: an umbrella review of randomised controlled trials and an updated meta-analysis. Bjog  2023;130:264–75. https://doi.org/10.1111/1471-0528.17304
   
655	Mottola   MF, Davenport   MH, Ruchat   SM, Davies   GA, Poitras   VJ, Gray   CE, et al.   2019 Canadian guideline for physical activity throughout pregnancy. Br J Sports Med  2018;52:1339–46. https://doi.org/10.1136/bjsports-2018-100056
   
656	Askie   LM, Duley   L, Henderson-Smart   DJ, Stewart   LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet  2007;369:1791–8. https://doi.org/10.1016/s0140-6736(07)60712-0
   
657	Duley   L, Meher   S, Hunter   KE, Seidler   AL, Askie   LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev  2019;2019:CD004659. https://doi.org/10.1002/14651858.CD004659.pub3
Google ScholarPubMedWorldCat 
658	Hofmeyr   GJ, Lawrie   TA, Atallah   ÁN, Torloni   MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev  2018;10:CD001059. https://doi.org/10.1002/14651858.CD001059.pub5
Google ScholarPubMedWorldCat 
659	Dwarkanath   P, Muhihi   A, Sudfeld   CR, Wylie   BJ, Wang   M, Perumal   N, et al.   Two randomized trials of low-dose calcium supplementation in pregnancy. N Engl J Med  2024;390:143–53. https://doi.org/10.1056/NEJMoa2307212
   
660	Abalos   E, Duley   L, Steyn   DW, Gialdini   C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev  2018;10:CD002252. https://doi.org/10.1002/14651858.CD002252.pub4
Google ScholarPubMedWorldCat 
661	Magee   LA, von Dadelszen   P, Rey   E, Ross   S, Asztalos   E, Murphy   KE, et al.   Less-tight versus tight control of hypertension in pregnancy. N Engl J Med  2015;372:407–17. https://doi.org/10.1056/NEJMoa1404595
   
662	Redman   CW. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet  1976;2:753–6. https://doi.org/10.1016/s0140-6736(76)90597-3
Google ScholarPubMedWorldCat 
663	Cockburn   J, Moar   VA, Ounsted   M, Redman   CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet  1982;1:647–9. https://doi.org/10.1016/s0140-6736(82)92202-4
Google ScholarPubMedWorldCat 
664	Bellos   I, Pergialiotis   V, Papapanagiotou   A, Loutradis   D, Daskalakis   G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol  2020;223:525–37. https://doi.org/10.1016/j.ajog.2020.03.016
   
665	Lydakis   C, Lip   GY, Beevers   M, Beevers   DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens  1999;12:541–7. https://doi.org/10.1016/s0895-7061(99)00031-x
   
666	Sridharan   K, Sequeira   RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol  2018;84:1906–16. https://doi.org/10.1111/bcp.13649
   
667	Bhat   AD, Keasler   PM, Kolluru   L, Dombrowski   MM, Palanisamy   A, Singh   PM, et al.   Treatment of acute-onset hypertension in pregnancy: a network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration. Pregnancy Hypertens  2023;34:74–82. https://doi.org/10.1016/j.preghy.2023.10.005
   
668	Ehikioya   E, Okobi   OE, Beeko   MAE, Abanga   R, Abah   NNI, Briggs   L, et al.   Comparing intravenous labetalol and intravenous hydralazine for managing severe gestational hypertension. Cureus  2023;15:e42332. https://doi.org/10.7759/cureus.42332
Google ScholarPubMedWorldCat 
669	Halpern   DG, Weinberg   CR, Pinnelas   R, Mehta-Lee   S, Economy   KE, Valente   AM, et al.   Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Cardiol  2019;73:457–76. https://doi.org/10.1016/j.jacc.2018.10.075
   
670	Goel   A, Maski   MR, Bajracharya   S, Wenger   JB, Zhang   D, Salahuddin   S, et al.   Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation  2015;132:1726–33. https://doi.org/10.1161/circulationaha.115.015721
   
671	Behrens   I, Basit   S, Melbye   M, Lykke   JA, Wohlfahrt   J, Bundgaard   H, et al.   Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ  2017;358:j3078. https://doi.org/10.1136/bmj.j3078
Google ScholarPubMedWorldCat 
672	Barrett   PM, McCarthy   FP, Evans   M, Kublickas   M, Perry   IJ, Stenvinkel   P, et al.   Hypertensive disorders of pregnancy and the risk of chronic kidney disease: a Swedish registry-based cohort study. PLoS Med  2020;17:e1003255. https://doi.org/10.1371/journal.pmed.1003255
   
673	Giorgione   V, Ridder   A, Kalafat   E, Khalil   A, Thilaganathan   B. Incidence of postpartum hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic review and meta-analysis. BJOG  2021;128:495–503. https://doi.org/10.1111/1471-0528.16545
   
674	Benschop   L, Duvekot   JJ, Versmissen   J, van Broekhoven   V, Steegers   EAP, Roeters van Lennep   JE, et al.   Blood pressure profile 1 year after severe preeclampsia. Hypertension  2018;71:491–8. https://doi.org/10.1161/hypertensionaha.117.10338
   
675	Kitt   J, Fox   R, Frost   A, Shanyinde   M, Tucker   K, Bateman   PA, et al.   Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: the POP-HT randomized clinical trial. JAMA  2023;330:1991–9. https://doi.org/10.1001/jama.2023.21523
   
676	van Oostwaard   MF, Langenveld   J, Schuit   E, Papatsonis   DNM, Brown   MA, Byaruhanga   RN, et al.   Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol  2015;212:624.e1–17. https://doi.org/10.1016/j.ajog.2015.01.009
   
677	Brown   MA, Mackenzie   C, Dunsmuir   W, Roberts   L, Ikin   K, Matthews   J, et al.   Can we predict recurrence of pre-eclampsia or gestational hypertension?  BJOG  2007;114:984–93. https://doi.org/10.1111/j.1471-0528.2007.01376.x
   
678	Heimberger   S, Perdigao   JL, Mueller   A, Shahul   S, Naseem   H, Minhas   R, et al.   Effect of blood pressure control in early pregnancy and clinical outcomes in African American women with chronic hypertension. Pregnancy Hypertens  2020;20:102–7. https://doi.org/10.1016/j.preghy.2020.03.008
   
679	Salazar   MR, Espeche   WG, Balbín   E, Leiva Sisnieguez   CE, Leiva Sisnieguez   BC, Stavile   RN, et al.   Office blood pressure values and the necessity of out-of-office measurements in high-risk pregnancies. J Hypertens  2019;37:1838–44. https://doi.org/10.1097/hjh.0000000000002140
   
680	Buawangpong   N, Teekachunhatean   S, Koonrungsesomboon   N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: a systematic review and meta-analysis. Pharmacol Res Perspect  2020;8:e00644. https://doi.org/10.1002/prp2.644
   
681	Weber-Schoendorfer   C, Kayser   A, Tissen-Diabaté   T, Winterfeld   U, Eleftheriou   G, Te Winkel   B, et al.   Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. J Hypertens  2020;38:133–41. https://doi.org/10.1097/hjh.0000000000002233
   
682	Chen   X, Mao   G, Leng   SX. Frailty syndrome: an overview. Clin Interv Aging  2014;9:433–41. https://doi.org/10.2147/cia.S45300
Google ScholarPubMedWorldCat 
683	Rodriguez-Mañas   L, Fried   LP. Frailty in the clinical scenario. Lancet  2015;385:e7–9. https://doi.org/10.1016/s0140-6736(14)61595-6
   
684	Fried   LP, Tangen   CM, Walston   J, Newman   AB, Hirsch   C, Gottdiener   J, et al.   Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci  2001;56:M146–156. https://doi.org/10.1093/gerona/56.3.m146
   
685	Fried   LP, Kronmal   RA, Newman   AB, Bild   DE, Mittelmark   MB, Polak   JF, et al.   Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA  1998;279:585–92. https://doi.org/10.1001/jama.279.8.585
   
686	Martens   DS, Thijs   L, Latosinska   A, Trenson   S, Siwy   J, Zhang   Z-Y, et al.   Urinary peptidomic profiles to address age-related disabilities: a prospective population study. Lancet Healthy Longev  2021;2:e690–703. https://doi.org/10.1016/s2666-7568(21)00226-9
   
687	Monahan   KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr Comp Physiol  2007;293:R3–r12. https://doi.org/10.1152/ajpregu.00031.2007
   
688	Paleczny   B, Niewiński   P, Rydlewska   A, Piepoli   MF, Borodulin-Nadzieja   L, Jankowska   EA, et al.   Age-related reflex responses from peripheral and central chemoreceptors in healthy men. Clin Auton Res  2014;24:285–96. https://doi.org/10.1007/s10286-014-0263-9
   
689	Anker   D, Santos-Eggimann   B, Zwahlen   M, Santschi   V, Rodondi   N, Wolfson   C, et al.   Blood pressure in relation to frailty in older adults: a population-based study. J Clin Hypertens (Greenwich)  2019;21:1895–904. https://doi.org/10.1111/jch.13722
   
690	Ravindrarajah   R, Hazra   NC, Hamada   S, Charlton   J, Jackson   SHD, Dregan   A, et al.   Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age: cohort study using electronic health records. Circulation  2017;135:2357–68. https://doi.org/10.1161/circulationaha.116.026687
   
691	Searle   SD, Mitnitski   A, Gahbauer   EA, Gill   TM, Rockwood   K. A standard procedure for creating a frailty index. BMC Geriatr  2008;8:24. https://doi.org/10.1186/1471-2318-8-24
   
692	Clegg   A, Bates   C, Young   J, Ryan   R, Nichols   L, Ann Teale   E, et al.   Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing  2016;45:353–60. https://doi.org/10.1093/ageing/afw039
   
693	Rockwood   K, Song   X, MacKnight   C, Bergman   H, Hogan   DB, McDowell   I, et al.   A global clinical measure of fitness and frailty in elderly people. CMAJ  2005;173:489–95. https://doi.org/10.1503/cmaj.050051
   
694	Nguyen   TN, Harris   K, Woodward   M, Chalmers   J, Cooper   M, Hamet   P, et al.   The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care  2021;44:1622–9. https://doi.org/10.2337/dc20-2664
   
695	Masoli   JAH, Delgado   J, Pilling   L, Strain   D, Melzer   D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing  2020;49:807–13. https://doi.org/10.1093/ageing/afaa028
   
696	Aparicio   LS, Thijs   L, Boggia   J, Jacobs   L, Barochiner   J, Odili   AN, et al.   Defining thresholds for home blood pressure monitoring in octogenarians. Hypertension  2015;66:865–73. https://doi.org/10.1161/hypertensionaha.115.05800
   
697	Gaffney   B, Jacobsen   AP, Pallippattu   AW, Leahy   N, McEvoy   JW. The diastolic blood pressure J-curve in hypertension management: links and risk for cardiovascular disease. Integr Blood Press Control  2021;14:179–87. https://doi.org/10.2147/ibpc.S286957
   
698	Warwick   J, Falaschetti   E, Rockwood   K, Mitnitski   A, Thijs   L, Beckett   N, et al.   No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med  2015;13:78. https://doi.org/10.1186/s12916-015-0328-1
   
699	Todd   OM, Wilkinson   C, Hale   M, Wong   NL, Hall   M, Sheppard   JP, et al.   Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing  2019;48:627–35. https://doi.org/10.1093/ageing/afz072
   
700	Li   Y, Thijs   L, Zhang   ZY, Asayama   K, Hansen   TW, Boggia   J, et al.   Opposing age-related trends in absolute and relative risk of adverse health outcomes associated with out-of-office blood pressure. Hypertension  2019;74:1333–42. https://doi.org/10.1161/hypertensionaha.119.12958
   
701	Beckett   NS, Peters   R, Fletcher   AE, Staessen   JA, Liu   L, Dumitrascu   D, et al.   Treatment of hypertension in patients 80 years of age or older. N Engl J Med  2008;358:1887–98. https://doi.org/10.1056/NEJMoa0801369
   
702	Peters   R, Beckett   N, McCormack   T, Fagard   R, Fletcher   A, Bulpitt   C. Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J  2014;35:1712–8. https://doi.org/10.1093/eurheartj/eht464
   
703	Travers   J, Romero-Ortuno   R, Bailey   J, Cooney   MT. Delaying and reversing frailty: a systematic review of primary care interventions. Br J Gen Pract  2019;69:e61–9. https://doi.org/10.3399/bjgp18X700241
   
704	Bogaerts   JMK, von Ballmoos   LM, Achterberg   WP, Gussekloo   J, Streit   S, van der Ploeg   MA, et al.   Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases. Age Ageing  2022;51:afab192. https://doi.org/10.1093/ageing/afab192
   
705	Sheppard   JP, Benetos   A, McManus   RJ. Antihypertensive deprescribing in older adults: a practical guide. Curr Hypertens Rep  2022;24:571–80. https://doi.org/10.1007/s11906-022-01215-3
   
706	McDonnell   CC, Rogers   KC, Regen   SM, Finks   SW. The Fall Risk with Alpha blockers Given InitiaL dose or Elderly status (FRAGILE) study. Ann Pharmacother  2020;54:226–31. https://doi.org/10.1177/1060028019880305
   
707	Hiremath   S, Ruzicka   M, Petrcich   W, McCallum   MK, Hundemer   GL, Tanuseputro   P, et al.   Alpha-blocker use and the risk of hypotension and hypotension-related clinical events in women of advanced age. Hypertension  2019;74:645–51. https://doi.org/10.1161/hypertensionaha.119.13289
   
708	Li   H, Xu   TY, Li   Y, Chia   Y-C, Buranakitjaroen   P, Cheng   H-M, et al.   Role of α1-blockers in the current management of hypertension. J Clin Hypertens (Greenwich)  2022;24:1180–6. https://doi.org/10.1111/jch.14556
   
709	Ravindrarajah   R, Dregan   A, Hazra   NC, Hamada   S, Jackson   SHD, Gulliford   MC, et al.   Declining blood pressure and intensification of blood pressure management among people over 80 years: cohort study using electronic health records. J Hypertens  2017;35:1276–82. https://doi.org/10.1097/hjh.0000000000001291
   
710	Chun   S, Han   K, Lee   S, Cho   M-H, Jeong   S-M, Jung   H-W, et al.   Impact of frailty on the relationship between blood pressure and cardiovascular diseases and mortality in young-old adults. J Pers Med  2022;12:418. https://doi.org/10.3390/jpm12030418
   
711	Khan   N, McAlister   FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ  2006;174:1737–42. https://doi.org/10.1503/cmaj.060110
   
712	Lavan   AH, Gallagher   P, Parsons   C, O’Mahony   D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing  2017;46:600–7. https://doi.org/10.1093/ageing/afx005
   
713	Eeftinck Schattenkerk   DW, van Gorp   J, Vogt   L, Peters   RJ, van den Born   BH. Isolated systolic hypertension of the young and its association with central blood pressure in a large multi-ethnic population. The HELIUS study. Eur J Prev Cardiol  2018;25:1351–9. https://doi.org/10.1177/2047487318777430
   
714	Franklin   SS, Jacobs   MJ, Wong   ND, L’Italien   GJ, Lapuerta   P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension  2001;37:869–74. https://doi.org/10.1161/01.hyp.37.3.869
   
715	Van Bortel   LM, Laurent   S, Boutouyrie   P, Chowienczyk   P, Cruickshank   JK, De Backer   T, et al.   Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens  2012;30:445–8. https://doi.org/10.1097/HJH.0b013e32834fa8b0
   
716	The Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J  2010;31:2338–50. https://doi.org/10.1093/eurheartj/ehq165
CrossrefPubMedWorldCat 
717	Li   Y, Wei   FF, Thijs   L, Boggia   J, Asayama   K, Hansen   TW, et al.   Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation  2014;130:466–74. https://doi.org/10.1161/circulationaha.113.004876
   
718	Staessen   JA, Gasowski   J, Wang   JG, Thijs   L, Hond   ED, Boissel   J-P, et al.   Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet  2000;355:865–72. https://doi.org/10.1016/s0140-6736(99)07330-4
   
719	McEniery   CM, Yasmin, Wallace   S, Maki-Petaja   K, McDonnell   B, Sharman   JE, et al.   Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension  2005;46:221–6. https://doi.org/10.1161/01.HYP.0000165310.84801.e0
   
720	Palatini   P, Rosei   EA, Avolio   A, Bilo   G, Casiglia   E, Ghiadoni   L, et al.   Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens  2018;36:1222–36. https://doi.org/10.1097/hjh.0000000000001726
   
721	Unger   T, Borghi   C, Charchar   F, Khan   NA, Poulter   NR, Prabhakaran   D, et al.   2020 International Society of Hypertension global hypertension practice guidelines. Hypertension  2020;75:1334–57. https://doi.org/10.1161/hypertensionaha.120.15026
   
722	Yano   Y, Chang Kim   H, Lee   H, Azahar   N, Ahmed   S, Kitaoka   K, et al.   Response to isolated diastolic hypertension and risk of cardiovascular disease: controversies in hypertension—con side of the argument. Hypertension  2022;79:1579. https://doi.org/10.1161/hypertensionaha.122.19493
   
723	Jacobsen   AP, McKittrick   M, Daya   N, Al Rifai   M, McEvoy   JW. Isolated diastolic hypertension and risk of cardiovascular disease: controversies in hypertension—con side of the argument. Hypertension  2022;79:1571–8. https://doi.org/10.1161/hypertensionaha.122.18458
   
724	Blank   SG, Mann   SJ, James   GD, West   JE, Pickering   TG. Isolated elevation of diastolic blood pressure. Real or artifactual?  Hypertension  1995;26:383–9. https://doi.org/10.1161/01.hyp.26.3.383
   
725	Cho   SMJ, Lee   H, Koyama   S, Zou   RS, Schuermans   A, Ganesh   S, et al.   Cumulative diastolic blood pressure burden in normal systolic blood pressure and cardiovascular disease. Hypertension  2024;81:273–81. https://doi.org/10.1161/hypertensionaha.123.22160
   
726	Grobman   B, Turkson-Ocran   RN, Staessen   JA, Yu   Y-L, Lipsitz   LA, Mukamal   KJ, et al.   Body position and orthostatic hypotension in hypertensive adults: results from the Syst-Eur trial. Hypertension  2023;80:820–7. https://doi.org/10.1161/hypertensionaha.122.20602
   
727	Juraschek   SP, Taylor   AA, Wright   JT  Jr, Evans   GW, Miller   ER, Plante   TB, et al.   Orthostatic hypotension, cardiovascular outcomes, and adverse events: results from SPRINT. Hypertension  2020;75:660–7. https://doi.org/10.1161/hypertensionaha.119.14309
   
728	Juraschek   SP, Daya   N, Appel   LJ, Miller   ER, McEvoy   JW, Matsushita   K, et al.   Orthostatic hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged adults. J Am Heart Assoc  2018;7:e008884. https://doi.org/10.1161/jaha.118.008884
   
729	Fleg   JL, Evans   GW, Margolis   KL, Barzilay   J, Basile   JN, Bigger   JT, et al.   Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance. Hypertension  2016;68:888–95. https://doi.org/10.1161/hypertensionaha.116.07474
   
730	Juraschek   SP, Hu   JR, Cluett   JL, Ishak   A, Mita   C, Lipsitz   LA, et al.   Effects of intensive blood pressure treatment on orthostatic hypotension : a systematic review and individual participant-based meta-analysis. Ann Intern Med  2021;174:58–68. https://doi.org/10.7326/m20-4298
   
731	Ylitalo   A, Airaksinen   KE, Sellin   L, Huikuri   HV. Effects of combination antihypertensive therapy on baroreflex sensitivity and heart rate variability in systemic hypertension. Am J Cardiol  1999;83:885–9. https://doi.org/10.1016/s0002-9149(98)01067-4
   
732	Ganjehei   L, Massumi   A, Razavi   M, Wilson   JM. Orthostatic hypotension as a manifestation of vitamin B12 deficiency. Tex Heart Inst J  2012;39:722–3.
Google ScholarPubMedWorldCat 
733	Shimbo   D, Barrett Bowling   C, Levitan   EB, Deng   L, Sim   JJ, Huang   L, et al.   Short-term risk of serious fall injuries in older adults initiating and intensifying treatment with antihypertensive medication. Circ Cardiovasc Qual Outcomes  2016;9:222–9. https://doi.org/10.1161/circoutcomes.115.002524
   
734	Krediet   CT, van Lieshout   JJ, Bogert   LW, Immink   RV, Kim   Y-S, Wieling   W, et al.   Leg crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled crossover study. Am J Physiol Heart Circ Physiol  2006;291:H1768–72. https://doi.org/10.1152/ajpheart.00287.2006
   
735	Okamoto   LE, Diedrich   A, Baudenbacher   FJ, Harder   R, Whitfield   JS, Iqbal   F, et al.   Efficacy of servo-controlled splanchnic venous compression in the treatment of orthostatic hypotension: a randomized comparison with midodrine. Hypertension  2016;68:418–26. https://doi.org/10.1161/hypertensionaha.116.07199
   
736	Okamoto   LE, Celedonio   JE, Smith   EC, Gamboa   A, Shibao   CA, Diedrich   A, et al.   Local passive heat for the treatment of hypertension in autonomic failure. J Am Heart Assoc  2021;10:e018979. https://doi.org/10.1161/jaha.120.018979
   
737	Buyken   AE, von Eckardstein   A, Schulte   H, Cullen   P, Assmann   G. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil  2007;14:230–6. https://doi.org/10.1097/HJR.0b013e3280142037
   
738	Nathan   DM. Long-term complications of diabetes mellitus. N Engl J Med  1993;328:1676–85. https://doi.org/10.1056/nejm199306103282306
   
739	Marx   N, Federici   M, Schütt   K, Müller-Wieland   D, Ajjan   RA, Antunes   MJ, et al.   2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J  2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
   
740	Pylypchuk   R, Wells   S, Kerr   A, Poppe   K, Harwood   M, Mehta   S, et al.   Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study. Lancet  2021;397:2264–74. https://doi.org/10.1016/s0140-6736(21)00572-9
   
741	Danaei   G, Fahimi   S, Lu   Y, Zhou   B, Hajifathalian   K, Di Cesare   M, et al.   Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331288 participants. Lancet Diabetes Endocrinol  2015;3:624–37. https://doi.org/10.1016/S2213-8587(15)00129-1
   
742	Wright   AK, Suarez-Ortegon   MF, Read   SH, Kontopantelis   E, Buchan   I, Emsley   R, et al.   Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. Circulation  2020;142:1925–36. https://doi.org/10.1161/circulationaha.120.046783
   
743	Adamsson Eryd   S, Gudbjörnsdottir   S, Manhem   K, Rosengren   A, Svensson   A-M, Miftaraj   M, et al.   Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ  2016;354:i4070. https://doi.org/10.1136/bmj.i4070
Google ScholarPubMedWorldCat 
744	Brunström   M, Carlberg   B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ  2016;352:i717. https://doi.org/10.1136/bmj.i717
Google ScholarPubMedWorldCat 
745	Emdin   CA, Rahimi   K, Neal   B, Callender   T, Perkovic   V, Patel   A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA  2015;313:603–15. https://doi.org/10.1001/jama.2014.18574
   
746	Thomopoulos   C, Parati   G, Zanchetti   A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens  2017;35:922–44. https://doi.org/10.1097/hjh.0000000000001276
   
747	Rahman   F, McEvoy   JW, Ohkuma   T, Marre   M, Hamet   P, Harrap   S, et al.   Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus. Hypertension  2019;73:1291–9. https://doi.org/10.1161/hypertensionaha.118.12414
   
748	Agashe   S, Petak   S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc J  2018;14:251–6. https://doi.org/10.14797/mdcj-14-4-251
   
749	Beddhu   S, Chertow   GM, Greene   T, Whelton   PK, Ambrosius   WT, Cheung   AK, et al.   Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc  2018;7:e009326. https://doi.org/10.1161/jaha.118.009326
   
750	Buckley   LF, Dixon   DL, Wohlford   GF, Wijesinghe   DS, Baker   WL, Van Tassell   BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care  2017;40:1733–8. https://doi.org/10.2337/dc17-1366
   
751	Brouwer   TF, Vehmeijer   JT, Kalkman   DN, Berger   WR, van den Born   B-JH, Peters   RJ, et al.   Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care  2018;41:1142–8. https://doi.org/10.2337/dc17-1722
   
752	Shi   S, Gouskova   N, Najafzadeh   M, Wei   LJ, Kim   DH. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open  2021;11:e050335. https://doi.org/10.1136/bmjopen-2021-050335
   
753	Palmer   SC, Mavridis   D, Navarese   E, Craig   JC, Tonelli   M, Salanti   G, et al.   Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet  2015;385:2047–56. https://doi.org/10.1016/s0140-6736(14)62459-4
   
754	Ying   A, Arima   H, Czernichow   S, Woodward   M, Huxley   R, Turnbull   F, et al.   Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet  2015;385:867–74. https://doi.org/10.1016/s0140-6736(14)61171-5
Google ScholarPubMedWorldCat 
755	Nazarzadeh   M, Bidel   Z, Canoy   D, Copland   E, Wamil   M, Majert   J, et al.   Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet  2021;398:1803–10. https://doi.org/10.1016/s0140-6736(21)01920-6
   
756	Kearney   PM, Whelton   M, Reynolds   K, Muntner   P, Whelton   PK, He   J, et al.   Global burden of hypertension: analysis of worldwide data. Lancet  2005;365:217–23. https://doi.org/10.1016/s0140-6736(05)17741-1
   
757	Jager   KJ, Kovesdy   C, Langham   R, Rosenberg   M, Jha   V, Zoccali   C, et al.   A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int  2019;96:1048–50. https://doi.org/10.1016/j.kint.2019.07.012
   
758	Foreman   KJ, Marquez   N, Dolgert   A, Fukutaki   K, Fullman   N, McGaughey   M, et al.   Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet  2018;392:2052–90. https://doi.org/10.1016/s0140-6736(18)31694-5
   
759	Ortiz   A, Sanchez-Niño   MD, Crespo-Barrio   M, De-Sequera-Ortiz   P, Fernández-Giráldez   E, García-Maset   R, et al.   The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia (Engl Ed)  2019;39:29–34. https://doi.org/10.1016/j.nefro.2018.09.002
   
760	Law   JP, Pickup   L, Pavlovic   D, Townend   JN, Ferro   CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J Hum Hypertens  2023;37:1–19. https://doi.org/10.1038/s41371-022-00751-4
   
761	Fay   KS, Cohen   DL. Resistant hypertension in people with CKD: a review. Am J Kidney Dis  2021;77:110–21. https://doi.org/10.1053/j.ajkd.2020.04.017
   
762	Webster   AC, Nagler   EV, Morton   RL, Masson   P. Chronic kidney disease. Lancet  2017;389:1238–52. https://doi.org/10.1016/s0140-6736(16)32064-5
   
763	Ninomiya   T, Perkovic   V, Turnbull   F, Neal   B, Barzi   F, Cass   A, et al.   Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ  2013;347:f5680. https://doi.org/10.1136/bmj.f5680
Google ScholarPubMedWorldCat 
764	Aggarwal   R, Petrie   B, Bala   W, Chiu   N. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension  2019;73:1275–82. https://doi.org/10.1161/hypertensionaha.119.12697
   
765	Bangalore   S, Toklu   B, Gianos   E, Schwartzbard   A, Weintraub   H, Ogedegbe   G, et al.   Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med  2017;130:707–19.e8. https://doi.org/10.1016/j.amjmed.2017.01.004
   
766	Lv   J, Ehteshami   P, Sarnak   MJ, Tighiouart   H, Jun   M, Ninomiya   T, et al.   Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ  2013;185:949–57. https://doi.org/10.1503/cmaj.121468
   
767	Tsai   WC, Wu   HY, Peng   YS, Yang   J-Y, Chen   H-Y, Chiu   Y-L, et al.   Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med  2017;177:792–9. https://doi.org/10.1001/jamainternmed.2017.0197
   
768	Thompson   S, Wiebe   N, Padwal   RS, Gyenes   G, Headley   SAE, Radhakrishnan   J, et al.   The effect of exercise on blood pressure in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One  2019;14:e0211032. https://doi.org/10.1371/journal.pone.0211032
   
769	Huang   M, Lv   A, Wang   J, Xu   N, Ma   G, Zhai   Z, et al.   Exercise training and outcomes in hemodialysis patients: systematic review and meta-analysis. Am J Nephrol  2019;50:240–54. https://doi.org/10.1159/000502447
   
770	Zhang   Y, He   D, Zhang   W, Xing   Y, Guo   Y, Wang   F, et al.   ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: a network meta-analysis of randomised clinical trials. Drugs  2020;80:797–811. https://doi.org/10.1007/s40265-020-01290-3
   
771	Jafar   TH, Stark   PC, Schmid   CH, Landa   M, Maschio   G, de Jong   PE, et al.   Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med  2003;139:244–52. https://doi.org/10.7326/0003-4819-139-4-200308190-00006
   
772	Xie   X, Liu   Y, Perkovic   V, Li   X, Ninomiya   T, Hou   W, et al.   Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis  2016;67:728–41. https://doi.org/10.1053/j.ajkd.2015.10.011
   
773	Wu   HY, Huang   JW, Lin   HJ, Liao   W-C, Peng   Y-S, Hung   K-Y, et al.   Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ  2013;347:f6008. https://doi.org/10.1136/bmj.f6008
   
774	Agarwal   R, Sinha   AD, Cramer   AE, Balmes-Fenwick   M, Dickinson   JH, Ouyang   F, et al.   Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med  2021;385:2507–19. https://doi.org/10.1056/NEJMoa2110730
   
775	Beddhu   S, Shen   J, Cheung   AK, Kimmel   PL, Chertow   GM, Wei   G, et al.   Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT. J Am Soc Nephrol  2019;30:1523–33. https://doi.org/10.1681/asn.2018121261
   
776	Herrington   WG, Staplin   N, Wanner   C, Green   JB, Hauske   SJ, Emberson   JR, et al.   Empagliflozin in patients with chronic kidney disease. N Engl J Med  2023;388:117–27. https://doi.org/10.1056/NEJMoa2204233
Google ScholarPubMedWorldCat 
777	Heerspink   HJL, Stefánsson   BV, Correa-Rotter   R, Chertow   GM, Greene   T, Hou   F-F, et al.   Dapagliflozin in patients with chronic kidney disease. N Engl J Med  2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816
   
778	Pitt   B, Filippatos   G, Agarwal   R, Anker   SD, Bakris   GL, Rossing   P, et al.   Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med  2021;385:2252–63. https://doi.org/10.1056/NEJMoa2110956
   
779	Ku   E, McCulloch   CE, Inker   LA, Tighiouart   H, Schaefer   F, Wühl   E, et al.   Intensive BP control in patients with CKD and risk for adverse outcomes. J Am Soc Nephrol  2023;34:385–93. https://doi.org/10.1681/asn.0000000000000072
   
780	Lewis   EJ, Hunsicker   LG, Clarke   WR, Berl   T, Pohl   MA, Lewis   JB, et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med  2001;345:851–60. https://doi.org/10.1056/NEJMoa011303
   
781	Brenner   BM, Cooper   ME, de Zeeuw   D, Keane   WF, Mitch   WE, Parving   H-H, et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med  2001;345:861–9. https://doi.org/10.1056/NEJMoa011161
   
782	The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet  1997;349:1857–63. https://doi.org/10.1016/S0140-6736(96)11445-8
CrossrefPubMedWorldCat 
783	Cruickshank   JM, Thorp   JM, Zacharias   FJ. Benefits and potential harm of lowering high blood pressure. Lancet  1987;1:581–4. https://doi.org/10.1016/s0140-6736(87)90231-5
Google ScholarPubMedWorldCat 
784	Staessen   J, Bulpitt   C, Clement   D, De Leeuw   P, Fagard   R, Fletcher   A, et al.   Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European working party on high blood pressure in the elderly. BMJ  1989;298:1552–6. https://doi.org/10.1136/bmj.298.6687.1552
   
785	Böhm   M, Schumacher   H, Teo   KK, Lonn   EM, Mahfoud   F, Mann   JFE, et al.   Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet  2017;389:2226–37. https://doi.org/10.1016/s0140-6736(17)30754-7
   
786	Böhm   M, Ferreira   JP, Mahfoud   F, Duarte   K, Pitt   B, Zannad   F, et al.   Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. Eur Heart J  2020;41:1673–83. https://doi.org/10.1093/eurheartj/ehaa132
   
787	McEvoy   JW, Chen   Y, Rawlings   A, Hoogeveen   RC, Ballantyne   CM, Blumenthal   RS, et al.   Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol  2016;68:1713–22. https://doi.org/10.1016/j.jacc.2016.07.754
   
788	Mancia   G, Kreutz   R, Brunström   M, Burnier   M, Grassi   G, Januszewicz   A, et al.   2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens  2023;41:1874–2071. https://doi.org/10.1097/hjh.0000000000003480
   
789	Carvalho   JJ, Baruzzi   RG, Howard   PF, Poulter   N, Alpers   M P, Franco   L J, et al.   Blood pressure in four remote populations in the INTERSALT study. Hypertension  1989;14:238–46. https://doi.org/10.1161/01.hyp.14.3.238
   
790	Birrane   JP, Foschi   M, Sacco   S, McEvoy   JW. Another nail in the coffin of causality for the diastolic blood pressure J curve. Hypertension  2022;79:794–7. https://doi.org/10.1161/hypertensionaha.122.18997
   
791	Mueller   NT, Noya-Alarcon   O, Contreras   M, Appel   LJ, Dominguez-Bello   MG. Association of age with blood pressure across the lifespan in isolated Yanomami and Yekwana villages. JAMA Cardiol  2018;3:1247–9. https://doi.org/10.1001/jamacardio.2018.3676
   
792	Ilkun   OL, Greene   T, Cheung   AK, Whelton   PK, Wei   G, Boucher   RE, et al.   The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care  2020;43:1878–84. https://doi.org/10.2337/dc19-2047
   
793	Shihab   S, Boucher   RE, Abraham   N, Wei   G, Beddhu   S. Influence of baseline diastolic blood pressure on the effects of intensive systolic blood pressure lowering on the risk of stroke. Hypertension  2022;79:785–93. https://doi.org/10.1161/hypertensionaha.121.18172
   
794	Vahanian   A, Beyersdorf   F, Praz   F, Milojevic   M, Baldus   S, Bauersachs   J, et al.   2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J  2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395
   
795	McDonagh   TA, Metra   M, Adamo   M, Gardner   RS, Baumbach   A, Böhm   M, et al.   2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2021;42:3599–726. https://doi.org/10.1093/eurheartj/ehab368
   
796	Mancusi   C, de Simone   G, Brguljan Hitij   J, Sudano   I, Mahfoud   F, Parati   G, et al.   Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother  2021;7:242–50. https://doi.org/10.1093/ehjcvp/pvaa040
   
797	Nielsen   OW, Sajadieh   A, Sabbah   M, Greve   AM, Olsen   MH, Boman   K, et al.   Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: the simvastatin ezetimibe in aortic stenosis study (SEAS). Circulation  2016;134:455–68. https://doi.org/10.1161/circulationaha.115.021213
   
798	McDonagh   TA, Metra   M, Adamo   M, Gardner   RS, Baumbach   A, Böhm   M, et al.   2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195
   
799	Yusuf   S, Pfeffer   MA, Swedberg   K, Granger   CB, Held   P, McMurray   JJV, et al.   Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet  2003;362:777–81. https://doi.org/10.1016/s0140-6736(03)14285-7
   
800	Pitt   B, Pfeffer   MA, Assmann   SF, Boineau   R, Anand   IS, Claggett   B, et al.   Spironolactone for heart failure with preserved ejection fraction. N Engl J Med  2014;370:1383–92. https://doi.org/10.1056/NEJMoa1313731
   
801	Nazarzadeh   M, Pinho-Gomes   AC, Bidel   Z, Canoy   D, Dehghan   A, Byrne   KS, et al.   Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study. Genome Med  2021;13:38. https://doi.org/10.1186/s13073-021-00849-3
   
802	Emdin   CA, Anderson   SG, Salimi-Khorshidi   G, Woodward   M, MacMahon   S, Dwyer   T, et al.   Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol  2017;46:162–72. https://doi.org/10.1093/ije/dyw053
Google ScholarPubMedWorldCat 
803	Hindricks   G, Potpara   T, Dagres   N, Arbelo   E, Bax   JJ, Blomström-Lundqvist   C, et al.   2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J  2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
   
804	Alber   J, Alladi   S, Bae   HJ, Barton   DA, Beckett   LA, Bell   JM, et al.   White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities. Alzheimers Dement (N Y)  2019;5:107–17. https://doi.org/10.1016/j.trci.2019.02.001
   
805	Georgakis   MK, Duering   M, Wardlaw   JM, Dichgans   M. WMH and long-term outcomes in ischemic stroke: a systematic review and meta-analysis. Neurology  2019;92:e1298–308. https://doi.org/10.1212/wnl.0000000000007142
   
806	Jokinen   H, Koikkalainen   J, Laakso   HM, Melkas   S, Nieminen   T, Brander   A, et al.   Global burden of small vessel disease-related brain changes on MRI predicts cognitive and functional decline. Stroke  2020;51:170–8. https://doi.org/10.1161/strokeaha.119.026170
   
807	Potter   T, Lioutas   VA, Tano   M, Pan   A, Meeks   J, Woo   D, et al.   Cognitive impairment after intracerebral hemorrhage: a systematic review of current evidence and knowledge gaps. Front Neurol  2021;12:716632. https://doi.org/10.3389/fneur.2021.716632
   
808	Wang   F, Hua   S, Zhang   Y, Zhu   J, Liu   R, Jiang   Z. Association between small vessel disease markers, medial temporal lobe atrophy and cognitive impairment after stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis  2021;30:105460. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105460
   
809	Ungvari   Z, Toth   P, Tarantini   S, Prodan   CI, Sorond   F, Merkely   B, et al.   Hypertension-induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol  2021;17:639–54. https://doi.org/10.1038/s41581-021-00430-6
   
810	Kelly   D, Rothwell   PM. Disentangling the multiple links between renal dysfunction and cerebrovascular disease. J Neurol Neurosurg Psychiatry  2020;91:88–97. https://doi.org/10.1136/jnnp-2019-320526
   
811	Papanastasiou   CA, Theochari   CA, Zareifopoulos   N, Arfaras-Melainis   A, Giannakoulas   G, Karamitsos   TD, et al.   Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and Alzheimer’s disease: a systematic review and meta-analysis. J Gen Intern Med  2021;36:3122–35. https://doi.org/10.1007/s11606-021-06954-8
   
812	Li   J, Wu   Y, Zhang   D, Nie   J. Associations between heart failure and risk of dementia: a PRISMA-compliant meta-analysis. Medicine (Baltimore)  2020;99:e18492. https://doi.org/10.1097/md.0000000000018492
   
813	Canavan   M, O’Donnell   MJ. Hypertension and cognitive impairment: a review of mechanisms and key concepts. Front Neurol  2022;13:821135. https://doi.org/10.3389/fneur.2022.821135
   
814	Dawson   J, Béjot   Y, Christensen   LM, De Marchis   GM, Dichgans   M, Hagberg   G, et al.   European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J  2022;7:I–XLI. https://doi.org/10.1177/23969873221100032
   
815	Kleindorfer   DO, Towfighi   A, Chaturvedi   S, Cockroft   KM, Gutierrez   J, Lombardi-Hill   D, et al.   2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke  2021;52:e364–467. https://doi.org/10.1161/str.0000000000000375
   
816	Zonneveld   TP, Richard   E, Vergouwen   MD, Nederkoorn   PJ, de Haan   RJ, Roos   YB, et al.   Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev  2018;7:CD007858. https://doi.org/10.1002/14651858.CD007858.pub2
Google ScholarPubMedWorldCat 
817	Boncoraglio   GB, Del Giovane   C, Tramacere   I. Antihypertensive drugs for secondary prevention after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke  2021;52:1974–82. https://doi.org/10.1161/strokeaha.120.031945
   
818	Fischer   U, Cooney   MT, Bull   LM, Silver   LE, Chalmers   J, Anderson   CS, et al.   Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study. Lancet Neurol  2014;13:374–84. https://doi.org/10.1016/s1474-4422(14)70031-6
   
819	Yusuf   S, Diener   HC, Sacco   RL, Cotton   D, Ôunpuu   S, Lawton   WA, et al.   Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med  2008;359:1225–37. https://doi.org/10.1056/NEJMoa0804593
   
820	PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet  2001;358:1033–41. https://doi.org/10.1016/s0140-6736(01)06178-5
CrossrefPubMedWorldCat 
821	McGurgan   IJ, Kelly   PJ, Turan   TN, Rothwell   PM. Long-term secondary prevention: management of blood pressure after a transient ischemic attack or stroke. Stroke  2022;53:1085–103. https://doi.org/10.1161/strokeaha.121.035851
   
822	Rudd   AG, Bowen   A, Young   GR, James   MA. The latest national clinical guideline for stroke. Clin Med (Lond)  2017;17:154–5. https://doi.org/10.7861/clinmedicine.17-2-154
   
823	Arima   H, Chalmers   J, Woodward   M, Anderson   C, Rodgers   A, Davis   S, et al.   Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens  2006;24:1201–8. https://doi.org/10.1097/01.hjh.0000226212.34055.86
   
824	Kitagawa   K, Yamamoto   Y, Arima   H, Maeda   T, Sunami   N, Kanzawa   T, et al.   Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol  2019;76:1309–18. https://doi.org/10.1001/jamaneurol.2019.2167
   
825	Suchard   MA, Schuemie   MJ, Krumholz   HM, You   SC, Chen   R, Pratt   N, et al.   Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet  2019;394:1816–26. https://doi.org/10.1016/s0140-6736(19)32317-7
   
826	Wang   WT, You   LK, Chiang   CE, Sung   S-H, Chuang   S-Y, Cheng   H-M, et al.   Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore)  2016;95:e3302. https://doi.org/10.1097/md.0000000000003302
   
827	Bath   PM, Scutt   P, Blackburn   DJ, Ankolekar   S, Krishnan   K, Ballard   C, et al.   Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot ‘Prevention of Decline in Cognition after Stroke Trial’ (PODCAST) randomised controlled trial. PLoS One  2017;12:e0164608. https://doi.org/10.1371/journal.pone.0164608
   
828	Mant   J, McManus   RJ, Roalfe   A, Fletcher   K, Taylor   CJ, Martin   U, et al.   Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke—Blood Pressure) randomised controlled trial. BMJ  2016;352:i708. https://doi.org/10.1136/bmj.i708
Google ScholarPubMedWorldCat 
829	Kolmos   M, Christoffersen   L, Kruuse   C. Recurrent ischemic stroke—a systematic review and meta-analysis. J Stroke Cerebrovasc Dis  2021;30:105935. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105935
   
830	Livingston   G, Huntley   J, Sommerlad   A, Ames   D, Ballard   C, Banerjee   S, et al.   Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet  2020;396:413–46. https://doi.org/10.1016/s0140-6736(20)30367-6
   
831	Ou   YN, Tan   CC, Shen   XN, Xu   W, Hou   X-H, Dong   Q, et al.   Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension  2020;76:217–25. https://doi.org/10.1161/hypertensionaha.120.14993
   
832	Abell   JG, Kivimäki   M, Dugravot   A, Tabak   AG, Fayosse   A, Shipley   M, et al.   Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J  2018;39:3119–25. https://doi.org/10.1093/eurheartj/ehy288
   
833	Alpérovitch   A, Blachier   M, Soumaré   A, Ritchie   K, Dartigues   J-F, Richard-Harston   S, et al.   Blood pressure variability and risk of dementia in an elderly cohort, the Three-City study. Alzheimers Dement  2014;10:S330–337. https://doi.org/10.1016/j.jalz.2013.05.1777
   
834	McGrath   ER, Beiser   AS, DeCarli   C, Plourde   KL, Vasan   RS, Greenberg   S, et al.   Blood pressure from mid- to late life and risk of incident dementia. Neurology  2017;89:2447–54. https://doi.org/10.1212/wnl.0000000000004741
   
835	Skoog   I, Nilsson   L, Persson   G, Lernfelt   B, Landahl   S, Palmertz   B, et al.   15-year longitudinal study of blood pressure and dementia. Lancet  1996;347:1141–5. https://doi.org/10.1016/s0140-6736(96)90608-x
   
836	Launer   LJ, Masaki   K, Petrovitch   H, Foley   D, Havlik   RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia aging study. JAMA  1995;274:1846–51. https://doi.org/10.1001/jama.1995.03530230032026
   
837	Gottesman   RF, Albert   MS, Alonso   A, Coker   LH, Coresh   J, Davis   SM, et al.   Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in Communities (ARIC) cohort. JAMA Neurol  2017;74:1246–54. https://doi.org/10.1001/jamaneurol.2017.1658
   
838	Levine   DA, Springer   MV, Brodtmann   A. Blood pressure and vascular cognitive impairment. Stroke  2022;53:1104–13. https://doi.org/10.1161/strokeaha.121.036140
   
839	Bosch   J, O’Donnell   M, Swaminathan   B, Lonn   EM, Sharma   M, Dagenais   G, et al.   Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study. Neurology  2019;92:e1435–46. https://doi.org/10.1212/wnl.0000000000007174
   
840	Applegate   WB, Pressel   S, Wittes   J, Luhr   J, Shekelle   RB, Camel   GH, et al.   Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med  1994;154:2154–60. https://doi.org/10.1001/archinte.1994.00420190047006
   
841	Williamson   JD, Pajewski   NM, Auchus   AP, Bryan   RN, Chelune   G, Cheung   AK, et al.   Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA  2019;321:553–61. https://doi.org/10.1001/jama.2018.21442
Google ScholarPubMedWorldCat 
842	Peters   R, Beckett   N, Forette   F, Tuomilehto   J, Clarke   R, Ritchie   C, et al.   Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol  2008;7:683–9. https://doi.org/10.1016/s1474-4422(08)70143-1
   
843	Lithell   H, Hansson   L, Skoog   I, Elmfeldt   D, Hofman   A, Olofsson   B, et al.   The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens  2003;21:875–86. https://doi.org/10.1097/00004872-200305000-00011
   
844	White   WB, Wakefield   DB, Moscufo   N, Guttmann   CRG, Kaplan   RF, Bohannon   RW, et al.   Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY). Circulation  2019;140:1626–35. https://doi.org/10.1161/circulationaha.119.041603
   
845	Tzourio   C, Anderson   C, Chapman   N, Woodward   M, Neal   B, MacMahon   S, et al.   Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med  2003;163:1069–75. https://doi.org/10.1001/archinte.163.9.1069
Google ScholarPubMedWorldCat 
846	Peters   R, Yasar   S, Anderson   CS, Andrews   S, Antikainen   R, Arima   H, et al.   Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology  2020;94:e267–81. https://doi.org/10.1212/wnl.0000000000008732
Google ScholarPubMedWorldCat 
847	Yang   W, Luo   H, Ma   Y, Si   S, Zhao   H. Effects of antihypertensive drugs on cognitive function in elderly patients with hypertension: a review. Aging Dis  2021;12:841–51. https://doi.org/10.14336/ad.2020.1111
   
848	Iseli   R, Nguyen   VTV, Sharmin   S, Reijnierse   EM, Lim   WK, Maier   AB, et al.   Orthostatic hypotension and cognition in older adults: a systematic review and meta-analysis. Exp Gerontol  2019;120:40–9. https://doi.org/10.1016/j.exger.2019.02.017
   
849	Ernst   ME, Ryan   J, Chowdhury   EK, Margolis   KL, Beilin   LJ, Reid   CM, et al.   Long-term blood pressure variability and risk of cognitive decline and dementia among older adults. J Am Heart Assoc  2021;10:e019613. https://doi.org/10.1161/jaha.120.019613
   
850	Nakamura   K, Stefanescu Schmidt   A. Treatment of hypertension in coarctation of the aorta. Curr Treat Options Cardiovasc Med  2016;18:40. https://doi.org/10.1007/s11936-016-0462-x
   
851	Dijkema   EJ, Leiner   T, Grotenhuis   HB. Diagnosis, imaging and clinical management of aortic coarctation. Heart  2017;103:1148–55. https://doi.org/10.1136/heartjnl-2017-311173
   
852	Panzer   J, Bové   T, Vandekerckhove   K, De Wolf   D. Hypertension after coarctation repair-a systematic review. Transl Pediatr  2022;11:270–9. https://doi.org/10.21037/tp-21-418
   
853	Schaefer   BM, Lewin   MB, Stout   KK, Gill   E, Prueitt   A, Byers   P H, et al.   The bicuspid aortic valve: an integrated phenotypic classification of leaflet morphology and aortic root shape. Heart  2008;94:1634–8. https://doi.org/10.1136/hrt.2007.132092
   
854	Wang   J, Deng   W, Lv   Q, Li   Y, Liu   T, Xie   M, et al.   Aortic dilatation in patients with bicuspid aortic valve. Front Physiol  2021;12:615175. https://doi.org/10.3389/fphys.2021.615175
   
855	Davies   RR, Kaple   RK, Mandapati   D, Gallo   A, Botta   DM, Elefteriades   JA, et al.   Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg  2007;83:1338–44. https://doi.org/10.1016/j.athoracsur.2006.10.074
   
856	Lindman   BR, Otto   CM. Time to treat hypertension in patients with aortic stenosis. Circulation  2013;128:1281–3. https://doi.org/10.1161/circulationaha.113.005275
   
857	Erbel   R, Aboyans   V, Boileau   C, Bossone   E, Di Bartolomeo   R, Eggebrecht   H, et al.   2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J  2014;35:2873–926. https://doi.org/10.1093/eurheartj/ehu281
Google ScholarPubMedWorldCat 
858	Shores   J, Berger   KR, Murphy   EA, Pyeritz   RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med  1994;330:1335–41. https://doi.org/10.1056/nejm199405123301902
   
859	Groenink   M, den Hartog   AW, Franken   R, Radonic   T, de Waard   V, Timmermans   J, et al.   Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J  2013;34:3491–500. https://doi.org/10.1093/eurheartj/eht334
   
860	Pitcher   A, Spata   E, Emberson   J, Davies   K, Halls   H, Holland   L, et al.   Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet  2022;400:822–31. https://doi.org/10.1016/s0140-6736(22)01534-3
   
861	Mazzolai   L, Rodriguez-Palomares   JF, Teixido-Tura   G, Lanzi   S, Boc   V, Bossone   E, et al.   2024 ESC Guidelines for the management peripheral arterial and aortic diseases. Eur Heart J  2024. https://doi.org/10.1093/eurheartj/ehae179
Google ScholarWorldCat 
862	Rechel   B, Mladovsky   P, Ingleby   D, Mackenbach   JP, McKee   M. Migration and health in an increasingly diverse Europe. Lancet  2013;381:1235–45. https://doi.org/10.1016/s0140-6736(12)62086-8
   
863	Modesti   PA, Reboldi   G, Cappuccio   FP, Agyemang   C, Remuzzi   G, Rapi   S, et al.   Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One  2016;11:e0147601. https://doi.org/10.1371/journal.pone.0147601
   
864	Whelton   PK, Einhorn   PT, Muntner   P, Appel   LJ, Cushman   WC, Diez Roux   AV, et al.   Research needs to improve hypertension treatment and control in African Americans. Hypertension  2016;68:1066–72. https://doi.org/10.1161/hypertensionaha.116.07905
   
865	Kaufman   JS, Cooper   RS, McGee   DL. Socioeconomic status and health in blacks and whites: the problem of residual confounding and the resiliency of race. Epidemiology  1997;8:621–8.
Google ScholarPubMedWorldCat 
866	Agyemang   C, van Oeffelen   AA, Norredam   M, Kappelle   LJ, Klijn   CJM, Bots   ML, et al.   Socioeconomic inequalities in stroke incidence among migrant groups: analysis of nationwide data. Stroke  2014;45:2397–403. https://doi.org/10.1161/strokeaha.114.005505
   
867	Mehanna   M, Gong   Y, McDonough   CW, Beitelshees   AL, Gums   JG, Chapman   AB, et al.   Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich)  2017;19:1301–8. https://doi.org/10.1111/jch.13094
   
868	Faconti   L, McNally   RJ, Farukh   B, Adeyemi   O, Cruickshank   JK, Wilkinson   IB, et al.   Differences in hypertension phenotypes between Africans and Europeans: role of environment. J Hypertens  2020;38:1278–85. https://doi.org/10.1097/hjh.0000000000002403
   
869	Schutte   AE, Kruger   R, Gafane-Matemane   LF, Breet   Y, Strauss-Kruger   M, Cruickshank   JK, et al.   Ethnicity and arterial stiffness. Arterioscler Thromb Vasc Biol  2020;40:1044–54. https://doi.org/10.1161/atvbaha.120.313133
   
870	Erlinger   TP, Vollmer   WM, Svetkey   LP, Appel   LJ. The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. Prev Med  2003;37:327–33. https://doi.org/10.1016/s0091-7435(03)00140-3
   
871	The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA  2002;288:2981–97. https://doi.org/10.1001/jama.288.23.2981
CrossrefPubMedWorldCat 
872	Wright   JT  Jr, Dunn   JK, Cutler   JA, Davis   BR, Cushman   WC, Ford   CE, et al.   Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA  2005;293:1595–608. https://doi.org/10.1001/jama.293.13.1595
   
873	Wright   JT  Jr, Harris-Haywood   S, Pressel   S, Barzilay   J, Baimbridge   C, Bareis   CJ, et al.   Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med  2008;168:207–17. https://doi.org/10.1001/archinternmed.2007.66
   
874	Ojji   DB, Mayosi   B, Francis   V, Badri   M, Cornelius   V, Smythe   W, et al.   Comparison of dual therapies for lowering blood pressure in Black Africans. N Engl J Med  2019;380:2429–39. https://doi.org/10.1056/NEJMoa1901113
   
875	van der Linden   EL, Couwenhoven   BN, Beune   E, Daams   JG, van den Born   B-JH, Agyemang   C. Hypertension awareness, treatment and control among ethnic minority populations in Europe: a systematic review and meta-analysis. J Hypertens  2021;39:202–13. https://doi.org/10.1097/hjh.0000000000002651
   
876	Agyemang   C, Nyaaba   G, Beune   E, Meeks   K, Owusu-Dabo   E, Addo   J, et al.   Variations in hypertension awareness, treatment, and control among Ghanaian migrants living in Amsterdam, Berlin, London, and nonmigrant Ghanaians living in rural and urban Ghana—the RODAM study. J Hypertens  2018;36:169–77. https://doi.org/10.1097/hjh.0000000000001520
   
877	van Laer   SD, Snijder   MB, Agyemang   C, Peters   RJ, van den Born   BH. Ethnic differences in hypertension prevalence and contributing determinants – the HELIUS study. Eur J Prev Cardiol  2018;25:1914–22. https://doi.org/10.1177/2047487318803241
   
878	Costello   HM, Gumz   ML. Circadian rhythm, clock genes, and hypertension: recent advances in hypertension. Hypertension  2021;78:1185–96. https://doi.org/10.1161/hypertensionaha.121.14519
   
879	O’Brien   E, Sheridan   J, O’Malley   K. Dippers and non-dippers. Lancet  1988;2:397. https://doi.org/10.1016/s0140-6736(88)92867-x
Google ScholarPubMedWorldCat 
880	Pickering   TG, Shimbo   D, Haas   D. Ambulatory blood-pressure monitoring. N Engl J Med  2006;354:2368–74. https://doi.org/10.1056/NEJMra060433
   
881	Abdalla   M, Goldsmith   J, Muntner   P, Diaz   KM, Reynolds   K, Schwartz   JE, et al.   Is isolated nocturnal hypertension a reproducible phenotype?  Am J Hypertens  2016;29:33–8. https://doi.org/10.1093/ajh/hpv058
   
882	Mancia   G, Facchetti   R, Bombelli   M, Quarti-Trevano   F, Cuspidi   C, Grassi   G. Short- and long-term reproducibility of nighttime blood pressure phenotypes and nocturnal blood pressure reduction. Hypertension  2021;77:1745–55. https://doi.org/10.1161/hypertensionaha.120.16827
   
883	Nolde   JM, Kiuchi   MG, Lugo-Gavidia   LM, Ho   JK, Chan   J, Matthews   VB, et al.   Nocturnal hypertension: a common phenotype in a tertiary clinical setting associated with increased arterial stiffness and central blood pressure. J Hypertens  2021;39:250–8. https://doi.org/10.1097/hjh.0000000000002620
   
884	Thomas   SJ, Booth   JN  III, Jaeger   BC, Hubbard   D, Sakhuja   S, Abdalla   M, et al.   Association of sleep characteristics with nocturnal hypertension and nondipping blood pressure in the CARDIA study. J Am Heart Assoc  2020;9:e015062. https://doi.org/10.1161/jaha.119.015062
   
885	Kario   K, Hoshide   S, Haimoto   H, Yamagiwa   K, Uchiba   K, Nagasaka   S, et al.   Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan morning surge home blood pressure (J-HOP) study. J Clin Hypertens (Greenwich)  2015;17:340–8. https://doi.org/10.1111/jch.12500
   
886	de la Sierra   A, Gorostidi   M, Banegas   JR, Segura   J, de la Cruz   JJ, Ruilope   LM, et al.   Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?  Am J Hypertens  2014;27:680–7. https://doi.org/10.1093/ajh/hpt175
   
887	Wijkman   M, Länne   T, Engvall   J, Lindström   T, Östgren   CJ, Nystrom   FH, et al.   Masked nocturnal hypertension—a novel marker of risk in type 2 diabetes. Diabetologia  2009;52:1258–64. https://doi.org/10.1007/s00125-009-1369-9
   
888	Muntner   P, Lewis   CE, Diaz   KM, Carson   AP, Kim   Y, Calhoun   D, et al.   Racial differences in abnormal ambulatory blood pressure monitoring measures: results from the coronary artery risk development in young adults (CARDIA) study. Am J Hypertens  2015;28:640–8. https://doi.org/10.1093/ajh/hpu193
   
889	Thomas   SJ, Booth   JN  III, Bromfield   SG, Seals   SR, Spruill   TM, Ogedegbe   G, et al.   Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson heart study. J Am Soc Hypertens  2017;11:204–212.e205. https://doi.org/10.1016/j.jash.2017.02.001
   
890	Husain   A, Lin   FC, Tuttle   LA, Olsson   E, Viera   AJ. The reproducibility of racial differences in ambulatory blood pressure phenotypes and measurements. Am J Hypertens  2017;30:961–7. https://doi.org/10.1093/ajh/hpx079
   
891	Li   Y, Wang   JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension  2013;61:278–83. https://doi.org/10.1161/hypertensionaha.111.00217
   
892	Hoshide   S, Kario   K, de la Sierra   A, Bilo   G, Schillaci   G, Banegas   JR, et al.   Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. Hypertension  2015;66:750–6. https://doi.org/10.1161/hypertensionaha.115.05958
   
893	Banegas   JR, Ruilope   LM, de la Sierra   A, Gorostidi   M, Segura   J, Martell   N, et al.   High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J  2014;35:3304–12. https://doi.org/10.1093/eurheartj/ehu016
   
894	Huang   JF, Zhang   DY, Sheng   CS, An   D-W, Li   M, Cheng   Y-B, et al.   Isolated nocturnal hypertension in relation to host and environmental factors and clock genes. J Clin Hypertens (Greenwich)  2022;24:1255–62. https://doi.org/10.1111/jch.14532
   
895	Matsumoto   T, Tabara   Y, Murase   K, Setoh   K, Kawaguchi   T, Nagashima   S, et al.   Nocturia and increase in nocturnal blood pressure: the Nagahama study. J Hypertens  2018;36:2185–92. https://doi.org/10.1097/hjh.0000000000001802
   
896	Seif   F, Patel   SR, Walia   HK, Rueschman   M, Bhatt   DL, Blumenthal   RS, et al.   Obstructive sleep apnea and diurnal nondipping hemodynamic indices in patients at increased cardiovascular risk. J Hypertens  2014;32:267–75. https://doi.org/10.1097/hjh.0000000000000011
   
897	Kimura   G, Dohi   Y, Fukuda   M. Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovascular events. Hypertens Res  2010;33:515–20. https://doi.org/10.1038/hr.2010.47
   
898	Drawz   PE, Alper   AB, Anderson   AH, Brecklin   CS, Charleston   J, Chen   J, et al.   Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol  2016;11:642–52. https://doi.org/10.2215/cjn.08530815
   
899	Kanno   A, Metoki   H, Kikuya   M, Terawaki   H, Hara   A, Hashimoto   T, et al.   Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study. Hypertens Res  2010;33:1192–8. https://doi.org/10.1038/hr.2010.139
   
900	Kushiro   T, Kario   K, Saito   I, Teramukai   S, Sato   Y, Okuda   Y, et al.   Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST study. Hypertens Res  2017;40:87–95. https://doi.org/10.1038/hr.2016.87
   
901	Lurbe   E, Redon   J, Kesani   A, Pascual   JM, Tacons   J, Alvarez   V, et al.   Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med  2002;347:797–805. https://doi.org/10.1056/NEJMoa013410
   
902	Cuspidi   C, Sala   C, Tadic   M, Gherbesi   E, De Giorgi   A, Grassi   G, et al.   Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review. J Clin Hypertens (Greenwich)  2017;19:713–21. https://doi.org/10.1111/jch.13023
   
903	Wu   Q, Hong   M, Xu   J, Tang   X, Zhu   L, Gao   P, et al.   Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism. Endocrine  2021;72:835–43. https://doi.org/10.1007/s12020-021-02606-3
   
904	Kario   K, Hoshide   S, Mizuno   H, Kabutoya   T, Nishizawa   M, Yoshida   T, et al.   Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation  2020;142:1810–20. https://doi.org/10.1161/circulationaha.120.049730
   
905	Kario   K, Hoshide   S, Nagai   M, Okawara   Y, Kanegae   H. Sleep and cardiovascular outcomes in relation to nocturnal hypertension: the J-HOP nocturnal blood pressure study. Hypertens Res  2021;44:1589–96. https://doi.org/10.1038/s41440-021-00709-y
   
906	Wang   Q, Wang   Y, Wang   J, Zhang   L, Zhao   MH. Nocturnal systolic hypertension and adverse prognosis in patients with CKD. Clin J Am Soc Nephrol  2021;16:356–64. https://doi.org/10.2215/cjn.14420920
   
907	Hansen   TW, Li   Y, Boggia   J, Thijs   L, Richart   T, Staessen   JA. Predictive role of the nighttime blood pressure. Hypertension  2011;57:3–10. https://doi.org/10.1161/hypertensionaha.109.133900
   
908	Staessen   JA, Thijs   L, Fagard   R, O’Brien   ET, Clement   D, de Leeuw   PW, et al.   Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA  1999;282:539–46. https://doi.org/10.1001/jama.282.6.539
   
909	Verdecchia   P, Porcellati   C, Schillaci   G, Borgioni   C, Ciucci   A, Battistelli   M, et al.   Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension  1994;24:793–801. https://doi.org/10.1161/01.hyp.24.6.793
   
910	Ohkubo   T, Hozawa   A, Yamaguchi   J, Kikuya   M, Ohmori   K, Michimata   M, et al.   Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens  2002;20:2183–9. https://doi.org/10.1097/00004872-200211000-00017
   
911	Nagai   M, Hoshide   S, Ishikawa   J, Shimada   K, Kario   K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens  2008;26:1636–41. https://doi.org/10.1097/HJH.0b013e3283018333
   
912	Staessen   JA, Thijs   L, Ohkubo   T, Kikuya   M, Richart   T, Boggia   J, et al.   Thirty years of research on diagnostic and therapeutic thresholds for the self-measured blood pressure at home. Blood Press Monit  2008;13:352–65. https://doi.org/10.1097/MBP.0b013e3283108f93
   
913	Kario   K, Shimada   K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens  2004;26:177–89. https://doi.org/10.1081/ceh-120028556
   
914	Tan   X, Sundström   J, Lind   L, Franzon   K, Kilander   L, Benedict   C, et al.   Reverse dipping of systolic blood pressure is associated with increased dementia risk in older men: a longitudinal study over 24 years. Hypertension  2021;77:1383–90. https://doi.org/10.1161/hypertensionaha.120.16711
   
915	Judd   E, Calhoun   DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens  2014;28:463–8. https://doi.org/10.1038/jhh.2013.140
   
916	Denker   MG, Haddad   DB, Townsend   RR, Cohen   DL. Blood pressure control 1 year after referral to a hypertension specialist. J Clin Hypertens (Greenwich)  2013;15:624–9. https://doi.org/10.1111/jch.12146
   
917	Blumenthal   JA, Hinderliter   AL, Smith   PJ, Mabe   S, Watkins   LL, Craighead   L, et al.   Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation  2021;144:1212–26. https://doi.org/10.1161/circulationaha.121.055329
   
918	Hung   SC, Kuo   KL, Peng   CH, Wu   C-H, Lien   Y-C, Wang   Y-C, et al.   Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int  2014;85:703–9. https://doi.org/10.1038/ki.2013.336
   
919	Taler   SJ, Textor   SC, Augustine   JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension  2002;39:982–8. https://doi.org/10.1161/01.hyp.0000016176.16042.2f
   
920	Gaddam   KK, Nishizaka   MK, Pratt-Ubunama   MN, Pimenta   E, Aban   I, Oparil   S, et al.   Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med  2008;168:1159–64. https://doi.org/10.1001/archinte.168.11.1159
   
921	Roush   GC, Ernst   ME, Kostis   JB, Tandon   S, Sica   DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension  2015;65:1041–6. https://doi.org/10.1161/hypertensionaha.114.05021
   
922	Peterzan   MA, Hardy   R, Chaturvedi   N, Hughes   AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension  2012;59:1104–9. https://doi.org/10.1161/hypertensionaha.111.190637
   
923	Chen   C, Zhu   XY, Li   D, Lin   Q, Zhou   K. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore)  2020;99:e21694. https://doi.org/10.1097/md.0000000000021694
   
924	Zhao   D, Liu   H, Dong   P, Zhao   J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol  2017;233:113–7. https://doi.org/10.1016/j.ijcard.2016.12.158
   
925	Bazoukis   G, Thomopoulos   C, Tsioufis   C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens  2018;36:987–94. https://doi.org/10.1097/hjh.0000000000001671
   
926	Oxlund   CS, Henriksen   JE, Tarnow   L, Schousboe   K, Gram   J, Jacobsen   IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens  2013;31:2094–102. https://doi.org/10.1097/HJH.0b013e3283638b1a
   
927	Desai   R, Park   H, Brown   JD, Mohandas   R, Pepine   CJ, Smith   SM. Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension. Hypertension  2022;79:2305–15. https://doi.org/10.1161/hypertensionaha.122.19280
   
928	Juurlink   DN, Mamdani   MM, Lee   DS, Kopp   A, Austin   PC, Laupacis   A, et al.   Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med  2004;351:543–51. https://doi.org/10.1056/NEJMoa040135
   
929	Agarwal   R, Rossignol   P, Romero   A, Garza   D, Mayo   MR, Warren   S, et al.   Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet  2019;394:1540–50. https://doi.org/10.1016/s0140-6736(19)32135-x
   
930	Burton   TJ, Mackenzie   IS, Balan   K, Koo   B, Bird   N, Soloviev   DV, et al.   Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab  2012;97:100–9. https://doi.org/10.1210/jc.2011-1537
   
931	Rossi   GP, Maiolino   G, Seccia   TM. Adrenal venous sampling: where do we stand?  Endocrinol Metab Clin North Am  2019;48:843–58. https://doi.org/10.1016/j.ecl.2019.08.012
   
932	Wu   X, Senanayake   R, Goodchild   E, Bashari   WA, Salsbury   J, Cabrera   CP, et al.   [(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. Nat Med  2023;29:190–202. https://doi.org/10.1038/s41591-022-02114-5
   
933	Lenzini   L, Prisco   S, Caroccia   B, Rossi   GP. Saga of familial hyperaldosteronism: yet a new channel. Hypertension  2018;71:1010–4. https://doi.org/10.1161/hypertensionaha.118.11150
   
934	Parthasarathy   HK, Ménard   J, White   WB, Young   WF, Williams   GH, Williams   B, et al.   A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens  2011;29:980–90. https://doi.org/10.1097/HJH.0b013e3283455ca5
   
935	Shagjaa   T, Sanga   V, Rossi   GP. Skin hyperpigmentation due to post-surgical adrenal insufficiency regressed with the dexamethasone treatment. J Clin Med  2022;11:5379. https://doi.org/10.3390/jcm11185379
   
936	Sanga   V, Lenzini   L, Seccia   TM, Rossi   GP. Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone. Blood Press  2021;30:133–7. https://doi.org/10.1080/08037051.2020.1863771
   
937	Persu   A, Touzé   E, Mousseaux   E, Barral   X, Joffre   F, Plouin   P-F. Diagnosis and management of fibromuscular dysplasia: an expert consensus. Eur J Clin Invest  2012;42:338–47. https://doi.org/10.1111/j.1365-2362.2011.02577.x
   
938	Wheatley   K, Ives   N, Gray   R, Kalra   PA, Moss   JG, Baigent   C, et al.   Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med  2009;361:1953–62. https://doi.org/10.1056/NEJMoa0905368
Google ScholarPubMedWorldCat 
939	Cooper   CJ, Murphy   TP, Cutlip   DE, Jamerson   K, Henrich   W, Reid   DM, et al.   Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med  2014;370:13–22. https://doi.org/10.1056/NEJMoa1310753
   
940	Bailey   SR, Beckman   JA, Dao   TD, Misra   S, Sobieszczyk   PS, White   CJ, et al.   ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol  2019;73:214–37. https://doi.org/10.1016/j.jacc.2018.10.002
   
941	Trinquart   L, Mounier-Vehier   C, Sapoval   M, Gagnon   N, Plouin   PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension  2010;56:525–32. https://doi.org/10.1161/hypertensionaha.110.152918
   
942	Sanga   V, Bertoli   E, Crimì   F, Barbiero   G, Battistel   M, Teresa Seccia   M, et al.   Pickering syndrome: an overlooked renovascular cause of recurrent heart failure. J Am Heart Assoc  2023;12:e030474. https://doi.org/10.1161/jaha.123.030474
   
943	Bhalla   V, Textor   SC, Beckman   JA, Casanegra   AI, Cooper   CJ, Kim   ESH, et al.   Revascularization for renovascular disease: a scientific statement from the American Heart Association. Hypertension  2022;79:e128–43. https://doi.org/10.1161/hyp.0000000000000217
   
944	Bravo   E, Fouad-Tarazi   F, Rossi   G, Imamura   M, Lin   WW, Madkour   MA, et al.   A reevaluation of the hemodynamics of pheochromocytoma. Hypertension  1990;15:I128–131. https://doi.org/10.1161/01.hyp.15.2_suppl.i128
   
945	Cohen   JB, Brown   NJ, Brown   SA, Dent   S, van Dorst   DCH, Herrmann   SM, et al.   Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension  2023;80:e46–57. https://doi.org/10.1161/hyp.0000000000000224
Google ScholarPubMedWorldCat 
946	Lyon   AR, López-Fernández   T, Couch   LS, Asteggiano   R, Aznar   MC, Bergler-Klein   J, et al.   ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J  2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244
   
947	Boulestreau   R, van den Born   BH, Lip   GYH, Gupta   A. Malignant hypertension: current perspectives and challenges. J Am Heart Assoc  2022;11:e023397. https://doi.org/10.1161/jaha.121.023397
   
948	Ma   L, Hu   X, Song   L, Chen   X, Ouyang   M, Billot   L, et al.   The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet  2023;402:27–40. https://doi.org/10.1016/s0140-6736(23)00806-1
   
949	Moullaali   TJ, Wang   X, Sandset   EC, Woodhouse   LJ, Law   ZK, Arima   H, et al.   Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. J Neurol Neurosurg Psychiatry  2022;93:6–13. https://doi.org/10.1136/jnnp-2021-327195
   
950	Wang   X, Di Tanna   GL, Moullaali   TJ, Martin   R’ H, Shipes   VB, Robinson   TG, et al.   J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: a pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke  2022;17:1129–36. https://doi.org/10.1177/17474930211064076
   
951	Qureshi   AI, Huang   W, Lobanova   I, Barsan   WG, Hanley   DF, Hsu   CY, et al.   Outcomes of intensive systolic blood pressure reduction in patients with intracerebral hemorrhage and excessively high initial systolic blood pressure: post hoc analysis of a randomized clinical trial. JAMA Neurol  2020;77:1355–65. https://doi.org/10.1001/jamaneurol.2020.3075
   
952	Bath   PM, Krishnan   K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev  2014;2014:CD000039. https://doi.org/10.1002/14651858.CD000039.pub3
Google ScholarPubMedWorldCat 
953	Berge   E, Whiteley   W, Audebert   H, De Marchis   GM, Fonseca   AC, Padiglioni   C, et al.   European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J  2021;6:I–LXII. https://doi.org/10.1177/2396987321989865
   
954	LeCouffe   NE, Kappelhof   M, Treurniet   KM, Lingsma   HF, Zhang   G, van den Wijngaard   IR, et al.   2B, 2C, or 3: what should be the angiographic target for endovascular treatment in ischemic stroke?  Stroke  2020;51:1790–6. https://doi.org/10.1161/strokeaha.119.028891
   
955	Mistry   EA, Hart   KW, Davis   LT, Gao   Y, Prestigiacomo   CJ, Mittal   S, et al.   Blood pressure management after endovascular therapy for acute ischemic stroke: the BEST-II randomized clinical trial. JAMA  2023;330:821–31. https://doi.org/10.1001/jama.2023.14330
   
956	Lee   M, Ovbiagele   B, Hong   KS, Wu   Y-L, Lee   J-E, Rao   NM, et al.   Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke  2015;46:1883–9. https://doi.org/10.1161/strokeaha.115.009552
   
957	Anderson   CS, Huang   Y, Lindley   RI, Chen   X, Arima   H, Chen   G, et al.   Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet  2019;393:877–88. https://doi.org/10.1016/s0140-6736(19)30038-8
   
958	Mazighi   M, Richard   S, Lapergue   B, Sibon   I, Gory   B, Berge   J, et al.   Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. Lancet Neurol  2021;20:265–74. https://doi.org/10.1016/s1474-4422(20)30483-x
   
959	Yang   P, Song   L, Zhang   Y, Zhang   X, Chen   X, Li   Y, et al.   Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. Lancet  2022;400:1585–96. https://doi.org/10.1016/s0140-6736(22)01882-7
   
960	Sandset   EC, Anderson   CS, Bath   PM, Christensen   H, Fischer   U, Gąsecki   D, et al.   European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J  2021;6:Xlviii–lxxxix. https://doi.org/10.1177/23969873211012133
   
961	Anderson   CS, Heeley   E, Huang   Y, Wang   J, Stapf   C, Delcourt   C, et al.   Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med  2013;368:2355–65. https://doi.org/10.1056/NEJMoa1214609
   
962	Qureshi   AI, Palesch   YY, Barsan   WG, Hanley   DF, Hsu   CY, Martin   RL, et al.   Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med  2016;375:1033–43. https://doi.org/10.1056/NEJMoa1603460
   
963	Moullaali   TJ, Wang   X, Woodhouse   LJ, Law   ZK, Delcourt   C, Sprigg   N, et al.   Lowering blood pressure after acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis using individual patient data from randomised controlled trials participating in the blood pressure in acute stroke collaboration (BASC). BMJ Open  2019;9:e030121. https://doi.org/10.1136/bmjopen-2019-030121
   
964	American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol  2020;135:e237–60. https://doi.org/10.1097/aog.0000000000003891
CrossrefPubMedWorldCat 
965	Garovic   VD, Dechend   R, Easterling   T, Karumanchi   SA, Baird   SM, Magee   LA, et al.   Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension  2022;79:e21–41. https://doi.org/10.1161/hyp.0000000000000208
   
966	Magee   LA, Nicolaides   KH, von Dadelszen   P. Preeclampsia. N Engl J Med  2022;386:1817–32. https://doi.org/10.1056/NEJMra2109523
   
967	Altman   D, Carroli   G, Duley   L, Farrell   B, Moodley   J, Neilson   J, et al.   Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet  2002;359:1877–90. https://doi.org/10.1016/s0140-6736(02)08778-0
Google ScholarPubMedWorldCat 
968	Poon   LC, Magee   LA, Verlohren   S, Shennan   A, von Dadelszen   P, Sheiner   E, et al.   A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the pregnancy and non-communicable diseases committee of FIGO (the International Federation of Gynecology and Obstetrics). Int J Gynaecol Obstet  2021;154 Suppl 1:3–31. https://doi.org/10.1002/ijgo.13763
Google ScholarPubMedWorldCat 
969	Muhammad   S, Usman   H, Dawha   YM, Yahya   A, Yekeen   A, Bako   B. Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: a randomized controlled trial. Pregnancy Hypertens  2022;29:1–6. https://doi.org/10.1016/j.preghy.2022.05.001
   
970	Magee   LA, Cham   C, Waterman   EJ, Ohlsson   A, von Dadelszen   P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ  2003;327:955–60. https://doi.org/10.1136/bmj.327.7421.955
   
971	Wu   HZ, Cheng   Y, Yu   D, Li   J-B, Jiang   Y-F, Zhu   Z-N. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. Hypertens Pregnancy  2022;41:126–38. https://doi.org/10.1080/10641955.2022.2056196
   
972	Halvorsen   S, Mehilli   J, Cassese   S, Hall   TS, Abdelhamid   M, Barbato   E, et al.   2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J  2022;43:3826–924. https://doi.org/10.1093/eurheartj/ehac270
   
973	Lizano-Díez   I, Poteet   S, Burniol-Garcia   A, Cerezales   M. The burden of perioperative hypertension/hypotension: a systematic review. PLoS One  2022;17:e0263737. https://doi.org/10.1371/journal.pone.0263737
   
974	Futier   E, Lefrant   JY, Guinot   PG, Godet   T, Lorne   E, Cuvillon   P, et al.   Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA  2017;318:1346–57. https://doi.org/10.1001/jama.2017.14172
   
975	Sanders   RD, Hughes   F, Shaw   A, Thompson   A, Bader   A, Hoeft   A, et al.   Perioperative quality initiative consensus statement on preoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth  2019;122:552–62. https://doi.org/10.1016/j.bja.2019.01.018
   
976	Messina   A, Robba   C, Calabrò   L, Zambelli   D, Iannuzzi   F, Molinari   E, et al.   Association between perioperative fluid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care  2021;25:43. https://doi.org/10.1186/s13054-021-03464-1
   
977	Meng   L, Yu   W, Wang   T, Zhang   L, Heerdt   PM, Gelb   AW. Blood pressure targets in perioperative care. Hypertension  2018;72:806–17. https://doi.org/10.1161/hypertensionaha.118.11688
   
978	Wanner   PM, Wulff   DU, Djurdjevic   M, Korte   W, Schnider   TW, Filipovic   M. Targeting higher intraoperative blood pressures does not reduce adverse cardiovascular events following noncardiac surgery. J Am Coll Cardiol  2021;78:1753–64. https://doi.org/10.1016/j.jacc.2021.08.048
   
979	Blessberger   H, Lewis   SR, Pritchard   MW, Fawcett   LJ, Domanovits   H, Schlager   O, et al.   Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev  2019;9:CD013438. https://doi.org/10.1002/14651858.CD013438
Google ScholarPubMedWorldCat 
980	McGory   ML, Maggard   MA, Ko   CY. A meta-analysis of perioperative beta blockade: what is the actual risk reduction?  Surgery  2005;138:171–9. https://doi.org/10.1016/j.surg.2005.03.022
   
981	Kertai   MD, Cooter   M, Pollard   RJ, Buhrman   W, Aronson   S, Mathew   JP, et al.   Is compliance with surgical care improvement project cardiac (SCIP-Card-2) measures for perioperative β-blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery?  Anesth Analg  2018;126:1829–38. https://doi.org/10.1213/ane.0000000000002577
   
982	Roshanov   PS, Rochwerg   B, Patel   A, Salehian   O, Duceppe   E, Belley-Côté   EP, et al.   Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patIents cOhort evaluatioN prospective cohort. Anesthesiology  2017;126:16–27. https://doi.org/10.1097/aln.0000000000001404
   
983	Shiffermiller   JF, Monson   BJ, Vokoun   CW, Beachy   MW, Smith   MP, Sullivan   JN, et al.   Prospective randomized evaluation of preoperative angiotensin-converting enzyme inhibition (PREOP-ACEI). J Hosp Med  2018;13:661–7. https://doi.org/10.12788/jhm.3036
   
984	Hollmann   C, Fernandes   NL, Biccard   BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg  2018;127:678–87. https://doi.org/10.1213/ane.0000000000002837
   
985	Ackland   GL, Patel   A, Abbott   TEF, Begum   S, Dias   P, Crane   DR, et al.   Discontinuation vs. continuation of renin–angiotensin system inhibition before non-cardiac surgery: the SPACE trial. Eur Heart J  2024;45:1146–55. https://doi.org/10.1093/eurheartj/ehad716
   
986	McEvoy   MD, Gupta   R, Koepke   EJ, Feldheiser   A, Michard   F, Levett   D, et al.   Perioperative quality initiative consensus statement on postoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth  2019;122:575–86. https://doi.org/10.1016/j.bja.2019.01.019
   
987	Ekman   I, Swedberg   K, Taft   C, Lindseth   A, Norberg   A, Brink   E, et al.   Person-centered care—ready for prime time. Eur J Cardiovasc Nurs  2011;10:248–51. https://doi.org/10.1016/j.ejcnurse.2011.06.008
   
988	Krist   AH, Tong   ST, Aycock   RA, Longo   DR. Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform  2017;240:284–302. https://doi.org/10.3233/ISU-170826
Google ScholarPubMedWorldCat 
989	Johnson   RA, Huntley   A, Hughes   RA, Hughes   RA, Cramer   H, Turner   KM, et al.   Interventions to support shared decision making for hypertension: a systematic review of controlled studies. Health Expect  2018;21:1191–207. https://doi.org/10.1111/hex.12826
   
990	Johnson   RL, Roter   D, Powe   NR, Cooper   LA. Patient race/ethnicity and quality of patient–physician communication during medical visits. Am J Public Health  2004;94:2084–90. https://doi.org/10.2105/ajph.94.12.2084
   
991	Williams   MV, Davis   T, Parker   RM, Weiss   BD. The role of health literacy in patient-physician communication. Fam Med  2002;34:383–9.
Google ScholarPubMedWorldCat 
992	Karmali   KN, Persell   SD, Perel   P, Lloyd-Jones   DM, Berendsen   MA, Huffman   MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev  2017;3:CD006887. https://doi.org/10.1002/14651858.CD006887.pub4
Google ScholarPubMedWorldCat 
993	Ma   C, Zhou   Y, Zhou   W, Huang   C. Evaluation of the effect of motivational interviewing counselling on hypertension care. Patient Educ Couns  2014;95:231–7. https://doi.org/10.1016/j.pec.2014.01.011
   
994	Huang   X, Xu   N, Wang   Y, Sun   Y, Guo   A. The effects of motivational interviewing on hypertension management: a systematic review and meta-analysis. Patient Educ Couns  2023;112:107760. https://doi.org/10.1016/j.pec.2023.107760
   
995	Glaser   E, Richard   C, Lussier   MT. The impact of a patient web communication intervention on reaching treatment suggested guidelines for chronic diseases: a randomized controlled trial. Patient Educ Couns  2017;100:2062–70. https://doi.org/10.1016/j.pec.2017.05.022
   
996	Richard   AA, Shea   K. Delineation of self-care and associated concepts. J Nurs Scholarsh  2011;43:255–64. https://doi.org/10.1111/j.1547-5069.2011.01404.x
Google ScholarPubMedWorldCat 
997	Wilkinson   A, Whitehead   L. Evolution of the concept of self-care and implications for nurses: a literature review. Int J Nurs Stud  2009;46:1143–7. https://doi.org/10.1016/j.ijnurstu.2008.12.011
   
998	Bodenheimer   T, Lorig   K, Holman   H, Grumbach   K. Patient self-management of chronic disease in primary care. JAMA  2002;288:2469–75. https://doi.org/10.1001/jama.288.19.2469
   
999	Barlow   J, Wright   C, Sheasby   J, Turner   A, Hainsworth   J. Self-management approaches for people with chronic conditions: a review. Patient Educ Couns  2002;48:177–87. https://doi.org/10.1016/s0738-3991(02)00032-0
   
1000	Hallberg   I, Ranerup   A, Kjellgren   K. Supporting the self-management of hypertension: patients’ experiences of using a mobile phone-based system. J Hum Hypertens  2016;30:141–6. https://doi.org/10.1038/jhh.2015.37
   
1001	Almeida   GO, Aidar   FJ, Matos   DG, Almeida-Neto   PF, Melo   EV, Barreto Filho   JAS, et al.   Non-targeted self-measurement of blood pressure: association with self-medication, unscheduled emergency visits and anxiety. Medicina (Kaunas)  2021;57:75. https://doi.org/10.3390/medicina57010075
   
1002	Greaves   F, Joshi   I, Campbell   M, Roberts   S, Patel   N, Powell   J, et al.   What is an appropriate level of evidence for a digital health intervention?  Lancet  2019;392:2665–7. https://doi.org/10.1016/s0140-6736(18)33129-5
   
1003	Morton   K, Dennison   L, May   C, Murray   E, Little   P, McManus   RJ, et al.   Using digital interventions for self-management of chronic physical health conditions: a meta-ethnography review of published studies. Patient Educ Couns  2017;100:616–35. https://doi.org/10.1016/j.pec.2016.10.019
   
1004	McKinstry   B, Hanley   J, Wild   S, Pagliari   C, Paterson   M, Lewis   S, et al.   Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ  2013;346:f3030. https://doi.org/10.1136/bmj.f3030
   
1005	Persell   SD, Peprah   YA, Lipiszko   D, Lee   JY, Li   JJ, Ciolino   JD, et al.   Effect of home blood pressure monitoring via a smartphone hypertension coaching application or tracking application on adults with uncontrolled hypertension: a randomized clinical trial. JAMA Netw Open  2020;3:e200255. https://doi.org/10.1001/jamanetworkopen.2020.0255
   
1006	Andersson   U, Nilsson   PM, Kjellgren   K, Hoffmann   M, Wennersten   A, Midlöv   P, et al.   PERson-centredness in Hypertension management using Information Technology: a randomized controlled trial in primary care. J Hypertens  2023;41:246–53. https://doi.org/10.1097/hjh.0000000000003322
   
1007	Bergland   OU, Halvorsen   LV, Søraas   CL, Hjørnholm   U, Kjær   VN, Rognstad   S, et al.   Detection of nonadherence to antihypertensive treatment by measurements of serum drug concentrations. Hypertension  2021;78:617–28. https://doi.org/10.1161/hypertensionaha.121.17514
   
1008	Durand   H, Hayes   P, Morrissey   EC, Newell   J, Casey   M, Murphy   AW, et al.   Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens  2017;35:2346–57. https://doi.org/10.1097/hjh.0000000000001502
   
1009	Kronish   IM, Thorpe   CT, Voils   CI. Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts. Transl Behav Med  2021;11:104–13. https://doi.org/10.1093/tbm/ibz133
   
1010	DiMatteo   MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol  2004;23:207–18. https://doi.org/10.1037/0278-6133.23.2.207
   
1011	Houle   SK, Chatterley   T, Tsuyuki   RT. Multidisciplinary approaches to the management of high blood pressure. Curr Opin Cardiol  2014;29:344–53. https://doi.org/10.1097/hco.0000000000000071
   
1012	Woodham   NS, Taneepanichskul   S, Somrongthong   R, Kitsanapun   A, Sompakdee   B. Effectiveness of a multidisciplinary approach intervention to improve blood pressure control among elderly hypertensive patients in rural Thailand: a quasi-experimental study. J Multidiscip Healthc  2020;13:571–80. https://doi.org/10.2147/jmdh.S254286
   
1013	Mattei da Silva   ÂT, de Fátima Mantovani   M, Castanho Moreira   R, Perez Arthur   J, Molina de Souza   R. Nursing case management for people with hypertension in primary health care: a randomized controlled trial. Res Nurs Health  2020;43:68–78. https://doi.org/10.1002/nur.21994
   
1014	He   J, Ouyang   N, Guo   X, Sun   G, Li   Z, Mu   J, et al.   Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet  2023;401:928–38. https://doi.org/10.1016/s0140-6736(22)02603-4
   
1015	Creegan   D, McEvoy   JW. Selected highlights in the updated treatment of hypertension. Trends Cardiovasc Med  https://doi.org/10.1016/j.tcm.2023.11.001
WorldCat 
1016	Jaffe   MG, Lee   GA, Young   JD, Sidney   S, Go   AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA  2013;310:699–705. https://doi.org/10.1001/jama.2013.108769
   
1017	Hänsel   M, Steigmiller   K, Luft   AR, Gebhard   C, Held   U, Wegener   S, et al.   Neurovascular disease in Switzerland: 10-year trends show non-traditional risk factors on the rise and higher exposure in women. Eur J Neurol  2022;29:2851–60. https://doi.org/10.1111/ene.15434
   
1018	de Ruiter   SC, Schmidt   AF, Grobbee   DE, den Ruijter   HM, Peters   SAE. Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment: spotlight on hypertension. J Hum Hypertens  2023;37:602–8. https://doi.org/10.1038/s41371-023-00821-1
   
1019	Chapman   N, Ching   SM, Konradi   AO, Nuyt   AM, Khan   T, Twumasi-Ankrah   B, et al.   Arterial hypertension in women: state of the art and knowledge gaps. Hypertension  2023;80:1140–9. https://doi.org/10.1161/hypertensionaha.122.20448
   
1020	Tamargo   J, Caballero   R, Mosquera   ED. Sex and gender differences in the treatment of arterial hypertension. Expert Rev Clin Pharmacol  2023;16:329–47. https://doi.org/10.1080/17512433.2023.2189585
   
1021	Olsen   MH, Angell   SY, Asma   S, Boutouyrie   P, Burger   D, Chirinos   JA, et al.   A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet  2016;388:2665–712. https://doi.org/10.1016/s0140-6736(16)31134-5
   

## Author notes

John William McEvoy and Rhian M Touyz Chairpersons contributed equally to the document and are joint corresponding authors.

Cian P McCarthy and Rosa Maria Bruno Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

<sup>1</sup>Representing the European Renal Association (ERA), <sup>2</sup>Representing the European Society of Endocrinology (ESE), <sup>3</sup>Representing the European Stroke Organisation (ESO), <sup>4</sup>Representing the European Geriatric Medicine Society (EuGMS).

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council on Hypertension, Council on Stroke.

**Working Groups:** Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, E-Cardiology.

**Patient Forum**

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

**Permissions.** The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of the _European Heart Journal_ and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

 ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il3.jpeg?Expires=1728462844&Signature=K7wnmHXf5cZujSGBklwEG9yUEZa661k4aJHJ6mbsRM-dLpGrNc03w2qgjWbwNHB71B5wgOJf2-BsL~rQsLElkYfi~hLbhfXjswDu7QWL9V5bH90h0z8FsfRgnnhec1R7DzFb9~L8A1f-9IC1XxyO4OaS0oT9dAXIQVDzpKyXZmE-AJVSJBAwHIhpZMPRvdcgwrS4PU4sWtJ-CP49LKSQ0iIyej5MfOTuMmsQbvlU~MVZ-IJq6sWRzLz3VAvL6umIG~kLP9dRoe6pqDKHrs0LDa2AcbQfBKW~mMbJxGcKT8qH3l-hFBCd1XJgZvC--BssbXFc4y3ga2zFLCzWvQnjwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) All experts involved in the development of these guidelines have submitted declarations of interest, which are reported in a supplementary document to the guidelines. See the _European Heart Journal_ online or [www.escardio.org/Guidelines](https://www.escardio.org/Guidelines) for supplementary documents, as well as evidence tables.

  ![graphic](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/m_ehae178il4.jpeg?Expires=1728462844&Signature=Uok7hDvPxFT3d~1RJy9LSmybAUAgvvgord~KlDRiQKZ88AMXHz9o4X15d1PsK2yVQ0VxGXPeoUCFNqKQ-Qb-n4RpImN5fVooV5060kD6jtBqmFJVY-ZDEuVR6uBgYDYlVoGTJnsEU7EdNFNAyjztFXZlbYXKO3vocogQ4UXRI51gv1ouSmwujlS63F0twr0MqIFkn8F~yiZUrnwpvtXC0~bCDuwdmFDsFcQyOv4IGiZ71BkKWNrchFwE~-B64ue1J3mdlmyYUT09Glfb38ZNvBbcOTYpW24ld6q4AMjc4dM-k4oD~pIXGwjwnY0S7EXzaeVTMcr1HH5AbgsJE-hVSQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)  [Click here](https://doi.org/10.1093/med/9780198784906.001.0001) to access the corresponding ESC CardioMed chapters.

© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/pages/standard-publication-reuse-rights](https://academic.oup.com/pages/standard-publication-reuse-rights))

## Supplementary data

[ehae178\_Supplementary\_Data](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/ehae178_supplementary_data.pdf?Expires=1728462845&Signature=eChRhsUBjDtSvX0XHjF46e5LYIdyCYplv25dByU0f8Kx1M9eNwiS~lwVqfU-kUm72DTU8Gb1Xm~UsUaa54dOE1yN7Aqv2Y6OoMKHBYc5gIbWAO9pgTtwW1Y~KhjxywB8K1pgd6T6XbhVSgi9o8kjcPMoksFwvpEdZfyD4~kXMQEZSQyTadLu2OPAaWWkBQjuxmjnNcsYxpTKtJ~JX2i7sPtv4DIX0up3oUGtNiS3pgOpRv6o1Zu85HV6XzHMyDewxqwicq1T41ph2G0ixQwqM14ul4AhqK~FmKY14BxZdkurv-71D82hGpQo30APmpMBHo4HP~NuGMyTFKF0wpAPOQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[2024\_Hypertension\_Guidelines\_Evidence\_Tables](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/2024_hypertension_guidelines_evidence_tables.pdf?Expires=1728462845&Signature=ouEM5I5CibCYM3GqloI7s9~JI00H8MfD81BoIcnVDVsDGQivmOCeLZtur9zJTFeWYqCcClqeEMk6Pu0FKutcCpA3bCVfHIEHxBgecDL8vuHWpTPZVNGaxkfDYObx8AXhAa4H9qrnjxJWbz-oz-o97M3f-IAMk7bfizdl2eplf2-SW9UvRMVT1zsx7sRR0mqQlsBgWq6v9Jq5FRHMKEx5ze25J0xci6V8Z0qKuOBP7BOT0TWXLf6qonytosxqeN4Jx4lAYEpH6O2JNn94hfqMt0kU3e5tmelGvUXUu2Hz8zROsR8n-lHF9BVUo9oWq4O5G4iKmeQyJ~CWvk9ITlriNg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

[DOI\_Summary\_2024\_ESC\_Guidelines\_elevated\_BP\_and\_htn\_ehae178](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/eurheartj/PAP/10.1093_eurheartj_ehae178/1/doi_summary_2024_esc_guidelines_elevated_bp_and_htn_ehae178.pdf?Expires=1728462845&Signature=BsdfAFp6KSnR~otqXyYWVu~FuLBgct1F6AdpxFsnD7aRwF1x8xmTBFpfvx4IRTuumO5qeODW2RG6Xzfs6WMYYVl5k2U3GVusiq0wbZNJ8vbHAcuM8QLb7qsodTt3IceeLpgW~fWczWf74QtEF3aQQWR6Q6hw4p82aFcBQsNSWIt8zbSScSLaeso-t4T53cFJrJ2Ot4B1stClcu4EuWlWQER~ve19SfGE8M6AaGGuRr8Y8lmOTO-7j4QCxzsg-IYdkm220v4WJoO8O~gx~9JhwhcaNjDQYo2kSAAj93uAiOAruFeOtwOAFjinQIJrAKulMcOMJFXPj5GxQEUEVkEV6A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA) - pdf file

